Atorvastatin with or without an Antibody to PCSK9 in Primary Hypercholesterolemia by Roth, Eli M. et al.
Protocol
This trial protocol has been provided by the authors to give readers additional information about their work.
Protocol for: Roth EM, McKenney JM, Hanotin C, Asset G, Stein EA. Atorvastatin with or without an antibody to 
PCSK9 in primary hypercholesterolemia. N Engl J Med 2012;367:1891-900. DOI: 10.1056/NEJMoa1201832
 
This supplement contains the following items: 
1. Initial protocol (26 Nov 2010), amendment 1 (16 Feb 2011), amended protocol (16 Feb 
2011).  
The amendment 1 of protocol lists the differences between the initial protocol and the 
amended one. There were no further amendments after Feb 16, 2011. 
 
2. Statistical analysis plan.  
Please note there were some modifications in the statistical analysis in the SAP 
compared to what was described in the protocol. This is indicated in section 1.5 of the 
SAP. 
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CLINICAL TRIAL SUMMARY 
COMPOUND: SAR236553 STUDY No : DFI11566 
TITLE A randomized, double-blind, parallel-group, placebo-controlled, fixed 
dose/dose regimen, multicenter study evaluating the efficacy and 
safety of SAR236553 when co-administered with 80 mg of 
atorvastatin over 8 weeks in patients with primary 
hypercholesterolemia and LDL-cholesterol ≥ 100 mg/dL 
(≥2.59 mmol/L) on atorvastatin 10 mg. 
INVESTIGATOR/TRIAL LOCATION US – Multicenter study 
STUDY OBJECTIVE(S) 
 
Primary Objective 
To evaluate the effect of SAR236553 on low-density lipoprotein 
cholesterol (LDL-C) levels compared with placebo when co-
administered with 80 mg of atorvastatin after 8 weeks of treatment in 
patients with LDL-C ≥ 100mg/dL (≥ 2.59 mmol/L) on atorvastatin 
10 mg. 
Secondary Objective(s) 
- To evaluate the effects of SAR236553 on other lipid levels in 
comparison with placebo, when co-administered with 80 mg of 
atorvastatin after 8 weeks of treatment.  
- To evaluate the efficacy of SAR236553 when co-administered with 
a high dose of atorvastatin (80 mg) versus atorvastatin 10mg. 
- To evaluate the safety and tolerability of SAR236553 when 
co-administered with 2 different doses of atorvastatin. 
- To evaluate the development of anti-SAR236553 antibodies. 
- To evaluate the pharmacokinetics of SAR236553.  
STUDY DESIGN This is a double-blind, randomized, placebo-controlled, 
parallel-group study that comprises three periods. 
- A screening period with 2 options depending on the status of the 
patient at screening: 
a) Option 1: for patients receiving atorvastatin 10 mg at stable 
dose for at least 6 weeks prior to screening, the screening 
period will be of 1 week. This screening period will start by a 
screening visit (Week -1, V1), during which patients will be 
evaluated for eligibility to enter the double-blind treatment 
period. 
b) Option 2: for patients receiving a lipid lowering treatment other 
than atorvastatin/ or not at stable dose of atorvastatin 10 mg for 
at least 6 weeks prior to screening, or for drug naive patients. 
This screening period includes a run-in period on atorvastatin 
10 mg with: 
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 c) This screening period includes a run-in period on atorvastatin 
10 mg with: 
• a pre-screening visit (Week -7, V1a) during which 
pre-eligibility assessments will be performed to permit the 
entry of patients into the run-in period. If applicable, at this 
pre-screening visit (Week -7, V1a) patients will be asked to 
stop any lipid lowering treatment previously received. Then 
after 6 weeks of run-in period, a screening visit (Week -1, 
V1) will be held during which the full eligibility assessment 
will be performed. 
- A randomized, double-blind, placebo-controlled, parallel-group 
treatment period of 8 weeks where patients will be randomized as 
follows: 
• Either to the group of SAR236553 + high dose of 
atorvastatin (80 mg). 
• Or to the group of SAR236553 placebo + high dose of 
atorvastatin (80 mg). 
• Or to the group of SAR236553 + maintenance of 
atorvastatin dose previously received (10 mg). 
- A follow-up period of 8 weeks after the end of treatment period 
(Week 8). 
All patients will be instructed to be on a stable diet (NCEP-ATPIII 
TLC diet or equivalent) throughout the entire study duration from 
screening. 
STUDY POPULATION  
Main selection criteria: 
 
Inclusion Criteria: 
- Patients ( patients receiving a lipid lowering treatment other than 
atorvastatin/ or not at stable dose of atorvastatin 10 mg for at least 
6 weeks prior to screening period, or drug naive patients) with 
primary hypercholesterolemia likely to have LDL-C ≥ 100 mg/dL 
(≥ 2.59 mmol/L) at the end of the run-in period on atorvastatin 
therapy (Week -1). 
OR 
- Patients with primary hypercholesterolemia treated with stable dose 
of atorvastatin 10 mg for at least 6 weeks prior to screening period 
and likely to have LDL-C ≥ 100 mg/dL (≥ 2.59 mmol/L) at the 
screening visit (Week -1). 
Exclusion Criteria 
- LDL-C < 100 mg/dL (< 2.59 mmol/L) at Week -1 (V1): 
• After the run-in period on atorvastatin 10 mg for patients 
receiving a lipid lowering treatment other than atorvastatin/ 
or not at stable dose of atorvastatin 10 mg for at least 
6 weeks prior to screening period, or drug naive patients. 
 
OR  
 
Clinical Trial Protocol  26-Nov-2010 
SAR236553-DFI11566 -   Version number: 1 (electronic 1.0) 
Property of the sanofi-aventis group - strictly confidential Page 5 
• At the first visit for patients who are being treated with 
atorvastatin 10 mg at stable dose for at least 6 weeks prior 
to screening visit Week -1. 
- Use of a statin other than atorvastatin 10 mg, or use of other lipid-
lowering drugs including but not limited to fibrates, bile acid resins, 
niacin > 500 mg, intestinal cholesterol absorption (ICA) blockers, or 
omega-3 fatty acids at doses > 1000 mg between the screening and 
the baseline Visits. 
- Type 1 diabetes. 
- Type 2 diabetes treated with insulin. 
- Type 2 diabetes with an HbA1c ≥ 8.5% at Week -7 or Week -1 
(considered poorly controlled). 
- Triglycerides (TG) > 350 mg/dL (3.95 mmol/L) at Week -7 or 
 Week -1. 
Total expected number of patients: Approximately 90 randomized (30 patients/group) 
STUDY TREATMENT(s)  
Investigational Product(s) 
 
Formulation 
Tested drug: SAR236553 and placebo for SAR236553 
 
Vials : SAR236553 150mg/mL, or Placebo  
Route(s) of administration: Subcutaneous (SC)  
Injection volume: 1mL in total 
One injection of 1 mL will be done through SC administration in the 
abdomen. 
Dose regimen: - SAR236553 150 mg or placebo for SAR236553: every 2 Weeks 
(Week 0, Week 2, Week 4, and Week 6). 
Other Investigational Product 
 
Formulation 
Atorvastatin 10 mg and atorvastatin 80 mg and matching placebo 
capsules 
 
Tablets of atorvastatin will be overencapsulated. 
Capsules for atorvastatin 10mg tablets, atorvastatin 40mg tablets 
and matching placebo capsules. 
Route(s) of administration: Oral 
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Dose regimen: 
 
Double-blind treatment period: 
During the double-blind treatment period, 2 capsules of study drug 
will be administered once daily in the evening, with dinner, as 
specified in the table below 
 
 10 mg group 80 mg group 
ATOR 10 mg 1 0 
ATOR 40 mg 0 2 
Placebo 1 0 
 
 
Non Investigational Product(s)  
 
Formulation 
During Run-in period: 
Atorvastatin 10 mg administered in an open-label manner. 
 
Tablet of atorvastatin 10 mg. 
Route(s) of administration: Oral 
Dose regimen: During the run-in period atorvastatin is considered a non 
investigational product. One tablet of atorvastatin 10 mg once daily 
in the evening, with dinner. 
 
PRIMARY AND SECONDARY 
ENDPOINT(S) 
Primary Endpoint: 
Percent change in LDL-C from baseline to Week 8. 
Secondary Endpoint (s): 
- Absolute change in calculated LDL-C from baseline to Week 8. 
- Proportion of patients achieving an LDL-C level lower than 
100 mg/dL (2.59 mmol/L) at Week 8. 
- Proportion of patients achieving an LDL-C level lower than 
70 mg/dL (1.81 mmol/L) at Week 8. 
- Percent change in total cholesterol, HDL C, TG, non-HDL-C, ApoB, 
ApoA-1, Lp(a) from baseline to Week 8. 
- Absolute change in total cholesterol, HDL C, TG, non-HDL-C, ratio 
ApoB/ApoA-1 from baseline to Week 8. 
Safety endpoint(s): 
- Adverse events, serious adverse events, vital signs, ECG, 
hematology, serum chemistry. 
Antibody assessment:  
- Anti-SAR236553 antibodies at Week 0 (baseline), Week 4, Week 8, 
and then Week 12 and Week 16 (follow-up visits). 
Pharmacokinetics: 
- Serum SAR236553 concentrations at Week 0 (Day 1), and then at 
each visit up to the last visit of the follow-up period (Weeks 2, 4, 6, 8, 
12, and 16). 
ASSESSMENT SCHEDULE Screening period 
a) Option1 (for patients receiving atorvastatin 10 mg at stable 
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dose for at least 6 weeks prior to screening): 
Screening Visit (Week-1, V1) followed by a screening period of 1 
week. At the end of this screening period, baseline Visit (V2, 
Week 0) will be performed and eligible patients will be randomized in 
the double-blind study treatment period. 
b) Option 2 (for patients receiving a lipid lowering treatment other 
than atorvastatin/ or not at stable dose of atorvastatin 10 mg for 
at least 6 weeks prior to screening, or drug naive patients): 
A pre-screening Visit (Week-7, V1a) will be followed by a run-in 
period with atorvastatin 10 mg at stable dose. At the end of this 
run-in period of 6 weeks on atorvastatin treatment, patients will 
attend the screening visit (Week-1, V1) where the full eligibility 
assessments will be performed. 
Patients will take atorvastatin 10 mg until Week 0 (V2, baseline visit). 
At Week 0, the baseline Visit (V2) will be performed, and eligible 
patients will be randomized in the double-blind study treatment 
period. 
Treatment period 
Visits schedule from randomization (baseline Visit, V2 (Week 0): 
Patients assessed on Week 0 (V2 (Day 1), randomization visit) and 
then every 2 weeks up to the end of the double-blind treatment 
period: Week 2 (V3), Week 4 (V4), Week 6 (V5), and Week 8 (V6). 
Follow-up period 
Follow-up visits will be performed at Week 12 (V7) and Week 16 
(V8). 
STATISTICAL CONSIDERATIONS 
 
Sample size determination: 
The study is expected to enrol approximately 90 patients. 
To detect a difference of 20% in LDL-C percent change from 
baseline to Week 8 between SAR236553 + high dose of atorvastatin 
group and SAR236553 placebo + high dose of atorvastatin group, 
assuming a 5% rate of unevaluable primary endpoint, 30 patients by 
arm will result in 95% power, with a standard deviation of 20%, and 
using a two-sided t-test at the 0.05 significance level. 
Calculations were made using nQuery Advisor 6.01 
Analysis Population: 
The primary efficacy analysis population will be the modified intent-
to-treat (mITT) population, defined as the ITT population (i.e., 
randomized population) with an evaluable primary endpoint. The 
primary endpoint will be considered as evaluable when both of the 
following conditions are met: 
- The Week -1 or Week 0 LDL-C value is available, 
- At least one on-treatment LDL-C value is available. The on-
treatment period for the primary efficacy variable will be defined as 
the time from the first SAR236553 or placebo for SAR236553 
injection up to 21 days after the last injection, or up to 84 days after 
the first SAR236553 or placebo for SAR236553 injection, whichever 
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come first. 
Patients in the mITT population will be analyzed according to the 
treatment group allocated by randomization. 
The safety analysis will be performed on the safety population. The 
safety population consists of the randomized population who did 
actually receive at least one dose or partial dose of SAR236553 or 
placebo for SAR236553 analyzed according to the treatment actually 
received. 
Primary Analysis: 
The percent change in LDL-C from baseline to Week 8 will be 
analyzed using an analysis of covariance (ANCOVA) model with 
treatment group as fixed effect and the baseline LDL-C as covariate. 
The treatment group factor will have three levels: SAR236553 + high 
dose of atorvastatin (80 mg), SAR236553 placebo + high dose of 
atorvastatin (80 mg), SAR236553 + maintenance of atorvastatin 
dose previously received (10 mg). 
Throughout the ANCOVA model, the SAR236553 + high dose of 
atorvastatin group will be compared to the SAR236553 placebo + 
high dose of atorvastatin group using appropriate contrast, and the 
95% CI of the difference will be provided. No formal comparisons 
with the SAR236553 + maintenance of atorvastatin dose group will 
be performed: only 95% CI for the difference versus other arms will 
be provided. 
The baseline LDL-C value will be the average of the Week -1 and 
Week 0 evaluations. In case of missing Week 8 LDL-C on-treatment 
value, the last-observation-carried-forward (LOCF) principle will be 
used. 
Analysis of secondary endpoints 
Continuous secondary endpoints will be analyzed using the same 
ANCOVA model as for the primary endpoint with treatment group as 
fixed effect, and the corresponding baseline value as covariate. 
The proportion of patients achieving an LDL-C level lower than 100 
mg/dL (2.59 mmol/L) as well as a LDL-C level lower than 70 mg/dL 
(1.81 mmol/L) at Week 8 will be analyzed using a logistic regression 
model with factor for treatment and adjustment for LDL-C values at 
baseline. 
DURATION OF STUDY PERIOD (per  
patient)  a) Option 1: for patients receiving atorvastatin 10 mg at stable dose for at least 6 weeks prior to screening:  
Approximately 17 weeks (screening: 1 week, double-blind treatment: 
8 weeks, follow-up period: 8 weeks). 
b) Option 2: for patients receiving a lipid lowering treatment other 
than atorvastatin/ or not at stable dose of atorvastatin 10 mg for 
at least 6 weeks prior to screening, or drug naive patients: 
Approximately 23 weeks (screening/run-in: 7 weeks, double-blind 
treatment: 8 weeks, follow-up period: 8 weeks). 
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1 FLOW CHARTS 
1.1 GRAPHICAL STUDY DESIGN 
Figure 1 - Study design: patients receiving a lipid lowering treatment other than atorvastatin/ or not at stable dose of atorvastatin 10 mg for at least 6 
weeks prior to screening, or drug naive patients 
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Figure 2 - Study design: patients receiving atorvastatin 10 mg at stable dose for at least 6 weeks prior to screening 
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1.2 STUDY FLOWCHART 
Table 1 - Screening/run-in schedule assessments – Patients receiving a lipid lowering treatment other than atorvastatin/ or not at stable dose of 
atorvastatin 10 mg for at least 6 weeks prior to screening, or drug naive patients 
 Screening/run-in phase 
Evaluation 
 
WEEK W-7 W-1 
DAY -49±3  -7±1 
VISIT NUMBER V1a 
Pre-eligibility assessments  
V1 
Full eligibility assessments 
Design: 
Inclusion/Exclusion Criteria X X 
Medical/surgical history, alcohol habits, smoking habits X  
Informed Consent /Patient Demography X  
Prior Medication History X  
Clinical Examination X  
Body weight X  
Height X  
IVRS/IWRS contact X  
Treatment: 
Atorvastatin 10 mg dispensation (open label) X  
Compliance check for atorvastatin  X 
Instruction/check on diet (NCEP-ATPIII TLC diet or equivalent) X X 
Concomitant Medication X X 
Vital signs: 
Heart Rate, blood pressure X X 
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 Screening/run-in phase 
Evaluation 
 
WEEK W-7 W-1 
DAY -49±3  -7±1 
Safety: 
AE /SAE recording 1) X X 
12-lead ECG 2)  X 
VISIT NUMBER V1a 
Pre-eligibility assessments  
V1 
Full eligibility assessments 
Laboratory Testing / Efficacy: 
Lipids: Total cholesterol, LDL-cholesterol, HDL-cholesterol, Triglycerides, non-HDL-C X X 
Lipids: ApoB, ApoA-1, ratio ApoB/ApoA-1, and Lp (a)   
Laboratory Testing / Safety: 
Fasting plasma glucose X X 
HbA1c X  
Standard hematology, serum chemistry3) X X 
Liver tests4), CPK  X 
Sensitive TSH  X 
Hepatitis B and C serology  X 
Serum  X Pregnancy test (for women of childbearing potential) 
Urine X  
1) Adverse event (AE) collection from the time of informed consent signature. 
2) Using a centralized automatic and manual reading of all ECGs. 
3) Hematology includes: complete blood count (CBC) including hematocrit, hemoglobin, red blood cell count, white blood cell count with differential count and platelets. Serum chemistry includes: sodium, potassium, 
chloride, bicarbonate, calcium, phosphorous, urea nitrogen, creatinine, uric acid, total protein, and albumin. 
4) Liver tests: ALT, AST, alkaline phosphatase (ALP), and γGT and total bilirubin. 
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Table 2 - Screening schedule assessments – Patients receiving atorvastatin 10 mg at stable dose for at least 6 weeks prior to screening 
 Screening 
Evaluation 
 
WEEK W-1 
DAY -7±1 
VISIT NUMBER V1 
Full eligibility assessments 
Design: 
Inclusion/Exclusion Criteria X 
Medical/surgical history, alcohol habits, smoking habits X 
Informed Consent /Patient Demography X 
Prior Medication History X 
Clinical Examination X 
Body weight X 
Height X 
IVRS/IWRS contact X 
Treatment: 
Atorvastatin 10 mg dispensation (open label) X 
Instruction on diet (NCEP-ATPIII TLC diet or equivalent) X 
Concomitant Medication X 
Vital signs: 
Heart Rate, blood pressure X 
Safety: 
AE /SAE recording 1) X 
12-lead ECG 2) X 
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 Screening 
Evaluation 
 
WEEK W-1 
DAY -7±1 
VISIT NUMBER V1 
Full eligibility assessments 
Laboratory Testing / Efficacy: 
Lipids: Total cholesterol, LDL-cholesterol, HDL-cholesterol, Triglycerides, non-HDL-C X 
Lipids: ApoB, ApoA-1, ratio ApoB/ApoA-1, and Lp (a)  
Laboratory Testing / Safety: 
Fasting plasma glucose, HbA1c X 
Standard hematology, serum chemistry3) X 
Liver tests4), CPK X 
Sensitive TSH X 
Hepatitis B and C serology X 
Serum pregnancy test (for women of childbearing potential) X 
1) Adverse event (AE) collection from the time of informed consent signature. 
2) Using a centralized automatic and manual reading of all ECGs. 
3) Hematology includes: complete blood count (CBC) including hematocrit, hemoglobin, red blood cell count, white blood cell count with differential count and platelets. Serum chemistry includes: sodium, potassium, 
chloride, bicarbonate, calcium, phosphorous, urea nitrogen, creatinine, uric acid, total protein, and albumin. 
4) Liver tests: ALT, AST, alkaline phosphatase (ALP), and γGT and total bilirubin. 
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Table 3 - Double-blind treatment and follow-up periods – All patients 
 Study phase 
Evaluation Double-blind treatment  Post-treatment follow-up 
WEEK W0 W2 W4 W6 W85) W12 W16 
DAY 1 15±3 29±3 43±3 57±3 85±7 113±7 
VISIT NUMBER V2 V3 V4 V5 V6 V7 V8 
Design: 
Inclusion/Exclusion Criteria X       
Medical/surgical history, alcohol habits, smoking habits        
Informed Consent /Patient Demography        
Prior Medication History        
Clinical Examination X    X  X 
Body weight X X X X X X X 
Height        
Randomization X       
IVRS/IWRS contact X X X X X  X 
Treatment: 
Atorvastatin IP dispensation X  X     
SAR236553 IP administration X X X X    
SAR236553 IP X X X X    Compliance 
check Atorvastatin IP X X X X X   
Check on diet (NCEP-ATPIII TLC diet or equivalent) X X X X X X X 
Concomitant Medication X X X X X X X 
Vital signs: 
Heart Rate, blood pressure X X X X X  X 
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 Study phase 
Evaluation Double-blind treatment  Post-treatment follow-up 
WEEK W0 W2 W4 W6 W85) W12 W16 
DAY 1 15±3 29±3 43±3 57±3 85±7 113±7 
VISIT NUMBER V2 V3 V4 V5 V6 V7 V8 
Safety: 
AE /SAE recording 1) X X X X X X X 
12-lead ECG 2)   X  X   
Laboratory Testing / Efficacy: 
Lipids: Total cholesterol, LDL-cholesterol, HDL-
cholesterol, Triglycerides, non-HDL-C X X X X X X X 
Lipids: ApoB, ApoA-1, ratio ApoB/ApoA-1, and Lp (a) X  X  X   
hs-CRP, library samples X  X  X   
Laboratory Testing / Safety: 
Fasting plasma glucose X    X   
HbA1c     X   
Standard hematology, serum chemistry3) X  X  X X6) X6) 
Liver tests4), CPK X  X  X X6) X6) 
Urine pregnancy test (for women of childbearing 
potential) X  X  X X X 
Anti-SAR236553 antibodies8) X  X  X X X7) 
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 Study phase 
Evaluation Double-blind treatment  Post-treatment follow-up 
WEEK W0 W2 W4 W6 W85) W12 W16 
DAY 1 15±3 29±3 43±3 57±3 85±7 113±7 
VISIT NUMBER V2 V3 V4 V5 V6 V7 V8 
PK and Genotyping: 
PK of SAR2365538) X X X X X X X 
DNA (for specifically consented patients only) X       
1) Adverse event (AE) collection from the time of informed consent signature. 
2) Using a centralized automatic and manual reading of all ECGs. 
3) Hematology includes: complete blood count (CBC) including hematocrit, hemoglobin, red blood cell count, white blood cell count with differential count and platelets. Serum chemistry includes: sodium, 
potassium, chloride, bicarbonate, calcium, phosphorous, urea nitrogen, creatinine, uric acid, total protein, and albumin. 
4) Liver tests: ALT, AST, alkaline phosphatase (ALP), and γGT and total bilirubin. 
5) In case of premature discontinuation of study treatment, all assessments planned in Week 8 (V5, final on-treatment assessment) should be performed before premature treatment discontinuation. 
6) Only in case of persistent clinically relevant abnormal values for these parameters at the end of study treatment. 
7) Only in case of persistent and not decreased anti-SAR236653 antibody levels at Week 16 (V7) patients will be asked for one additional antibody sample 6 to 12 months after last dosing. 
8) PK and antibody samples to be collected prior IP administration. 
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3 LIST OF ABBREVIATIONS 
AE  Adverse event 
AEPM  Adverse events with pre-specified monitoring 
ALP  Alkaline phosphatase 
ALT  Alanine aminotransferase 
ANCOVA Analysis of covariance 
Apo  Apolipoprotein 
ARF   Acute renal failure 
AST  Aspartate aminotransferase 
BMI  Body mass index 
CABG  Coronary artery bypass graft surgery  
CBC  Complete blood count 
CHD  Coronary Heart Disease 
CI  Confidence interval 
CIB  Clinical Investigator's brochure 
CPK  Creatine Phosphokinase 
CRO  Contract Research Organization 
CSR  Clinical Study Report 
DBP  Diastolic blood pressure 
DMC  Data Monitoring Committee 
DNA  Deoxyribonucleic acid 
DRF  Discrepancy resolution form 
DSM/IV Diagnostic and Statistical Manual-IV 
ECG  Electrocardiogram 
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e.g.  Exempli gratia = for example 
e-CRF  Electronic case report form 
EDTA  Ethylene diamine tetra-acetic acid 
E2W  Every two weeks 
E4W  Every four weeks 
ELISA  Enzyme linked immuno-sorbent assay 
FIH  First-in-human 
FU  Follow-up 
GCP  Good Clinical Practice 
γ-GT  Gamma-glutamyl Transferase 
HbA1c   Glycated haemoglobin A1c 
HDL-C High density lipoprotein cholesterol 
HLGT  High level group term 
HLT  High level term 
HR  Heart rate 
hs-CRP High-sensitivity C-reactive protein  
ICF  Informed consent form 
ICH  International Conference on Harmonization 
i.e.  Id est = that is 
IEC  Independent ethics committee 
INN  International Nonproprietary Name 
IP  Investigational Product 
IRB  Institutional review board 
ITT  Intent-to-treat 
IVRS  Interactive Voice Response System 
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IWRS  Interactive Web Response System 
Kg  Kilogram 
LDL-C Low density lipoprotein cholesterol 
LDLR  Low-density lipoprotein receptor 
LLN  Lower limit of normal range 
LLT  Lowest level term 
LOCF  Last-observation-carried-forward 
Lp(a)  Lipoprotein a 
MedDRA Medical Dictionary for Regulatory Activities 
µg  Microgram 
mITT  Modified intent-to-treat 
mmHg  Millimeter of mercury 
NCEPATPIII National Cholesterol Education Program Adult Treatment Panel III  
TLC  Therapeutic lifestyles changes  
NIP  Non Investigational Product 
PCI  Percutaneous coronary intervention 
PCSA  Potentially Clinically Significant Abnormality 
PCSK9 Proprotein convertase subtilisin/kexin type 9 
PD  Pharmacodynamics 
PDM  Project Demand Manager 
PK  Pharmacokinetics 
PT  Preferred term 
PTC  Product technical complaint 
SAE  Serious Adverse Event 
SAP  Statistical analysis plan 
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SBP  Systolic blood pressure 
SC  Subcutaneous 
SD  Standard deviation 
SOC  System-organ-class 
SUSAR Suspected Unexpected Serious Adverse Reaction 
TC  Total cholesterol 
TEAE  Treatment Emergent Adverse Event 
TG  Triglycerides 
TIA  Transient ischemic attack 
TSH  Thyroid stimulating hormone 
ULN  Upper limit of normal range 
WBC  White blood cell 
WHO-DD World Health Organization-Drug Dictionary 
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4 INTRODUCTION AND RATIONALE 
SAR236553 is also referred to as REGN727. However, in the context of the DFI11566 study 
protocol, it will be referred to as SAR236553. 
Hypercholesterolemia, particularly an increase in low-density lipoprotein cholesterol (LDL-C) 
levels, constitutes a major risk for the development of atherosclerosis and coronary heart disease 
(CHD) (1) the leading cause of death and disability in the Western world (2). LDL-C is identified 
as the primary target of cholesterol lowering therapy (3) and is accepted as a valid surrogate 
endpoint (4) (5). Numerous studies have demonstrated a strong direct relationship between 
LDL-C level and CHD events; for each 1% reduction of LDL-C, the risk of CHD is lowered by 
2% (6) (7). Greater reductions in LDL-C produce greater reduction in events (8), and recent data 
suggest that the lower the LDL-C level, the greater the benefit (9). Results from primary and 
secondary cardiovascular prevention trials with lipid lowering therapies, in particular with statins, 
have shown that lowering cholesterol levels is associated with a reduced risk of coronary related 
events, resulting in reduced cardiovascular morbidity and mortality (10) (11).  
Statins are the most commonly prescribed lipid lowering agents as they have shown a great ability 
to lower LDL-C. Recent studies have reported that high dose of statin results in an additional 
benefit compared with a moderate lipid lowering therapy (12) (13) (14). However there are 
limitations in some patients where adequate LDL-C lowering is not achieved with statins, even at 
maximal or tolerated doses (15). Therefore the addition of a second agent with a complementary 
mechanism of action to the high statin dose may facilitate the achievement of the therapeutic 
objectives. Beside this observation, it is also known that in some patients, the use of statins is 
limited by the occurrence of adverse events, mainly muscle aches, with an increased incidence of 
these adverse events associated with the increase of the dosage of statin. For these patients, adding 
another lipid lowering treatment would be an alternative to increasing the statin dose with a 
similar efficacy. 
Proprotein convertase subtilisin kexin type 9 (PCSK9) belongs to the subtilisin family of serine 
proteases and is highly expressed in the liver. PCSK9 is involved in regulating the levels of the 
low-density lipoprotein receptor (LDLR) protein (16) (17). Once PCSK9 is secreted into plasma it 
directly binds to the LDLR and promotes the degradation of the LDLRs. The increased 
degradation of LDLRs leads to a reduced LDL-C removal and, therefore higher LDL-C 
circulating levels. Experiments with mice have shown that increasing PCSK9 protein levels 
decreases levels of LDLR protein in the liver (18) (19), while PCSK9 knockout mice have 
increased levels of LDLR in the liver (20). In humans, PCSK9 mutations have been identified: the 
gain-of-function mutations are rare and cause an autosomal dominant form of severe 
hypercholesterolemia and premature CHD (21), whereas loss-of-function mutations are more 
common and are associated with reduced plasma levels of LDL-C and protection from CHD (22). 
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Therefore blocking PCSK9 binding to the LDL-R can potentially benefit patients suffering from 
hypercholesterolemia by decreasing their plasma LDL-C levels. In addition, PCSK9 messenger 
ribonucleic acid (mRNA) and protein levels are increased in response to statins, potentially 
attenuating their cholesterol-lowering effect, and it can be expected that an anti-PCSK9 treatment 
will function synergistically with statins to enhance LDLR regulation (23). 
SAR236553 is a fully human monoclonal antibody that binds (PCSK9). All information 
concerning the compound is available in the Clinical Investigator’s Brochure (CIB) (24). 
Direct evidence that the inhibition of PCSK9 by SAR236553 reduces LDL-C in animals was 
demonstrated in an experiment in which 3 cynomolgus monkeys were treated with either a single 
intravenous (IV) dose of 5 mg/kg or 15 mg/kg SAR236553, or with placebo. Reductions between 
56% and 72% from baseline LDL-C levels were observed by Day-3 and lasted longer than 
30 days. Following the fifth administration of SAR236553 in the 5-week subcutaneous (SC) 
monkey study LDL-C was decreased ~34-86% across all dose groups in males and females. 
Three Phase 1 studies have been set up with SAR236553. One study has been recently completed 
and the two other studies are still ongoing:  
• The R727-CL-0902 study, the first-in-human (FIH) study investigated the safety and 
tolerability of a single ascending dose of IV SAR236553 in healthy volunteers who were 
not indicated for statin therapy.  A total of 40 subjects were enrolled at 1 study site.  
Subjects in each dose cohort (0.3, 1.0, 3.0, 6.0, or 12 mg/kg) were randomized to receive a 
single dose of SAR236553 (n=6) or placebo (n=2). The total observation period was 
15 weeks (up to day 106). This study is completed; all doses were well-tolerated.  
Preliminary study results are available in the Investigator’s Brochure. 
• The R727-CL-0904 study is investigating the safety and tolerability of a single ascending 
dose of subcutaneous (SC) SAR236553 in healthy volunteers who are not indicated for 
statin therapy. A total of 32 subjects were enrolled at 2 study sites.  Subjects in each dose 
cohort (50, 100, 150, or 250 mg) were randomized to receive a single dose of SAR236553 
(n=6) or placebo (n=2). The total observation period is 15 weeks (up to Day 106). In this 
ongoing study the enrollment is complete. As of October 2010, all doses have been 
well-tolerated. 
• The R727-CL-1001 Phase 1 multiple-dose study is investigating the safety of SC 
SAR236553 in hyperlipidemic patients (familial and non-familial) receiving stable doses 
of atorvastatin, or hyperlipidemic patients (non-familial) who are not taking a concomitant 
statin. This study is currently enrolling. As of October 2010, all doses have been 
well-tolerated. 
The present study is to evaluate the efficacy and safety of the co-administration of SAR236553 
and a high dose of atorvastatin (80 mg) in comparison to placebo and a high dose of atorvastatin 
in patients with primary hypercholesterolemia, a situation that may arise when a rapid decrease in 
LDL-C levels is needed, e.g. after an acute coronary syndrome (25). Its main objective will be to 
assess the effects of SAR236553 on LDL-C level reduction. This study will also allow evaluating 
the efficacy and safety of SAR236553 when co-administered with 2 different doses of 
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atorvastatin. The dose of SAR236553 as well as the dose regimen tested in this study (150 mg 
every 2 weeks) is one of the dose/dose regimen administered to healthy subjects that have 
demonstrated safety and biological activity in the Phase 1 studies. 
The duration of treatment will be 8 weeks that is considered sufficient to demonstrate the efficacy 
of SAR236553 in terms of LDL-C reduction. This treatment duration should also provide a 
sufficient duration of “exposure” to appreciate tolerability and safety profiles of the compound. 
Based on preliminary PK and PD data of studies R727-CL-0902, R727-CL-0904 and 
R727-CL-1001, serum concentrations of SAR236553 > 10 µg/mL are expected for approximately 
35 days (5 weeks) following the highest administered subcutaneous dose (i.e., 300 mg) and 
approximately 21 days (3 weeks) following administration of 150 mg dose. Having reached a 
serum concentration of approximately 10 µg/mL, SAR236553 is then eliminated with a terminal 
elimination half-life of approximately 7 days. To ensure sufficient low, non-effective SAR236553 
serum concentrations it is recommended to continue the study for an additional five half-lives 
(5x7=35 days), therefore according to a conservative approach using PK data of the 300 mg dose 
a follow-up period of at least 10 weeks after last dosing (i.e.,35 days + (5x7=35days) = 70 days = 
10 weeks) is required. Given these assumptions, the last follow-up visit will be performed at 
Week 16 which is 10 weeks after the last SAR236553 dose. 
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5 STUDY OBJECTIVES 
5.1 PRIMARY 
To evaluate the effect of SAR236553 on low-density lipoprotein cholesterol (LDL-C) levels 
compared with placebo when co-administered with 80 mg of atorvastatin after 8 weeks of 
treatment in patients with LDL-C ≥ 100mg/dL (≥ 2.59 mmol/L) on atorvastatin 10 mg. 
5.2 SECONDARY 
The secondary objectives are: 
• To evaluate the effects of SAR236553 on other lipid levels in comparison with placebo, 
when co-administered with 80 mg of atorvastatin after 8 weeks of treatment.  
• To evaluate the efficacy of SAR236553 when co-administered with a high dose of 
atorvastatin (80 mg) versus atorvastatin 10 mg. 
• To evaluate the safety and tolerability of SAR236553 when co-administered with 
2 different doses of atorvastatin. 
• To evaluate the development of anti-SAR236553 antibodies. 
• To evaluate the pharmacokinetics of SAR236553. 
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6 STUDY DESIGN 
This will be a multicenter, randomized, double-blind, parallel-group, placebo-controlled, 8-week 
study conducted in the United States to assess the efficacy and safety of SAR236553 in patients 
with an elevated LDL-C (≥ 100 mg/dL or 2.59 mmol/L) treated with a stable dose of atorvastatin 
10 mg. During the screening/run-in period, patients will be stabilized to atorvastatin 10 mg for at 
least 6 weeks, if they are not already. During the double-blind treatment period, patients will 
return to the site every 2 weeks to receive study treatment: SAR236553 150 mg or SAR236553 
placebo, as well as atorvastatin 80 mg, or atorvastatin 10 mg. The double-blind treatment period 
will be then followed by an 8-week follow-up period. 
6.1 DESCRIPTION OF THE PROTOCOL 
The study comprises three periods. 
• A screening period with 2 options depending on the status of the patient at screening: 
a) Option 1: for patients receiving atorvastatin 10 mg at stable dose for at least 6 weeks prior to 
screening, the screening period will be of 1 week. This screening period will start by a 
screening visit (Week -1, V1), during which patients will be evaluated for eligibility to enter 
the double-blind treatment period. 
b) Option 2 : for patients receiving a lipid lowering treatment other than atorvastatin/ or not at 
stable dose of atorvastatin 10 mg for at least 6 weeks prior to screening, or for drug naive 
patients. This screening period includes a run-in period on atorvastatin 10 mg with: 
- a pre-screening visit (Week -7, V1a) during which pre-eligibility assessments will be 
performed to permit the entry of patients into the run-in period. If applicable, at this 
pre-screening visit (Week -7, V1a) patients will be asked to stop any lipid lowering 
treatment previously received. Then after 6 weeks of run-in period, a screening visit 
(Week -1, V1) will be held during which the full eligibility assessment will be 
performed. 
• A randomized, double-blind, placebo-controlled, parallel-group treatment period of 
8 weeks where patients will be randomized as follows: 
- Either to the group of SAR236553 150 mg  + high dose of atorvastatin (80 mg). 
- Or to the group of SAR236553 placebo + high dose of atorvastatin (80 mg). 
- Or to the group of SAR236553 150 mg + maintenance of atorvastatin dose previously 
received (10 mg). 
• A follow-up period of 8 weeks during which patients will return for follow-up visits 4 and 
8 weeks after the end of study treatment period (Week 8). 
All patients will be instructed to be on a stable diet (NCEP-ATPIII TLC diet or equivalent) 
throughout the entire study duration from screening.  
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6.1.1 Screening period/run-in period 
• Patients who are on a stable dose of atorvastatin 10 mg will enter a screening period as 
follows: 
- Duration: 1 week. 
- From screening visit (Week-1, V1) to the baseline visit (Week 0, V2; 
randomization).  
- Visit planned on Week-1 (V1). 
- Patients will take atorvastatin 10 mg in an open label manner until Week 0 (V2, 
baseline visit). 
During this screening visit (Week-1), the full eligibility assessments will be performed to permit 
the randomization of the patients in the study. 
• Patients who are receiving a lipid lowering treatment other than atorvastatin/ or not at 
stable dose of atorvastatin 10 mg for at least 6 weeks prior to screening, or drug naive 
patients will enter into a screening/run-in period. The screening period will start by a 
pre-screening Visit (Week-7, V1a) immediately followed by a run-in period of 6 weeks: 
- Duration: 7 weeks. 
- From pre-screening visit (Week-7, V1a) to the baseline visit (Week 0, V2, 
randomization). 
- Patients will take atorvastatin 10 mg in an open label manner. 
- Visits planned on Week-7 (V1a) and Week-1 (V1). 
At the pre-screening visit Week-7 (V1a), pre-eligibility assessments will be performed before 
starting the run-in period. Then the screening visit will be performed at Week-1 (V1), where the 
full eligibility assessments will be performed to permit the randomization of the patients in the 
study. 
Dose of atorvastatin (10 mg) should be stable during the screening period. Also during this period 
patients should be on a stable diet (NCEP-ATPIII TLC diet or equivalent). 
6.1.2 Double-blind treatment period 
• Randomized, double-blind, placebo-controlled treatment period, using a 1:1:1 
randomization ratio. Patients can be randomized only once. 
• Duration: 8 weeks. 
• From baseline Visit (Week 0, V2, Day1) to the end of the double-blind treatment period 
(Week 8, V6). 
• Visits planned on Week 0 (V2), Week 2 (V3), Week 4 (V4), Week 6 (V5) and Week 8 
(V6). 
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Patients meeting all inclusion/exclusion criteria assessed at visit(s) performed during the 
screening period (Week -7 and Week -1) may undergo baseline assessments (Week 0, V2). After 
the baseline assessments patients will be randomized on Day 1 into one of the 3 treatment groups: 
SAR236553 150 mg E2W + high atorvastatin dose (80 mg), or SAR236553 placebo E2W + high 
atorvastatin dose (80 mg), or SAR236553 150 mg E2W + atorvastatin 10 mg. Atorvastatin will 
also be administered in a blinded manner. 
Patients should start both study treatments (SAR236553, atorvastatin) on the day of 
randomization, i.e. at baseline visit (Week 0, V2, Day 1).  
During the double-blind treatment period all patients will attend a visit every 2 weeks. They will 
receive the SAR236553 study treatment through SC injection at Week 0 (V2), Week 2 (V3), 
Week 4 (V4), and Week 6 (V5). The atorvastatin study treatment will be dispensed at Week 0 
(V2), and Week 4 (V4) with the instruction to take it orally once daily in the evening, with dinner.  
Diet (NCEP-ATPIII TLC diet or equivalent) should be stable throughout this period.  
For all visits after baseline a timeframe will be allowed using Week 0 (Day 1) as reference (if one 
visit date is changed, the next visit should take place according to the original schedule (see 
Section 1.2– Study Flowchart). 
6.1.3 Follow-up period 
• Duration: 8 weeks. 
• From last visit of the double-blind treatment period (Week 8, V6) to the end of the 
follow-up period (Week 16, V8). 
• Visits planned on Week 12 (V7) and Week 16 (V8). 
6.2 DURATION OF STUDY PARTICIPATION 
6.2.1 Duration of study participation for each patient 
The duration of study participation will depend on the status of the patient at screening: 
• For patients receiving atorvastatin 10 mg at stable dose for at least 6 weeks prior to 
screening, the study participation will be approximately 17 weeks including a screening 
period of 1 week, a double-blind treatment period of 8 weeks and a follow-up period of 
8 weeks. 
• For patients receiving a lipid lowering treatment other than atorvastatin/ or not at stable 
dose of atorvastatin 10 mg for at least 6 weeks prior to screening, or drug naive patients 
the study participation will be approximately 23 weeks with a screening period of 7 weeks 
(including a run-in period of 6 weeks), a double-blind treatment period of 8 weeks and a 
follow-up period of 8 weeks. 
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6.2.2 Determination of end of clinical trial (all patients) 
The end of the study is defined as being the last visit of the follow-up period for each patient 
6.3 INTERIM ANALYSIS 
Not applicable. 
6.4 STUDY COMMITTEES 
6.4.1 Data Monitoring Committee 
A Data Monitoring Committee (DMC), composed of members independent from the Sponsor and 
the study investigators, is implemented in order to monitor patient safety by conducting formal 
reviews of accumulated safety data that will be blinded by treatment group; if requested, the DMC 
may have access to the treatment allocation code or any other requested data for the purposes of a 
risk-benefit assessment. The DMC will provide the Sponsor with appropriate recommendations on 
the conduct of the clinical trial to ensure the protection and the safety of the enrolled patients in 
the study. In addition, the DMC will also institute any measures that may be required for ensuring 
the integrity of the study results during the study execution.  
All activities and responsibilities of the DMC will be described in the DMC charter. 
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7 SELECTION OF PATIENTS 
7.1 NUMBER OF PATIENTS PLANNED 
Approximately 90 patients will be randomized in a 1:1:1 randomization ratio to the following 
groups: 
• SAR236553 150 mg every 2 weeks + high dose of atorvastatin (80 mg): approximately 
30 patients. 
• Placebo for SAR236553 + high dose of atorvastatin (80 mg): approximately 30 patients. 
• SAR236553 150 mg every 2 weeks + atorvastatin 10 mg: approximately 30 patients. 
7.2  INCLUSION CRITERIA 
I 01. Patients (patients receiving a lipid lowering treatment other than atorvastatin/ or not at 
stable dose of atorvastatin 10 mg for at least 6 weeks prior to screening period, or drug 
naive patients) with primary hypercholesterolemia likely to have LDL-C ≥ 100 mg/dL 
(≥ 2.59 mmol/L) at the end of the run-in period on atorvastatin therapy (Week -1). 
OR 
Patients with primary hypercholesterolemia treated with stable dose of atorvastatin 10 mg 
for at least 6 weeks prior to screening period and likely to have LDL-C ≥ 100 mg/dL 
(≥ 2.59 mmol/L) at the screening visit (Week -1). 
I 02. Signed written informed consent. 
7.3 EXCLUSION CRITERIA 
Patients who have met all the above inclusion criteria listed in Section 7.2 will be screened for the 
following exclusion criteria which are sorted and numbered in the following three sub-sections: 
7.3.1 Exclusion criteria related to study methodology 
E 01. LDL-C < 100 mg/dL (< 2.59 mmol/L) at Week -1 (V1): 
• After the run-in period on atorvastatin 10 mg for patients receiving a lipid lowering 
treatment other than atorvastatin/ or not at stable dose of atorvastatin 10 mg for at least 
6 weeks prior to the screening period, or drug naive patients.  
OR  
• At the first visit for patients who are being treated with atorvastatin 10 mg at stable dose 
for at least 6 weeks prior to screening visit Week -1. 
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E 02. Patients aged < 18 or > 75 years at Week -7 or Week -1.  
E 03. Body mass index (BMI) < 18 or > 40 kg/m² at Week -7 or Week -1. 
E 04. Patients not previously instructed on a cholesterol-lowering diet. 
E 05. Use of a statin other than atorvastatin 10 mg, or use of other lipid lowering drugs including 
but not limited to fibrates, bile acid resins, niacin > 500 mg, intestinal cholesterol 
absorption (ICA) blockers, or omega-3 fatty acids at doses > 1000 mg during the screening 
period. 
E 06. Use of nutraceutical products that may affect lipids (e.g., omega-3 fatty acids at doses 
< 1000 mg, red yeast rice, plant stanols such as found in Benecol, flax seed oil, psyllium) not 
on stable dose for at least 6 weeks prior to screening period and/or during the screening 
period and/or not intended to be used at stable dose throughout the study.  
E 07. Patients with type 1 diabetes. 
E 08. Patients with type 2 diabetes treated with insulin. 
E 09. Patients with type 2 diabetes and with an HbA1c ≥ 8.5% at Week -7 or Week -1 
(considered poorly controlled). 
E 10. Presence of any clinically significant endocrine disease known to influence serum lipids or 
lipoproteins.  
Note: Patients on thyroid replacement therapy can be included if the dosage of thyroxine 
has been stable for at least 12 weeks prior to screening and their s-Thyroid Stimulating 
Hormone (s-TSH) level is within ±10% of the normal range of the Central Laboratory. 
E 11. Patients with uncontrolled blood pressure (> 150/95 mmHg) at Week -7, or Week -1, or 
Week 0. 
E 12. History of myocardial infarction, coronary artery bypass graft surgery (CABG), 
percutaneous coronary intervention (PCI), unstable angina pectoris, carotid surgery or 
stenting, cerebrovascular accident, or transient ischemic attack (TIA) within 6 months prior 
to the screening period. 
E 13. History of heart failure (NYHA Class II-IV) within 12 months prior to the screening 
period. 
E 14. History of ileal bypass, gastric bypass or other bariatric surgery within 12 months prior to 
screening, or if surgery took place more than 12 months prior to the screening period, 
unstable weight (variation > 5 kg) within 2 months prior to the screening period. 
E 15. Presence or history of cancer within the past 5 years with the exception of adequately 
treated localized basal skin cancer. 
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E 16. Patients with a history (during the past 6 months) or concurrent DSM-IV substance abuse 
or dependence (excluding nicotine and caffeine). 
E 17. Conditions/situations such as: 
• Any clinically significant abnormality identified at the time of screening that in the 
judgment of the Investigator or any sub-Investigator would preclude safe completion of 
the study or constrain endpoints assessment such as major systemic diseases, patients with 
short life expectancy. 
• Patients considered by the Investigator or any sub-Investigator as inappropriate for this 
study for any reason, e.g.: 
- Those deemed unable to meet specific protocol requirements, such as scheduled visits. 
- Those with likelihood of requiring treatment during the screening phase and treatment 
phase with drugs not permitted by the clinical study protocol. 
- Investigator or any sub-Investigator, pharmacist, study coordinator, other study staff or 
relative thereof directly involved in the conduct of the protocol, etc. 
- Presence of any other conditions (e.g. geographic, social….) actual or anticipated, that 
the Investigator feels would restrict or limit the patient’s participation for the duration 
of the study. 
E 18. Patient who has previously participated in any clinical trial of SAR236553. 
E 19. Patient who has taken other investigational drugs within 1 month or 5 half lives, whichever 
is longer. 
E 20. Patient who withdraws consent during the screening period (patient who is not willing to 
continue or fails to return). 
E 21. Laboratory findings measured before randomization:  
• Positive test for hepatitis B surface antigen and/or hepatitis C antibody. 
• Triglycerides (TG) > 350 mg/dL (> 3.95 mmol/L) at Week -7 or Week -1. 
• Neutrophils < 1,500/mm3 and/or platelets < 100,000/mm3. 
• Positive serum or urine pregnancy test in females of childbearing potential.  
• Abnormal sensitive TSH level (> ULN or < LLN) according to the normal values of the 
Central Laboratory (for patients on thyroid replacement therapy, refer to exclusion 
criterion E 10). 
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• Evidence of renal impairment as determined by: 
- Men: serum creatinine > 1.5 x ULN. 
- Women: serum creatinine > 1.4 x ULN. 
• ALT or AST > 2xULN (1 repeat lab is allowed). 
• CPK > 3xULN (1 repeat lab is allowed). 
7.3.2 Exclusion criteria related to the active comparator and/or mandatory background 
therapies  
E 22. All contraindications to the protocol mandated background therapy (i.e., atorvastatin) or 
warning/precaution of use (when appropriate) as displayed in the respective National 
Product Labeling that was used for defining these exclusion criteria. 
7.3.3 Exclusion criteria related to the current knowledge of sanofi-aventis compound  
E 23. Known sensitivity to monoclonal antibody therapeutics. 
E 24. Pregnant or breast-feeding women. 
E 25. Women of childbearing potential with no effective contraceptive method. 
Women of childbearing potential must have a confirmed negative urine pregnancy test at 
screening and baseline Visits. They must use an effective contraceptive method throughout 
the study, and agree to repeat urine pregnancy test at designated visits. The applied 
methods of contraception have to meet the criteria for a highly effective method of birth 
control according to the “Note for guidance on non-clinical safety studies for the conduct 
of human clinical trials for pharmaceuticals (CPMP/ICH/286/95)” (26). Postmenopausal 
women must be amenorrheic for at least 12 months. 
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8 STUDY TREATMENTS 
8.1 INVESTIGATIONAL PRODUCTS 
8.1.1 SAR236553 
Sterile SAR236553 drug product will be supplied at a concentration of 150 mg/mL in 10 mM 
histidine, pH 6.0, 0.2% (w/v) polysorbate 20, and 10% (w/v) sucrose. Drug product will be 
supplied as a liquid with a 1.2 mL maximum withdrawable content in a nominal 5 mL glass vial. 
Details on storage and dose preparation will be provided in the pharmacy manual. 
Placebo for SAR236553 will be prepared in the same formulation as SAR236553 without the 
addition of protein. 
8.1.1.1 Dose administration and schedule 
Prior to SC administration, the pharmacist or designee will withdraw the required amount of study 
drug into a syringe. The procedure for preparing SAR236553 dosing solution and the volume to 
load into the syringe are provided in the pharmacy manual. The syringes and needles to be used 
for the dose and administration will be described in the pharmacy manual and will be supplied to 
the investigator site. 
Study treatment (SAR236553) will be administered in 1 SC injection of 1 mL every 2 weeks on 
Week 0 (V2), Week 2 (V3), Week 4 (V4), and Week 6 (V5). SC injections will be performed 
while maintaining the treatment blind by “unmasked” specified personnel who are otherwise 
removed from study conduct or outcome assessment. 
All SAR236553 Investigational Product (IP) injections will be administered in the abdomen; 
administration to the extremities is not allowed as this may lead to different bioavailability 
absorption.  
8.1.2 Atorvastatin 
During the double-blind treatment period:  
Atorvastatin will consist of 10 mg, or 40 mg tablets that will be supplied in over-encapsulated 
tablets. 
Matching placebo capsules will be supplied. 
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8.1.2.1 Dose administration and schedule 
During the double-blind treatment period:  
• Atorvastatin 10 mg: over-encapsulated tablet of 10 mg. 
• Atorvastatin 40 mg: over-encapsulated tablet of 40 mg. 
• Atorvastatin matching placebo capsule.   
Two capsules of atorvastatin IP will be administered once daily in the evening with the dinner, as 
described in the table below:  
 
 10 mg group 80 mg group 
Atorvastatin 10 mg 1 0 
Atorvastatin 40 mg 0 2 
Placebo 1 0 
 
8.2 NON INVESTIGATIONAL PRODUCTS 
During the run-in period: 
Tablets of atorvastatin 10 mg will be given in an open-label manner. All patients should be treated 
with atorvastatin 10 mg, once daily in the evening with the dinner. 
Atorvastatin dose will be recorded throughout the run-in period on the electronic Case Report 
Form (e-CRF) 
Atorvastatin 10 mg will be supplied to the patients throughout the entire duration of the run-in 
period. 
8.3 DESCRIPTION OF BLINDING METHODS 
8.3.1 Description of blinding methods for SAR236553 
SAR236553 and placebo for SAR236553 will be provided in identically matched glass 5  mL 
vials. Each vial contains 1.8 mL of SAR236553 or placebo for SAR236553 solution with 1.2 mL 
maximum permitted withdrawal volume. 
Each treatment kit will be labelled with a number, which will be generated by a computer 
program from sanofi-aventis. The treatment kit numbers will be obtained by the investigator at the 
time of patient randomization and subsequent patient scheduled visits via IVRS/IWRS that will be 
available 24 hours a day. 
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In accordance with the double-blind design, study patients, investigators and study site personnel 
(except the pharmacist and the third-party “unmasked” injector) will remain blinded to study 
treatment and will not have access to the randomization (treatment codes) except under 
circumstances described in Section 8.7. 
SC injections will be performed by “unmasked” specified personnel who are otherwise removed 
from study conduct or outcome assessment . In addition, the administration of the IP will be 
obstructed to patients who will be in supine position and to other viewers other than the 
“unmasked” specified personnel. 
8.3.2 Description of blinding methods for atorvastatin 
Capsules of atorvastatin will consist of 10 mg or 40 mg atorvastatin tablets over-encapsulated. 
Patients randomized to receive 80 mg atorvastatin dosing will receive 2 capsules containing each 
a 40 mg atorvastatin tablet. Patients randomized to receive 10 mg atorvastatin dosing will receive 
1 capsule containing a 10 mg atorvastatin tablet and 1 capsule of placebo for atorvastatin. 
Capsules of atorvastatin and matching placebo will be identical. A double-blind design will be 
used for packaging (see Section 8.5). All atorvastatin treatments will be packaged in child-
resistant identical wallet-cards. 
Each treatment kit will be labelled with a number, which will be generated by a computer 
program from sanofi-aventis. The treatment kit numbers will be obtained by the investigator at the 
time of patient randomization and subsequent patient scheduled visits via IVRS/IWRS that will be 
available 24 hours a day. 
In accordance with the double-blind design, study patients, investigators and study site personnel 
will remain blinded to study treatment and will not have access to the randomization (treatment 
codes) except under circumstances described in Section 8.7. 
8.4 METHOD OF ASSIGNING PATIENTS TO TREATMENT GROUP 
Two randomized treatment number lists (one list for SAR236553 and one list for atorvastatin) will 
be generated centrally by sanofi-aventis. The SAR236553 Investigational Product (IP) 
(SAR236553 150mg, or placebo) will be packaged in accordance with SAR236553 list. The 
treatment kits for the atorvastatin IP (atorvastatin 80 mg, or atorvastatin 10 mg) will be prepared 
in accordance with atorvastatin list, containing different numbers than the SAR236553 list. 
The Project Demand manager (PDM) will provide the randomized treatment kit number lists and 
the Study Biostatistician will provide two randomization schemes to the centralized treatment 
allocation system. Then, this centralized treatment allocation system will generate the patient two 
randomization lists according to which it will allocate the treatments to the patients. 
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During the double-blind treatment period, patients will be randomized to receive either 
SAR236553 150 mg, or placebo for SAR236553, both in combination with atorvastatin 80 mg, or 
to SAR236553 150 mg in combination with atorvastatin 10 mg. The randomization ratio will be 
1:1:1. 
For each randomized patient, there will be 2 treatment kit numbers corresponding to SAR236553 
IP (SAR236553 150 mg, or placebo) and atorvastatin IP (atorvastatin 80 mg, or atorvastatin 
10 mg), respectively, which will be allocated through the centralized treatment allocation system. 
Throughout the double-blind treatment period, several corresponding treatment kit numbers for 
SAR236553 IP and atorvastatin IP will be allocated. 
The treatment kit numbers for SAR236553 IP will be allocated using the centralized treatment 
allocation system on baseline visit (V2, Week 0 or Day 1), and then at V3 (Week 2), V4 (Week 4), 
and V5 (Week 6). The treatment kit numbers for atorvastatin IP will be allocated using the 
centralized treatment allocation system on baseline visit (V2, Week 0 or Day 1), and then at V4 
(Week 4). Before randomizing a patient, the Investigator or designee will have to contact the 
centralized treatment allocation system and to provide some information (such as patient number 
provided by the site using the laboratory requisition form at pre-screening/screening visit, date of 
birth, etc.). 
A randomized patient is defined as a patient who is registered and assigned with a treatment kit 
number from the centralized treatment allocation system, as documented from its log file. A 
patient cannot be randomized more than once in the study. 
Two types of centralized treatment allocation system will be used, the Interactive Voice Response 
System (IVRS) and the Interactive Web Response System (IWRS) depending on the choice of the 
site. 
8.5 PACKAGING AND LABELING 
8.5.1 Packaging and labeling for SAR236553 
Each treatment kit will be prepared to contain 1 vial in accordance to its respective dosage 
SAR236553 150 mg or placebo. 
The vial within a treatment kit box will be labeled with double-blind label. In order to protect the 
blind, all treatment kit boxes will have the same look and feel and therefore will be labeled with a 
double blind label and secured with tamper-evident seals.  
The content of the labeling is in accordance with the local regulatory specifications and 
requirements. 
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8.5.2 Packaging and labeling for atorvastatin 
Two treatment kits for 8 weeks of treatment will be available for each patient. 
Each treatment kit will contain 5 weekly wallets (8 days in each) of 80 capsules and depending on 
the allocated group will be composed as follows:  
• Atorvastatin 80 mg daily dose: 2 atorvastatin 40 mg capsules. 
• Atorvastatin 10 mg daily dose: 1 atorvastatin 10 mg capsule and 1 placebo capsule. 
The content of the labeling will be in accordance with the local regulatory specifications and 
requirements. 
8.6 STORAGE CONDITIONS AND SHELF LIFE 
All Investigational Products (IPs) should be stored in an appropriate locked room under the 
responsibility of the Investigator or other authorized persons (e.g. pharmacists) in accordance with 
labeling specifications, local regulations, policies ad procedures. 
Prior to the first use, the SAR236553 (or placebo) kits will be stored in a refrigerator between 
+2ºC and +8ºC (36ºF - 46º F). The temperature of the refrigerator should be checked daily and 
recorded on a log sheet.   
The atorvastatin kits will be stored at a temperature between +2º C and +25 º C (36ºF -77 º F). 
8.7 RANDOMIZATION CODE BREAKING DURING THE STUDY 
Please refer to Section 9.4 - Measures to protect blinding of this trial. 
In case of an AE, the code must be broken only in exceptional circumstances when knowledge of 
the IP is essential for treating the patient. If possible, a contact should be initiated with the 
Monitoring Team/Medical Monitor before breaking the code. All calls will be documented by the 
Monitoring Team as appropriate to include date and time of the call, name of the person contacted 
within the Monitoring Team, patient ID, documentation of the request, and decision for 
unblinding or not. 
Code breaking can be performed at any time by using the proper module of the IVR/Interactive 
Web Response (IWR) system and/or by calling any other phone number provided by the Sponsor 
for that purpose.  If the blind is broken, the Investigator should document the date, time of day, 
and reason for code breaking, and report this information on the appropriate page of the e-CRF. 
The decision to withdraw the patient from IP administration should be discussed on a case by case 
basis.  
Note that when documenting the reason for unblinding, the Investigator must not provide any 
detail regarding the nature of the Investigational Product. The Investigator should not divulge 
medication detail to the Sponsor’s representative or to any staff members until database closure. 
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Furthermore, when completing forms (e.g., AE, SAE), the study treatment should not be disclosed 
on the forms. In case of SAE, the procedure for unblinding is described in Section 9.4. 
No code-breaking material will be provided to the Investigators. For each patient, code-breaking 
could be performed by the Investigator contacting the IVR/IWR system. However, it is preferable 
to contact the Medical Monitor to discuss the case before unblinding through IVRS.  
The code-breaking material will be also kept at the entity responsible for the "24 hour alert 
system"; but this system should be used in very exceptional cases only (i.e., unavailability of 
IVR/IWR system or inability to contact Investigator and/or site staff). However, the preferred 
option is to unblind using IVRS.The Investigators will be informed by the clinical monitoring 
team about the availability of the local code-breaking material. A patient card, including the 
relevant “24 hour alert system” telephone number will be provided to every patient who will 
participate in the study. 
8.8 RESPONSIBILITIES 
The Investigator, the Hospital Pharmacist, or other personnel allowed to store and dispense 
Investigational Product (SAR236553 IP, atorvastatin IP) will be responsible for ensuring that the 
IPs used in the clinical trial are securely maintained as specified by the Sponsor and in accordance 
with the applicable regulatory requirements. 
All IPs shall be dispensed in accordance with the Clinical Trial Protocol and it is the Pharmacist 
role under the Investigator’s responsibility to ensure that an accurate record of IPs issued and 
returned is maintained. 
Any quality issue noticed with the receipt or use of the IPs (deficiency in condition, appearance, 
pertaining documentation, labeling, expiration date, etc.) should be promptly notified to the 
Sponsor. Some deficiencies may be recorded through a complaint procedure (i.e., Product 
Technical Complaint (PTC) form) 
A potential defect in the quality of IPs may be subject to initiation of a recall procedure by the 
Sponsor. In this case, the Investigator will be responsible for promptly addressing any request 
made by the Sponsor, in order to recall IPs and eliminate potential hazards. 
Under no circumstances will the Investigator supply IPs to a third party, allows the IPs to be used 
other than as directed by this Clinical Trial Protocol, or dispose of IPs in any other manner. 
8.9 CONCOMITANT MEDICATION 
A concomitant medication is any treatment received by the patient concomitantly to any IP(s).  
Treatments in addition to the IPs should be kept to a minimum during the study. However, if these 
are considered necessary for the patient’s welfare and are unlikely to interfere with the IPs, they 
may be given at the discretion of the Investigator, with a stable dose (when possible). 
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8.9.1 Prohibited concomitant therapy 
The following drugs will not be permitted during the study, including the post-treatment 
follow-up period: 
• Statin other than atorvastatin at the doses indicated in the protocol, and other lipid 
lowering drugs including but not limited to fibrates, bile acid resins, niacin > 500 mg, 
intestinal cholesterol absorption (ICA) blockers, or omega-3 fatty acids at doses > 
1000 mg. 
• Thyroid preparations or thyroxin treatment (except in patients on replacement therapy). 
8.9.2 Permitted concomitant therapy 
Any therapy other than the prohibited concomitant therapy described above, will be allowed and 
will have to be recorded in the e-CRF and source data (please refer to Section 12.2). 
Nutraceutical product that may affect lipids (e.g., omega-3 fatty acids at doses < 1000 mg, red 
yeast rice, plant stanols such as found in Benecol, flax seed oil, psyllium) are allowed only if they 
have been used at a stable dose for at least 6 weeks prior to and during the screening period, and if 
they are maintained at a stable dose throughout the study. 
8.10 TREATMENT ACCOUNTABILITY AND COMPLIANCE 
8.10.1 Treatment accountability and compliance for SAR236553 
Measures taken to ensure and document treatment compliance and investigational product 
accountability are described below: 
• Once the pharmacist or designee gets the treatment kit number from the Investigator. The 
pharmacist or designee will then prepare the dose as 1 mL in one syringe and will 
complete the corresponding treatment log form with the treatment kit number.  
• Just after investigational product preparation, the pharmacist or designee will perform 
reconciliation by checking the consistency of the treatment number(s) between 
IVRS/IWRS assignment notification, the kit and treatment log forms and then will place 
the vials back into its respective treatment kit and will re-seal the kit with a tamper evident 
seal provided in the kit box. 
• The syringe and the treatment log form will be dispensed to the third-party “unmasked” 
injector who will administer (SC injection) the SAR236553 IP to the patient in supine 
position. Then the third-party “unmasked” person will complete the corresponding 
treatment log form (date and time of administration, volume of IP injected). 
• The Investigator/study coordinator will enter data in the appropriate e-CRF screens, 
according to data recorded in the treatment log form.  
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• An unblinded monitor will check the data consistency between e-CRF screens, treatment 
log forms, and the vial of a corresponding kit. After this verification the unblinded monitor 
will re-seal the kit.  
8.10.2 Treatment accountability and compliance for atorvastatin 
The Investigator (or delegates) will assess the compliance by counting the returned capsules in 
each wallet-card at each visit during the double-blind treatment period: Week 2 (V3), Week 4 
(V4), Week 6 (V5), and Week 8 (V6) and will fill in the Treatment Log Form.  
The Investigator (or delegates) will record the dosing information on the appropriate page(s) of 
the e-CRF. 
The monitor in charge of the study will then check the e-CRF data by comparing them with the 
atorvastatin IP that will be retrieved and treatment log forms. 
8.11 RETURN AND/OR DESTRUCTION OF TREATMENTS 
All partially used or unused treatments will be retrieved by the Sponsor. A detailed treatment log 
of the returned investigational products will be established with the pharmacist or designee and 
the third party “unmasked” injector, and countersigned by the Investigator and the Monitoring 
Team. 
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9 ASSESSMENT OF INVESTIGATIONAL PRODUCT 
9.1 EFFICACY 
9.1.1 Primary endpoint 
The primary endpoint of this study is the percent change in calculated LDL-C from baseline 
(mean Week -1 and Week 0) to Week 8.  
9.1.2 Secondary endpoint 
• Absolute change in calculated LDL-C from baseline to Week 8. 
• Proportion of patients achieving an LDL-C level lower than 100 mg/dL (2.59 mmol/L) at 
Week 8. 
• Proportion of patients achieving an LDL-C level lower than 70 mg/dL (1.81 mmol/L) at 
Week 8. 
• Percent change in TC, HDL-C, TG and non HDL-C from baseline (average of levels at 
Week -1 and Week 0) to Week 8. 
• Absolute change in TC, HDL-C, TG and non HDL-C from baseline (average of levels at 
Week -1 and Week 0) to Week 8. 
• Percent change in Apo-B from baseline (Week 0, Day 1) to Week 8. 
• Percent change in Apo-A1 from baseline (Week 0, Day 1) to Week 8.  
• Absolute change in the ratio ApoB/ApoA-1 from baseline (Week 0, Day 1) to Week 8. 
• Percent change in Lp(a) from baseline (Week 0, Day 1) to Week 8. 
9.1.3 Efficacy assessment methods 
9.1.3.1 Lipid parameters 
The blood sampling for determination of lipid parameters [i.e. TC, LDL-C, HDL-C, triglycerides 
(TG), non-HDL-C; Apo-B, Apo-A1, ratio ApoB/ApoA-1, Lp(a)] should be performed in the 
morning, in fasting condition (at least 10-12 hours fast and refrain from smoking), before any 
drug intake. Alcohol consumption within 48 hours and intense physical exercise within 24 hours 
preceding the blood sampling are discouraged. If the patient is not fasting at any visits, he/she will 
be asked to come the day after for the blood sampling. 
Total cholesterol, HDL-C, TG, Apo-B, Apo-A1, ratio ApoB/ApoA-1, and Lp(a) will be directly 
measured by a Central Laboratory. LDL-C levels will be calculated using the Friedewald formula 
(24) at all visits. Non-HDL-C will be calculated in subtracting HDL cholesterol from the total 
cholesterol. 
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Blood sampling for TC, LDL-C, HDL-C, TG and non-HDL-C determination will be performed at 
Week -7 for patients with run-in period and Week -1 in all patients. 
All patients will be qualified for randomization based on the LDL-C value obtained at Week -1 
(V1) (see Section 6.1). 
The Week -1 - LDL-C value will be averaged with the randomization-visit determination 
(Week 0) to calculate the baseline LDL-C value for the analysis. 
During the double-blind treatment period:  
• Samples for TC, LDL-C, HDL-C, TG and non-HDL-C determination will be collected at 
baseline (Week 0, V2), Week 2 (V3), Week 4 (V4), Week 6 (V5), and Week 8 (V6).  
• Samples for Apo-B, Apo-A1 and Lp(a) will be collected at baseline (Week 0, V2), Week 4 
(V4), and Week 8 (V6). 
During the follow-up period: 
• Samples for TC, LDL-C, HDL-C, TG, and non-HDL-C determination will be collected at 
Week 12 (V7) and Week 16 (V8). 
All the parameters will be measured by a Central Laboratory during the study. The lipid results 
will not be communicated to the investigators and the Sponsor from the baseline Visit to the end 
of the follow-up period.  
These parameters will assess the effects of SAR236553 on lipid levels. Primary efficacy endpoints 
described in the protocol will not be considered as Adverse Events (AEs), i.e. increases in LDL-C 
levels. 
9.1.3.2 Other blood parameters 
All other blood parameters will also be measured by a Central Laboratory during the study, and 
performed in the morning in fasting condition (at least 10-12 hours fast and refrain from 
smoking), before any drug intake. Alcohol consumption within 48 hours and intense physical 
exercise within 24 hours preceding the blood sampling are discouraged. 
HbA1c will be measured at a central laboratory at Week -7 (only for patients with run-in) or 
Week -1 (for patients without run-in), and Week 8 (V6). 
Fasting plasma glucose will be measured at a central laboratory at Week -7 (only for patients with 
run-in), Week -1, Week 0 (baseline visit, V2), and Week 8 (V6). 
The blood sampling for inflammatory parameter [i.e. high-sensitivity C-reactive protein 
(hs-CRP)] will be collected at Week 0 (baseline visit, V2), Week 4 (V4), and Week 8 (V6). 
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9.1.3.3 Library samples:  
• Plasma samples for exploratory research will be collected in one 8.5 mL blood collection 
tube (BD P100) for exploratory research that may include the study of PCSK9 function, 
effect(s) of PCSK9 inhibition with a monoclonal antibody, and mechanisms of 
hyperlipidemia and heart disease. If needed, samples may also be used to identify markers 
associated with toxicity. 
• Whole blood samples will be collected in one PaxGene tube of 2.5 mL blood. Library 
samples will be coded to maintain patient confidentiality and may be stored for up to 
10 years for use in experiments as noted above.  
Library samples (plasma and whole blood) will be collected at Week 0 (baseline visit, V2), 
Week 4 (V4), and Week 8 (V6) and sent to a central laboratory (only for randomized patients) for 
long-term storage between –70°C to –85°C. 
9.1.3.4 Body weight 
Body weight should be obtained with the patient wearing undergarments or very light clothing 
and no shoes, and with an empty bladder. The same scale should be used throughout the study, 
and calibrated on a regular basis as recommended by the manufacturer. 
The use of balance scales is recommended; if digital scales are used, testing with standard weights 
is of particular importance. The floor surface on which the scale rests must be hard and should not 
be carpeted or covered with other soft material. The scale should be balanced with both weights at 
zero and the balance bar aligned. The patient should stand in the center of the platform as standing 
off-center may affect measurement. The weights are moved until the beam balances (the arrows 
are aligned). The weight is read and recorded in the e-CRF and Source Data. Self-reported 
weights are not acceptable; patients must not read the scales themselves. 
Body weight will be measured at Week -7 (only for patients with run-in) or Week -1 (for patients 
without run-in), Week 0 (baseline visit, V2), and then at all visits until the last follow-up visit 
(Week 16, V8). 
9.2 SAFETY 
Safety will be assessed by: 
• Clinical examination.  
• Vital signs (supine systolic and diastolic blood pressure and heart rate). 
• Recording of adverse events. 
• Standard laboratory tests (hematology and serum chemistry). 
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• Liver function tests [ALT, AST, Alkaline Phosphatase (ALP), γ Glutamyl Transferase 
(γGT) and total bilirubin]. 
• Creatine Phospho Kinase (CPK). 
• Electrocardiogram (ECG).  
The study-specific and general safety criteria are developed in Section 10.1. 
9.3 PHARMACOKINETICS AND ANTI-SAR236553 ANTIBODY ASSESSMENTS 
9.3.1 Sampling time 
SAR236553 PK sampling 
Serum samples for PK measurements will be collected before SAR236553 investigational product 
injection (pre-dose) at Week 0 (baseline visit, V2), and then at each visit until the end of the 
follow-up period (Weeks 2, 4, 6, 8, 12, and 16; Visits V3, V4, V5, V6, V7, V8). 
Anti-SAR236553 antibody sampling 
Serum samples for anti-SAR236553 antibodies determination will be drawn before investigational 
product injection (pre-dose) at Week 0 (baseline visit, V2), Week 4 (V4), Week 8 (V6), Week 12 
(V7), and Week 16 (V8). 
Only in case of persistent and absence of decreased anti-SAR236653 antibody levels at Week 16 
(V8) patients will be asked for one additional antibody sample 6 to 12 months after last dosing. 
9.3.2 PK and antibody sample handling procedure 
Detailed procedure of sample preparation, storage and shipment are described in the specific 
laboratory manual provided by Regeneron. Five (5) ml blood volume is to be collected for each 
PK and antibody sample. 
Remaining serum volume may be used for exploratory research purposes, as described in the 
Section 9.1.3.3. 
9.3.3 Bioanalytical method 
All PK and antibody samples are analyzed by the Regeneron Sample Analysis group. 
PK samples 
PK samples are analyzed using a validated enzyme-linked immunosorbent assay (ELISA) for the 
determination of total concentrations of SAR236553 (i.e., free SAR236553 and SAR236553 
present in PCSK9:SAR236553 complexes) in acid-treated human serum with a lower limit of 
quantification of 0.078 µg/mL [REGN727-AV-09104-SA-01V1]. 
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Antibody samples  
Antibody samples are analyzed using a validated electrochemiluminescence assay for the 
determination of anti-SAR236553 antibody titers in acid-treated human serum with a lower limit 
of detection of approximately 1.5 ng/mL [REGN727-AV-10014-SA-01V1].  
9.3.4 Pharmacogenetic Samples 
An optional pharmacogenomic sub-study will be conducted to identify genetic associations with 
clinical or biomarker response to PCSK9 inhibition, hyperlipidemia, or cardiovascular disease.  If 
needed, samples may also be used to identify markers associated with toxicity. 
Patients who agree to participate in the genetics sub-study will be required to sign a separate 
genetics sub-study ICF prior to collection of the DNA sample. Blood for DNA extraction should 
be collected before investigational product injection (pre-dose) on baseline visit (Week 0, V2); 
however, it may be collected at any time during the study. Patients who choose not to enroll in the 
genomics sub-study are still eligible to enroll in the primary study.  
Special procedures for storage and shipping of pharmacogenetic samples are summarized below 
(Table 4) and are described in detail in Appendix B. 
Table 4 - Summary of handling procedures for DNA storage samples 
Sample Type(s) Pharmacogenetics 
Blood Sample 
Volume 12 mL (2 x 6 mL) 
Tube Type 2 x 6 mL Becton Dickinson K2 EDTA VACUTAINER™ Plus tubes with HEMOGARD™ closure (PN367863/4) sterile tubes 
Anticoagulant K2 EDTA 
Blood Handling 
Procedures Keep blood on ice or frozen at -20°C (or colder) within 30 min of sampling time.  DO NOT CENTRIFUGE. 
Storage Conditions In collection tube at approximately -20°C (or colder) 
 
The Sponsor has included safeguards for protecting patient confidentiality. The blood sample and 
DNA that is extracted from it will be assigned a second number, a Genetic ID (de-identification 
code) that is different from the Subject ID. This “double coding” is performed to separate a 
patient’s medical information and DNA data. The clinical study data (coded by Subject ID) will 
be stored in a distinct database at a different location from the database containing the 
pharmacogenetic data (coded by Genetic ID). The key linking Subject ID and Genetic ID will be 
maintained by a third party, under appropriate access control. The matching of clinical data and 
pharmacogenetic data, for the purpose of data analysis, will be possible only by using this key, 
which will be under strict access control. All data will be reported only in coded form in order to 
maintain confidentiality. 
DNA may be stored and used for analyses for up to 15 years from the completion of the Clinical 
Study Report.  Analyses may include sequence determination or single nucleotide polymorphisms 
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(SNP) from candidate genes. Candidate genes may include (but are not limited to) PCSK9, ApoB 
and LDL-R. Genome-wide studies, including (but not limited to) SNP analyses and/or genomic 
sequencing may also be performed. 
9.4 MEASURES TO PROTECT BLINDING OF THIS TRIAL 
In case of an adverse event, the Investigator should only break the code in exceptional 
circumstances when knowledge of the Investigational Product is essential for treating the patient. 
Please also refer to Section 8.7 - randomization code breaking during the study. 
The treatment code will be unblinded by the Pharmacovigilance Department for reporting to the 
Health Authority of any Suspected Unexpected Serious Adverse Reaction (SUSAR) and 
reasonably associated with the use of the IP according to either the judgment of the Investigator 
and /or the Sponsor. 
At the assay institutions charged for PK measurements and determination of antibodies, samples 
will be analyzed prior data base lock leading to unblinding of responsible bioanalysts. Bioanalysts 
are excluded from the clinical trial team. 
In addition, lipid parameters including LDL-C levels determination will not be communicated to 
the investigators throughout the study, including the follow-up period, so that they cannot deduce 
the treatment group of their patients based on LDL-C level attained. 
The Data Monitoring Committee will receive blinded by treatment group or unblinded (if 
necessary) confidential reports from an independent statistician for review, which have to be 
handled strictly confidentially. None of these reports can be delivered to unauthorized persons 
(please refer to 6.4.1).  
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10 PATIENT SAFETY 
10.1 SAFETY ENDPOINTS ASSESSED IN THIS TRIAL 
• Local tolerability at injection site (please refer to Section 10.2.1. 
• Acute injection reactions (please refer to Section 10.2.2. 
• Other adverse events and serious adverse events. 
• Vital signs. 
• 12-lead ECG. 
• Laboratory tests: hematology (red blood cell count, hemoglobin, hematocrit, platelets, 
white blood cell count with differential blood count), serum chemistry (sodium, potassium, 
chloride, bicarbonate, calcium, phosphorous, urea nitrogen, creatinine, uric acid, total 
protein, and albumin), liver tests (ALT, AST, ALP, γGT and total bilirubin), and CPK. 
10.1.1 Clinical safety  
Clinical safety will be assessed by: 
• Clinical examination at Week -7 (only for patients with run-in) or Week -1(for patients 
without run-in), Week 0 (baseline, V2), Week 8 (V6), and Week 16 (V8). 
• Vital signs including supine blood pressure and heart rate at Week -7 (only for patients with 
run-in), Week -1, Week 0 (baseline, V2), Week 2 (V3), Week 4 (V4), Week 8 (V6), Week 16 
(V8). 
Blood pressure should be measured in supine position under standardized conditions, 
approximately at the same time of the day, on the same arm, with the same apparatus (after the 
patient has rested comfortably in supine position for at least five minutes). Values are to be 
recorded in the e-CRF; both systolic blood pressure (SBP) and diastolic blood pressure (DBP) 
should be recorded. 
At Week -7 (only for patients with run-in) or Week -1 (for patients without run-in), supine blood 
pressure should be measured in both arms. The arm with the highest diastolic pressure will be 
determined at this visit, and blood pressure should be measured on this arm throughout the study. 
This highest value will be recorded in the e-CRF. 
Heart rate will be measured at the time of the measurement of supine blood pressure. 
10.1.2 Adverse event collection 
Adverse events and serious adverse events will be collected from the time of informed consent 
signature and then at each visit until the end of the study. 
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10.1.3 ECG 
A 12-lead ECG will be performed at Week -1 (V1), Week 4 (V4), and Week 8 (V6).  
Heart rate, QRS duration, PR interval, QT interval, QRS axis, ST deviation, T-wave morphology, 
U wave presence or absence will be determined using a centralized automatic and manual reading 
of all ECGs. 
The 12-lead ECGs should be performed after at least 10 minutes rest in supine position. The 
electrodes are to be positioned at the same place for each ECG recording throughout the study. 
Each trace will be analyzed in comparison with the screening recorded trace. The original trace 
will be kept as source data. 
Note: 
Any new clinically significant changes in ECG parameters should be immediately rechecked for 
confirmation before making any decision for the concerned patient. Any clinically significant 
abnormality should be documented as an AE/SAE as applicable. Please also refer to 
Section 10.5.1. 
10.1.4 Safety laboratory 
The following laboratory data are collected from fasting patients in accordance with the study 
schedule and forwarded to the central laboratory: 
• Hematology: red blood cell count, hemoglobin, hematocrit, platelets, white blood cell count 
with differential blood count (neutrophils, lymphocytes, monocytes, eosinophils, basophils) at 
Week -7 (V1a - only for patients with run-in), Week -1 (V1), Week 0 (baseline, V2), Week 4 
(V4), Week 8 (V6), and during the follow-up period [Week 12 (V7), Week 16 (V8)] in case of 
persistent clinically relevant abnormal values at Week 8 (V6, end of treatment). 
• Serum chemistry: sodium, potassium, chloride, bicarbonate, calcium, phosphorous, urea 
nitrogen, creatinine, uric acid, total protein, and albumin at Week -7 (V1a - only for patients 
with run-in), Week -1 (V1), Week 0 (baseline, V2), Week 4 (V4), Week 8 (V6), and during 
the follow-up period [Week 12 (V7), Week 16 (V8)] in case of persistent clinically relevant 
abnormal values at Week 8 (V6, end of treatment). 
•  Liver tests: ALT, AST, ALP, γGT and total bilirubin (and, in case of values above the normal 
range, differentiation in conjugated and non-conjugated bilirubin) at Week -1 (V1), Week 0 
(baseline, V2), Week 4 (V4), Week 8 (V6), and during the follow-up period [Week 12 (V7), 
Week 16 (V8)] in case of persistent clinically relevant abnormal values at Week 8 (V6, end of 
treatment). 
• CPK at Week -1 (V1), Week 0 (baseline, V2), Week 4 (V4), Week 8 (V6), and during the 
follow-up period [Week 12 (V7), Week 16 (V8)] in case of persistent clinically relevant 
abnormal values at Week 8 (V6, end of treatment). 
• Sensitive TSH, hepatitis B surface antigen and hepatitis C antibody at Week -1 (V1). 
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• Pregnancy test: 
- Serum pregnancy test in females of childbearing potential at Week -1 (V1). 
- Urine pregnancy test in females of childbearing potential at Week -7 (V1a - only for 
patients with run-in), Week 0 (baseline, V2), Week 4 (V4), Week 8 (V6), Week 12 
(V7), and Week 16 (V8).  
Note: 
- Any abnormal laboratory value should be immediately rechecked (whenever possible 
using the central laboratory) for confirmation before making any decision for the 
concerned patient. It should be documented as an AE/SAE as applicable. Please also 
refer to Section 10.5.1. 
Decision trees for the management of certain laboratory abnormalities by sanofi-aventis are 
provided in Appendix A.  
Please also refer to Section 11. 
10.2 SAFETY INSTRUCTIONS 
10.2.1 Local tolerability 
In case the Investigator or the patient recognizes any signs of local intolerability this should be 
recorded in the e-CRF on the standard AE form. 
10.2.2 Management of Acute Injection Reactions 
Acute injection reactions are defined as any AE that is associated with the injection. Emergency 
equipment and medication for the treatment of these potential adverse effects (e.g., antihistamines, 
bronchodilators, oxygen, IV saline, corticosteroids, acetaminophen, and epinephrine) must be 
available for immediate use. 
Patients will be monitored at the investigational site for at least 30 minutes following each 
SAR236553 IP injection. Patients should be treated symptomatically if any AEs are observed. 
Patients are to remain at the site until any acute injection reaction is assessed as stable, per the 
investigator’s discretion.  
10.3 ADVERSE EVENTS MONITORING 
All events will be managed and reported in compliance with all applicable regulations, and 
included in the final clinical study report. 
 
Clinical Trial Protocol  26-Nov-2010 
SAR236553-DFI11566 -   Version number: 1 (electronic 1.0) 
Property of the sanofi-aventis group - strictly confidential Page 57 
10.4 DEFINITIONS OF ADVERSE EVENT (AE) AND SERIOUS ADVERSE EVENT (SAE) 
An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical investigation 
patient administered a pharmaceutical product and which does not necessarily have to have a 
causal relationship with this treatment. 
A Serious Adverse Event (SAE) is any untoward medical occurrence that at any dose: 
• Results in death or; 
• Is life-threatening or; 
Note: The term "life-threatening" in the definition of "serious" refers to an event in which the 
patient was at risk of death at the time of the event; it does not refer to an event which 
hypothetically might have caused death if it were more severe. 
• Requires inpatient hospitalization or prolongation of existing hospitalization or; 
• Results in persistent or significant disability/incapacity or; 
• Is a congenital anomaly/birth defect; 
• Is a medically important event: 
Medical and scientific judgment should be exercised in deciding whether expedited reporting 
is appropriate in other situations, such as important medical events that may not be 
immediately life-threatening or result in death or hospitalization but may jeopardize the 
patient or may require intervention (i.e., specific measures or corrective treatment) to prevent 
one of the other outcomes listed in the definition above. 
Note: The following medical important events intend to serve as a guideline for determining 
which condition has to be considered as a medically important event. It is not intended to be 
exhaustive: 
• Intensive treatment in an emergency room or at home for: 
- allergic bronchospasm,  
- blood dyscrasias (i.e., agranulocytosis, aplastic anemia, bone marrow aplasia, 
myelodysplasia, pancytopenia…),  
- convulsions (seizures, epilepsy, epileptic fit, absence…) 
• Development of drug dependency or drug abuse, 
• ALT > 3 ULN + total bilirubin > 2 ULN or asymptomatic ALT increase > 10 ULN , 
• Suicide attempt or any event suggestive of suicidality, 
• Syncope, loss of consciousness (except if documented as a consequence of blood 
sampling), 
• Bullous cutaneous eruptions, 
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• Cancers diagnosed during the study or aggravated during the study (only if judged as 
unusual/significant by the Investigators in oncology studies), 
• Chronic neurodegenerative diseases (newly diagnosed) or aggravated during the study 
(only if judged as unusual/significant by the Investigators in studies assessing specifically 
the effect of a study drug on these diseases). 
10.5 OBLIGATION OF THE INVESTIGATOR REGARDING SAFETY REPORTING 
10.5.1 Adverse Events 
All AEs regardless of seriousness or relationship to IPs, spanning from the signature of the 
informed consent form, until the end of the study as defined by the protocol for that patient, are to 
be recorded on the corresponding screen(s) included in the e-CRF. 
Whenever possible, diagnosis or single syndrome should be reported instead of symptoms. The 
Investigator should specify the date of onset, intensity, action taken with respect to IP, corrective 
treatment/therapy given, additional investigations performed, outcome and his/her opinion as to 
whether there is a reasonable possibility that the AE was caused by the IP. 
Laboratory, vital signs or ECG abnormalities are to be recorded as AEs only if:  
• symptomatic and/or  
• requiring either corrective treatment or consultation, and/or  
• leading to IP discontinuation or modification of dosing, and/or  
• fulfilling a seriousness criterion, and/or  
• defined as an AE with pre-specified monitoring with immediate notification. 
10.5.2 Serious Adverse Events 
In the case of occurrence of a SAE, the Investigator must immediately: 
• ENTER (within 1 working day) the information related to the SAE in the appropriate 
screens of the e-CRF; the system will automatically send the notification to the Monitoring 
Team and Pharmacovigilance after approval of the Investigator within the e-CRF or after a 
standard delay. 
• SEND (preferably by fax or e-mail) the photocopy of all examinations carried out and the 
dates on which these examinations were performed, to the representative of the 
Monitoring Team whose name, fax number and email address appear on the Clinical Trial 
Protocol;. Care should be taken to ensure that the patient's identity is protected and the 
patient's identifiers in the Clinical Trial are properly mentioned on any copy of source 
document provided to the Sponsor. For laboratory results, include the laboratory normal 
ranges. 
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• All further data updates should be recorded in the e-CRF as appropriate, and further 
documentation as well as additional information (for Lab data, concomitant Medication, 
patient status ..) should be sent (by fax or e-mail) to the Monitoring Team within 
1 working day of knowledge. In addition, any effort should be made to further document 
each Serious AE that is fatal or life threatening within the week (7 days) following initial 
notification. 
• A back-up plan is used (using paper flow) when the e-CRF system does not work. 
10.5.3 Safety Observations 
• The Investigator should take all appropriate measures to ensure the safety of the patients, 
notably he/she should follow up the outcome of SAE /AEs with pre-specified monitoring 
until clinical recovery is complete and laboratory results have returned to normal or until 
progression has been stabilized or death. In all cases, this may imply that observations will 
continue beyond the last planned visit per protocol, and that additional investigations may 
be requested by the Monitoring Team up to as noticed by the sponsor. 
• When treatment is prematurely discontinued, the patient’s observations will continue until 
the end of the study as defined by the protocol for that patient. 
• In case of any SAE/AEPM with immediate notification brought to the attention of the 
Investigator at any time after the end of the study for the patient and considered by him/her 
to be caused by the IP with a reasonable possibility, this should be reported to the 
Monitoring team. 
10.5.4 Adverse events with pre-specified monitoring (AEPM)  
Adverse events requiring pre-specified monitoring are AEs (serious or non-serious) that need to 
be monitored, documented, and managed in a pre-specified manner described in the protocol. 
10.5.4.1 AEPM with immediate notification 
For these AEs, the Sponsor will be informed immediately (i.e. within 1 working day), as per SAEs 
notification described in Section 10.5.2, even if not fulfilling a seriousness criterion, using the 
corresponding screens in the e-CRF.  
• ALT increase (Appendix A). 
• Pregnancy 
- Pregnancy occurring in a female patient included in the clinical trial. Pregnancy will be 
recorded as a pre-specified AE with immediate notification in all cases. It will be 
qualified as an SAE only if it fulfills the SAE criteria. 
- In the event of pregnancy, IP should be discontinued.  
- The follow-up of the pregnancy will be mandatory until the outcome has been 
determined. 
 
Clinical Trial Protocol  26-Nov-2010 
SAR236553-DFI11566 -   Version number: 1 (electronic 1.0) 
Property of the sanofi-aventis group - strictly confidential Page 60 
• Symptomatic Overdose with IP 
- An overdose with the IP is an event suspected by the Investigator and defined as at 
least twice the dose during the planned intervals. 
- The circumstances (i.e., accidental or intentional) should be clearly specified in the 
verbatim and symptoms, if any, entered on separate AE forms. 
10.5.4.2 AEPM without immediate notification 
• Asymptomatic overdose with IP: same definition as above; to be reported using the 
corresponding screens in the e-CRF using the Preferred Term “Asymptomatic 
OVERDOSE (accidental or intentional)”. 
10.5.5 Laboratory abnormalities with pre-specified monitoring 
Laboratory abnormalities should be monitored, documented, and managed according to the 
related flowchart in protocol appendices Appendix A: 
• Neutropenia. 
• Thrombocytopenia. 
• Increase in ALT. 
• Acute renal insufficiency. 
• Suspicion of rhabdomyolysis. 
10.6 OBLIGATIONS OF THE SPONSOR 
During the course of the study, the Sponsor will report in an expedited manner all SAEs that are 
both unexpected and at least reasonably related to the IP (SUSAR), to the Health Authorities, 
IECs / IRBs as appropriate and to the Investigators.  
In addition, the Sponsor will report in an expedited manner all SAEs that are expected and at least 
reasonably related to the IPs to the Authorities, according to local regulations. 
In this study, some AEs are considered related to the underlying condition and thus will not be 
considered unexpected as given in the Investigator’s Brochure.  
Any other AE not listed as an expected event in the Investigator’s Brochure or in this protocol 
will be considered as unexpected. 
The Sponsor will report all safety observations made during the conduct of the trial in the clinical 
study report (CSR). 
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11 HANDLING OF PATIENT TEMPORARY OR PERMANENT 
TREATMENT DISCONTINUATION AND OF PATIENT STUDY 
DISCONTINUATION 
The IP should be continued whenever possible. In case the IP is stopped, it should be determined 
if the stop can be made temporarily; permanent IP discontinuation should be a last resort. Any IP 
discontinuation should be fully documented in the e-CRF. In any case, the patient should remain 
in the study as long as possible, attending all visits and undergoing all assessments. 
Pregnancy will lead to definitive treatment discontinuation in all cases. Stopping rules described 
in Appendix A should be applied.  
11.1 TEMPORARY TREATMENT DISCONTINUATION WITH INVESTIGATIONAL 
PRODUCT(S) 
Temporary treatment discontinuation may be considered by the Investigator because of suspected 
AEs. Reinitiation of treatment with the IP will be done under close and appropriate clinical/and or 
laboratory monitoring once the Investigator will have considered according to his/her best medical 
judgment that the responsibility of the IP in the occurrence of the concerned event was unlikely 
and if the selection criteria for the study are still met (refer to Sections 7.2 and 7.3). 
All temporary treatment discontinuation, duration should be recorded by the Investigator in the 
appropriate pages when considered as confirmed. 
11.2 PERMANENT TREATMENT DISCONTINUATION WITH INVESTIGATIONAL 
PRODUCT(S) 
Permanent treatment discontinuation is any treatment discontinuation associated with the 
definitive decision from the Investigator or the patient not to re-expose the patient to the IP at any 
time. 
11.2.1 List of criteria for definitive treatment discontinuation 
The patients may withdraw from treatment with IP if they decide to do so, at any time and 
irrespective of the reason, or this may be the Investigator’s decision. All efforts should be made to 
document the reasons for treatment discontinuation and this should be documented in the e-CRF. 
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Patients may discontinue the investigational product for the following reasons: 
• At their own request. 
• If, in the investigator's opinion, continuation with the administration of the study treatment 
would be detrimental to the patient's well-being. 
• Intercurrent condition that requires discontinuation of the study treatment (e.g. laboratory 
abnormalities, please refer to decision tree in Appendix A, pregnancy). 
• At the specific request of the Sponsor. 
Patient withdrawal from the study treatment or study should be avoided as much as possible. If 
this occurs, every attempt should be made to restart study drug if medically appropriate. In case of 
permanent study treatment discontinuation, patients should attend the scheduled visits until the 
end of study. 
11.2.2 Handling of patients after permanent treatment discontinuation 
Patients will be followed up according to the study procedures as specified in this protocol up to 
the scheduled date of study completion, or up to recovery or stabilization of any AE to be 
followed-up as specified in this protocol, whichever comes last. 
Patients who prematurely discontinue study treatment should have as soon as possible a visit with 
assessments normally planned at Week 8 (V6), visit considered as the final on-treatment visit.  
All definitive discontinuation of study treatment should be recorded by the Investigator in the 
appropriate screens of the e-CRF and in the patient’s medical records when considered as 
confirmed. IVRS/IWRS should be notified when a patient prematurely discontinues study 
treatment. 
11.3 PROCEDURE AND CONSEQUENCE FOR PATIENT WITHDRAWAL FROM STUDY  
The patients may withdraw from the study, before study completion if they decide to do so, at any 
time and irrespective of the reason. If possible, the patients should be assessed using the 
procedure defined above.  
All study withdrawals should be recorded by the Investigator in the appropriate screens of the e-
CRF and in the patient’s medical records (with, in this medical records, at least date of withdrawal 
and reason for) when considered as confirmed. 
For patients who fail to return to the site, the Investigator should make the best effort to re-contact 
the patient (e.g., contacting patient’s family or private physician, review available registries or 
health care database), and to determine his/her health status, including at least his/her vital status. 
Attempts to contact such patients must be documented in the patient’s records (e.g., times and 
dates of attempted telephone contact, receipt for sending a registered letter). 
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The statistical analysis plan will specify how these patients lost to follow-up for their primary 
endpoints will be considered. 
Patients who have withdrawn from the study cannot be re-randomized (treated) in the study. Their 
inclusion and treatment number must not be reused. 
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12 STUDY PROCEDURES 
The study consists of a screening period with a different duration according to the status of the 
patients: 
• A screening period of 1 week for patients receiving atorvastatin 10 mg at stable dose for at 
least 6 weeks prior to the screening period. 
• A screening period of 7 weeks, including a 6-week run-in period with atorvastatin 10 mg 
for patients receiving a lipid lowering treatment other than atorvastatin/ or not at stable 
dose of atorvastatin 10 mg for at least 6 weeks prior to the screening period, or drug naive 
patients. 
Following this screening/run-in period, eligible patients will be randomized to the double-blind 
treatment period of 8-week duration followed by a follow-up period of 8 weeks. 
All the visits should take place in the morning approximately at the same time. 
The patient will have to be in fasting conditions (i.e., overnight, at least 10-12 hours fast and 
refrain from smoking) for all visits from Week -7 to the final visit of the follow-up period 
Week 16 (V8). Alcohol consumption within 48 hours and intense physical exercise within 
24 hours preceding the blood sampling are discouraged. 
For all visits after baseline a timeframe of a certain number of days will be allowed using Day 1 
as reference (if one visit date is changed, the next visit should take place according to the original 
schedule): for Week 0 (V2) to Week 8 (V6) the timeframe will be ± 3 days, and from Week 8 
(V6) to Week 16 (V8) it will be ± 7 days. 
12.1 VISIT SCHEDULE 
12.1.1 Screening period  
12.1.1.1 Screening including run-in period 
This screening period will consist of 7 weeks including a run-in period with atorvastatin 10 mg, 
and will apply for patients receiving a lipid lowering treatment other than atorvastatin/ or not at 
stable dose of atorvastatin 10 mg for at least 6 weeks prior to the screening period, or drug naive 
patients. 
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12.1.1.1.1 Pre-screening visit with pre-eligibility assessments (V1a, Week -7) and entry in the 
atorvastatin run-in period 
The patient will receive verbal information concerning the aims and methods of the study, its 
constraints and risks and the study duration. A written summary in the form of an information 
leaflet will be given to the patient. The written informed consent must be dated and signed by the 
patient and the Investigator prior to any study assessments. Only patients who meet the inclusion 
criteria as noted in Section 7.2 may be screened. Women of childbearing potential will be 
requested to use a medically approved contraceptive method during the entire study. 
This visit will include: 
• Assessment of inclusion and exclusion criteria. 
• Demographic (age, gender, race, ethnicity). 
• Patient’s medical and surgical history and concomitant diseases, as well as alcohol and 
smoking habits. 
• Concomitant and previous medication (within the previous 12 weeks). 
• Βody weight and height measurements. 
• Clinical examination including vital signs: supine systolic and diastolic blood pressure, 
heart rate. 
• Instruction on diet (NCEP-ATPIII TLC diet or equivalent). 
• Collection of adverse events from this point onward. 
• IVRS/IWRS contact for notification of screening and entry in the run-in period: 
- Patients meeting the inclusion/exclusion criteria for eligibility at screening will enter 
the run-in period of the study. IVRS/IWRS is to be contacted for notification of 
screening. Patient number will be allocated by the site using the laboratory 
requisition form. This patient number is composed of a 9-digit number containing the 
3-digit country code, the 3-digit center code and the 3-digit patient chronological 
number (the 3-digit patient chronological number is 001 for the first patient screened 
in a center, 002 for the second patient screened in the same center...). 
• Fasting blood sample for: 
- Lipid parameters determination: TC, LDL-C, HDL-C, TG, non-HDL-C. 
- HbA1c, fasting plasma glucose. 
- Standard laboratory blood test (hematology, serum chemistry). 
Note: if the patient is not in fasting conditions, the blood sample will not be collected and a new 
appointment will be given the day after to the patient with instruction to be fasted (at least 
10-12 hours fast). 
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• Urine pregnancy test (females of childbearing potential only). 
• Dispensation of atorvastatin 10 mg. 
• The patient will be given: 
- An appointment for the next visit within 6 weeks ± 3 days (Week -1). The patient 
should be seen in the morning and in fasting condition. 
12.1.1.1.2 Screening visit with full eligibility assessments (V1, Week -1) 
This visit will include: 
• Assessment of inclusion and exclusion criteria. 
• Concomitant medication. 
• Check of the diet (NCEP-ATPIII TLC diet or equivalent). 
• Check of the compliance for atorvastatin 10 mg. 
• Vital signs: SBP and DBP, heart rate. 
• Collection of adverse events. 
• Fasting blood sample for: 
- Lipid parameters determination: TC, LDL-C, HDL-C, TG, non-HDL-C. 
- Fasting plasma glucose. 
- Standard laboratory blood test (hematology, serum chemistry). 
- Liver tests (ALT, AST, ALP, γGT and total bilirubin), CPK. 
- Sensitive TSH. 
- Hepatitis B surface antigen and Hepatitis C antibody tests. 
- Serum pregnancy test (females of childbearing potential only). 
Note: if the patient is not in fasting conditions, the blood sample will not be collected and a new 
appointment will be given the day after to the patient with instruction to be fasted (at least 
10-12 hours fast). 
• 12-lead ECG. 
• The patient will be instructed to continue atorvastatin at the same dose (i.e., 10 mg). 
• The patient will be given: 
- An appointment for the next visit within 1 week ± 1 day (7 days ± 1 day) (Week 0). 
The patient should be seen in the morning and in fasting condition. 
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12.1.1.2 Screening period without run-in period 
This screening period will consist of 1 week and will apply for patients receiving atorvastatin 
10 mg at stable dose for at least 6 weeks prior to the screening period. 
12.1.1.2.1 Screening visit with full eligibility assessments (V1, Week -1) 
The patient will receive verbal information concerning the aims and methods of the study, its 
constraints and risks and the study duration. A written summary in the form of an information 
leaflet will be given to the patient. The written informed consent must be dated and signed by the 
patient and the Investigator prior to any study assessments. Only patients who meet the inclusion 
criteria as noted in Section 7.2 may be screened. Women of childbearing potential will be 
requested to use a medically approved contraceptive method during the entire study. 
This visit will include: 
• Assessment of inclusion and exclusion criteria. 
• Demographic (age, gender, race, ethnicity). 
• Patient’s medical and surgical history and concomitant diseases, as well as alcohol and 
smoking habits. 
• Concomitant and previous medication (within the previous 12 weeks). 
• Βody weight and height measurements. 
• Clinical examination including vital signs: supine systolic and diastolic blood pressure, 
heart rate. 
• Instruction on diet (NCEP-ATPIII TLC diet or equivalent). 
• Collection of adverse events from this point onward. 
• IVRS/IWRS contact for notification of screening and entry in the run-in period: 
- Patients meeting the inclusion/exclusion criteria for eligibility at screening will enter 
the run-in period of the study. IVRS/IWRS is to be contacted for notification of 
screening. Patient number will be allocated by the site using the laboratory 
requisition form. This patient number is composed of a 9-digit number containing the 
3-digit country code, the 3-digit center code and the 3-digit patient chronological 
number (the 3-digit patient chronological number is 001 for the first patient screened 
in a center, 002 for the second patient screened in the same center...). 
• Fasting blood sample for: 
- Lipid parameters:determination TC, LDL-C, HDL-C, TG, non-HDL-C. 
- HbA1c, fasting plasma glucose. 
- Standard laboratory blood test (hematology, serum chemistry). 
- Liver tests (ALT, AST, ALP, γGT and total bilirubin), CPK. 
- Sensitive TSH. 
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- Hepatitis B surface antigen and Hepatitis C antibody tests. 
- Serum pregnancy test (females of childbearing potential only). 
Note: if the patient is not in fasting conditions, the blood sample will not be collected and a new 
appointment will be given the day after to the patient with instruction to be fasted (at least 
10-12 hours fast). 
• 12-lead ECG. 
• Dispensation of atorvastatin 10 mg to allow the patient to continue atorvastatin at the same 
dose until the next visit.  
• The patient will be given: 
- An appointment for the next visit within 1 week ± 1 day (7 days ± 1 day) (Week 0). 
The patient should be seen in the morning and in fasting condition. 
12.1.2 Double-blind treatment period: from Week 0 (V2, D1) to Week 8 (V6) 
12.1.2.1 Baseline (randomization) visit (V2, Week 0, D1) 
Week 0 (V2) should be scheduled 7 days (± 1 day) after Week -1 (V1). 
Patients should be seen in the morning after an overnight fast (no less than 10-12 hours). Only 
after the baseline assessments are completed and eligibility confirmed, the IVRS/IWRS 
should be contacted for randomization. The study treatment injection will take place at the 
investigational site.  
This visit will include: 
• Check of the exclusion criteria and record them in the e-CRF (as appropriate). 
• Βody weight. 
• Clinical examination including vital signs: supine systolic and diastolic blood pressure, 
heart rate. 
• Check of the diet (NCEP-ATPIII TLC diet or equivalent). 
• Recording of the use or change of any concomitant medications. 
• Check of the compliance for atorvastatin 10 mg. 
• Recording of adverse events. 
If the patient is confirmed eligible, the Investigator will start the next study procedures: 
• IVRS/IWRS contact for randomization and allocation of a 7-digit treatment kit number for 
both IPs (SAR236553 and atorvastatin) according to the randomization lists. Investigators 
should never allocate a treatment kit number to a patient without contacting 
IVRS/IWRS.  
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• Fasting blood sample before injection of the study treatment for: 
- Complete panel for lipid parameters determination: TC, LDL-C, HDL-C, TG, non-
HDL-C, ApoB, ApoA-1, ratio ApoB/ApoA-1, Lp(a). 
- Fasting plasma glucose. 
- Standard laboratory blood test (hematology, serum chemistry). 
- Liver tests (ALT, AST, ALP, γGT and total bilirubin), CPK. 
- hs-CRP, library serum. 
- PK assessment of SAR236553. 
- Anti-SAR236553 antibody assessment. 
- DNA sample (only in specifically consented patients).  
• Urine pregnancy test (females of childbearing potential only). 
• Injection of the study treatment (SAR236553 or placebo) and recording of compliance. 
• The patient will be given: 
- One box of five wallets of atorvastatin treatment. 
• The patient will be instructed to take the atorvastatin treatment (2 capsules each day in the 
evening with the dinner) until the next visit. 
An appointment for the next visit within 2 weeks ± 3 days (14 days ± 3 day) (Week 2) will be 
given. The patient should be seen in the morning and in fasting condition. 
12.1.2.2 Visit 3 (V3, Week 2) 
Week 2 (V3) should be scheduled 2 weeks ± 3 days (14 days ± 3 days) after Week 0 (V2). 
Patients should be seen in the morning after an overnight fast (no less than 10-12 hours). The 
study treatment injection will take place at the investigational site. 
This visit will include: 
• Body weight 
• Vital signs: SBP and DBP, heart rate. 
• Recording of the use or change of any concomitant medications. 
• Check of the diet (NCEP-ATPIII TLC diet or equivalent). 
• Recording of adverse events. 
• Fasting blood sample before injection of the study treatment for: 
- Lipid parameters determination: TC, LDL-C, HDL-C, TG, non-HDL-C. 
- PK assessment of SAR236553. 
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• IVRS/IWRS contact for allocation of a treatment kit for SAR236553 IP according to the 
randomization list. 
• Injection of the study treatment (SAR236553 or placebo) and recording of compliance. 
• The patient will be instructed to continue the atorvastatin treatment (2 capsules each day in 
the evening with the dinner) until the next visit. 
An appointment for the next visit within 2 weeks ± 3 days (14 days ± 3 days) (Week 4) will be 
given. The patient should be seen in the morning and in fasting condition. 
12.1.2.3 Visit 4 (V4, Week 4) 
Week 4 (V4) should be scheduled 2 weeks ± 3 days (14 days ± 3 days) after Week 2 (V3). 
Patients should be seen in the morning after an overnight fast (no less than 10-12 hours). The 
study treatment injection will take place at the investigational site. 
This visit will include: 
• Body weight. 
• Vital signs: SBP and DBP, heart rate. 
• Recording of the use or change of any concomitant medications. 
• Check of the diet (NCEP-ATPIII TLC diet or equivalent). 
• Check of the compliance for atorvastatin treatment. 
• Recording of adverse events. 
• Fasting blood sample before injection of the study treatment for: 
- Complete panel for lipid parameters determination: TC, LDL-C, HDL-C, TG, non-
HDL-C, ApoB, ApoA-1, ratio ApoB/ApoA-1, Lp(a). 
- Standard laboratory blood test (hematology, serum chemistry). 
- Liver tests (ALT, AST, ALP, γGT and total bilirubin), CPK. 
- hs-CRP, library serum. 
- PK assessment of SAR236553.  
- Anti-SAR236553 antibody assessment. 
• Urine pregnancy test (females of childbearing potential only). 
• 12-lead ECG. 
• IVRS/IWRS contact for allocation of a treatment kit for both IPs (SAR236553 and 
atorvastatin) according to the randomization lists. 
• Injection of the study treatment (SAR236553 or placebo) and recording of compliance. 
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• The patient will be given: 
- One box of five wallets of atorvastatin treatment. 
• The patient will be instructed to take the atorvastatin treatment (2 capsules each day in the 
evening with the dinner) until the next visit.  
An appointment for the next visit within 2 weeks ± 3 days (14 days ± 3 days) (Week 6) will be 
given. The patient should be seen in the morning and in fasting condition. 
12.1.2.4 Visit 5 (V5, Week 6) 
Week 6 (V5) should be scheduled 2 weeks ± 3 days (14 days ± 3 day) after Week 4 (V4). Patients 
should be seen in the morning after an overnight fast (no less than 10-12 hours). The study 
treatment injection will take place at the investigational site. 
This visit will include: 
• Body weight 
• Vital signs: SBP and DBP, heart rate. 
• Recording of the use or change of any concomitant medications. 
• Check of the diet (NCEP-ATPIII TLC diet or equivalent). 
• Recording of adverse events. 
• Fasting blood sample before injection of the study treatment for: 
- Lipid parameters determination: TC, LDL-C, HDL-C, TG, non-HDL-C. 
- PK assessment of SAR236553. 
• IVRS/IWRS contact for allocation of a treatment kit for SAR236553 IP according to the 
randomization list. 
• Injection of the study treatment (SAR236553 or placebo) and recording of compliance. 
• The patient will be instructed to continue the atorvastatin treatment (2 capsules each day in 
the evening with the dinner) until the next visit. 
An appointment for the next visit within 2 weeks ± 3 days (14 days ± 3 days) (Week 8) will be 
given. The patient should be seen in the morning and in fasting condition. 
12.1.2.5 Visit 6 (V6, Week 8) 
Week 8 (V6) should be scheduled 2 weeks ± 3 days (14 days ± 3 day) after Week 6 (V5). Patients 
should be seen in the morning after an overnight fast (no less than 10-12 hours). 
 
Clinical Trial Protocol  26-Nov-2010 
SAR236553-DFI11566 -   Version number: 1 (electronic 1.0) 
Property of the sanofi-aventis group - strictly confidential Page 72 
This visit will include: 
• Body weight. 
• Clinical examination including vital signs: supine systolic and diastolic blood pressure, 
heart rate. 
• Recording of the use or change of any concomitant medications. 
• Check of the diet (NCEP-ATPIII TLC diet or equivalent). 
• Check of the compliance for atorvastatin treatment. 
• Recording of adverse events. 
• Fasting blood sample for: 
- Complete panel for lipid parameters determination: TC, LDL-C, HDL-C, TG, non-
HDL-C, ApoB, ApoA-1, ratio ApoB/ApoA-1, Lp(a). 
- HbA1c, fasting plasma glucose. 
- Standard laboratory blood test (hematology, serum chemistry). 
- Liver tests (ALT, AST, ALP, γGT and total bilirubin), CPK. 
- hs-CRP, library serum. 
- PK assessment of SAR236553.  
- Anti-SAR236553 antibody assessment. 
• Urine pregnancy test (females of childbearing potential only). 
• 12-lead ECG. 
• IVRS/IWRS contact for notification of the end of study treatment (including SAR236553 
IP and atorvastatin IP). 
An appointment for the next visit within 4 weeks ± 7 days (28 days ± 7 days) (Week 12) will be 
given. The patient should be seen in the morning and in fasting condition. 
12.1.3 Follow-up period: from Week 8 (V6) to Week 16 (V8) 
12.1.3.1 Visit 7 (V7, Week 12) 
Week 12 (V7) should be scheduled 4 weeks ± 7 days (28 days ± 7 days) after Week 8 (V6). 
Patients should be seen in the morning after an overnight fast (no less than 10-12 hours). 
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This visit will include: 
• Body weight. 
• Recording of the use or change of any concomitant medications. 
• Check of the diet (NCEP-ATPIII TLC diet or equivalent). 
• Recording of adverse events. 
• Fasting blood sample for: 
- Lipid parameters determination: TC, LDL-C, HDL-C, TG, non-HDL-C. 
- PK assessment of SAR236553. 
- Anti-SAR236553 antibody assessment. 
- Only in case of persistent clinically relevant abnormal values at Week 8 (V5) for the 
corresponding parameter: 
- Standard laboratory blood test (hematology, serum chemistry). 
- Liver tests (ALT, AST, ALP, γGT and total bilirubin), CPK. 
• Urine pregnancy test (females of childbearing potential only). 
An appointment for the next visit within 4 weeks ± 7 days (28 days ± 7 days) (Week 16) will be 
given. The patient should be seen in the morning and in fasting condition. 
12.1.3.2 Visit 8 (V8, Week 16) 
Week 16 (V8) should be scheduled 4 weeks ± 7 days (28 days ± 7 days) after Week 12 (V7). 
Patients should be seen in the morning after an overnight fast (no less than 10-12 hours). 
This visit will include: 
• Body weight. 
• Clinical examination including vital signs: supine systolic and diastolic blood pressure, 
heart rate. 
• Recording of the use or change of any concomitant medications. 
• Check of the diet (NCEP-ATPIII TLC diet or equivalent). 
• Recording of adverse events. 
• Fasting blood sample for: 
- Lipid parameters determination: TC, LDL-C, HDL-C, TG, non-HDL-C. 
- PK assessment of SAR236553. 
- Anti-SAR236553 antibody assessment. 
- Only in case of persistent clinically relevant abnormal values at Week 8 (V6) and 
Week 12 (V7) for the corresponding parameter: 
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- Standard laboratory blood test (hematology, serum chemistry). 
- Liver tests (ALT, AST, ALP, γGT and total bilirubin), CPK. 
• Urine pregnancy test (females of childbearing potential only). 
• IVRS/IWRS contact for notification of the end of the study. 
12.2 DEFINITION OF SOURCE DATA 
Evaluations that are reported in the e-CRF must be supported by appropriately signed identified 
source documentation related but not limited to the following: 
• Agreement, date, and signature of informed consent mentioning the study identification. 
• Patient identification, last participation in a clinical trial, medical history, associated 
diseases, and data related to the studied pathology. 
• Contraception method for women of childbearing potential. 
• Previous and concomitant medication (including if applicable the lipid lowering 
treatment). 
• Study identification. 
• Treatment number, dates of administration. 
• Dates of visits and assessments including the examination report. 
• Vital signs, height, body weight. 
• Faxed central lab reports (dated and signed by the Principal Investigator or 
Sub-Investigator). 
• IVRS/IWRS confirmation fax (screening, screen failure, enter run-in, randomization, 
treatment reallocation, discontinuation, end of study, unblinding if applicable). 
• ECG records signed and dated. 
• Adverse events and follow-up: 
- In case of SAE, the site should file in the source document at least copies of the 
hospitalization reports and any relevant examination reports documenting the 
follow-up of the SAE. 
• Date of premature study discontinuation (if any) and reason. 
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Source documentation may be found in the following: 
• Patient’s identity. 
• Medical history. 
• Hospital records. 
• Nursing notes. 
• Physician’s notes. 
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13 STATISTICAL CONSIDERATIONS 
13.1 DETERMINATION OF SAMPLE SIZE 
The study is expected to enrol approximately 90 patients. 
To detect a difference of 20% in LDL-C percent change from baseline to Week 8 between 
SAR236553 + high dose of atorvastatin group and SAR236553 placebo + high dose of 
atorvastatin group, assuming a 5% rate of unevaluable primary endpoint, 30 patients by arm will 
result in 95% power, with a standard deviation of 20%, and using a two-sided t-test at the 0.05 
significance level. 
Calculations were made using nQuery Advisor 6.01. 
13.2 ANALYSIS ENDPOINTS 
13.2.1 Demographic and baseline characteristics  
The baseline value for demographic and baseline characteristics is generally defined as the last 
available value before randomization.   
13.2.1.1 Demographic and baseline characteristics 
Demographic characteristics 
Demographic variables are sex (Male, Female), race (White, Black or African American, Asian, 
American Indian or Alaska Native, Native Hawaiian or other Pacific Island, other) age in years 
(continuous and categorical variable : <45, [45 - 65[, and ≥ 65 years), ethnicity (Hispanic or 
Latino, Non Hispanic or Latino). 
Medical and surgical history 
This information will be coded using the version of MedDRA (Medical Dictionary for Regulatory 
Activities) currently in effect at sanofi-aventis at the time of the database lock. 
Disease characteristics at baseline  
Specific disease history includes type of lipid disorders according to the Fredrickson classification 
(IIa, IIb or IV), time from diagnosis, and presence of previous treatment with a lipid lowering 
agent. 
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Other baseline characteristics 
Other baseline characteristics include BMI in kg/m2 (continuous and categorical variable: <30, 
≥30), alcohol habits (frequency: Never, At least monthly, At least weekly, At least daily, and 
amount: 1 or 2, >2 standard drinks per day), smoking habits (Never smoked, Quit smoking, 
Currently smokes). 
13.2.1.2 Prior or concomitant medications 
All medications taken within 12 weeks (84 days) before randomization and until the end of the 
study, including atorvastatin (other than atorvastatin IP) and other Lipid Lowering Therapies are 
to be reported in the corresponding dedicated e-CRF screens. 
All medications will be coded using the World Health Organization-Drug Dictionary (WHO-DD) 
using version currently in effect at sanofi-aventis at the time of the database lock. 
Prior medications are those the patient used within 12 weeks (84 days) prior first injection of 
SAR236553 or placebo for SAR236553. Prior medications can be discontinued before first 
injection or can be ongoing during treatment phase. 
Concomitant medications are any treatments received by the patient concomitantly to the 
SAR236553 (or placebo for SAR236553), on or after randomization and before last injection + 
10 weeks (70 days). A given medication can be classified both as a prior medication and as a 
concomitant medication.  
Atorvastatin 10 mg is to be taken by all patients at stable dose as prior medication for at least 
7 weeks (49 days). 
13.2.2 Efficacy endpoints 
13.2.2.1 Primary efficacy endpoint(s) 
The primary efficacy variable is the percent change in calculated LDL-C from baseline to Week 8, 
which is defined as: 100x (calculated LDL-C value at Week 8 - calculated LDL-C value at 
baseline) / calculated LDL-C value at baseline. 
The baseline calculated LDL-C value will be the average of the last pre-randomization (Visit 1, 
Week -1) calculated LDL-C value and the randomization (Visit 2, Week 0) calculated LDL-C 
value. In case the randomization calculated LDL-C value would be missing, the baseline value 
will consist of the last pre-randomization (Week -1) calculated LDL-C value. 
If a patient discontinues the treatment prematurely during the 8-week treatment period or does not 
have calculated LDL-C value at Week 8, then the last available calculated LDL-C value measured 
during the on-treatment period and before Week 8 will be used as calculated LDL-C value at 
Week 8 (Last Observation Carried Forward [LOCF] procedure).  
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The on-treatment period for calculated LDL-C will be defined as the time from the first 
SAR236553 or placebo for SAR236553 injection up to 21 days after the last SAR236553 or 
placebo for SAR236553 injection, or up to 84 days after the first injection whichever come first.  
Indeed: 
- SAR236553 serum concentrations greater than 10 µg/mL are expected no more than 
21 days after last injection of SAR236553 150 mg dose. 
- In order to maintain steady state phase of SAR236553 serum concentration, 3 weeks 
between two injections of  SAR236553 150 mg should not be exceeded, and this 
would lead to a last visit 12 weeks (84 days) after first injection.  
All LDL-C measurements (scheduled or unscheduled, fasting or not fasting) may be used to 
provide a value for the primary efficacy variable if appropriate according to above definition. 
Time windows used to allocate a time point to a measurement will be defined in the SAP. 
13.2.2.2 Secondary efficacy endpoint(s) 
The secondary efficacy variables are: 
• The absolute change from baseline (mg/dL and mmol/L) in calculated LDL-C to Week 8 
defined as: (calculated LDL-C value at Week 8 - calculated LDL-C value at baseline), 
using same definitions and rules as those defined in Section 13.2.2.1 . 
• The proportion of patients achieving an LDL-C level lower than 100 mg/dL 
(2.59 mmol/L) at Week 8 defined as: (number of patients whose calculated LDL-C value 
at Week 8 is strictly lower than 100 mg/dL / number of patients in the mITT 
population)*100, using same definitions and rules as those defined in Section 13.2.2.1 . 
• The proportion of patients achieving an LDL-C level lower than 70 mg/dL (1.81 mmol/L) 
at Week 8 will be assessed similarly. 
• Percent and absolute (mg/dL and mmol/L) change in total cholesterol from baseline to 
Week 8: same definitions and rules as for percent and absolute change in calculated 
LDL-C from baseline to Week 8. 
• Percent and absolute (mg/dL and mmol/L) change in HDL-C from baseline to Week 8: 
same definitions and rules as for percent and absolute change in calculated LDL-C from 
baseline to Week 8. 
• Percent and absolute (mg/dL and mmol/L) change in TG from baseline to Week 8: same 
definitions and rules as for percent and absolute change in calculated LDL-C from 
baseline to Week 8, excluding measurements on not fasting patients.  
• Percent and absolute (mg/dL and mmol/L) change in non HDL-C from baseline to 
Week 8: same definitions and rules as for percent and absolute change in calculated 
LDL-C from baseline to Week 8. 
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• Percent change in Apo-B from baseline to Week 8: same definition and rules as for the 
percent change in calculated LDL-C from baseline to Week 8, except for baseline value 
that will be the randomization (Visit 2, Week 0) Apo-B value, or, if missing, the last 
unscheduled value assessed within 10 days before randomization. 
• Percent change in Apo-A1 from baseline to Week 8: same definition as for the percent 
change in Apo-B from baseline to Week 8. 
• Absolute change in the ratio Apo-B/Apo-A1 from baseline to Week 8: same definition as 
for the percent change in Apo-B from baseline to Week 8. 
• Percent change in Lp(a) from baseline to Week 8: same definition as for the percent 
change in Apo-B from baseline to Week 8. 
13.2.2.3 Exploratory variables 
Exploratory variables are: 
• Absolute change in HbA1c (%) from baseline to Week 8: same definition and rules as for 
the absolute change in calculated LDL-C from baseline to Week 8, except for baseline 
value that will be the last available value assessed within 10 days before randomization. 
• Absolute change from baseline in fasting plasma glucose (mg/dL and mmol/L) to Week 8: 
same definition and rules as for the absolute change in calculated LDL-C from baseline to 
Week 8, except for baseline value that will be the randomization (Visit 2, Week 0) fasting 
plasma glucose value, without replacement rule if missing. 
• Percent change from baseline in hs-CRP to Week 8: same definition and rules as for the 
percent change in calculated LDL-C from baseline to Week 8, except for baseline value 
that will be the randomization (Visit 2, Week 0) hs-CRP value, or, if missing, the last 
unscheduled value assessed within 10 days before randomization. In a second approach, 
hs-CRP values greater or equal to 10 mg/L will not be included in time point analyses. 
• Percent and absolute (kg) change from baseline in body weight to Week 8: same 
definitions and rules as for percent and absolute change in calculated LDL-C from 
baseline to Week 8, except for baseline value that will be the randomization (Visit 2, 
Week 0) body weight, or, if missing, the last value assessed within 10 days before 
randomization. 
13.2.3 Safety endpoints 
The safety analysis will be based on the reported adverse events (AEs) and other safety 
information, such as clinical laboratory data, vital signs, and ECG. 
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Observation period  
The observation period will be divided into 5 EPOCH: 
• The SCREENING epoch is defined as the time from the signed informed consent date up 
to randomization. 
• The TREATMENT epoch is defined as the time from first injection of SAR236553 or 
placebo for SAR236553 to last injection + 14 days. 
• The RESIDUAL TREATMENT epoch is defined as the time from last injection + 14 days 
to last injection + 70 days (10 weeks). 
The TEAE period will include both TREATMENT and RESIDUAL TREATMENT epochs. 
• The POST-TREATMENT period is defined as the period of time starting the day after the 
end of the TEAE period up to the end of the study (defined as last protocol planned visit or 
the resolution/stabilization of all SAE and AEs with pre-specified monitoring). 
• The on-study observation period is defined as the time from first injection of SAR236553 
or placebo for SAR236553 until the end of the study (defined as last protocol planned visit 
or the resolution/stabilization of all SAE and AEs with pre-specified monitoring). 
13.2.3.1 Adverse events 
AE observation period:  
The AE observations are per the observation periods defined above. 
Adverse event observation period: 
• Pre-treatment AEs are AEs that developed or worsened or became serious from the signed 
informed consent date up to first injection of  SAR236553 or placebo for SAR236553; 
• Treatment-emergent AEs (TEAEs) are AEs that developed or worsened or became serious 
during the TEAE period; 
• Post-treatment AEs are AEs that developed or worsened or became serious during the 
post-treatment period. 
All AEs (including SAEs and AEs with pre-specified monitoring) will be coded to a “Lower 
Level Term (LLT)”, “Preferred Term (PT)”, “High Level term (HLT)”, “High Group Level Term 
(HLGT)” and associated primary “System Organ Class (SOC)” using the version of MedDRA 
(Medical Dictionary for Regulatory Activities) currently in effect at sanofi-aventis at the time of 
the database lock. 
Record the occurrence of AEs (including SAEs and AEs with pre-specified monitoring) from the 
time of signed informed consent until the end of the study. 
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13.2.3.2 Deaths 
Death observation period:  
The deaths observation period are per the observation periods defined above: 
• Death on-study: deaths occurring during the on-study observation period 
• Death on-treatment: deaths occurring during the TEAE period 
• Death post-study: deaths occurring after the end of study 
13.2.3.3 Laboratory safety variables 
The clinical laboratory data consist of blood analysis (hematology, clinical chemistry and 
urinalysis). Clinical laboratory values, provided in conventional units, will be also converted into 
standard international units. Standard international units will be used in all listings and tables. 
13.2.3.4 Vital signs 
Vital Signs include: Heart Rate (HR), Systolic and Diastolic Blood Pressure (SBP and DBP) in 
supine position.  
13.2.3.5 ECG variables 
The ECG will be determined using a centralized automatic and manual reading of all ECGs. 
ECG parameters include: Heart rate, QRS duration, PR interval, QT interval as well as corrected 
QTc (according to both Bazett and Fridericia formula).  
13.2.3.6 Anti-SAR236553 antibodies 
Anti-SAR236553 antibodies (status and titers) will be assessed at Week 0 (baseline), Week 4, 
Week 8, then during the follow-up period at Week 12, and Week 16. 
13.2.4 Pharmacokinetic variables 
Serum SAR236553 concentrations will be assessed at Week 0 (Day 1), and then at each visit up to 
the last visit of the follow-up period (Weeks 2, 4, 6, 8, 12, and 16). 
13.2.5 Pharmacodynamic/genomics variables 
The statistical analysis of the pharmacogenomic substudy will be fully developed in a specific 
SAP. It will include the type and list of markers, as well as the statistical methods and analyses to 
perform. This analysis will be exploratory in nature, with the aim to search for potential 
association between genetic/genomic markers and the response to the treatment.  
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The primary analysis of the candidate genes (PCSK9, ApoB, LDL-R)  will consist in assessing the 
association between each polymorphism (SNP) taken individually first and the primary endpoint. 
Then, in the presence of more than one significant or suggestive association, these SNPs may be 
explored in a multi-marker model.  
The percent change from baseline in LDL-C at week 8 will be analyzed via a statistical model 
similar to the model used in the primary analysis of the study and including additional terms for 
SNP and treatment*SNP interaction. Genotypes will be coded appropriately based on the a priori 
assumed mode of inheritance (dominant, recessive, additive), which will be specified in the 
pharmacogenetic SAP.  
Significance of the genetic association will be assessed with a likelihood ratio test (LRT). In all 
null models, the genetic effect is assumed to be zero (i.e., without treatment*SNP).  Significance 
of the maximum likelihood estimate will be assessed by comparing the alternative model (i.e., 
with treatment*SNP) to its corresponding null model using an LRT, which is chi-square 
distributed with degrees of freedom equal to the number of differing parameters. 
If it is determined that the above approach including the interaction term is not sufficient due to 
technical difficulties or sample size complications, then an alternative strategy will be employed 
to test for SNP main effects within individual treatment arms. A comparison will then be made to 
placebo to assess whether the genetic association is specific to the SAR236553, or seen in all 
groups. The significance in this single SNP association analysis will be determined using the false 
discovery rate (FDR) procedure. 
13.2.6 Health economic variables 
Not applicable. 
13.2.7 Further therapy after stop of IP administration during the study 
Not applicable. 
13.3 DISPOSITION OF PATIENTS 
Screened patients are defined as any patient who met the inclusion criteria and signed the 
informed consent.  
Randomized patients consist of all patients, with signed inform consent, with a treatment kit 
number allocated and recorded in the IVRS/IWRS database, regardless of whether the treatment 
kit was used or not. Patients treated without being randomized will not be considered as 
randomized and will not be included in any efficacy population.   
For any patient randomized more than once, only the data associated with the first randomization 
will be used in any analysis population. The safety experience associated with any later 
randomization will be assessed separately. 
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The safety experience of patients treated and not randomized will be reported separately, and 
these patients will not be in the safety population. 
13.4 ANALYSIS POPULATIONS 
13.4.1 Efficacy populations 
The primary efficacy analysis population will be the modified intent-to-treat (mITT) population. 
13.4.1.1 Modified intent-to-treat population 
Modified ITT (mITT) population: ITT population (i.e., randomized population) with an evaluable 
primary endpoint. The primary endpoint will be considered as evaluable when both of the 
following conditions are met: 
• The Week -1 or Week 0 calculated LDL-C value is available. 
• At least one on-treatment LDL-C value is available. The on-treatment period for the 
primary efficacy variable will be defined as the time from the first SAR236553 or placebo 
for SAR236553 injection up to 21 days after the last injection, or up to 84 days after the 
first SAR236553 or placebo for SAR236553 injection, whichever come first. 
Patients in the mITT population will be analyzed according to the treatment group allocated by 
randomization. 
13.4.2 Safety population 
Safety population is defined as:  
Randomized population who did actually receive at least one dose or partial dose of SAR236553 
or placebo for SAR236553 analyzed according to the treatment actually received.  
In addition:  
• Non-randomized but treated patients will not be part of the safety population, but their 
safety data will be presented separately.  
• Randomized patients for whom it is unclear whether they received SAR236553 (or 
placebo for SAR236553) will be included in the safety population as randomized. 
• For patients receiving SAR236553 IP (active/placebo) differing from the allocated ones, 
the treatment group allocation for as-treated analysis will be defined and documented on a 
case by case basis and in a blinded manner during Data Review: all possible scenarios for 
the identified case will be listed and a treatment group for as-treated analysis will be 
allocated for each scenario using the following principles: to allocate the treatment group 
the closest to the actual treatment received by the patient.   
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13.4.3 Other analysis population 
Analysis populations for anti-SAR236553 antibodies and PK will be defined in the SAP. 
13.5 STATISTICAL METHODS 
13.5.1 Demographic and baseline characteristics 
Continuous data will be summarized using number of available data, mean, SD, median, 
minimum, and maximum for each treatment group. Categorical and ordinal data will be 
summarized using number and percentage of patients in each treatment group. 
Parameters will be summarized on the all randomized population, analyzed in the treatment group 
to which they were randomized.  
Parameters described in Section 13.2.1.1 will be summarized by treatment group and overall using 
descriptive statistics. Medical and surgical history will be presented by decreasing frequency of 
Primary System Organ Class based on the overall incidence across treatment group. 
P-values on demographic and baseline characteristic data will not be calculated. 
No specific description of the safety parameters will be provided at baseline. If relevant, the 
baseline values will be described along with each safety analysis. 
No specific description of the efficacy parameters will be provided at baseline. If relevant, the 
baseline values will be described along with each efficacy analysis. 
13.5.2 Prior or concomitant medications 
The prior and concomitant medications will be presented on the randomized population.  
Medications will be summarized by treatment group according to the WHO-DD dictionary, 
considering the first digit of the ATC class (anatomic category) and the first three digits of the 
ATC class (therapeutic category). All ATC codes corresponding to a medication will be 
summarized, patients will be counted once in each ATC categories (anatomic or therapeutic) 
linked to the medication, therefore patients may be counted several time for the same medication.  
The tables for prior medications will be sorted by decreasing frequency of anatomic category 
followed by all other therapeutic classes based on the overall incidence across treatment groups. 
In case of equal frequency regarding anatomic categories (respectively therapeutic categories), 
alphabetical order will be used. 
The tables for concomitant medications will be sorted by decreasing frequency of anatomic 
category followed by all other therapeutic classes based on the incidence of the SAR236553 
150mg every two weeks + atorvastatin 80 mg group. In case of equal frequency regarding 
anatomic categories (respectively therapeutic categories), alphabetical order will be used. 
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In addition, the following specific medications will be summarized:  
• Background atorvastatin use (as reported in the dedicated e-CRF screen): prior use 
between 84 days and 46 days prior to first SAR236553 or placebo for SAR236553 
injection and within 45 days prior to first SAR236553 or placebo for SAR236553 injection 
will be summarized separately; concomitant use after last SAR236553 or placebo for 
SAR236553 injection will be summarized. Atorvastatin use will be summarized by 
treatment group using average total daily dose (mg/day). 
• Prior, and concomitant other lipid lowering therapies (as reported in the dedicated e-CRF 
screen): prior lipid lowering therapies used between 84 days and 46 days prior to first 
SAR236553 or placebo for SAR236553 injection and within 45 days prior to first 
SAR236553 or placebo for SAR236553 injection will be summarized separately; 
concomitant lipid lowering therapies used up to 21 days after last SAR236553 or placebo 
for SAR236553 injection, and those used more than 21 days after last injection will be 
summarized separately. These medications will be summarized by International 
Nonproprietary Name (INN) and presented by treatment group using counts and 
percentages. 
13.5.3 Extent of study treatment exposure and compliance 
The extent of study treatment exposure and compliance will be assessed and summarized by 
actual SAR236553 treatment received within the safety population. 
13.5.3.1 Extent of investigational product exposure 
The extent of exposure will be assessed by: 
• the actual number of weeks on SAR236553 treatment, defined as: (last injection date – 
first injection date + 14 days)/7 
• the total number of  SAR236553 or placebo for SAR236553 injections by patients. 
SAR236553 or placebo for SAR236553 injection ahead/delay:  
An injection k will be considered as delayed if the time interval between the date of injection k 
and the date of injection (k-1) is > 14 + 3 days (i.e. > 3 days compared to the theoretical day). 
An injection k will be considered as advanced if the time interval between the date of injection 
k and the date of injection (k-1) is < 14 - 3 days (i.e. < 3 days compared to the theoretical day). 
The first injection will not be counted for injection delay/ahead.  
Injection delay will be classified as following: between 4 and 7 days of delay, or more than 
7 days of delay. Injection ahead will be classified as following: between 4 and 7 days ahead, 
or more than 7 days ahead. 
Total number of injections delayed, advanced and number of patients with at least one 
injection delayed, advanced will be summarized by treatment group.  
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13.5.3.2 Compliance to atorvastatin IP 
A given atorvastatin IP administration will be considered as non compliant if the patient did not 
take the planned dose of atorvastatin IP as required by the protocol.  No imputation will be made 
for patients with missing or incomplete data. Atorvastatin IP compliance, above-planned and 
under-planned dosing percentages will be summarized descriptively (N, Mean, SD, Median, Min, 
and Max). The percentage of patients with compliance is < 80% will be summarized. In addition, 
number and percentage of patients with at least one above-planned dosing administration will be 
given, as well as the number and percentage of patients with 0, (0, 20%], and >20% 
under-planned dosing administrations. 
13.5.4 Analyses of efficacy endpoints 
13.5.4.1 Analysis of primary efficacy endpoint(s) 
The percent change from baseline in calculated LDL-C at Week 8-LOCF as defined in  
Section 13.2.2.1 will be analyzed in the mITT population using an analysis of covariance 
(ANCOVA) model with treatment group as fixed effect and the baseline LDL-C as covariate. The 
treatment group factor will have three levels: SAR236553 placebo + atorvastatin 80 mg, 
SAR236553 + atorvastatin 10 mg, SAR236553 + atorvastatin 80 mg.  
Throughout the ANCOVA model, the SAR236553 + atorvastatin 80 mg group will be compared 
to SAR236553 placebo + atorvastatin 80 mg group using appropriate contrast and the 95% 
confidence interval (CI) of the difference will be provided. No formal comparisons with the 
SAR236553 + atorvastatin 10 mg group will be performed: only 95% CIs for difference versus 
other arms will be provided. 
Model assumption checks 
Homogeneity of slopes: 
A treatment group-by-baseline LDL-C interaction term will be added in the primary ANCOVA 
model and the significance of its effect based on SAS Type III sum-of-squares will be tested at the 
10% significance level. If the interaction is significant, a separate-slopes model with terms for 
treatment group and treatment group- by-baseline LDL-C interaction will be fitted to the data, and 
the graph presenting the separate slopes for each treatment group by baseline LDL-C values will 
be provided. 
Gaussian distribution: 
The normality of the residuals of the ANCOVA model will be assessed graphically using 
histogram, and plots of the percentiles (resp. quantiles) of fitted Gaussian distribution versus 
ordered residual values. Skewness and Kurtosis measures, as well as Shapiro-Wilk statistic will be 
also examined. If substantial deviations from the assumptions are found, the normalized (using 
Tukey’s) rank transformation approach to the same ANCOVA model (without Tukey’s rank 
transformation for the baseline covariate) will be performed as a sensitivity test. 
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Homogeneity of variance: 
The homogeneity of variances will be checked by displaying the standard deviations of the 
residuals within each level of the treatment group.  
13.5.4.2 Analyses of secondary efficacy endpoints 
Continuous secondary Week 8-LOCF variables defined in Section 13.2.2.2 will be analyzed in the 
mITT population using the same ANCOVA model as for the primary endpoint with treatment 
group as fixed effect, and corresponding baseline value as covariate. 
Absolute (mg/dL and mmol/L) and percent change from baseline in calculated LDL-C, TC, HDL-
C, TG, and non HDL-C at Week 2, Week 4, Week 6, and Week 8 will be summarized in the 
mITT population using number of available data, mean, SD, median, minimum, and maximum for 
each treatment group. All on-treatment measurements (up to 21 days after the last SAR236553 or 
placebo for SAR236553 injection, or up to 84 days after the first injection whichever come first), 
scheduled or unscheduled, will be assigned to time windows defined in the SAP in order to 
provide an assessment for these time points. For TG, measurements on not fasting patients will be 
excluded. The time profile of each parameter will be also plotted by treatment group with the 
corresponding standard errors. The plots will include LOCF values, and available Week 12 and 
Week 16 post-treatment values. Same kind of plots will be provided for other lipids parameters: 
Apo-B, Apo-A1, ratio Apo-B/Apo-A1, Lp(a). 
Binary secondary variables defined in Section 13.2.2.2 will be analyzed in the mITT population 
using a logistic regression model with factor for treatment and baseline LDL-C value as covariate. 
Exploratory variables defined in Section 13.2.2.2 will be summarized by time points in the mITT 
population using number of available data, mean, SD, median, minimum, and maximum for each 
treatment group (for hs-CRP, Q1 and Q2 will be also provided). The time profile for body weight 
will be also plotted by treatment group with the corresponding standard errors. The plot will also 
include LOCF value, and available Week 12 and Week 16 post-treatment values. 
13.5.4.3 Multiplicity Considerations 
Not applicable. 
13.5.5 Analyses of safety data 
The summary of safety results will be presented by treatment group.  
All safety analyses will be performed on the Safety population as defined in Section 13.4.2, unless 
otherwise specified, using the following common rules: 
• Safety data in patients who do not belong to the safety population (e.g., exposed but not 
randomized) will be listed separately 
• The baseline value is defined as the last available value before randomization. 
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The following definitions will be applied to safety laboratory parameters, vital signs and ECG. 
• The Potentially Clinically Significant Abnormality (PCSA) values are defined as abnormal 
values considered medically important by the sponsor according to predefined 
criteria/thresholds based on literature review and defined by the sponsor for clinical 
laboratory tests, vital signs and ECG.  
• PCSA criteria will determine which patients had at least one PCSA during the on-
treatment period, taking into account all evaluations performed during the on-treatment 
period, including non-scheduled or repeated evaluations.  The number of all such patients 
will be the numerator for the on-treatment PCSA percentage.   
Adverse event incidence tables will present by system-organ-class (SOC) (sorted by 
internationally agreed order), High level group term (HLGT), High level term (HLT) and 
preferred term (PT) sorted in alphabetical order for each treatment group, the number (n) and 
percentage (%) of patients experiencing an AE.  Multiple occurrences of the same event in the 
same patient will be counted only once in the tables within a treatment phase. The denominator 
for computation of percentages is the safety population within each treatment group. 
 
Death: The following deaths summaries will be generated: 
• Number (%) of patients who died by study period (TEAE, on-study, post-study) 
summarized on the safety population by treatment received 
• Death in non-randomized patients or randomized and not treated patients   
TEAE leading to death (death as an outcome on the AE e-CRF screen as reported by the 
Investigator) by primary SOC , HLGT, HLT and PT showing number (%) of patients sorted by 
internationally agreed order of SOC and alphabetic order of HLGT, HLT, and PT. 
13.5.6 Analyses of pharmacokinetic and pharmacodynamic variables 
The antibody status (positive/negative) and antibody titers will be summarized by treatment group 
and visit using descriptive statistics. If appropriate, correlations between antibody titers and PD or 
PK endpoints will be provided by graphical methods. 
Serum SAR236553 concentrations will be summarized by treatment group and visit using 
descriptive statistics.  Serum concentration time profiles will be provided by treatment group. 
Additional plots will be prepared, as deemed necessary. 
Further details will be provided in SAP. 
13.5.7 Analyses of quality of life/health economics variables 
Not applicable. 
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13.6 DATA HANDLING CONVENTIONS 
This section describes general rules for data handling conventions, especially for patients with 
missing data. 
Missing dates will be handled using conservative approaches, and no imputation will be applied at 
the data level: 
• If the date of the last dose of investigational drug is missing, the exposition duration 
should be kept as missing. 
• If a medication date or time is missing or partially missing, it will be considered as a prior, 
and concomitant medication, when no reasonable conclusion can be reached in this 
situation. 
• If onset dates and times are missing or partially missing, the AE will be classified as 
treatment-emergent. If the date and time of the first investigational drug is missing, all 
AEs that occurred after or on the day of randomization will be considered as treatment 
emergent AEs. 
• Handling of PCSAs: If a subject has a missing baseline he will be grouped in the category 
“normal /missing at baseline”. For PCSA with two conditions, one based on a change from 
baseline value or a normal range and the other one on a threshold value, the first condition 
being missing, the PCSA will be based only on the second condition. For PCSA defined 
on a threshold and / or a normal range, this PCSA will be derived using this threshold only 
if the normal range is missing.  For example, for eosinophils the PCSA is > 0.5 GIGA/L or 
> ULN if ULN ≥ 0.5 GIGA /L . When ULN is missing the value 0.5 should be used. 
13.7 INTERIM ANALYSIS 
No interim analysis planned for this study. 
13.8 DATABASE LOCK 
The database is planned to be locked 28 days after Last Patient Last Visit. 
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14 ETHICAL AND REGULATORY STANDARDS 
14.1 ETHICAL PRINCIPLES 
This Clinical Trial will be conducted in accordance with the principles laid down by the 18th 
World Medical Assembly (Helsinki, 1964) and all applicable amendments laid down by the 
World Medical Assemblies, and the ICH guidelines for Good Clinical Practice (GCP). 
In compliance with sanofi-aventis public disclosure commitments, this clinical trial will be 
recorded in the public registry website clinicaltrials.gov before the enrollment of the first patient. 
The registry will contain basic information about the trial sufficient to inform interested patients 
(and their healthcare practitioners) how to enroll in the trial. 
14.2 LAWS AND REGULATIONS 
This Clinical Trial will be conducted in compliance with all international guidelines, and national 
laws and regulations of the country(ies) in which the Clinical Trial is performed, as well as any 
applicable guidelines. Please see Section 15.1. 
14.3 INFORMED CONSENT 
The Investigator (according to applicable regulatory requirements), or a person designated by the 
Investigator, and under the Investigator's responsibility, should fully inform the Patient of all 
pertinent aspects of the Clinical Trial including the written information giving approval/favorable 
opinion by the Ethics Committee (IRB/IEC). All participants should be informed to the fullest 
extent possible about the study, in language and terms they are able to understand. 
Prior to a patient’s participation in the Clinical Trial, the written Informed Consent Form should 
be signed, name filled in and personally dated by the patient or by the patient’s legally acceptable 
representative, and by the person who conducted the informed consent discussion. A copy of the 
signed and dated written Informed Consent Form will be provided to the patient.  
The Informed Consent Form used by the Investigator for obtaining the patient's informed consent 
must be reviewed and approved by the Sponsor prior to submission to the appropriate Ethics 
Committee (IRB/IEC) for approval/favorable opinion. 
14.4 INSTITUTIONAL REVIEW BOARD/INDEPENDENT ETHICS COMMITTEE (IRB/IEC) 
As required by local regulation, the Investigator or the Sponsor must submit this Clinical Trial 
Protocol to the appropriate Ethics Committee (IRB/IEC), and is required to forward to the 
respective other party  a copy of the written and dated approval/favorable opinion signed by the 
Chairman with Ethics Committee (IRB/IEC) composition. 
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The Clinical Trial (study number, Clinical Trial Protocol title and version number), the documents 
reviewed (Clinical Trial Protocol, Informed Consent Form, Investigator’s Brochure, Investigator’s 
curriculum vitae [CV], etc.) and the date of the review should be clearly stated on the written 
(IRB/IEC) approval/favorable opinion. 
IP/NIP will not be released at the study site and the Investigator will not start the study before the 
written and dated approval/favorable opinion is received by the Investigator and the Sponsor. 
During the Clinical Trial, any amendment or modification to the Clinical Trial Protocol should be 
submitted to the Ethics Committee (IRB/IEC) before implementation, unless the change is 
necessary to eliminate an immediate hazard to the patients, in which case the IRB/IEC should be 
informed as soon as possible. It should also be informed of any event likely to affect the safety of 
patients or the continued conduct of the Clinical Trial, in particular any change in safety. All 
updates to the Investigator’s Brochure will be sent to the Ethics Committee (IRB/IEC). 
A progress report is sent to the Ethics Committee (IRB/IEC) at least annually and a summary of 
the Clinical Trial’s outcome at the end of the Clinical Trial. 
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15 STUDY MONITORING 
15.1 RESPONSIBILITIES OF THE INVESTIGATOR(S) 
The Investigator(s) and delegated Investigator staff undertake(s) to perform the Clinical Trial in 
accordance with this Clinical Trial Protocol, ICH guidelines for Good Clinical Practice and the 
applicable regulatory requirements. 
The Investigator is required to ensure compliance with all procedures required by the Clinical 
Trial Protocol and with all study procedures provided by the Sponsor (including security rules). 
The Investigator agrees to provide reliable data and all information requested by the Clinical Trial 
Protocol (with the help of the e-CRF, Discrepancy Resolution Form [DRF] or other appropriate 
instrument) in an accurate and legible manner according to the instructions provided and to ensure 
direct access to source documents by Sponsor representatives. 
If any circuit includes transfer of data particular attention should be paid to the confidentiality of 
the patient's data to be transferred. 
The Investigator may appoint such other individuals as he/she may deem appropriate as Sub-
Investigators to assist in the conduct of the Clinical Trial in accordance with the Clinical Trial 
Protocol. All Sub-Investigators shall be appointed and listed in a timely manner. The 
Sub-Investigators will be supervised by and work under the responsibility of the Investigator. The 
Investigator will provide them with a copy of the Clinical Trial Protocol and all necessary 
information. 
15.2 RESPONSIBILITIES OF THE SPONSOR 
The Sponsor of this Clinical Trial is responsible to Health Authorities for taking all reasonable 
steps to ensure the proper conduct of the Clinical Trial Protocol as regards ethics, Clinical Trial 
Protocol compliance, and integrity and validity of the data recorded on the e-CRFs. Thus, the 
main duty of the Monitoring Team is to help the Investigator and the Sponsor maintain a high 
level of ethical, scientific, technical and regulatory quality in all aspects of the Clinical Trial. 
At regular intervals during the Clinical Trial, the site will be contacted, through monitoring visits, 
letters or telephone calls, by a representative of the Monitoring Team to review study progress, 
Investigator and patient compliance with Clinical Trial Protocol requirements and any emergent 
problems. These monitoring visits, will include but not be limited to review of the following 
aspects : patient informed consent, patient recruitment and follow-up, SAE documentation and 
reporting, AEs with pre-specified monitoring documentation and reporting, AE documentation, IP 
allocation, patient compliance with the IP regimen, IP accountability, concomitant therapy use 
and quality of data. 
 
Clinical Trial Protocol  26-Nov-2010 
SAR236553-DFI11566 -   Version number: 1 (electronic 1.0) 
Property of the sanofi-aventis group - strictly confidential Page 93 
15.3 SOURCE DOCUMENT REQUIREMENTS 
According to the ICH guidelines for Good Clinical Practice, the Monitoring Team must check the 
e-CRF entries against the source documents, except for the pre-identified source data directly 
recorded in the e-CRF. The Informed Consent Form will include a statement by which the patient 
allows the Sponsor’s duly authorized personnel, the Ethics Committee (IRB/IEC), and the 
regulatory authorities to have direct access to original medical records  which support the data on 
the e-CRFs (e.g., patient's medical file, appointment books, original laboratory records, etc.). 
These personnel, bound by professional secrecy, must maintain the confidentiality of all personal 
identity or personal medical information (according to confidentiality and personal data protection 
rules). 
15.4 USE AND COMPLETION OF CASE REPORT FORMS (CRFS) AND ADDITIONAL 
REQUEST 
It is the responsibility of the Investigator to maintain adequate and accurate e-CRFs (according to 
the technology used) designed by the Sponsor to record (according to Sponsor instructions) all 
observations and other data pertinent to the clinical investigation in a timely manner. All e-CRFs 
should be completed in their entirety in a neat, legible manner to ensure accurate interpretation of 
data. 
Should a correction be made, the corrected information will be entered in the e-CRF overwriting 
the initial information. An audit trail allows identifying the modification.  
Data are available within the system to the sponsor as soon as they are entered in the e-CRF. 
The computerized handling of the data by the Sponsor when available in the e-CRF may generate 
additional requests (DRF) to which the Investigator is obliged to respond by confirming or 
modifying the data questioned. The requests with their responses will be managed through the 
e-CRF. 
15.5 USE OF COMPUTERIZED SYSTEMS 
Computerized systems used during the different steps of the study are: 
• For data management activities, an e-CRF will be built using Oracle Clinical. 
• For pharmacokinetic activities, WinNonlin. 
• For statistical activities, nQuery Advisor 6.01, SAS. 
• For pharmacovigilance activities, Clintrace and AWARE.  
• For monitoring activities, IMPACT. 
• For medical writing activities, DOMASYS FDA 21 CFR Part 11 compliant system will be 
used. 
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16 ADMINISTRATIVE RULES 
16.1 CURRICULUM VITAE 
A  current copy of the curriculum vitae describing the experience, qualification and training of 
each Investigator and Sub-Investigator will be signed, dated and provided to the Sponsor prior to 
the beginning of the Clinical Trial. 
16.2 RECORD RETENTION IN STUDY SITES (S) 
The Investigator must maintain confidential all study documentation, and take measures to 
prevent accidental or premature destruction of these documents. 
The Investigator should retain the study documents at least fifteen (15) years after the completion 
or discontinuation of the Clinical Trial. 
However, applicable regulatory requirements should be taken into account in the event that a 
longer period is required. 
The Investigator must notify the Sponsor prior to destroying any study essential documents 
following the Clinical Trial completion or discontinuation. 
If the Investigator's personal situation is such that archiving can no longer be ensured by him/her, 
the Investigator shall inform the Sponsor and the relevant records shall be transferred to a 
mutually agreed upon designee. 
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17 CONFIDENTIALITY 
All information disclosed or provided by the Sponsor (or any company/institution acting on their 
behalf), or produced during the Clinical Trial, including, but not limited to, the Clinical Trial 
Protocol, the CRFs, the Investigator's Brochure and the results obtained during the course of the 
Clinical Trial, is confidential, prior to the publication of results. The Investigator and any person 
under his/her authority agree to undertake to keep confidential and not to disclose the information 
to any third party without the prior written approval of the Sponsor. 
However, the submission of this Clinical Trial Protocol and other necessary documentation to the 
Ethics Committee (IRB/IEC) is expressly permitted, the IRB/IEC members having the same 
obligation of confidentiality. 
The Sub-Investigators shall be bound by the same obligation as the Investigator. The Investigator 
shall inform the Sub-Investigators of the confidential nature of the Clinical Trial. 
The Investigator and the Sub-Investigators shall use the information solely for the purposes of the 
Clinical Trial, to the exclusion of any use for their own or for a third party's account. 
Furthermore, the Investigator and the Sponsor agree to adhere to the principles of personal data 
confidentiality in relation to the patients, Investigator and its collaborators involved in the study. 
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18 PROPERTY RIGHTS 
All information, documents and IP provided by the Sponsor or its designee are and remain the 
sole property of the Sponsor. 
The Investigator shall not mention any information or the Product in any application for a patent 
or for any other intellectual property rights. 
All the results, data, documents and inventions, which arise directly or indirectly from the Clinical 
Trial in any form, shall be the immediate and exclusive property of the Sponsor. 
The Sponsor may use or exploit all the results at its own discretion, without any limitation to its 
property right (territory, field, continuance). The Sponsor shall be under no obligation to patent, 
develop, market or otherwise use the results of the Clinical Trial. 
As the case may be, the Investigator and/or the Sub-Investigators shall provide all assistance 
required by the Sponsor, at the Sponsor's expense, for obtaining and defending any patent, 
including signature of legal documents. 
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19 DATA PROTECTION 
• The patient's personal data, which are included in the Sponsor database shall be treated in 
compliance with all applicable laws and regulations; 
• When archiving or processing personal data pertaining to the Investigator and/or to the 
patients, the Sponsor shall take all appropriate measures to safeguard and prevent access to 
this data by any unauthorized third party. 
• The Sponsor also collects specific data regarding Investigator as well as personal data 
from any person involved in the study which may be included in the Sponsor’s databases, 
shall be treated by both the Sponsor and the Investigator in compliance with all applicable 
laws and regulations. 
 
Clinical Trial Protocol  26-Nov-2010 
SAR236553-DFI11566 -   Version number: 1 (electronic 1.0) 
Property of the sanofi-aventis group - strictly confidential Page 98 
20 INSURANCE COMPENSATION 
The Sponsor certifies that it has taken out a liability insurance policy covering all clinical trials 
under its sponsorship.  This insurance policy is in accordance with local laws and requirements. 
The insurance of the Sponsor does not relieve the Investigator and the collaborators from 
maintaining their own liability insurance policy. An insurance certificate will be provided to the 
Ethics committees/IRB or Health Authorities in countries requiring this document. 
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21 SPONSOR AUDITS AND INSPECTIONS BY REGULATORY 
AGENCIES 
For the purpose of ensuring compliance with the Clinical Trial Protocol, Good Clinical Practice 
and applicable regulatory requirements, the Investigator should permit auditing by or on the 
behalf of the Sponsor and inspection by regulatory authorities. 
The Investigator agrees to allow the auditors/inspectors to have direct access to his/her study 
records for review, being understood that these personnel is bound by professional secrecy, and as 
such will not disclose any personal identity or personal medical information. 
The Investigator will make every effort to help with the performance of the audits and inspections, 
giving access to all necessary facilities, data, and documents. 
As soon as the Investigator is notified of a planned inspection by the authorities, he will inform 
the Sponsor and authorize the Sponsor to participate in this inspection. 
The confidentiality of the data verified and the protection of the patients should be respected 
during these inspections. 
Any result and information arising from the inspections by the regulatory authorities will be 
immediately communicated by the Investigator to the Sponsor. 
The Investigator shall take appropriate measures required by the Sponsor to take corrective 
actions for all problems found during the audit or inspections. 
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22 PREMATURE DISCONTINUATION OF THE STUDY OR 
PREMATURE CLOSE-OUT OF A SITE 
22.1 DECIDED BY THE SPONSOR IN THE FOLLOWING CASES: 
• If the information on the product leads to doubt as to the benefit/risk ratio; 
• If the Investigator has received from the Sponsor all IP, means and information necessary 
to perform the Clinical Trial and has not included any patient after a reasonable period of 
time mutually agreed upon; 
• In the event of breach by the Investigator of a fundamental obligation under this 
agreement, including but not limited to breach of the Clinical Trial Protocol, breach of the 
applicable laws and regulations or breach of the ICH guidelines for Good Clinical 
Practice; 
• If the total number of patients are included earlier than expected; 
In any case the Sponsor will notify the Investigator of its decision by written notice. 
22.2 DECIDED BY THE INVESTIGATOR 
The Investigator must notify (30 days' prior notice) the Sponsor of his/her decision and give the 
reason in writing. 
In all cases (decided by the Sponsor or by the Investigator), the appropriate Ethics Committee(s) 
(IRB/IEC) and Health Authorities should be informed according to applicable regulatory 
requirements. 
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23 CLINICAL TRIAL RESULTS 
The Sponsor will be responsible for preparing a Clinical Study Report and to provide a summary 
of study results to the Investigator.  
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24 PUBLICATIONS AND COMMUNICATIONS 
The Investigator undertakes not to make any publication or release pertaining to the Study and/or 
results of the Study prior to the Sponsor’s written consent, being understood that the Sponsor will 
not unreasonably withhold its approval. 
As the Study is being conducted at multiple sites, the Sponsor agrees that, consistent with 
scientific standards, first presentation or publication of the results of the Study shall be made only 
as part of a publication of the results obtained by all sites performing the Protocol.  However, if no 
multicenter publication has occurred within twelve (12) months of the completion of this Study at 
all sites, the Investigator shall have the right to publish or present independently the results of this 
Study to the review procedure set forth herein.   The Investigator shall provide the Sponsor with a 
copy of any such presentation or publication derived from the Study for review and comment at 
least thirty (30) days in advance of any presentation or submission for publication.  In addition, if 
requested by the Sponsor, any presentation or submission for publication shall be delayed for a 
limited time, not to exceed ninety (90) days, to allow for filing of a patent application or such 
other measures as the Sponsor deems appropriate to establish and preserve its proprietary rights.  
The Investigator shall not use the name(s) of the Sponsor and/or its employees in advertising or 
promotional material or publication without the prior written consent of the Sponsor. The Sponsor 
shall not use the name(s) of the Investigator and/or the collaborators in advertising or promotional 
material or publication without having received his/her and/or their prior written consent(s). 
The sponsor has the right at any time to publish the results of the study. 
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25 CLINICAL TRIAL PROTOCOL AMENDMENTS 
All appendices attached hereto and referred to herein are made part of this Clinical Trial Protocol. 
The Investigator should not implement any deviation from, or changes of the Clinical Trial 
Protocol without agreement by the Sponsor and prior review and documented approval/favorable 
opinion from the IRB/IEC of an amendment, except where necessary to eliminate an immediate 
hazard(s) to Clinical Trial Patients, or when the change(s) involves only logistical or 
administrative aspects of the trial. Any change agreed upon will be recorded in writing, the 
written amendment will be signed by the Investigator and by the Sponsor and the signed 
amendment will be filed with this Clinical Trial Protocol. 
Any amendment to the Clinical Trial Protocol requires written approval/favorable opinion by the 
Ethics Committee (IRB/IEC) prior to its implementation, unless there are overriding safety 
reasons. 
In some instances, an amendment may require a change to the Informed Consent Form. The 
Investigator must receive an IRB/IEC approval/favorable opinion concerning the revised 
Informed Consent Form prior to implementation of the change and patient signature should be 
re-collected if necessary. 
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Appendix A General Guidance for the follow-up of laboratory 
abnormalities by sanofi-aventis  
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NOTE: IN ADDITION, AS SOON AS A SERIOUSNESS CRITERION IS MET, THE EVENT SHOULD BE 
NOTIFIED WITHIN 1 WORKING DAY TO THE MONITORING TEAM. 
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Appendix B DNA storage samples (Note: this appendix is for use 
in Phase II-III studies) 
1. PROCEDURE FOR COLLECTION, HANDLING, AND SHIPMENT OF 
OPTIONAL DNA STORAGE SPECIMENS  
• Collection schedule: per protocol. 
• Labeling of samples 
- Each sample tube should have attached to it the label provided by Covance. 
DNA  Subject ID:XXX-001-YYY 
Study Number / Compound (pre-printed) 
Bar Code (preprinted) 
Accession Number (pre-printed) 
- In the event of damage or loss of the provided labels, a new label should be 
immediately requested from Covance. 
• Procedure 
- Using a waterproof pen, write Subject ID Number on label in space provided. 
- Collect 6 mL of blood, using the 6 mL Vacutainer (Becton Dickinson; K2 EDTA with 
HEMOGARD Closure) provided, and gently invert tube at least 8 times permitting the 
specimen to mix with the anticoagulant. 
- Under no circumstances should the tube be centrifuged. 
- Ensure the sample tube is clearly and appropriately labeled as described above and in 
detail in the Covance Laboratory Manual. 
- Immediately freeze and maintain the blood in an upright position at -20°C or colder for 
storage. Samples must be stored on dry ice if a freezer is not immediately available. 
- Complete the Laboratory Requisition Form (provided by Covance) for each sample. 
• Storage 
- Samples must be kept at -20 ºC or colder, organized in a rack in numeric order 
according to the Subject ID, until ready for packaging and shipping. 
• Packaging and shipment 
- Samples and accompanying documents should be packaged according to the detailed 
instructions in the Covance Laboratory Manual provided at the initiation of the study. 
- Samples must be packaged according to IATA Dangerous Goods Regulations, Packing 
Instructions 650, using the packing materials provided by contracted company. 
- In the event that the packaging materials or instructions are lost, please contact the 
study sponsor. 
- Ship samples on dry ice to Covance as described in the Global Study Schedule, using 
the shipping materials provided. 
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• Note: Additional detailed information can be found in the Covance Laboratory Manual, 
provided at the beginning of the study. This includes additional details regarding: 
- Sample collection kits 
- Sample collection procedures 
- Documentation procedures 
- Packing and shipping instructions 
- Sample kit resupply 
- How to get help 
2. SHIPMENT CONTACT NAMES AND ADDRESSES 
 
For Optional DNA Banking Samples: 
Use for the Americas: USA and Canada, as well as Latin America and the Islands (Dominican 
Republic, etc): 
Covance CLS Indianapolis 
8211 SciCor Drive 
Indianapolis, IN 
46214-2985 USA 
Tel. +1 (317) 271-1200 
(local calls) 
Tel: +1 800-462-8885 
Fax: (317) 273-4030 
 
Use for Europe, the Middle East, and Africa: 
Covance CLS Genève 
Rue Moïse-Marcinhes 7 
1217 Meyrin/Genève-CH 
Tel: +41 22-989-7000 
Fax: +41 22-989-1999 
 
Use for Asia-Pacific, including Thailand, Malaysia, and Australia: 
Covance CLS Singapore 
1 International Business Park 
#05-12A/B The Synergy 
Singapore 609917 
Tel: 65-6560-8793 
Fax: 65-6565-5901 
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Use for China only: 
Covance CLS Shanghai 
1st Floor, No. 6 Building 
151 Li Bing Rd 
Zhangjiang Hi-Tech Park 
Shanghai 201203 
China 
Tel: +86 21 51371111 
Fax:+86 21 51371301 
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REASON FOR AMENDMENT: 
The reasons of this amendment are detailed below: 
• During a 5-week study in rats, minimal to slight degenerative cardiomyopathy was noted 
in all dose groups, including control. This finding was considered to be incidental, 
reflecting a background lesion that is common to animals of this species and strain, and to 
be of no toxicological significance; the lesions were generally minimal (slight in a single 
case) and focal corresponding to inflammatory infiltrates rather than direct effects on 
cardiomyocytes. However as a result of these findings, the FDA has recommended to 
evaluate troponin levels in current studies. Thus troponin I levels will be added to the 
safety laboratory parameters. 
• Minor miscellaneous changes related to omissions or typing errors. 
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DESCRIPTION OF CHANGE AND WHAT IS BEING CHANGED: 
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1 FLOW CHARTS 
1.2 STUDY FLOWCHART 
The footnote corresponding to the following Table: 
Table 1 - Screening/run-in schedule assessments – Patients receiving a lipid lowering treatment other than atorvastatin/ or 
not at stable dose of atorvastatin 10 mg for at least 6 weeks prior to screening, or drug naive patients 
 Screening/run-in phase 
Evaluation 
 
WEEK W-7 W-1 
DAY -49±3  -7±1 
VISIT NUMBER V1a 
Pre-eligibility assessments  
V1 
Full eligibility assessments 
Design: 
…   
Laboratory Testing / Safety: 
…   
Standard hematology, serum chemistry3) X X 
…   
1) Adverse event (AE) collection from the time of informed consent signature. 
2) Using a centralized automatic and manual reading of all ECGs. 
3) Hematology includes: complete blood count (CBC) including hematocrit, hemoglobin, red blood cell count, white blood cell count with differential count and platelets. Serum chemistry includes: 
sodium, potassium, chloride, bicarbonate, calcium, phosphorous, urea nitrogen, creatinine, uric acid, total protein, and albumin. 
4) Liver tests: ALT, AST, alkaline phosphatase (ALP), and γGT and total bilirubin. 
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Is replaced by: 
Table 1 - Screening/run-in schedule assessments – Patients receiving a lipid lowering treatment other than atorvastatin/ or 
not at stable dose of atorvastatin 10 mg for at least 6 weeks prior to screening, or drug naive patients 
 Screening/run-in phase 
Evaluation 
 
WEEK W-7 W-1 
DAY -49±3  -7±1 
VISIT NUMBER V1a 
Pre-eligibility assessments  
V1 
Full eligibility assessments 
Design: 
…   
Laboratory Testing / Safety: 
…   
Standard hematology, serum chemistry3) X X 
…   
1) Adverse event (AE) collection from the time of informed consent signature. 
2) Using a centralized automatic and manual reading of all ECGs. 
3) Hematology includes: complete blood count (CBC) including hematocrit, hemoglobin, red blood cell count, white blood cell count with differential count and platelets. Serum chemistry includes: 
sodium, potassium, chloride, bicarbonate, calcium, phosphorous, urea nitrogen, creatinine, uric acid, total protein, and albumin, and troponin I. 
4) Liver tests: ALT, AST, alkaline phosphatase (ALP), and γGT and total bilirubin. 
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The footnote corresponding to the following Table: 
Table 2 - Screening schedule assessments – Patients receiving atorvastatin 10 mg at stable dose for at least 6 weeks prior 
to screening 
 Screening 
Evaluation 
 
WEEK W-1 
DAY -7±1 
VISIT NUMBER V1 
Full eligibility assessments 
Design: 
…  
Laboratory Testing / Safety: 
…  
Standard hematology, serum chemistry3) X 
…  
1) Adverse event (AE) collection from the time of informed consent signature. 
2) Using a centralized automatic and manual reading of all ECGs. 
3) Hematology includes: complete blood count (CBC) including hematocrit, hemoglobin, red blood cell count, white blood cell count with differential count and platelets. Serum chemistry includes: 
sodium, potassium, chloride, bicarbonate, calcium, phosphorous, urea nitrogen, creatinine, uric acid, total protein, and albumin. 
4) Liver tests: ALT, AST, alkaline phosphatase (ALP), and γGT and total bilirubin. 
 
 
 
Clinical Trial Protocol Amendment No. 1  16-Feb-2011 
DFI11566 -  SAR236553 Version number: 1 (electronic 1.0) 
Property of the sanofi-aventis group - strictly confidential Page 8 
Is replaced by: 
Table 2 - Screening schedule assessments – Patients receiving atorvastatin 10 mg at stable dose for at least 6 weeks prior 
to screening 
 Screening 
Evaluation 
 
WEEK W-1 
DAY -7±1 
VISIT NUMBER V1 
Full eligibility assessments 
Design: 
…  
Laboratory Testing / Safety: 
…  
Standard hematology, serum chemistry3) X 
…  
1) Adverse event (AE) collection from the time of informed consent signature. 
2) Using a centralized automatic and manual reading of all ECGs. 
3) Hematology includes: complete blood count (CBC) including hematocrit, hemoglobin, red blood cell count, white blood cell count with differential count and platelets. Serum chemistry includes: 
sodium, potassium,  chloride, bicarbonate, calcium, phosphorous, urea nitrogen, creatinine, uric acid, total protein, and albumin, and troponin I. 
4) Liver tests: ALT, AST, alkaline phosphatase (ALP), and γGT and total bilirubin. 
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The footnote corresponding to the following Table: 
Table 3 - Double-blind treatment and follow-up periods – All patients 
 Study phase 
Evaluation Double-blind treatment  Post-treatment follow-up 
WEEK W0 W2 W4 W6 W85) W12 W16 
DAY 1 15±3 29±3 43±3 57±3 85±7 113±7 
VISIT NUMBER V2 V3 V4 V5 V6 V7 V8 
Design: 
…        
Laboratory Testing / Safety: 
…        
Standard hematology, serum chemistry3) X  X  X X6) X6) 
…        
1) Adverse event (AE) collection from the time of informed consent signature. 
2) Using a centralized automatic and manual reading of all ECGs. 
3) Hematology includes: complete blood count (CBC) including hematocrit, hemoglobin, red blood cell count, white blood cell count with differential count and platelets. Serum chemistry 
includes: sodium, potassium, chloride, bicarbonate, calcium, phosphorous, urea nitrogen, creatinine, uric acid, total protein, and albumin. 
4) Liver tests: ALT, AST, alkaline phosphatase (ALP), and γGT and total bilirubin. 
5) In case of premature discontinuation of study treatment, all assessments planned in Week 8 (V5, final on-treatment assessment) should be performed before premature treatment 
discontinuation. 
6) Only in case of persistent clinically relevant abnormal values for these parameters at the end of study treatment. 
7) Only in case of persistent and not decreased anti-SAR236653 antibody levels at Week 16 (V7) patients will be asked for one additional antibody sample 6 to 12 months after last dosing. 
8) PK and antibody samples to be collected prior IP administration. 
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Is replaced by: 
Table 3 - Double-blind treatment and follow-up periods – All patients 
 Study phase 
Evaluation Double-blind treatment Post-treatment follow-up 
WEEK W0 W2 W4 W6 W85) W12 W16 
DAY 1 15±3 29±3 43±3 57±3 85±7 113±7 
VISIT NUMBER V2 V3 V4 V5 V6 V7 V8 
Design: 
…        
Laboratory Testing / Safety: 
…        
Standard hematology, serum chemistry3) X  X  X X6) X6) 
…        
1) Adverse event (AE) collection from the time of informed consent signature. 
2) Using a centralized automatic and manual reading of all ECGs. 
3) Hematology includes: complete blood count (CBC) including hematocrit, hemoglobin, red blood cell count, white blood cell count with differential count and platelets. Serum chemistry 
includes: sodium, potassium, chloride, bicarbonate, calcium, phosphorous, urea nitrogen, creatinine, uric acid, total protein, and albumin, and troponin I. 
4) Liver tests: ALT, AST, alkaline phosphatase (ALP), and γGT and total bilirubin. 
5) In case of premature discontinuation of study treatment, all assessments planned in Week 8 (V5, final on-treatment assessment) should be performed before premature treatment 
discontinuation. 
6) Only in case of persistent clinically relevant abnormal values for these parameters at the end of study treatment. 
7) Only in case of persistent and not decreased anti-SAR236653 antibody levels at Week 16 (V7) patients will be asked for one additional antibody sample 6 to 12 months after last dosing. 
8) PK and antibody samples to be collected prior IP administration. 
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8 STUDY TREATMENTS 
8.4 METHOD OF ASSIGNING PATIENTS TO TREATMENT GROUP 
The following text:  
... 
The Project Demand manager (PDM) will provide the randomized treatment kit number lists and 
the Study Biostatistician will provide two randomization schemes to the centralized treatment 
allocation system. Then, this centralized treatment allocation system will generate the patient two 
randomization lists according to which it will allocate the treatments to the patients. 
… 
 
Is replaced by: 
… 
The Project Demand manager (PDM) will provide the randomized treatment kit number lists and 
the Study Biostatistician will provide two the randomization schemes to the centralized treatment 
allocation system. Then, this centralized treatment allocation system will generate the patient two 
randomization lists according to which it will allocate the treatments to the patients. 
… 
8.9 CONCOMITANT MEDICATION 
8.9.1  Prohibited concomitant therapy 
The following text:  
The following drugs will not be permitted during the study, including the post-treatment 
follow-up period: 
• Statin other than atorvastatin at the doses indicated in the protocol, and other lipid 
lowering drugs including but not limited to fibrates, bile acid resins, niacin > 500 mg, 
intestinal cholesterol absorption (ICA) blockers, or omega-3 fatty acids at doses > 
1000 mg. 
• Thyroid preparations or thyroxin treatment (except in patients on replacement therapy). 
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Is replaced by: 
The following drugs will not be permitted during the study, including the post-treatment 
follow-up period: 
• Statin other than atorvastatin at the doses indicated in the protocol, and other lipid 
lowering drugs including but not limited to fibrates, bile acid resins, niacin > 500 mg, 
intestinal cholesterol absorption (ICA) blockers, or omega-3 fatty acids at doses > 
1000 mg. 
• Thyroid preparations or thyroxin treatment (except in patients on replacement therapy). 
• Insulin treatment. 
10 PATIENT SAFETY 
10.1 SAFETY ENDPOINTS ASSESSED IN THIS TRIAL 
The following text:  
• Local tolerability at injection site (please refer to Section 10.2.1). 
• … 
• Laboratory tests: hematology (red blood cell count, hemoglobin, hematocrit, platelets, 
white blood cell count with differential blood count), serum chemistry (sodium, potassium, 
chloride, bicarbonate, calcium, phosphorous, urea nitrogen, creatinine, uric acid, total 
protein, and albumin), liver tests (ALT, AST, ALP, γGT and total bilirubin), and CPK. 
 
Is replaced by: 
• Local tolerability at injection site (please refer to Section 10.2.1). 
• … 
• Laboratory tests: hematology (red blood cell count, hemoglobin, hematocrit, platelets, 
white blood cell count with differential blood count), serum chemistry (sodium, potassium, 
chloride, bicarbonate, calcium, phosphorous, urea nitrogen, creatinine, uric acid, total 
protein, and albumin, and troponin I), liver tests (ALT, AST, ALP, γGT and total 
bilirubin), and CPK. 
10.1.4 Safety Laboratory  
The following text: 
The following laboratory data are collected from fasting patients in accordance with the study 
schedule and forwarded to the central laboratory: 
• … 
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• Serum chemistry: sodium, potassium, chloride, bicarbonate, calcium, phosphorous, urea 
nitrogen, creatinine, uric acid, total protein, and albumin at Week -7 (V1a - only for patients 
with run-in), Week -1 (V1), Week 0 (baseline, V2), Week 4 (V4), Week 8 (V6), and during 
the follow-up period [Week 12 (V7), Week 16 (V8)] in case of persistent clinically relevant 
abnormal values at Week 8 (V6, end of treatment). 
•  … 
 
Is replaced by: 
The following laboratory data are collected from fasting patients in accordance with the study 
schedule and forwarded to the central laboratory: 
• … 
• Serum chemistry: sodium, potassium, chloride, bicarbonate, calcium, phosphorous, urea 
nitrogen, creatinine, uric acid, total protein, and albumin, and troponin I at Week -7 (V1a - 
only for patients with run-in), Week -1 (V1), Week 0 (baseline, V2), Week 4 (V4), Week 8 
(V6), and during the follow-up period [Week 12 (V7), Week 16 (V8)] in case of persistent 
clinically relevant abnormal values at Week 8 (V6, end of treatment). 
•  … 
 
  
Any and all information presented in this document shall be treated as confidential and shall remain the exclusive property of sanofi-aventis (or 
any of its affiliated companies). The use of such confidential information must be restricted to the recipient for the agreed purpose and must not 
be disclosed, published or otherwise communicated to any unauthorized persons, for any reason, in any form whatsoever without the prior 
written consent of sanofi-aventis (or the concerned affiliated company); ‘affiliated company’ means any corporation, partnership or other entity 
which at the date of communication or afterwards (i) controls directly or indirectly sanofi-aventis, (ii) is directly or indirectly controlled by sanofi-
aventis, with ‘control’ meaning direct or indirect ownership of more than 50% of the capital stock or the voting rights in such corporation, 
partnership or other entity 
 
According to template: QSD-002579 VERSION N°3.0 (11-JUN-2010) Page 1 
AMENDED CLINICAL TRIAL PROTOCOL 1 
 
COMPOUND: SAR236553 (REGN727) 
A randomized, double-blind, parallel-group, placebo-controlled, fixed dose/dose 
regimen, multicenter study evaluating the efficacy and safety of SAR236553 when 
co-administered with 80 mg of atorvastatin over 8 weeks in patients with primary 
hypercholesterolemia and LDL-cholesterol ≥ 100 mg/dL (≥2.59 mmol/L) on 
atorvastatin 10 mg 
STUDY NUMBER: DFI11566 
VERSION DATE / STATUS: Approval date / Status of the Amended Protocol 
CLINICAL STUDY DIRECTOR: Maria ROJESKI 
 
 
 
   
Amended Clinical Trial Protocol 1 Version number: 1 (electronic 1.0) Date : 16 Feb 2011 
Protocol Amendment1 Version number: 1 (electronic 1.0) Date : 16 Feb 2011 
Clinical Trial Protocol Version number: 1 (electronic 1.0) Date : 26 Nov 2010 
EudraCT or IND number: 105574  
 
 
 
Amended Clinical Trial Protocol 1  16-Feb-2011  
DFI11566 - SAR236553  Version number: 1 (electronic 1.0) 
Property of the sanofi-aventis group - strictly confidential Page 2 
NAMES AND ADDRESSES OF 
COORDINATING 
INVESTIGATOR 
 
Name: 
Address: 
 
 
Tel: 
Fax: 
E-mail: 
 
 
MONITORING TEAM’S 
REPRESENTATIVE 
 
Name: 
Address: 
 
 
 
Tel: 
Fax: 
E-mail: 
 
 
SPONSOR 
 
Company: 
Address: 
 
 
 
 
 
 
OTHER EMERGENCY 
TELEPHONE NUMBERS 
 
  
 
Amended Clinical Trial Protocol 1  16-Feb-2011  
DFI11566 - SAR236553  Version number: 1 (electronic 1.0) 
Property of the sanofi-aventis group - strictly confidential Page 3 
CLINICAL TRIAL SUMMARY 
COMPOUND: SAR236553 STUDY No : DFI11566 
TITLE A randomized, double-blind, parallel-group, placebo-controlled, fixed 
dose/dose regimen, multicenter study evaluating the efficacy and 
safety of SAR236553 when co-administered with 80 mg of 
atorvastatin over 8 weeks in patients with primary 
hypercholesterolemia and LDL-cholesterol ≥ 100 mg/dL 
(≥2.59 mmol/L) on atorvastatin 10 mg. 
INVESTIGATOR/TRIAL LOCATION US – Multicenter study 
STUDY OBJECTIVE(S) 
 
Primary Objective 
To evaluate the effect of SAR236553 on low-density lipoprotein 
cholesterol (LDL-C) levels compared with placebo when co-
administered with 80 mg of atorvastatin after 8 weeks of treatment in 
patients with LDL-C ≥ 100mg/dL (≥ 2.59 mmol/L) on atorvastatin 
10 mg. 
Secondary Objective(s) 
- To evaluate the effects of SAR236553 on other lipid levels in 
comparison with placebo, when co-administered with 80 mg of 
atorvastatin after 8 weeks of treatment.  
- To evaluate the efficacy of SAR236553 when co-administered with 
a high dose of atorvastatin (80 mg) versus atorvastatin 10mg. 
- To evaluate the safety and tolerability of SAR236553 when 
co-administered with 2 different doses of atorvastatin. 
- To evaluate the development of anti-SAR236553 antibodies. 
- To evaluate the pharmacokinetics of SAR236553.  
STUDY DESIGN This is a double-blind, randomized, placebo-controlled, 
parallel-group study that comprises three periods. 
- A screening period with 2 options depending on the status of the 
patient at screening: 
a) Option 1: for patients receiving atorvastatin 10 mg at stable 
dose for at least 6 weeks prior to screening, the screening 
period will be of 1 week. This screening period will start by a 
screening visit (Week -1, V1), during which patients will be 
evaluated for eligibility to enter the double-blind treatment 
period. 
b) Option 2: for patients receiving a lipid lowering treatment other 
than atorvastatin/ or not at stable dose of atorvastatin 10 mg for 
at least 6 weeks prior to screening, or for drug naive patients. 
This screening period includes a run-in period on atorvastatin 
10 mg with: 
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 c) This screening period includes a run-in period on atorvastatin 
10 mg with: 
• a pre-screening visit (Week -7, V1a) during which 
pre-eligibility assessments will be performed to permit the 
entry of patients into the run-in period. If applicable, at this 
pre-screening visit (Week -7, V1a) patients will be asked to 
stop any lipid lowering treatment previously received. Then 
after 6 weeks of run-in period, a screening visit (Week -1, 
V1) will be held during which the full eligibility assessment 
will be performed. 
- A randomized, double-blind, placebo-controlled, parallel-group 
treatment period of 8 weeks where patients will be randomized as 
follows: 
• Either to the group of SAR236553 + high dose of 
atorvastatin (80 mg). 
• Or to the group of SAR236553 placebo + high dose of 
atorvastatin (80 mg). 
• Or to the group of SAR236553 + maintenance of 
atorvastatin dose previously received (10 mg). 
- A follow-up period of 8 weeks after the end of treatment period 
(Week 8). 
All patients will be instructed to be on a stable diet (NCEP-ATPIII 
TLC diet or equivalent) throughout the entire study duration from 
screening. 
STUDY POPULATION  
Main selection criteria: 
 
Inclusion Criteria: 
- Patients ( patients receiving a lipid lowering treatment other than 
atorvastatin/ or not at stable dose of atorvastatin 10 mg for at least 
6 weeks prior to screening period, or drug naive patients) with 
primary hypercholesterolemia likely to have LDL-C ≥ 100 mg/dL 
(≥ 2.59 mmol/L) at the end of the run-in period on atorvastatin 
therapy (Week -1). 
OR 
- Patients with primary hypercholesterolemia treated with stable dose 
of atorvastatin 10 mg for at least 6 weeks prior to screening period 
and likely to have LDL-C ≥ 100 mg/dL (≥ 2.59 mmol/L) at the 
screening visit (Week -1). 
Exclusion Criteria 
- LDL-C < 100 mg/dL (< 2.59 mmol/L) at Week -1 (V1): 
• After the run-in period on atorvastatin 10 mg for patients 
receiving a lipid lowering treatment other than atorvastatin/ 
or not at stable dose of atorvastatin 10 mg for at least 
6 weeks prior to screening period, or drug naive patients. 
 
OR  
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• At the first visit for patients who are being treated with 
atorvastatin 10 mg at stable dose for at least 6 weeks prior 
to screening visit Week -1. 
- Use of a statin other than atorvastatin 10 mg, or use of other lipid-
lowering drugs including but not limited to fibrates, bile acid resins, 
niacin > 500 mg, intestinal cholesterol absorption (ICA) blockers, or 
omega-3 fatty acids at doses > 1000 mg between the screening and 
the baseline Visits. 
- Type 1 diabetes. 
- Type 2 diabetes treated with insulin. 
- Type 2 diabetes with an HbA1c ≥ 8.5% at Week -7 or Week -1 
(considered poorly controlled). 
- Triglycerides (TG) > 350 mg/dL (3.95 mmol/L) at Week -7 or 
 Week -1. 
Total expected number of patients: Approximately 90 randomized (30 patients/group) 
STUDY TREATMENT(s)  
Investigational Product(s) 
 
Formulation 
Tested drug: SAR236553 and placebo for SAR236553 
 
Vials : SAR236553 150mg/mL, or Placebo  
Route(s) of administration: Subcutaneous (SC)  
Injection volume: 1mL in total 
One injection of 1 mL will be done through SC administration in the 
abdomen. 
Dose regimen: - SAR236553 150 mg or placebo for SAR236553: every 2 Weeks 
(Week 0, Week 2, Week 4, and Week 6). 
Other Investigational Product 
 
Formulation 
Atorvastatin 10 mg and atorvastatin 80 mg and matching placebo 
capsules 
 
Tablets of atorvastatin will be overencapsulated. 
Capsules for atorvastatin 10mg tablets, atorvastatin 40mg tablets 
and matching placebo capsules. 
Route(s) of administration: Oral 
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Dose regimen: 
 
Double-blind treatment period: 
During the double-blind treatment period, 2 capsules of study drug 
will be administered once daily in the evening, with dinner, as 
specified in the table below 
 
 10 mg group 80 mg group 
ATOR 10 mg 1 0 
ATOR 40 mg 0 2 
Placebo 1 0 
 
 
Non Investigational Product(s)  
 
Formulation 
During Run-in period: 
Atorvastatin 10 mg administered in an open-label manner. 
 
Tablet of atorvastatin 10 mg. 
Route(s) of administration: Oral 
Dose regimen: During the run-in period atorvastatin is considered a non 
investigational product. One tablet of atorvastatin 10 mg once daily 
in the evening, with dinner. 
 
PRIMARY AND SECONDARY 
ENDPOINT(S) 
Primary Endpoint: 
Percent change in LDL-C from baseline to Week 8. 
Secondary Endpoint (s): 
- Absolute change in calculated LDL-C from baseline to Week 8. 
- Proportion of patients achieving an LDL-C level lower than 
100 mg/dL (2.59 mmol/L) at Week 8. 
- Proportion of patients achieving an LDL-C level lower than 
70 mg/dL (1.81 mmol/L) at Week 8. 
- Percent change in total cholesterol, HDL C, TG, non-HDL-C, ApoB, 
ApoA-1, Lp(a) from baseline to Week 8. 
- Absolute change in total cholesterol, HDL C, TG, non-HDL-C, ratio 
ApoB/ApoA-1 from baseline to Week 8. 
Safety endpoint(s): 
- Adverse events, serious adverse events, vital signs, ECG, 
hematology, serum chemistry. 
Antibody assessment:  
- Anti-SAR236553 antibodies at Week 0 (baseline), Week 4, Week 8, 
and then Week 12 and Week 16 (follow-up visits). 
Pharmacokinetics: 
- Serum SAR236553 concentrations at Week 0 (Day 1), and then at 
each visit up to the last visit of the follow-up period (Weeks 2, 4, 6, 8, 
12, and 16). 
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ASSESSMENT SCHEDULE Screening period 
a) Option1 (for patients receiving atorvastatin 10 mg at stable 
dose for at least 6 weeks prior to screening): 
Screening Visit (Week-1, V1) followed by a screening period of 1 
week. At the end of this screening period, baseline Visit (V2, 
Week 0) will be performed and eligible patients will be randomized in 
the double-blind study treatment period. 
b) Option 2 (for patients receiving a lipid lowering treatment other 
than atorvastatin/ or not at stable dose of atorvastatin 10 mg for 
at least 6 weeks prior to screening, or drug naive patients): 
A pre-screening Visit (Week-7, V1a) will be followed by a run-in 
period with atorvastatin 10 mg at stable dose. At the end of this 
run-in period of 6 weeks on atorvastatin treatment, patients will 
attend the screening visit (Week-1, V1) where the full eligibility 
assessments will be performed. 
Patients will take atorvastatin 10 mg until Week 0 (V2, baseline visit). 
At Week 0, the baseline Visit (V2) will be performed, and eligible 
patients will be randomized in the double-blind study treatment 
period. 
Treatment period 
Visits schedule from randomization (baseline Visit, V2 (Week 0): 
Patients assessed on Week 0 (V2 (Day 1), randomization visit) and 
then every 2 weeks up to the end of the double-blind treatment 
period: Week 2 (V3), Week 4 (V4), Week 6 (V5), and Week 8 (V6). 
Follow-up period 
Follow-up visits will be performed at Week 12 (V7) and Week 16 
(V8). 
STATISTICAL CONSIDERATIONS 
 
Sample size determination: 
The study is expected to enrol approximately 90 patients. 
To detect a difference of 20% in LDL-C percent change from 
baseline to Week 8 between SAR236553 + high dose of atorvastatin 
group and SAR236553 placebo + high dose of atorvastatin group, 
assuming a 5% rate of unevaluable primary endpoint, 30 patients by 
arm will result in 95% power, with a standard deviation of 20%, and 
using a two-sided t-test at the 0.05 significance level. 
Calculations were made using nQuery Advisor 6.01 
Analysis Population: 
The primary efficacy analysis population will be the modified intent-
to-treat (mITT) population, defined as the ITT population (i.e., 
randomized population) with an evaluable primary endpoint. The 
primary endpoint will be considered as evaluable when both of the 
following conditions are met: 
- The Week -1 or Week 0 LDL-C value is available, 
- At least one on-treatment LDL-C value is available. The on-
treatment period for the primary efficacy variable will be defined as 
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the time from the first SAR236553 or placebo for SAR236553 
injection up to 21 days after the last injection, or up to 84 days after 
the first SAR236553 or placebo for SAR236553 injection, whichever 
come first. 
Patients in the mITT population will be analyzed according to the 
treatment group allocated by randomization. 
The safety analysis will be performed on the safety population. The 
safety population consists of the randomized population who did 
actually receive at least one dose or partial dose of SAR236553 or 
placebo for SAR236553 analyzed according to the treatment actually 
received. 
Primary Analysis: 
The percent change in LDL-C from baseline to Week 8 will be 
analyzed using an analysis of covariance (ANCOVA) model with 
treatment group as fixed effect and the baseline LDL-C as covariate. 
The treatment group factor will have three levels: SAR236553 + high 
dose of atorvastatin (80 mg), SAR236553 placebo + high dose of 
atorvastatin (80 mg), SAR236553 + maintenance of atorvastatin 
dose previously received (10 mg). 
Throughout the ANCOVA model, the SAR236553 + high dose of 
atorvastatin group will be compared to the SAR236553 placebo + 
high dose of atorvastatin group using appropriate contrast, and the 
95% CI of the difference will be provided. No formal comparisons 
with the SAR236553 + maintenance of atorvastatin dose group will 
be performed: only 95% CI for the difference versus other arms will 
be provided. 
The baseline LDL-C value will be the average of the Week -1 and 
Week 0 evaluations. In case of missing Week 8 LDL-C on-treatment 
value, the last-observation-carried-forward (LOCF) principle will be 
used. 
Analysis of secondary endpoints 
Continuous secondary endpoints will be analyzed using the same 
ANCOVA model as for the primary endpoint with treatment group as 
fixed effect, and the corresponding baseline value as covariate. 
The proportion of patients achieving an LDL-C level lower than 100 
mg/dL (2.59 mmol/L) as well as a LDL-C level lower than 70 mg/dL 
(1.81 mmol/L) at Week 8 will be analyzed using a logistic regression 
model with factor for treatment and adjustment for LDL-C values at 
baseline. 
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DURATION OF STUDY PERIOD (per  
patient)  a) Option 1: for patients receiving atorvastatin 10 mg at stable dose for at least 6 weeks prior to screening:  
Approximately 17 weeks (screening: 1 week, double-blind treatment: 
8 weeks, follow-up period: 8 weeks). 
b) Option 2: for patients receiving a lipid lowering treatment other 
than atorvastatin/ or not at stable dose of atorvastatin 10 mg for 
at least 6 weeks prior to screening, or drug naive patients: 
Approximately 23 weeks (screening/run-in: 7 weeks, double-blind 
treatment: 8 weeks, follow-up period: 8 weeks). 
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1 FLOW CHARTS 
1.1 GRAPHICAL STUDY DESIGN 
Figure 1 - Study design: patients receiving a lipid lowering treatment other than atorvastatin/ or not at stable dose of atorvastatin 10 mg for at least 6 
weeks prior to screening, or drug naive patients 
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Figure 2 - Study design: patients receiving atorvastatin 10 mg at stable dose for at least 6 weeks prior to screening 
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1.2 STUDY FLOWCHART 
Table 1 - Screening/run-in schedule assessments – Patients receiving a lipid lowering treatment other than atorvastatin/ or not at stable dose of 
atorvastatin 10 mg for at least 6 weeks prior to screening, or drug naive patients 
 Screening/run-in phase 
Evaluation 
 
WEEK W-7 W-1 
DAY -49±3  -7±1 
VISIT NUMBER V1a 
Pre-eligibility assessments  
V1 
Full eligibility assessments 
Design: 
Inclusion/Exclusion Criteria X X 
Medical/surgical history, alcohol habits, smoking habits X  
Informed Consent /Patient Demography X  
Prior Medication History X  
Clinical Examination X  
Body weight X  
Height X  
IVRS/IWRS contact X  
Treatment: 
Atorvastatin 10 mg dispensation (open label) X  
Compliance check for atorvastatin  X 
Instruction/check on diet (NCEP-ATPIII TLC diet or equivalent) X X 
Concomitant Medication X X 
Vital signs: 
Heart Rate, blood pressure X X 
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 Screening/run-in phase 
Evaluation 
 
WEEK W-7 W-1 
DAY -49±3  -7±1 
Safety: 
AE /SAE recording 1) X X 
12-lead ECG 2)  X 
VISIT NUMBER V1a 
Pre-eligibility assessments  
V1 
Full eligibility assessments 
Laboratory Testing / Efficacy: 
Lipids: Total cholesterol, LDL-cholesterol, HDL-cholesterol, Triglycerides, non-HDL-C X X 
Lipids: ApoB, ApoA-1, ratio ApoB/ApoA-1, and Lp (a)   
Laboratory Testing / Safety: 
Fasting plasma glucose X X 
HbA1c X  
Standard hematology, serum chemistry3) X X 
Liver tests4), CPK  X 
Sensitive TSH  X 
Hepatitis B and C serology  X 
Serum  X Pregnancy test (for women of childbearing potential) 
Urine X  
1) Adverse event (AE) collection from the time of informed consent signature. 
2) Using a centralized automatic and manual reading of all ECGs. 
3) Hematology includes: complete blood count (CBC) including hematocrit, hemoglobin, red blood cell count, white blood cell count with differential count and platelets. Serum chemistry includes: sodium, potassium, chloride, bicarbonate, calcium, phosphorous, urea nitrogen, creatinine, uric acid, total protein,  albumin and 
troponin I. 
4) Liver tests: ALT, AST, alkaline phosphatase (ALP), and γGT and total bilirubin. 
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Table 2 - Screening schedule assessments – Patients receiving atorvastatin 10 mg at stable dose for at least 6 weeks prior to screening 
 Screening 
Evaluation 
 
WEEK W-1 
DAY -7±1 
VISIT NUMBER V1 
Full eligibility assessments 
Design: 
Inclusion/Exclusion Criteria X 
Medical/surgical history, alcohol habits, smoking habits X 
Informed Consent /Patient Demography X 
Prior Medication History X 
Clinical Examination X 
Body weight X 
Height X 
IVRS/IWRS contact X 
Treatment: 
Atorvastatin 10 mg dispensation (open label) X 
Instruction on diet (NCEP-ATPIII TLC diet or equivalent) X 
Concomitant Medication X 
Vital signs: 
Heart Rate, blood pressure X 
Safety: 
AE /SAE recording 1) X 
12-lead ECG 2) X 
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 Screening 
Evaluation 
 
WEEK W-1 
DAY -7±1 
VISIT NUMBER V1 
Full eligibility assessments 
Laboratory Testing / Efficacy: 
Lipids: Total cholesterol, LDL-cholesterol, HDL-cholesterol, Triglycerides, non-HDL-C X 
Lipids: ApoB, ApoA-1, ratio ApoB/ApoA-1, and Lp (a)  
Laboratory Testing / Safety: 
Fasting plasma glucose, HbA1c X 
Standard hematology, serum chemistry3) X 
Liver tests4), CPK X 
Sensitive TSH X 
Hepatitis B and C serology X 
Serum pregnancy test (for women of childbearing potential) X 
1) Adverse event (AE) collection from the time of informed consent signature. 
2) Using a centralized automatic and manual reading of all ECGs. 
3) Hematology includes: complete blood count (CBC) including hematocrit, hemoglobin, red blood cell count, white blood cell count with differential count and platelets. Serum chemistry includes: sodium, potassium,  chloride, bicarbonate, calcium, phosphorous, urea nitrogen, creatinine, uric acid, total protein, albumin, and 
troponin I. 
4) Liver tests: ALT, AST, alkaline phosphatase (ALP), and γGT and total bilirubin. 
 
Amended Clinical Trial Protocol 1  16-Feb-2011 
DFI11566 - SAR236553  Version number: 1 (electronic 1.0) 
Property of the sanofi-aventis group - strictly confidential Page 16 
Table 3 - Double-blind treatment and follow-up periods – All patients 
 Study phase 
Evaluation Double-blind treatment  Post-treatment follow-up 
WEEK W0 W2 W4 W6 W85) W12 W16 
DAY 1 15±3 29±3 43±3 57±3 85±7 113±7 
VISIT NUMBER V2 V3 V4 V5 V6 V7 V8 
Design: 
Inclusion/Exclusion Criteria X       
Medical/surgical history, alcohol habits, smoking habits        
Informed Consent /Patient Demography        
Prior Medication History        
Clinical Examination X    X  X 
Body weight X X X X X X X 
Height        
Randomization X       
IVRS/IWRS contact X X X X X  X 
Treatment: 
Atorvastatin IP dispensation X  X     
SAR236553 IP administration X X X X    
SAR236553 IP X X X X    Compliance 
check Atorvastatin IP X X X X X   
Check on diet (NCEP-ATPIII TLC diet or equivalent) X X X X X X X 
Concomitant Medication X X X X X X X 
Vital signs: 
Heart Rate, blood pressure X X X X X  X 
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 Study phase 
Evaluation Double-blind treatment  Post-treatment follow-up 
WEEK W0 W2 W4 W6 W85) W12 W16 
DAY 1 15±3 29±3 43±3 57±3 85±7 113±7 
VISIT NUMBER V2 V3 V4 V5 V6 V7 V8 
Safety: 
AE /SAE recording 1) X X X X X X X 
12-lead ECG 2)   X  X   
Laboratory Testing / Efficacy: 
Lipids: Total cholesterol, LDL-cholesterol, HDL-
cholesterol, Triglycerides, non-HDL-C X X X X X X X 
Lipids: ApoB, ApoA-1, ratio ApoB/ApoA-1, and Lp (a) X  X  X   
hs-CRP, library samples X  X  X   
Laboratory Testing / Safety: 
Fasting plasma glucose X    X   
HbA1c     X   
Standard hematology, serum chemistry3) X  X  X X6) X6) 
Liver tests4), CPK X  X  X X6) X6) 
Urine pregnancy test (for women of childbearing 
potential) X  X  X X X 
Anti-SAR236553 antibodies8) X  X  X X X7) 
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 Study phase 
Evaluation Double-blind treatment  Post-treatment follow-up 
WEEK W0 W2 W4 W6 W85) W12 W16 
DAY 1 15±3 29±3 43±3 57±3 85±7 113±7 
VISIT NUMBER V2 V3 V4 V5 V6 V7 V8 
PK and Genotyping: 
PK of SAR2365538) X X X X X X X 
DNA (for specifically consented patients only) X       
1) Adverse event (AE) collection from the time of informed consent signature. 
2) Using a centralized automatic and manual reading of all ECGs. 
3) Hematology includes: complete blood count (CBC) including hematocrit, hemoglobin, red blood cell count, white blood cell count with differential count and platelets. Serum chemistry includes: sodium, potassium, chloride, bicarbonate, calcium, phosphorous, urea nitrogen, creatinine, uric acid, total protein, 
albumin and troponin I. 
4) Liver tests: ALT, AST, alkaline phosphatase (ALP), and γGT and total bilirubin. 
5) In case of premature discontinuation of study treatment, all assessments planned in Week 8 (V5, final on-treatment assessment) should be performed before premature treatment discontinuation. 
6) Only in case of persistent clinically relevant abnormal values for these parameters at the end of study treatment. 
7) Only in case of persistent and not decreased anti-SAR236653 antibody levels at Week 16 (V7) patients will be asked for one additional antibody sample 6 to 12 months after last dosing. 
8) PK and antibody samples to be collected prior IP administration. 
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3 LIST OF ABBREVIATIONS 
AE  Adverse event 
AEPM  Adverse events with pre-specified monitoring 
ALP  Alkaline phosphatase 
ALT  Alanine aminotransferase 
ANCOVA Analysis of covariance 
Apo  Apolipoprotein 
ARF   Acute renal failure 
AST  Aspartate aminotransferase 
BMI  Body mass index 
CABG  Coronary artery bypass graft surgery  
CBC  Complete blood count 
CHD  Coronary Heart Disease 
CI  Confidence interval 
CIB  Clinical Investigator's brochure 
CPK  Creatine Phosphokinase 
CRO  Contract Research Organization 
CSR  Clinical Study Report 
DBP  Diastolic blood pressure 
DMC  Data Monitoring Committee 
DNA  Deoxyribonucleic acid 
DRF  Discrepancy resolution form 
DSM/IV Diagnostic and Statistical Manual-IV 
ECG  Electrocardiogram 
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e.g.  Exempli gratia = for example 
e-CRF  Electronic case report form 
EDTA  Ethylene diamine tetra-acetic acid 
E2W  Every two weeks 
E4W  Every four weeks 
ELISA  Enzyme linked immuno-sorbent assay 
FIH  First-in-human 
FU  Follow-up 
GCP  Good Clinical Practice 
γ-GT  Gamma-glutamyl Transferase 
HbA1c   Glycated haemoglobin A1c 
HDL-C High density lipoprotein cholesterol 
HLGT  High level group term 
HLT  High level term 
HR  Heart rate 
hs-CRP High-sensitivity C-reactive protein  
ICF  Informed consent form 
ICH  International Conference on Harmonization 
i.e.  Id est = that is 
IEC  Independent ethics committee 
INN  International Nonproprietary Name 
IP  Investigational Product 
IRB  Institutional review board 
ITT  Intent-to-treat 
IVRS  Interactive Voice Response System 
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IWRS  Interactive Web Response System 
Kg  Kilogram 
LDL-C Low density lipoprotein cholesterol 
LDLR  Low-density lipoprotein receptor 
LLN  Lower limit of normal range 
LLT  Lowest level term 
LOCF  Last-observation-carried-forward 
Lp(a)  Lipoprotein a 
MedDRA Medical Dictionary for Regulatory Activities 
µg  Microgram 
mITT  Modified intent-to-treat 
mmHg  Millimeter of mercury 
NCEPATPIII National Cholesterol Education Program Adult Treatment Panel III  
TLC  Therapeutic lifestyles changes  
NIP  Non Investigational Product 
PCI  Percutaneous coronary intervention 
PCSA  Potentially Clinically Significant Abnormality 
PCSK9 Proprotein convertase subtilisin/kexin type 9 
PD  Pharmacodynamics 
PDM  Project Demand Manager 
PK  Pharmacokinetics 
PT  Preferred term 
PTC  Product technical complaint 
SAE  Serious Adverse Event 
SAP  Statistical analysis plan 
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SBP  Systolic blood pressure 
SC  Subcutaneous 
SD  Standard deviation 
SOC  System-organ-class 
SUSAR Suspected Unexpected Serious Adverse Reaction 
TC  Total cholesterol 
TEAE  Treatment Emergent Adverse Event 
TG  Triglycerides 
TIA  Transient ischemic attack 
TSH  Thyroid stimulating hormone 
ULN  Upper limit of normal range 
WBC  White blood cell 
WHO-DD World Health Organization-Drug Dictionary 
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4 INTRODUCTION AND RATIONALE 
SAR236553 is also referred to as REGN727. However, in the context of the DFI11566 study 
protocol, it will be referred to as SAR236553. 
Hypercholesterolemia, particularly an increase in low-density lipoprotein cholesterol (LDL-C) 
levels, constitutes a major risk for the development of atherosclerosis and coronary heart disease 
(CHD) (1) the leading cause of death and disability in the Western world (2). LDL-C is identified 
as the primary target of cholesterol lowering therapy (3) and is accepted as a valid surrogate 
endpoint (4) (5). Numerous studies have demonstrated a strong direct relationship between 
LDL-C level and CHD events; for each 1% reduction of LDL-C, the risk of CHD is lowered by 
2% (6) (7). Greater reductions in LDL-C produce greater reduction in events (8), and recent data 
suggest that the lower the LDL-C level, the greater the benefit (9). Results from primary and 
secondary cardiovascular prevention trials with lipid lowering therapies, in particular with statins, 
have shown that lowering cholesterol levels is associated with a reduced risk of coronary related 
events, resulting in reduced cardiovascular morbidity and mortality (10) (11).  
Statins are the most commonly prescribed lipid lowering agents as they have shown a great ability 
to lower LDL-C. Recent studies have reported that high dose of statin results in an additional 
benefit compared with a moderate lipid lowering therapy (12) (13) (14). However there are 
limitations in some patients where adequate LDL-C lowering is not achieved with statins, even at 
maximal or tolerated doses (15). Therefore the addition of a second agent with a complementary 
mechanism of action to the high statin dose may facilitate the achievement of the therapeutic 
objectives. Beside this observation, it is also known that in some patients, the use of statins is 
limited by the occurrence of adverse events, mainly muscle aches, with an increased incidence of 
these adverse events associated with the increase of the dosage of statin. For these patients, adding 
another lipid lowering treatment would be an alternative to increasing the statin dose with a 
similar efficacy. 
Proprotein convertase subtilisin kexin type 9 (PCSK9) belongs to the subtilisin family of serine 
proteases and is highly expressed in the liver. PCSK9 is involved in regulating the levels of the 
low-density lipoprotein receptor (LDLR) protein (16) (17). Once PCSK9 is secreted into plasma it 
directly binds to the LDLR and promotes the degradation of the LDLRs. The increased 
degradation of LDLRs leads to a reduced LDL-C removal and, therefore higher LDL-C 
circulating levels. Experiments with mice have shown that increasing PCSK9 protein levels 
decreases levels of LDLR protein in the liver (18) (19), while PCSK9 knockout mice have 
increased levels of LDLR in the liver (20). In humans, PCSK9 mutations have been identified: the 
gain-of-function mutations are rare and cause an autosomal dominant form of severe 
hypercholesterolemia and premature CHD (21), whereas loss-of-function mutations are more 
common and are associated with reduced plasma levels of LDL-C and protection from CHD (22). 
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Therefore blocking PCSK9 binding to the LDL-R can potentially benefit patients suffering from 
hypercholesterolemia by decreasing their plasma LDL-C levels. In addition, PCSK9 messenger 
ribonucleic acid (mRNA) and protein levels are increased in response to statins, potentially 
attenuating their cholesterol-lowering effect, and it can be expected that an anti-PCSK9 treatment 
will function synergistically with statins to enhance LDLR regulation (23). 
SAR236553 is a fully human monoclonal antibody that binds (PCSK9). All information 
concerning the compound is available in the Clinical Investigator’s Brochure (CIB) (24). 
Direct evidence that the inhibition of PCSK9 by SAR236553 reduces LDL-C in animals was 
demonstrated in an experiment in which 3 cynomolgus monkeys were treated with either a single 
intravenous (IV) dose of 5 mg/kg or 15 mg/kg SAR236553, or with placebo. Reductions between 
56% and 72% from baseline LDL-C levels were observed by Day-3 and lasted longer than 
30 days. Following the fifth administration of SAR236553 in the 5-week subcutaneous (SC) 
monkey study LDL-C was decreased ~34-86% across all dose groups in males and females. 
Three Phase 1 studies have been set up with SAR236553. One study has been recently completed 
and the two other studies are still ongoing:  
• The R727-CL-0902 study, the first-in-human (FIH) study investigated the safety and 
tolerability of a single ascending dose of IV SAR236553 in healthy volunteers who were 
not indicated for statin therapy.  A total of 40 subjects were enrolled at 1 study site.  
Subjects in each dose cohort (0.3, 1.0, 3.0, 6.0, or 12 mg/kg) were randomized to receive a 
single dose of SAR236553 (n=6) or placebo (n=2). The total observation period was 
15 weeks (up to day 106). This study is completed; all doses were well-tolerated.  
Preliminary study results are available in the Investigator’s Brochure. 
• The R727-CL-0904 study is investigating the safety and tolerability of a single ascending 
dose of subcutaneous (SC) SAR236553 in healthy volunteers who are not indicated for 
statin therapy. A total of 32 subjects were enrolled at 2 study sites.  Subjects in each dose 
cohort (50, 100, 150, or 250 mg) were randomized to receive a single dose of SAR236553 
(n=6) or placebo (n=2). The total observation period is 15 weeks (up to Day 106). In this 
ongoing study the enrollment is complete. As of October 2010, all doses have been 
well-tolerated. 
• The R727-CL-1001 Phase 1 multiple-dose study is investigating the safety of SC 
SAR236553 in hyperlipidemic patients (familial and non-familial) receiving stable doses 
of atorvastatin, or hyperlipidemic patients (non-familial) who are not taking a concomitant 
statin. This study is currently enrolling. As of October 2010, all doses have been 
well-tolerated. 
The present study is to evaluate the efficacy and safety of the co-administration of SAR236553 
and a high dose of atorvastatin (80 mg) in comparison to placebo and a high dose of atorvastatin 
in patients with primary hypercholesterolemia, a situation that may arise when a rapid decrease in 
LDL-C levels is needed, e.g. after an acute coronary syndrome (25). Its main objective will be to 
assess the effects of SAR236553 on LDL-C level reduction. This study will also allow evaluating 
the efficacy and safety of SAR236553 when co-administered with 2 different doses of 
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atorvastatin. The dose of SAR236553 as well as the dose regimen tested in this study (150 mg 
every 2 weeks) is one of the dose/dose regimen administered to healthy subjects that have 
demonstrated safety and biological activity in the Phase 1 studies. 
The duration of treatment will be 8 weeks that is considered sufficient to demonstrate the efficacy 
of SAR236553 in terms of LDL-C reduction. This treatment duration should also provide a 
sufficient duration of “exposure” to appreciate tolerability and safety profiles of the compound. 
Based on preliminary PK and PD data of studies R727-CL-0902, R727-CL-0904 and 
R727-CL-1001, serum concentrations of SAR236553 > 10 µg/mL are expected for approximately 
35 days (5 weeks) following the highest administered subcutaneous dose (i.e., 300 mg) and 
approximately 21 days (3 weeks) following administration of 150 mg dose. Having reached a 
serum concentration of approximately 10 µg/mL, SAR236553 is then eliminated with a terminal 
elimination half-life of approximately 7 days. To ensure sufficient low, non-effective SAR236553 
serum concentrations it is recommended to continue the study for an additional five half-lives 
(5x7=35 days), therefore according to a conservative approach using PK data of the 300 mg dose 
a follow-up period of at least 10 weeks after last dosing (i.e.,35 days + (5x7=35days) = 70 days = 
10 weeks) is required. Given these assumptions, the last follow-up visit will be performed at 
Week 16 which is 10 weeks after the last SAR236553 dose. 
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5 STUDY OBJECTIVES 
5.1 PRIMARY 
To evaluate the effect of SAR236553 on low-density lipoprotein cholesterol (LDL-C) levels 
compared with placebo when co-administered with 80 mg of atorvastatin after 8 weeks of 
treatment in patients with LDL-C ≥ 100mg/dL (≥ 2.59 mmol/L) on atorvastatin 10 mg. 
5.2 SECONDARY 
The secondary objectives are: 
• To evaluate the effects of SAR236553 on other lipid levels in comparison with placebo, 
when co-administered with 80 mg of atorvastatin after 8 weeks of treatment.  
• To evaluate the efficacy of SAR236553 when co-administered with a high dose of 
atorvastatin (80 mg) versus atorvastatin 10 mg. 
• To evaluate the safety and tolerability of SAR236553 when co-administered with 
2 different doses of atorvastatin. 
• To evaluate the development of anti-SAR236553 antibodies. 
• To evaluate the pharmacokinetics of SAR236553. 
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6 STUDY DESIGN 
This will be a multicenter, randomized, double-blind, parallel-group, placebo-controlled, 8-week 
study conducted in the United States to assess the efficacy and safety of SAR236553 in patients 
with an elevated LDL-C (≥ 100 mg/dL or 2.59 mmol/L) treated with a stable dose of atorvastatin 
10 mg. During the screening/run-in period, patients will be stabilized to atorvastatin 10 mg for at 
least 6 weeks, if they are not already. During the double-blind treatment period, patients will 
return to the site every 2 weeks to receive study treatment: SAR236553 150 mg or SAR236553 
placebo, as well as atorvastatin 80 mg, or atorvastatin 10 mg. The double-blind treatment period 
will be then followed by an 8-week follow-up period. 
6.1 DESCRIPTION OF THE PROTOCOL 
The study comprises three periods. 
• A screening period with 2 options depending on the status of the patient at screening: 
a) Option 1: for patients receiving atorvastatin 10 mg at stable dose for at least 6 weeks prior to 
screening, the screening period will be of 1 week. This screening period will start by a 
screening visit (Week -1, V1), during which patients will be evaluated for eligibility to enter 
the double-blind treatment period. 
b) Option 2 : for patients receiving a lipid lowering treatment other than atorvastatin/ or not at 
stable dose of atorvastatin 10 mg for at least 6 weeks prior to screening, or for drug naive 
patients. This screening period includes a run-in period on atorvastatin 10 mg with: 
- a pre-screening visit (Week -7, V1a) during which pre-eligibility assessments will be 
performed to permit the entry of patients into the run-in period. If applicable, at this 
pre-screening visit (Week -7, V1a) patients will be asked to stop any lipid lowering 
treatment previously received. Then after 6 weeks of run-in period, a screening visit 
(Week -1, V1) will be held during which the full eligibility assessment will be 
performed. 
• A randomized, double-blind, placebo-controlled, parallel-group treatment period of 
8 weeks where patients will be randomized as follows: 
- Either to the group of SAR236553 150 mg  + high dose of atorvastatin (80 mg). 
- Or to the group of SAR236553 placebo + high dose of atorvastatin (80 mg). 
- Or to the group of SAR236553 150 mg + maintenance of atorvastatin dose previously 
received (10 mg). 
• A follow-up period of 8 weeks during which patients will return for follow-up visits 4 and 
8 weeks after the end of study treatment period (Week 8). 
All patients will be instructed to be on a stable diet (NCEP-ATPIII TLC diet or equivalent) 
throughout the entire study duration from screening.  
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6.1.1 Screening period/run-in period 
• Patients who are on a stable dose of atorvastatin 10 mg will enter a screening period as 
follows: 
- Duration: 1 week. 
- From screening visit (Week-1, V1) to the baseline visit (Week 0, V2; 
randomization).  
- Visit planned on Week-1 (V1). 
- Patients will take atorvastatin 10 mg in an open label manner until Week 0 (V2, 
baseline visit). 
During this screening visit (Week-1), the full eligibility assessments will be performed to permit 
the randomization of the patients in the study. 
• Patients who are receiving a lipid lowering treatment other than atorvastatin/ or not at 
stable dose of atorvastatin 10 mg for at least 6 weeks prior to screening, or drug naive 
patients will enter into a screening/run-in period. The screening period will start by a 
pre-screening Visit (Week-7, V1a) immediately followed by a run-in period of 6 weeks: 
- Duration: 7 weeks. 
- From pre-screening visit (Week-7, V1a) to the baseline visit (Week 0, V2, 
randomization). 
- Patients will take atorvastatin 10 mg in an open label manner. 
- Visits planned on Week-7 (V1a) and Week-1 (V1). 
At the pre-screening visit Week-7 (V1a), pre-eligibility assessments will be performed before 
starting the run-in period. Then the screening visit will be performed at Week-1 (V1), where the 
full eligibility assessments will be performed to permit the randomization of the patients in the 
study. 
Dose of atorvastatin (10 mg) should be stable during the screening period. Also during this period 
patients should be on a stable diet (NCEP-ATPIII TLC diet or equivalent). 
6.1.2 Double-blind treatment period 
• Randomized, double-blind, placebo-controlled treatment period, using a 1:1:1 
randomization ratio. Patients can be randomized only once. 
• Duration: 8 weeks. 
• From baseline Visit (Week 0, V2, Day1) to the end of the double-blind treatment period 
(Week 8, V6). 
• Visits planned on Week 0 (V2), Week 2 (V3), Week 4 (V4), Week 6 (V5) and Week 8 
(V6). 
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Patients meeting all inclusion/exclusion criteria assessed at visit(s) performed during the 
screening period (Week -7 and Week -1) may undergo baseline assessments (Week 0, V2). After 
the baseline assessments patients will be randomized on Day 1 into one of the 3 treatment groups: 
SAR236553 150 mg E2W + high atorvastatin dose (80 mg), or SAR236553 placebo E2W + high 
atorvastatin dose (80 mg), or SAR236553 150 mg E2W + atorvastatin 10 mg. Atorvastatin will 
also be administered in a blinded manner. 
Patients should start both study treatments (SAR236553, atorvastatin) on the day of 
randomization, i.e. at baseline visit (Week 0, V2, Day 1).  
During the double-blind treatment period all patients will attend a visit every 2 weeks. They will 
receive the SAR236553 study treatment through SC injection at Week 0 (V2), Week 2 (V3), 
Week 4 (V4), and Week 6 (V5). The atorvastatin study treatment will be dispensed at Week 0 
(V2), and Week 4 (V4) with the instruction to take it orally once daily in the evening, with dinner.  
Diet (NCEP-ATPIII TLC diet or equivalent) should be stable throughout this period.  
For all visits after baseline a timeframe will be allowed using Week 0 (Day 1) as reference (if one 
visit date is changed, the next visit should take place according to the original schedule (see 
Section 1.2– Study Flowchart). 
6.1.3 Follow-up period 
• Duration: 8 weeks. 
• From last visit of the double-blind treatment period (Week 8, V6) to the end of the 
follow-up period (Week 16, V8). 
• Visits planned on Week 12 (V7) and Week 16 (V8). 
6.2 DURATION OF STUDY PARTICIPATION 
6.2.1 Duration of study participation for each patient 
The duration of study participation will depend on the status of the patient at screening: 
• For patients receiving atorvastatin 10 mg at stable dose for at least 6 weeks prior to 
screening, the study participation will be approximately 17 weeks including a screening 
period of 1 week, a double-blind treatment period of 8 weeks and a follow-up period of 
8 weeks. 
• For patients receiving a lipid lowering treatment other than atorvastatin/ or not at stable 
dose of atorvastatin 10 mg for at least 6 weeks prior to screening, or drug naive patients 
the study participation will be approximately 23 weeks with a screening period of 7 weeks 
(including a run-in period of 6 weeks), a double-blind treatment period of 8 weeks and a 
follow-up period of 8 weeks. 
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6.2.2 Determination of end of clinical trial (all patients) 
The end of the study is defined as being the last visit of the follow-up period for each patient 
6.3 INTERIM ANALYSIS 
Not applicable. 
6.4 STUDY COMMITTEES 
6.4.1 Data Monitoring Committee 
A Data Monitoring Committee (DMC), composed of members independent from the Sponsor and 
the study investigators, is implemented in order to monitor patient safety by conducting formal 
reviews of accumulated safety data that will be blinded by treatment group; if requested, the DMC 
may have access to the treatment allocation code or any other requested data for the purposes of a 
risk-benefit assessment. The DMC will provide the Sponsor with appropriate recommendations on 
the conduct of the clinical trial to ensure the protection and the safety of the enrolled patients in 
the study. In addition, the DMC will also institute any measures that may be required for ensuring 
the integrity of the study results during the study execution.  
All activities and responsibilities of the DMC will be described in the DMC charter. 
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7 SELECTION OF PATIENTS 
7.1 NUMBER OF PATIENTS PLANNED 
Approximately 90 patients will be randomized in a 1:1:1 randomization ratio to the following 
groups: 
• SAR236553 150 mg every 2 weeks + high dose of atorvastatin (80 mg): approximately 
30 patients. 
• Placebo for SAR236553 + high dose of atorvastatin (80 mg): approximately 30 patients. 
• SAR236553 150 mg every 2 weeks + atorvastatin 10 mg: approximately 30 patients. 
7.2  INCLUSION CRITERIA 
I 01. Patients (patients receiving a lipid lowering treatment other than atorvastatin/ or not at 
stable dose of atorvastatin 10 mg for at least 6 weeks prior to screening period, or drug 
naive patients) with primary hypercholesterolemia likely to have LDL-C ≥ 100 mg/dL 
(≥ 2.59 mmol/L) at the end of the run-in period on atorvastatin therapy (Week -1). 
OR 
Patients with primary hypercholesterolemia treated with stable dose of atorvastatin 10 mg 
for at least 6 weeks prior to screening period and likely to have LDL-C ≥ 100 mg/dL 
(≥ 2.59 mmol/L) at the screening visit (Week -1). 
I 02. Signed written informed consent. 
7.3 EXCLUSION CRITERIA 
Patients who have met all the above inclusion criteria listed in Section 7.2 will be screened for the 
following exclusion criteria which are sorted and numbered in the following three sub-sections: 
7.3.1 Exclusion criteria related to study methodology 
E 01. LDL-C < 100 mg/dL (< 2.59 mmol/L) at Week -1 (V1): 
• After the run-in period on atorvastatin 10 mg for patients receiving a lipid lowering 
treatment other than atorvastatin/ or not at stable dose of atorvastatin 10 mg for at least 
6 weeks prior to the screening period, or drug naive patients.  
OR  
• At the first visit for patients who are being treated with atorvastatin 10 mg at stable dose 
for at least 6 weeks prior to screening visit Week -1. 
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E 02. Patients aged < 18 or > 75 years at Week -7 or Week -1.  
E 03. Body mass index (BMI) < 18 or > 40 kg/m² at Week -7 or Week -1. 
E 04. Patients not previously instructed on a cholesterol-lowering diet. 
E 05. Use of a statin other than atorvastatin 10 mg, or use of other lipid lowering drugs including 
but not limited to fibrates, bile acid resins, niacin > 500 mg, intestinal cholesterol 
absorption (ICA) blockers, or omega-3 fatty acids at doses > 1000 mg during the screening 
period. 
E 06. Use of nutraceutical products that may affect lipids (e.g., omega-3 fatty acids at doses 
< 1000 mg, red yeast rice, plant stanols such as found in Benecol, flax seed oil, psyllium) not 
on stable dose for at least 6 weeks prior to screening period and/or during the screening 
period and/or not intended to be used at stable dose throughout the study.  
E 07. Patients with type 1 diabetes. 
E 08. Patients with type 2 diabetes treated with insulin. 
E 09. Patients with type 2 diabetes and with an HbA1c ≥ 8.5% at Week -7 or Week -1 
(considered poorly controlled). 
E 10. Presence of any clinically significant endocrine disease known to influence serum lipids or 
lipoproteins.  
Note: Patients on thyroid replacement therapy can be included if the dosage of thyroxine 
has been stable for at least 12 weeks prior to screening and their s-Thyroid Stimulating 
Hormone (s-TSH) level is within ±10% of the normal range of the Central Laboratory. 
E 11. Patients with uncontrolled blood pressure (> 150/95 mmHg) at Week -7, or Week -1, or 
Week 0. 
E 12. History of myocardial infarction, coronary artery bypass graft surgery (CABG), 
percutaneous coronary intervention (PCI), unstable angina pectoris, carotid surgery or 
stenting, cerebrovascular accident, or transient ischemic attack (TIA) within 6 months prior 
to the screening period. 
E 13. History of heart failure (NYHA Class II-IV) within 12 months prior to the screening 
period. 
E 14. History of ileal bypass, gastric bypass or other bariatric surgery within 12 months prior to 
screening, or if surgery took place more than 12 months prior to the screening period, 
unstable weight (variation > 5 kg) within 2 months prior to the screening period. 
E 15. Presence or history of cancer within the past 5 years with the exception of adequately 
treated localized basal skin cancer. 
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E 16. Patients with a history (during the past 6 months) or concurrent DSM-IV substance abuse 
or dependence (excluding nicotine and caffeine). 
E 17. Conditions/situations such as: 
• Any clinically significant abnormality identified at the time of screening that in the 
judgment of the Investigator or any sub-Investigator would preclude safe completion of 
the study or constrain endpoints assessment such as major systemic diseases, patients with 
short life expectancy. 
• Patients considered by the Investigator or any sub-Investigator as inappropriate for this 
study for any reason, e.g.: 
- Those deemed unable to meet specific protocol requirements, such as scheduled visits. 
- Those with likelihood of requiring treatment during the screening phase and treatment 
phase with drugs not permitted by the clinical study protocol. 
- Investigator or any sub-Investigator, pharmacist, study coordinator, other study staff or 
relative thereof directly involved in the conduct of the protocol, etc. 
- Presence of any other conditions (e.g. geographic, social….) actual or anticipated, that 
the Investigator feels would restrict or limit the patient’s participation for the duration 
of the study. 
E 18. Patient who has previously participated in any clinical trial of SAR236553. 
E 19. Patient who has taken other investigational drugs within 1 month or 5 half lives, whichever 
is longer. 
E 20. Patient who withdraws consent during the screening period (patient who is not willing to 
continue or fails to return). 
E 21. Laboratory findings measured before randomization:  
• Positive test for hepatitis B surface antigen and/or hepatitis C antibody. 
• Triglycerides (TG) > 350 mg/dL (> 3.95 mmol/L) at Week -7 or Week -1. 
• Neutrophils < 1,500/mm3 and/or platelets < 100,000/mm3. 
• Positive serum or urine pregnancy test in females of childbearing potential.  
• Abnormal sensitive TSH level (> ULN or < LLN) according to the normal values of the 
Central Laboratory (for patients on thyroid replacement therapy, refer to exclusion 
criterion E 10). 
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• Evidence of renal impairment as determined by: 
- Men: serum creatinine > 1.5 x ULN. 
- Women: serum creatinine > 1.4 x ULN. 
• ALT or AST > 2xULN (1 repeat lab is allowed). 
• CPK > 3xULN (1 repeat lab is allowed). 
7.3.2 Exclusion criteria related to the active comparator and/or mandatory background 
therapies  
E 22. All contraindications to the protocol mandated background therapy (i.e., atorvastatin) or 
warning/precaution of use (when appropriate) as displayed in the respective National 
Product Labeling that was used for defining these exclusion criteria. 
7.3.3 Exclusion criteria related to the current knowledge of sanofi-aventis compound  
E 23. Known sensitivity to monoclonal antibody therapeutics. 
E 24. Pregnant or breast-feeding women. 
E 25. Women of childbearing potential with no effective contraceptive method. 
Women of childbearing potential must have a confirmed negative urine pregnancy test at 
screening and baseline Visits. They must use an effective contraceptive method throughout 
the study, and agree to repeat urine pregnancy test at designated visits. The applied 
methods of contraception have to meet the criteria for a highly effective method of birth 
control according to the “Note for guidance on non-clinical safety studies for the conduct 
of human clinical trials for pharmaceuticals (CPMP/ICH/286/95)” (26). Postmenopausal 
women must be amenorrheic for at least 12 months. 
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8 STUDY TREATMENTS 
8.1 INVESTIGATIONAL PRODUCTS 
8.1.1 SAR236553 
Sterile SAR236553 drug product will be supplied at a concentration of 150 mg/mL in 10 mM 
histidine, pH 6.0, 0.2% (w/v) polysorbate 20, and 10% (w/v) sucrose. Drug product will be 
supplied as a liquid with a 1.2 mL maximum withdrawable content in a nominal 5 mL glass vial. 
Details on storage and dose preparation will be provided in the pharmacy manual. 
Placebo for SAR236553 will be prepared in the same formulation as SAR236553 without the 
addition of protein. 
8.1.1.1 Dose administration and schedule 
Prior to SC administration, the pharmacist or designee will withdraw the required amount of study 
drug into a syringe. The procedure for preparing SAR236553 dosing solution and the volume to 
load into the syringe are provided in the pharmacy manual. The syringes and needles to be used 
for the dose and administration will be described in the pharmacy manual and will be supplied to 
the investigator site. 
Study treatment (SAR236553) will be administered in 1 SC injection of 1 mL every 2 weeks on 
Week 0 (V2), Week 2 (V3), Week 4 (V4), and Week 6 (V5). SC injections will be performed 
while maintaining the treatment blind by “unmasked” specified personnel who are otherwise 
removed from study conduct or outcome assessment. 
All SAR236553 Investigational Product (IP) injections will be administered in the abdomen; 
administration to the extremities is not allowed as this may lead to different bioavailability 
absorption.  
8.1.2 Atorvastatin 
During the double-blind treatment period:  
Atorvastatin will consist of 10 mg, or 40 mg tablets that will be supplied in over-encapsulated 
tablets. 
Matching placebo capsules will be supplied. 
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8.1.2.1 Dose administration and schedule 
During the double-blind treatment period:  
• Atorvastatin 10 mg: over-encapsulated tablet of 10 mg. 
• Atorvastatin 40 mg: over-encapsulated tablet of 40 mg. 
• Atorvastatin matching placebo capsule.   
Two capsules of atorvastatin IP will be administered once daily in the evening with the dinner, as 
described in the table below:  
 
 10 mg group 80 mg group 
Atorvastatin 10 mg 1 0 
Atorvastatin 40 mg 0 2 
Placebo 1 0 
 
8.2 NON INVESTIGATIONAL PRODUCTS 
During the run-in period: 
Tablets of atorvastatin 10 mg will be given in an open-label manner. All patients should be treated 
with atorvastatin 10 mg, once daily in the evening with the dinner. 
Atorvastatin dose will be recorded throughout the run-in period on the electronic Case Report 
Form (e-CRF) 
Atorvastatin 10 mg will be supplied to the patients throughout the entire duration of the run-in 
period. 
8.3 DESCRIPTION OF BLINDING METHODS 
8.3.1 Description of blinding methods for SAR236553 
SAR236553 and placebo for SAR236553 will be provided in identically matched glass 5  mL 
vials. Each vial contains 1.8 mL of SAR236553 or placebo for SAR236553 solution with 1.2 mL 
maximum permitted withdrawal volume. 
Each treatment kit will be labelled with a number, which will be generated by a computer 
program from sanofi-aventis. The treatment kit numbers will be obtained by the investigator at the 
time of patient randomization and subsequent patient scheduled visits via IVRS/IWRS that will be 
available 24 hours a day. 
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In accordance with the double-blind design, study patients, investigators and study site personnel 
(except the pharmacist and the third-party “unmasked” injector) will remain blinded to study 
treatment and will not have access to the randomization (treatment codes) except under 
circumstances described in Section 8.7. 
SC injections will be performed by “unmasked” specified personnel who are otherwise removed 
from study conduct or outcome assessment . In addition, the administration of the IP will be 
obstructed to patients who will be in supine position and to other viewers other than the 
“unmasked” specified personnel. 
8.3.2 Description of blinding methods for atorvastatin 
Capsules of atorvastatin will consist of 10 mg or 40 mg atorvastatin tablets over-encapsulated. 
Patients randomized to receive 80 mg atorvastatin dosing will receive 2 capsules containing each 
a 40 mg atorvastatin tablet. Patients randomized to receive 10 mg atorvastatin dosing will receive 
1 capsule containing a 10 mg atorvastatin tablet and 1 capsule of placebo for atorvastatin. 
Capsules of atorvastatin and matching placebo will be identical. A double-blind design will be 
used for packaging (see Section 8.5). All atorvastatin treatments will be packaged in child-
resistant identical wallet-cards. 
Each treatment kit will be labelled with a number, which will be generated by a computer 
program from sanofi-aventis. The treatment kit numbers will be obtained by the investigator at the 
time of patient randomization and subsequent patient scheduled visits via IVRS/IWRS that will be 
available 24 hours a day. 
In accordance with the double-blind design, study patients, investigators and study site personnel 
will remain blinded to study treatment and will not have access to the randomization (treatment 
codes) except under circumstances described in Section 8.7. 
8.4 METHOD OF ASSIGNING PATIENTS TO TREATMENT GROUP 
Two randomized treatment number lists (one list for SAR236553 and one list for atorvastatin) will 
be generated centrally by sanofi-aventis. The SAR236553 Investigational Product (IP) 
(SAR236553 150mg, or placebo) will be packaged in accordance with SAR236553 list. The 
treatment kits for the atorvastatin IP (atorvastatin 80 mg, or atorvastatin 10 mg) will be prepared 
in accordance with atorvastatin list, containing different numbers than the SAR236553 list. 
The Project Demand manager (PDM) will provide the randomized treatment kit number lists and 
the Study Biostatistician will provide the randomization scheme to the centralized treatment 
allocation system. Then, this centralized treatment allocation system will generate the patient 
randomization lists according to which it will allocate the treatments to the patients. 
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During the double-blind treatment period, patients will be randomized to receive either 
SAR236553 150 mg, or placebo for SAR236553, both in combination with atorvastatin 80 mg, or 
to SAR236553 150 mg in combination with atorvastatin 10 mg. The randomization ratio will be 
1:1:1. 
For each randomized patient, there will be 2 treatment kit numbers corresponding to SAR236553 
IP (SAR236553 150 mg, or placebo) and atorvastatin IP (atorvastatin 80 mg, or atorvastatin 
10 mg), respectively, which will be allocated through the centralized treatment allocation system. 
Throughout the double-blind treatment period, several corresponding treatment kit numbers for 
SAR236553 IP and atorvastatin IP will be allocated. 
The treatment kit numbers for SAR236553 IP will be allocated using the centralized treatment 
allocation system on baseline visit (V2, Week 0 or Day 1), and then at V3 (Week 2), V4 (Week 4), 
and V5 (Week 6). The treatment kit numbers for atorvastatin IP will be allocated using the 
centralized treatment allocation system on baseline visit (V2, Week 0 or Day 1), and then at V4 
(Week 4). Before randomizing a patient, the Investigator or designee will have to contact the 
centralized treatment allocation system and to provide some information (such as patient number 
provided by the site using the laboratory requisition form at pre-screening/screening visit, date of 
birth, etc.). 
A randomized patient is defined as a patient who is registered and assigned with a treatment kit 
number from the centralized treatment allocation system, as documented from its log file. A 
patient cannot be randomized more than once in the study. 
Two types of centralized treatment allocation system will be used, the Interactive Voice Response 
System (IVRS) and the Interactive Web Response System (IWRS) depending on the choice of the 
site. 
8.5 PACKAGING AND LABELING 
8.5.1 Packaging and labeling for SAR236553 
Each treatment kit will be prepared to contain 1 vial in accordance to its respective dosage 
SAR236553 150 mg or placebo. 
The vial within a treatment kit box will be labeled with double-blind label. In order to protect the 
blind, all treatment kit boxes will have the same look and feel and therefore will be labeled with a 
double blind label and secured with tamper-evident seals.  
The content of the labeling is in accordance with the local regulatory specifications and 
requirements. 
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8.5.2 Packaging and labeling for atorvastatin 
Two treatment kits for 8 weeks of treatment will be available for each patient. 
Each treatment kit will contain 5 weekly wallets (8 days in each) of 80 capsules and depending on 
the allocated group will be composed as follows:  
• Atorvastatin 80 mg daily dose: 2 atorvastatin 40 mg capsules. 
• Atorvastatin 10 mg daily dose: 1 atorvastatin 10 mg capsule and 1 placebo capsule. 
The content of the labeling will be in accordance with the local regulatory specifications and 
requirements. 
8.6 STORAGE CONDITIONS AND SHELF LIFE 
All Investigational Products (IPs) should be stored in an appropriate locked room under the 
responsibility of the Investigator or other authorized persons (e.g. pharmacists) in accordance with 
labeling specifications, local regulations, policies ad procedures. 
Prior to the first use, the SAR236553 (or placebo) kits will be stored in a refrigerator between 
+2ºC and +8ºC (36ºF - 46º F). The temperature of the refrigerator should be checked daily and 
recorded on a log sheet.   
The atorvastatin kits will be stored at a temperature between +2º C and +25 º C (36ºF -77 º F). 
8.7 RANDOMIZATION CODE BREAKING DURING THE STUDY 
Please refer to Section 9.4 - Measures to protect blinding of this trial. 
In case of an AE, the code must be broken only in exceptional circumstances when knowledge of 
the IP is essential for treating the patient. If possible, a contact should be initiated with the 
Monitoring Team/Medical Monitor before breaking the code. All calls will be documented by the 
Monitoring Team as appropriate to include date and time of the call, name of the person contacted 
within the Monitoring Team, patient ID, documentation of the request, and decision for 
unblinding or not. 
Code breaking can be performed at any time by using the proper module of the IVR/Interactive 
Web Response (IWR) system and/or by calling any other phone number provided by the Sponsor 
for that purpose.  If the blind is broken, the Investigator should document the date, time of day, 
and reason for code breaking, and report this information on the appropriate page of the e-CRF. 
The decision to withdraw the patient from IP administration should be discussed on a case by case 
basis.  
Note that when documenting the reason for unblinding, the Investigator must not provide any 
detail regarding the nature of the Investigational Product. The Investigator should not divulge 
medication detail to the Sponsor’s representative or to any staff members until database closure. 
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Furthermore, when completing forms (e.g., AE, SAE), the study treatment should not be disclosed 
on the forms. In case of SAE, the procedure for unblinding is described in Section 9.4. 
No code-breaking material will be provided to the Investigators. For each patient, code-breaking 
could be performed by the Investigator contacting the IVR/IWR system. However, it is preferable 
to contact the Medical Monitor to discuss the case before unblinding through IVRS.  
The code-breaking material will be also kept at the entity responsible for the "24 hour alert 
system"; but this system should be used in very exceptional cases only (i.e., unavailability of 
IVR/IWR system or inability to contact Investigator and/or site staff). However, the preferred 
option is to unblind using IVRS.The Investigators will be informed by the clinical monitoring 
team about the availability of the local code-breaking material. A patient card, including the 
relevant “24 hour alert system” telephone number will be provided to every patient who will 
participate in the study. 
8.8 RESPONSIBILITIES 
The Investigator, the Hospital Pharmacist, or other personnel allowed to store and dispense 
Investigational Product (SAR236553 IP, atorvastatin IP) will be responsible for ensuring that the 
IPs used in the clinical trial are securely maintained as specified by the Sponsor and in accordance 
with the applicable regulatory requirements. 
All IPs shall be dispensed in accordance with the Clinical Trial Protocol and it is the Pharmacist 
role under the Investigator’s responsibility to ensure that an accurate record of IPs issued and 
returned is maintained. 
Any quality issue noticed with the receipt or use of the IPs (deficiency in condition, appearance, 
pertaining documentation, labeling, expiration date, etc.) should be promptly notified to the 
Sponsor. Some deficiencies may be recorded through a complaint procedure (i.e., Product 
Technical Complaint (PTC) form) 
A potential defect in the quality of IPs may be subject to initiation of a recall procedure by the 
Sponsor. In this case, the Investigator will be responsible for promptly addressing any request 
made by the Sponsor, in order to recall IPs and eliminate potential hazards. 
Under no circumstances will the Investigator supply IPs to a third party, allows the IPs to be used 
other than as directed by this Clinical Trial Protocol, or dispose of IPs in any other manner. 
8.9 CONCOMITANT MEDICATION 
A concomitant medication is any treatment received by the patient concomitantly to any IP(s).  
Treatments in addition to the IPs should be kept to a minimum during the study. However, if these 
are considered necessary for the patient’s welfare and are unlikely to interfere with the IPs, they 
may be given at the discretion of the Investigator, with a stable dose (when possible). 
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8.9.1 Prohibited concomitant therapy 
The following drugs will not be permitted during the study, including the post-treatment 
follow up period: 
• Statin other than atorvastatin at the doses indicated in the protocol, and other lipid 
lowering drugs including but not limited to fibrates, bile acid resins, niacin > 500 mg, 
intestinal cholesterol absorption (ICA) blockers, or omega-3 fatty acids at doses > 1000 
mg. 
• Thyroid preparations or thyroxin treatment (except in patients on replacement therapy). 
• Insulin treatment. 
8.9.2 Permitted concomitant therapy 
Any therapy other than the prohibited concomitant therapy described above, will be allowed and 
will have to be recorded in the e-CRF and source data (please refer to Section 12.2). 
Nutraceutical product that may affect lipids (e.g., omega-3 fatty acids at doses < 1000 mg, red 
yeast rice, plant stanols such as found in Benecol, flax seed oil, psyllium) are allowed only if they 
have been used at a stable dose for at least 6 weeks prior to and during the screening period, and if 
they are maintained at a stable dose throughout the study. 
8.10 TREATMENT ACCOUNTABILITY AND COMPLIANCE 
8.10.1 Treatment accountability and compliance for SAR236553 
Measures taken to ensure and document treatment compliance and investigational product 
accountability are described below: 
• Once the pharmacist or designee gets the treatment kit number from the Investigator. The 
pharmacist or designee will then prepare the dose as 1 mL in one syringe and will 
complete the corresponding treatment log form with the treatment kit number.  
• Just after investigational product preparation, the pharmacist or designee will perform 
reconciliation by checking the consistency of the treatment number(s) between 
IVRS/IWRS assignment notification, the kit and treatment log forms and then will place 
the vials back into its respective treatment kit and will re-seal the kit with a tamper evident 
seal provided in the kit box. 
• The syringe and the treatment log form will be dispensed to the third-party “unmasked” 
injector who will administer (SC injection) the SAR236553 IP to the patient in supine 
position. Then the third-party “unmasked” person will complete the corresponding 
treatment log form (date and time of administration, volume of IP injected). 
• The Investigator/study coordinator will enter data in the appropriate e-CRF screens, 
according to data recorded in the treatment log form.  
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• An unblinded monitor will check the data consistency between e-CRF screens, treatment 
log forms, and the vial of a corresponding kit. After this verification the unblinded monitor 
will re-seal the kit.  
8.10.2 Treatment accountability and compliance for atorvastatin 
The Investigator (or delegates) will assess the compliance by counting the returned capsules in 
each wallet-card at each visit during the double-blind treatment period: Week 2 (V3), Week 4 
(V4), Week 6 (V5), and Week 8 (V6) and will fill in the Treatment Log Form.  
The Investigator (or delegates) will record the dosing information on the appropriate page(s) of 
the e-CRF. 
The monitor in charge of the study will then check the e-CRF data by comparing them with the 
atorvastatin IP that will be retrieved and treatment log forms. 
8.11 RETURN AND/OR DESTRUCTION OF TREATMENTS 
All partially used or unused treatments will be retrieved by the Sponsor. A detailed treatment log 
of the returned investigational products will be established with the pharmacist or designee and 
the third party “unmasked” injector, and countersigned by the Investigator and the Monitoring 
Team. 
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9 ASSESSMENT OF INVESTIGATIONAL PRODUCT 
9.1 EFFICACY 
9.1.1 Primary endpoint 
The primary endpoint of this study is the percent change in calculated LDL-C from baseline 
(mean Week -1 and Week 0) to Week 8.  
9.1.2 Secondary endpoint 
• Absolute change in calculated LDL-C from baseline to Week 8. 
• Proportion of patients achieving an LDL-C level lower than 100 mg/dL (2.59 mmol/L) at 
Week 8. 
• Proportion of patients achieving an LDL-C level lower than 70 mg/dL (1.81 mmol/L) at 
Week 8. 
• Percent change in TC, HDL-C, TG and non HDL-C from baseline (average of levels at 
Week -1 and Week 0) to Week 8. 
• Absolute change in TC, HDL-C, TG and non HDL-C from baseline (average of levels at 
Week -1 and Week 0) to Week 8. 
• Percent change in Apo-B from baseline (Week 0, Day 1) to Week 8. 
• Percent change in Apo-A1 from baseline (Week 0, Day 1) to Week 8.  
• Absolute change in the ratio ApoB/ApoA-1 from baseline (Week 0, Day 1) to Week 8. 
• Percent change in Lp(a) from baseline (Week 0, Day 1) to Week 8. 
9.1.3 Efficacy assessment methods 
9.1.3.1 Lipid parameters 
The blood sampling for determination of lipid parameters [i.e. TC, LDL-C, HDL-C, triglycerides 
(TG), non-HDL-C; Apo-B, Apo-A1, ratio ApoB/ApoA-1, Lp(a)] should be performed in the 
morning, in fasting condition (at least 10-12 hours fast and refrain from smoking), before any 
drug intake. Alcohol consumption within 48 hours and intense physical exercise within 24 hours 
preceding the blood sampling are discouraged. If the patient is not fasting at any visits, he/she will 
be asked to come the day after for the blood sampling. 
Total cholesterol, HDL-C, TG, Apo-B, Apo-A1, ratio ApoB/ApoA-1, and Lp(a) will be directly 
measured by a Central Laboratory. LDL-C levels will be calculated using the Friedewald formula 
(24) at all visits. Non-HDL-C will be calculated in subtracting HDL cholesterol from the total 
cholesterol. 
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Blood sampling for TC, LDL-C, HDL-C, TG and non-HDL-C determination will be performed at 
Week -7 for patients with run-in period and Week -1 in all patients. 
All patients will be qualified for randomization based on the LDL-C value obtained at Week -1 
(V1) (see Section 6.1). 
The Week -1 - LDL-C value will be averaged with the randomization-visit determination 
(Week 0) to calculate the baseline LDL-C value for the analysis. 
During the double-blind treatment period:  
• Samples for TC, LDL-C, HDL-C, TG and non-HDL-C determination will be collected at 
baseline (Week 0, V2), Week 2 (V3), Week 4 (V4), Week 6 (V5), and Week 8 (V6).  
• Samples for Apo-B, Apo-A1 and Lp(a) will be collected at baseline (Week 0, V2), Week 4 
(V4), and Week 8 (V6). 
During the follow-up period: 
• Samples for TC, LDL-C, HDL-C, TG, and non-HDL-C determination will be collected at 
Week 12 (V7) and Week 16 (V8). 
All the parameters will be measured by a Central Laboratory during the study. The lipid results 
will not be communicated to the investigators and the Sponsor from the baseline Visit to the end 
of the follow-up period.  
These parameters will assess the effects of SAR236553 on lipid levels. Primary efficacy endpoints 
described in the protocol will not be considered as Adverse Events (AEs), i.e. increases in LDL-C 
levels. 
9.1.3.2 Other blood parameters 
All other blood parameters will also be measured by a Central Laboratory during the study, and 
performed in the morning in fasting condition (at least 10-12 hours fast and refrain from 
smoking), before any drug intake. Alcohol consumption within 48 hours and intense physical 
exercise within 24 hours preceding the blood sampling are discouraged. 
HbA1c will be measured at a central laboratory at Week -7 (only for patients with run-in) or 
Week -1 (for patients without run-in), and Week 8 (V6). 
Fasting plasma glucose will be measured at a central laboratory at Week -7 (only for patients with 
run-in), Week -1, Week 0 (baseline visit, V2), and Week 8 (V6). 
The blood sampling for inflammatory parameter [i.e. high-sensitivity C-reactive protein 
(hs-CRP)] will be collected at Week 0 (baseline visit, V2), Week 4 (V4), and Week 8 (V6). 
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9.1.3.3 Library samples:  
• Plasma samples for exploratory research will be collected in one 8.5 mL blood collection 
tube (BD P100) for exploratory research that may include the study of PCSK9 function, 
effect(s) of PCSK9 inhibition with a monoclonal antibody, and mechanisms of 
hyperlipidemia and heart disease. If needed, samples may also be used to identify markers 
associated with toxicity. 
• Whole blood samples will be collected in one PaxGene tube of 2.5 mL blood. Library 
samples will be coded to maintain patient confidentiality and may be stored for up to 
10 years for use in experiments as noted above.  
Library samples (plasma and whole blood) will be collected at Week 0 (baseline visit, V2), 
Week 4 (V4), and Week 8 (V6) and sent to a central laboratory (only for randomized patients) for 
long-term storage between –70°C to –85°C. 
9.1.3.4 Body weight 
Body weight should be obtained with the patient wearing undergarments or very light clothing 
and no shoes, and with an empty bladder. The same scale should be used throughout the study, 
and calibrated on a regular basis as recommended by the manufacturer. 
The use of balance scales is recommended; if digital scales are used, testing with standard weights 
is of particular importance. The floor surface on which the scale rests must be hard and should not 
be carpeted or covered with other soft material. The scale should be balanced with both weights at 
zero and the balance bar aligned. The patient should stand in the center of the platform as standing 
off-center may affect measurement. The weights are moved until the beam balances (the arrows 
are aligned). The weight is read and recorded in the e-CRF and Source Data. Self-reported 
weights are not acceptable; patients must not read the scales themselves. 
Body weight will be measured at Week -7 (only for patients with run-in) or Week -1 (for patients 
without run-in), Week 0 (baseline visit, V2), and then at all visits until the last follow-up visit 
(Week 16, V8). 
9.2 SAFETY 
Safety will be assessed by: 
• Clinical examination.  
• Vital signs (supine systolic and diastolic blood pressure and heart rate). 
• Recording of adverse events. 
• Standard laboratory tests (hematology and serum chemistry). 
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• Liver function tests [ALT, AST, Alkaline Phosphatase (ALP), γ Glutamyl Transferase 
(γGT) and total bilirubin]. 
• Creatine Phospho Kinase (CPK). 
• Electrocardiogram (ECG).  
The study-specific and general safety criteria are developed in Section 10.1. 
9.3 PHARMACOKINETICS AND ANTI-SAR236553 ANTIBODY ASSESSMENTS 
9.3.1 Sampling time 
SAR236553 PK sampling 
Serum samples for PK measurements will be collected before SAR236553 investigational product 
injection (pre-dose) at Week 0 (baseline visit, V2), and then at each visit until the end of the 
follow-up period (Weeks 2, 4, 6, 8, 12, and 16; Visits V3, V4, V5, V6, V7, V8). 
Anti-SAR236553 antibody sampling 
Serum samples for anti-SAR236553 antibodies determination will be drawn before investigational 
product injection (pre-dose) at Week 0 (baseline visit, V2), Week 4 (V4), Week 8 (V6), Week 12 
(V7), and Week 16 (V8). 
Only in case of persistent and absence of decreased anti-SAR236653 antibody levels at Week 16 
(V8) patients will be asked for one additional antibody sample 6 to 12 months after last dosing. 
9.3.2 PK and antibody sample handling procedure 
Detailed procedure of sample preparation, storage and shipment are described in the specific 
laboratory manual provided by Regeneron. Five (5) ml blood volume is to be collected for each 
PK and antibody sample. 
Remaining serum volume may be used for exploratory research purposes, as described in the 
Section 9.1.3.3. 
9.3.3 Bioanalytical method 
All PK and antibody samples are analyzed by the Regeneron Sample Analysis group. 
PK samples 
PK samples are analyzed using a validated enzyme-linked immunosorbent assay (ELISA) for the 
determination of total concentrations of SAR236553 (i.e., free SAR236553 and SAR236553 
present in PCSK9:SAR236553 complexes) in acid-treated human serum with a lower limit of 
quantification of 0.078 µg/mL [REGN727-AV-09104-SA-01V1]. 
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Antibody samples  
Antibody samples are analyzed using a validated electrochemiluminescence assay for the 
determination of anti-SAR236553 antibody titers in acid-treated human serum with a lower limit 
of detection of approximately 1.5 ng/mL [REGN727-AV-10014-SA-01V1].  
9.3.4 Pharmacogenetic Samples 
An optional pharmacogenomic sub-study will be conducted to identify genetic associations with 
clinical or biomarker response to PCSK9 inhibition, hyperlipidemia, or cardiovascular disease.  If 
needed, samples may also be used to identify markers associated with toxicity. 
Patients who agree to participate in the genetics sub-study will be required to sign a separate 
genetics sub-study ICF prior to collection of the DNA sample. Blood for DNA extraction should 
be collected before investigational product injection (pre-dose) on baseline visit (Week 0, V2); 
however, it may be collected at any time during the study. Patients who choose not to enroll in the 
genomics sub-study are still eligible to enroll in the primary study.  
Special procedures for storage and shipping of pharmacogenetic samples are summarized below 
(Table 4) and are described in detail in Appendix B. 
Table 4 - Summary of handling procedures for DNA storage samples 
Sample Type(s) Pharmacogenetics 
Blood Sample 
Volume 12 mL (2 x 6 mL) 
Tube Type 2 x 6 mL Becton Dickinson K2 EDTA VACUTAINER™ Plus tubes with HEMOGARD™ closure (PN367863/4) sterile tubes 
Anticoagulant K2 EDTA 
Blood Handling 
Procedures Keep blood on ice or frozen at -20°C (or colder) within 30 min of sampling time.  DO NOT CENTRIFUGE. 
Storage Conditions In collection tube at approximately -20°C (or colder) 
 
The Sponsor has included safeguards for protecting patient confidentiality. The blood sample and 
DNA that is extracted from it will be assigned a second number, a Genetic ID (de-identification 
code) that is different from the Subject ID. This “double coding” is performed to separate a 
patient’s medical information and DNA data. The clinical study data (coded by Subject ID) will 
be stored in a distinct database at a different location from the database containing the 
pharmacogenetic data (coded by Genetic ID). The key linking Subject ID and Genetic ID will be 
maintained by a third party, under appropriate access control. The matching of clinical data and 
pharmacogenetic data, for the purpose of data analysis, will be possible only by using this key, 
which will be under strict access control. All data will be reported only in coded form in order to 
maintain confidentiality. 
DNA may be stored and used for analyses for up to 15 years from the completion of the Clinical 
Study Report.  Analyses may include sequence determination or single nucleotide polymorphisms 
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(SNP) from candidate genes. Candidate genes may include (but are not limited to) PCSK9, ApoB 
and LDL-R. Genome-wide studies, including (but not limited to) SNP analyses and/or genomic 
sequencing may also be performed. 
9.4 MEASURES TO PROTECT BLINDING OF THIS TRIAL 
In case of an adverse event, the Investigator should only break the code in exceptional 
circumstances when knowledge of the Investigational Product is essential for treating the patient. 
Please also refer to Section 8.7 - randomization code breaking during the study. 
The treatment code will be unblinded by the Pharmacovigilance Department for reporting to the 
Health Authority of any Suspected Unexpected Serious Adverse Reaction (SUSAR) and 
reasonably associated with the use of the IP according to either the judgment of the Investigator 
and /or the Sponsor. 
At the assay institutions charged for PK measurements and determination of antibodies, samples 
will be analyzed prior data base lock leading to unblinding of responsible bioanalysts. Bioanalysts 
are excluded from the clinical trial team. 
In addition, lipid parameters including LDL-C levels determination will not be communicated to 
the investigators throughout the study, including the follow-up period, so that they cannot deduce 
the treatment group of their patients based on LDL-C level attained. 
The Data Monitoring Committee will receive blinded by treatment group or unblinded (if 
necessary) confidential reports from an independent statistician for review, which have to be 
handled strictly confidentially. None of these reports can be delivered to unauthorized persons 
(please refer to 6.4.1).  
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10 PATIENT SAFETY 
10.1 SAFETY ENDPOINTS ASSESSED IN THIS TRIAL 
• Local tolerability at injection site (please refer to Section 10.2.1. 
• Acute injection reactions (please refer to Section 10.2.2. 
• Other adverse events and serious adverse events. 
• Vital signs. 
• 12-lead ECG. 
• Laboratory tests: hematology (red blood cell count, hemoglobin, hematocrit, platelets, 
white blood cell count with differential blood count), serum chemistry (sodium, potassium, 
chloride, bicarbonate, calcium, phosphorous, urea nitrogen, creatinine, uric acid, total 
protein, albumin, and troponin I), liver tests (ALT, AST, ALP, γGT and total bilirubin), 
and CPK. 
10.1.1 Clinical safety  
Clinical safety will be assessed by: 
• Clinical examination at Week -7 (only for patients with run-in) or Week -1(for patients 
without run-in), Week 0 (baseline, V2), Week 8 (V6), and Week 16 (V8). 
• Vital signs including supine blood pressure and heart rate at Week -7 (only for patients with 
run-in), Week -1, Week 0 (baseline, V2), Week 2 (V3), Week 4 (V4), Week 8 (V6), Week 16 
(V8). 
Blood pressure should be measured in supine position under standardized conditions, 
approximately at the same time of the day, on the same arm, with the same apparatus (after the 
patient has rested comfortably in supine position for at least five minutes). Values are to be 
recorded in the e-CRF; both systolic blood pressure (SBP) and diastolic blood pressure (DBP) 
should be recorded. 
At Week -7 (only for patients with run-in) or Week -1 (for patients without run-in), supine blood 
pressure should be measured in both arms. The arm with the highest diastolic pressure will be 
determined at this visit, and blood pressure should be measured on this arm throughout the study. 
This highest value will be recorded in the e-CRF. 
Heart rate will be measured at the time of the measurement of supine blood pressure. 
10.1.2 Adverse event collection 
Adverse events and serious adverse events will be collected from the time of informed consent 
signature and then at each visit until the end of the study. 
 
Amended Clinical Trial Protocol 1  16-Feb-2011 
DFI11566 - SAR236553  Version number: 1 (electronic 1.0) 
Property of the sanofi-aventis group - strictly confidential Page 56 
10.1.3 ECG 
A 12-lead ECG will be performed at Week -1 (V1), Week 4 (V4), and Week 8 (V6).  
Heart rate, QRS duration, PR interval, QT interval, QRS axis, ST deviation, T-wave morphology, 
U wave presence or absence will be determined using a centralized automatic and manual reading 
of all ECGs. 
The 12-lead ECGs should be performed after at least 10 minutes rest in supine position. The 
electrodes are to be positioned at the same place for each ECG recording throughout the study. 
Each trace will be analyzed in comparison with the screening recorded trace. The original trace 
will be kept as source data. 
Note: 
Any new clinically significant changes in ECG parameters should be immediately rechecked for 
confirmation before making any decision for the concerned patient. Any clinically significant 
abnormality should be documented as an AE/SAE as applicable. Please also refer to 
Section 10.5.1. 
10.1.4 Safety laboratory 
The following laboratory data are collected from fasting patients in accordance with the study 
schedule and forwarded to the central laboratory: 
• Hematology: red blood cell count, hemoglobin, hematocrit, platelets, white blood cell count 
with differential blood count (neutrophils, lymphocytes, monocytes, eosinophils, basophils) at 
Week -7 (V1a - only for patients with run-in), Week -1 (V1), Week 0 (baseline, V2), Week 4 
(V4), Week 8 (V6), and during the follow-up period [Week 12 (V7), Week 16 (V8)] in case of 
persistent clinically relevant abnormal values at Week 8 (V6, end of treatment). 
• Serum chemistry: sodium, potassium, chloride, bicarbonate, calcium, phosphorous, urea 
nitrogen, creatinine, uric acid, total protein, albumin, and troponin I at Week -7 (V1a - only for 
patients with run-in), Week -1 (V1), Week 0 (baseline, V2), Week 4 (V4), Week 8 (V6), and 
during the follow-up period [Week 12 (V7), Week 16 (V8)] in case of persistent clinically 
relevant abnormal values at Week 8 (V6, end of treatment). 
•  Liver tests: ALT, AST, ALP, γGT and total bilirubin (and, in case of values above the normal 
range, differentiation in conjugated and non-conjugated bilirubin) at Week -1 (V1), Week 0 
(baseline, V2), Week 4 (V4), Week 8 (V6), and during the follow-up period [Week 12 (V7), 
Week 16 (V8)] in case of persistent clinically relevant abnormal values at Week 8 (V6, end of 
treatment). 
• CPK at Week -1 (V1), Week 0 (baseline, V2), Week 4 (V4), Week 8 (V6), and during the 
follow-up period [Week 12 (V7), Week 16 (V8)] in case of persistent clinically relevant 
abnormal values at Week 8 (V6, end of treatment). 
• Sensitive TSH, hepatitis B surface antigen and hepatitis C antibody at Week -1 (V1). 
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• Pregnancy test: 
- Serum pregnancy test in females of childbearing potential at Week -1 (V1). 
- Urine pregnancy test in females of childbearing potential at Week -7 (V1a - only for 
patients with run-in), Week 0 (baseline, V2), Week 4 (V4), Week 8 (V6), Week 12 
(V7), and Week 16 (V8).  
Note: 
- Any abnormal laboratory value should be immediately rechecked (whenever possible 
using the central laboratory) for confirmation before making any decision for the 
concerned patient. It should be documented as an AE/SAE as applicable. Please also 
refer to Section 10.5.1. 
Decision trees for the management of certain laboratory abnormalities by sanofi-aventis are 
provided in Appendix A.  
Please also refer to Section 11. 
10.2 SAFETY INSTRUCTIONS 
10.2.1 Local tolerability 
In case the Investigator or the patient recognizes any signs of local intolerability this should be 
recorded in the e-CRF on the standard AE form. 
10.2.2 Management of Acute Injection Reactions 
Acute injection reactions are defined as any AE that is associated with the injection. Emergency 
equipment and medication for the treatment of these potential adverse effects (e.g., antihistamines, 
bronchodilators, oxygen, IV saline, corticosteroids, acetaminophen, and epinephrine) must be 
available for immediate use. 
Patients will be monitored at the investigational site for at least 30 minutes following each 
SAR236553 IP injection. Patients should be treated symptomatically if any AEs are observed. 
Patients are to remain at the site until any acute injection reaction is assessed as stable, per the 
investigator’s discretion.  
10.3 ADVERSE EVENTS MONITORING 
All events will be managed and reported in compliance with all applicable regulations, and 
included in the final clinical study report. 
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10.4 DEFINITIONS OF ADVERSE EVENT (AE) AND SERIOUS ADVERSE EVENT (SAE) 
An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical investigation 
patient administered a pharmaceutical product and which does not necessarily have to have a 
causal relationship with this treatment. 
A Serious Adverse Event (SAE) is any untoward medical occurrence that at any dose: 
• Results in death or; 
• Is life-threatening or; 
Note: The term "life-threatening" in the definition of "serious" refers to an event in which the 
patient was at risk of death at the time of the event; it does not refer to an event which 
hypothetically might have caused death if it were more severe. 
• Requires inpatient hospitalization or prolongation of existing hospitalization or; 
• Results in persistent or significant disability/incapacity or; 
• Is a congenital anomaly/birth defect; 
• Is a medically important event: 
Medical and scientific judgment should be exercised in deciding whether expedited reporting 
is appropriate in other situations, such as important medical events that may not be 
immediately life-threatening or result in death or hospitalization but may jeopardize the 
patient or may require intervention (i.e., specific measures or corrective treatment) to prevent 
one of the other outcomes listed in the definition above. 
Note: The following medical important events intend to serve as a guideline for determining 
which condition has to be considered as a medically important event. It is not intended to be 
exhaustive: 
• Intensive treatment in an emergency room or at home for: 
- allergic bronchospasm,  
- blood dyscrasias (i.e., agranulocytosis, aplastic anemia, bone marrow aplasia, 
myelodysplasia, pancytopenia…),  
- convulsions (seizures, epilepsy, epileptic fit, absence…) 
• Development of drug dependency or drug abuse, 
• ALT > 3 ULN + total bilirubin > 2 ULN or asymptomatic ALT increase > 10 ULN , 
• Suicide attempt or any event suggestive of suicidality, 
• Syncope, loss of consciousness (except if documented as a consequence of blood 
sampling), 
• Bullous cutaneous eruptions, 
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• Cancers diagnosed during the study or aggravated during the study (only if judged as 
unusual/significant by the Investigators in oncology studies), 
• Chronic neurodegenerative diseases (newly diagnosed) or aggravated during the study 
(only if judged as unusual/significant by the Investigators in studies assessing specifically 
the effect of a study drug on these diseases). 
10.5 OBLIGATION OF THE INVESTIGATOR REGARDING SAFETY REPORTING 
10.5.1 Adverse Events 
All AEs regardless of seriousness or relationship to IPs, spanning from the signature of the 
informed consent form, until the end of the study as defined by the protocol for that patient, are to 
be recorded on the corresponding screen(s) included in the e-CRF. 
Whenever possible, diagnosis or single syndrome should be reported instead of symptoms. The 
Investigator should specify the date of onset, intensity, action taken with respect to IP, corrective 
treatment/therapy given, additional investigations performed, outcome and his/her opinion as to 
whether there is a reasonable possibility that the AE was caused by the IP. 
Laboratory, vital signs or ECG abnormalities are to be recorded as AEs only if:  
• symptomatic and/or  
• requiring either corrective treatment or consultation, and/or  
• leading to IP discontinuation or modification of dosing, and/or  
• fulfilling a seriousness criterion, and/or  
• defined as an AE with pre-specified monitoring with immediate notification. 
10.5.2 Serious Adverse Events 
In the case of occurrence of a SAE, the Investigator must immediately: 
• ENTER (within 1 working day) the information related to the SAE in the appropriate 
screens of the e-CRF; the system will automatically send the notification to the Monitoring 
Team and Pharmacovigilance after approval of the Investigator within the e-CRF or after a 
standard delay. 
• SEND (preferably by fax or e-mail) the photocopy of all examinations carried out and the 
dates on which these examinations were performed, to the representative of the 
Monitoring Team whose name, fax number and email address appear on the Clinical Trial 
Protocol;. Care should be taken to ensure that the patient's identity is protected and the 
patient's identifiers in the Clinical Trial are properly mentioned on any copy of source 
document provided to the Sponsor. For laboratory results, include the laboratory normal 
ranges. 
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• All further data updates should be recorded in the e-CRF as appropriate, and further 
documentation as well as additional information (for Lab data, concomitant Medication, 
patient status ..) should be sent (by fax or e-mail) to the Monitoring Team within 
1 working day of knowledge. In addition, any effort should be made to further document 
each Serious AE that is fatal or life threatening within the week (7 days) following initial 
notification. 
• A back-up plan is used (using paper flow) when the e-CRF system does not work. 
10.5.3 Safety Observations 
• The Investigator should take all appropriate measures to ensure the safety of the patients, 
notably he/she should follow up the outcome of SAE /AEs with pre-specified monitoring 
until clinical recovery is complete and laboratory results have returned to normal or until 
progression has been stabilized or death. In all cases, this may imply that observations will 
continue beyond the last planned visit per protocol, and that additional investigations may 
be requested by the Monitoring Team up to as noticed by the sponsor. 
• When treatment is prematurely discontinued, the patient’s observations will continue until 
the end of the study as defined by the protocol for that patient. 
• In case of any SAE/AEPM with immediate notification brought to the attention of the 
Investigator at any time after the end of the study for the patient and considered by him/her 
to be caused by the IP with a reasonable possibility, this should be reported to the 
Monitoring team. 
10.5.4 Adverse events with pre-specified monitoring (AEPM)  
Adverse events requiring pre-specified monitoring are AEs (serious or non-serious) that need to 
be monitored, documented, and managed in a pre-specified manner described in the protocol. 
10.5.4.1 AEPM with immediate notification 
For these AEs, the Sponsor will be informed immediately (i.e. within 1 working day), as per SAEs 
notification described in Section 10.5.2, even if not fulfilling a seriousness criterion, using the 
corresponding screens in the e-CRF.  
• ALT increase (Appendix A). 
• Pregnancy 
- Pregnancy occurring in a female patient included in the clinical trial. Pregnancy will be 
recorded as a pre-specified AE with immediate notification in all cases. It will be 
qualified as an SAE only if it fulfills the SAE criteria. 
- In the event of pregnancy, IP should be discontinued.  
- The follow-up of the pregnancy will be mandatory until the outcome has been 
determined. 
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• Symptomatic Overdose with IP 
- An overdose with the IP is an event suspected by the Investigator and defined as at 
least twice the dose during the planned intervals. 
- The circumstances (i.e., accidental or intentional) should be clearly specified in the 
verbatim and symptoms, if any, entered on separate AE forms. 
10.5.4.2 AEPM without immediate notification 
• Asymptomatic overdose with IP: same definition as above; to be reported using the 
corresponding screens in the e-CRF using the Preferred Term “Asymptomatic 
OVERDOSE (accidental or intentional)”. 
10.5.5 Laboratory abnormalities with pre-specified monitoring 
Laboratory abnormalities should be monitored, documented, and managed according to the 
related flowchart in protocol appendices Appendix A: 
• Neutropenia. 
• Thrombocytopenia. 
• Increase in ALT. 
• Acute renal insufficiency. 
• Suspicion of rhabdomyolysis. 
10.6 OBLIGATIONS OF THE SPONSOR 
During the course of the study, the Sponsor will report in an expedited manner all SAEs that are 
both unexpected and at least reasonably related to the IP (SUSAR), to the Health Authorities, 
IECs / IRBs as appropriate and to the Investigators.  
In addition, the Sponsor will report in an expedited manner all SAEs that are expected and at least 
reasonably related to the IPs to the Authorities, according to local regulations. 
In this study, some AEs are considered related to the underlying condition and thus will not be 
considered unexpected as given in the Investigator’s Brochure.  
Any other AE not listed as an expected event in the Investigator’s Brochure or in this protocol 
will be considered as unexpected. 
The Sponsor will report all safety observations made during the conduct of the trial in the clinical 
study report (CSR). 
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11 HANDLING OF PATIENT TEMPORARY OR PERMANENT 
TREATMENT DISCONTINUATION AND OF PATIENT STUDY 
DISCONTINUATION 
The IP should be continued whenever possible. In case the IP is stopped, it should be determined 
if the stop can be made temporarily; permanent IP discontinuation should be a last resort. Any IP 
discontinuation should be fully documented in the e-CRF. In any case, the patient should remain 
in the study as long as possible, attending all visits and undergoing all assessments. 
Pregnancy will lead to definitive treatment discontinuation in all cases. Stopping rules described 
in Appendix A should be applied.  
11.1 TEMPORARY TREATMENT DISCONTINUATION WITH INVESTIGATIONAL 
PRODUCT(S) 
Temporary treatment discontinuation may be considered by the Investigator because of suspected 
AEs. Reinitiation of treatment with the IP will be done under close and appropriate clinical/and or 
laboratory monitoring once the Investigator will have considered according to his/her best medical 
judgment that the responsibility of the IP in the occurrence of the concerned event was unlikely 
and if the selection criteria for the study are still met (refer to Sections 7.2 and 7.3). 
All temporary treatment discontinuation, duration should be recorded by the Investigator in the 
appropriate pages when considered as confirmed. 
11.2 PERMANENT TREATMENT DISCONTINUATION WITH INVESTIGATIONAL 
PRODUCT(S) 
Permanent treatment discontinuation is any treatment discontinuation associated with the 
definitive decision from the Investigator or the patient not to re-expose the patient to the IP at any 
time. 
11.2.1 List of criteria for definitive treatment discontinuation 
The patients may withdraw from treatment with IP if they decide to do so, at any time and 
irrespective of the reason, or this may be the Investigator’s decision. All efforts should be made to 
document the reasons for treatment discontinuation and this should be documented in the e-CRF. 
 
Amended Clinical Trial Protocol 1  16-Feb-2011 
DFI11566 - SAR236553  Version number: 1 (electronic 1.0) 
Property of the sanofi-aventis group - strictly confidential Page 63 
Patients may discontinue the investigational product for the following reasons: 
• At their own request. 
• If, in the investigator's opinion, continuation with the administration of the study treatment 
would be detrimental to the patient's well-being. 
• Intercurrent condition that requires discontinuation of the study treatment (e.g. laboratory 
abnormalities, please refer to decision tree in Appendix A, pregnancy). 
• At the specific request of the Sponsor. 
Patient withdrawal from the study treatment or study should be avoided as much as possible. If 
this occurs, every attempt should be made to restart study drug if medically appropriate. In case of 
permanent study treatment discontinuation, patients should attend the scheduled visits until the 
end of study. 
11.2.2 Handling of patients after permanent treatment discontinuation 
Patients will be followed up according to the study procedures as specified in this protocol up to 
the scheduled date of study completion, or up to recovery or stabilization of any AE to be 
followed-up as specified in this protocol, whichever comes last. 
Patients who prematurely discontinue study treatment should have as soon as possible a visit with 
assessments normally planned at Week 8 (V6), visit considered as the final on-treatment visit.  
All definitive discontinuation of study treatment should be recorded by the Investigator in the 
appropriate screens of the e-CRF and in the patient’s medical records when considered as 
confirmed. IVRS/IWRS should be notified when a patient prematurely discontinues study 
treatment. 
11.3 PROCEDURE AND CONSEQUENCE FOR PATIENT WITHDRAWAL FROM STUDY  
The patients may withdraw from the study, before study completion if they decide to do so, at any 
time and irrespective of the reason. If possible, the patients should be assessed using the 
procedure defined above.  
All study withdrawals should be recorded by the Investigator in the appropriate screens of the e-
CRF and in the patient’s medical records (with, in this medical records, at least date of withdrawal 
and reason for) when considered as confirmed. 
For patients who fail to return to the site, the Investigator should make the best effort to re-contact 
the patient (e.g., contacting patient’s family or private physician, review available registries or 
health care database), and to determine his/her health status, including at least his/her vital status. 
Attempts to contact such patients must be documented in the patient’s records (e.g., times and 
dates of attempted telephone contact, receipt for sending a registered letter). 
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The statistical analysis plan will specify how these patients lost to follow-up for their primary 
endpoints will be considered. 
Patients who have withdrawn from the study cannot be re-randomized (treated) in the study. Their 
inclusion and treatment number must not be reused. 
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12 STUDY PROCEDURES 
The study consists of a screening period with a different duration according to the status of the 
patients: 
• A screening period of 1 week for patients receiving atorvastatin 10 mg at stable dose for at 
least 6 weeks prior to the screening period. 
• A screening period of 7 weeks, including a 6-week run-in period with atorvastatin 10 mg 
for patients receiving a lipid lowering treatment other than atorvastatin/ or not at stable 
dose of atorvastatin 10 mg for at least 6 weeks prior to the screening period, or drug naive 
patients. 
Following this screening/run-in period, eligible patients will be randomized to the double-blind 
treatment period of 8-week duration followed by a follow-up period of 8 weeks. 
All the visits should take place in the morning approximately at the same time. 
The patient will have to be in fasting conditions (i.e., overnight, at least 10-12 hours fast and 
refrain from smoking) for all visits from Week -7 to the final visit of the follow-up period 
Week 16 (V8). Alcohol consumption within 48 hours and intense physical exercise within 
24 hours preceding the blood sampling are discouraged. 
For all visits after baseline a timeframe of a certain number of days will be allowed using Day 1 
as reference (if one visit date is changed, the next visit should take place according to the original 
schedule): for Week 0 (V2) to Week 8 (V6) the timeframe will be ± 3 days, and from Week 8 
(V6) to Week 16 (V8) it will be ± 7 days. 
12.1 VISIT SCHEDULE 
12.1.1 Screening period  
12.1.1.1 Screening including run-in period 
This screening period will consist of 7 weeks including a run-in period with atorvastatin 10 mg, 
and will apply for patients receiving a lipid lowering treatment other than atorvastatin/ or not at 
stable dose of atorvastatin 10 mg for at least 6 weeks prior to the screening period, or drug naive 
patients. 
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12.1.1.1.1 Pre-screening visit with pre-eligibility assessments (V1a, Week -7) and entry in the 
atorvastatin run-in period 
The patient will receive verbal information concerning the aims and methods of the study, its 
constraints and risks and the study duration. A written summary in the form of an information 
leaflet will be given to the patient. The written informed consent must be dated and signed by the 
patient and the Investigator prior to any study assessments. Only patients who meet the inclusion 
criteria as noted in Section 7.2 may be screened. Women of childbearing potential will be 
requested to use a medically approved contraceptive method during the entire study. 
This visit will include: 
• Assessment of inclusion and exclusion criteria. 
• Demographic (age, gender, race, ethnicity). 
• Patient’s medical and surgical history and concomitant diseases, as well as alcohol and 
smoking habits. 
• Concomitant and previous medication (within the previous 12 weeks). 
• Βody weight and height measurements. 
• Clinical examination including vital signs: supine systolic and diastolic blood pressure, 
heart rate. 
• Instruction on diet (NCEP-ATPIII TLC diet or equivalent). 
• Collection of adverse events from this point onward. 
• IVRS/IWRS contact for notification of screening and entry in the run-in period: 
- Patients meeting the inclusion/exclusion criteria for eligibility at screening will enter 
the run-in period of the study. IVRS/IWRS is to be contacted for notification of 
screening. Patient number will be allocated by the site using the laboratory 
requisition form. This patient number is composed of a 9-digit number containing the 
3-digit country code, the 3-digit center code and the 3-digit patient chronological 
number (the 3-digit patient chronological number is 001 for the first patient screened 
in a center, 002 for the second patient screened in the same center...). 
• Fasting blood sample for: 
- Lipid parameters determination: TC, LDL-C, HDL-C, TG, non-HDL-C. 
- HbA1c, fasting plasma glucose. 
- Standard laboratory blood test (hematology, serum chemistry). 
Note: if the patient is not in fasting conditions, the blood sample will not be collected and a new 
appointment will be given the day after to the patient with instruction to be fasted (at least 
10-12 hours fast). 
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• Urine pregnancy test (females of childbearing potential only). 
• Dispensation of atorvastatin 10 mg. 
• The patient will be given: 
- An appointment for the next visit within 6 weeks ± 3 days (Week -1). The patient 
should be seen in the morning and in fasting condition. 
12.1.1.1.2 Screening visit with full eligibility assessments (V1, Week -1) 
This visit will include: 
• Assessment of inclusion and exclusion criteria. 
• Concomitant medication. 
• Check of the diet (NCEP-ATPIII TLC diet or equivalent). 
• Check of the compliance for atorvastatin 10 mg. 
• Vital signs: SBP and DBP, heart rate. 
• Collection of adverse events. 
• Fasting blood sample for: 
- Lipid parameters determination: TC, LDL-C, HDL-C, TG, non-HDL-C. 
- Fasting plasma glucose. 
- Standard laboratory blood test (hematology, serum chemistry). 
- Liver tests (ALT, AST, ALP, γGT and total bilirubin), CPK. 
- Sensitive TSH. 
- Hepatitis B surface antigen and Hepatitis C antibody tests. 
- Serum pregnancy test (females of childbearing potential only). 
Note: if the patient is not in fasting conditions, the blood sample will not be collected and a new 
appointment will be given the day after to the patient with instruction to be fasted (at least 
10-12 hours fast). 
• 12-lead ECG. 
• The patient will be instructed to continue atorvastatin at the same dose (i.e., 10 mg). 
• The patient will be given: 
- An appointment for the next visit within 1 week ± 1 day (7 days ± 1 day) (Week 0). 
The patient should be seen in the morning and in fasting condition. 
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12.1.1.2 Screening period without run-in period 
This screening period will consist of 1 week and will apply for patients receiving atorvastatin 
10 mg at stable dose for at least 6 weeks prior to the screening period. 
12.1.1.2.1 Screening visit with full eligibility assessments (V1, Week -1) 
The patient will receive verbal information concerning the aims and methods of the study, its 
constraints and risks and the study duration. A written summary in the form of an information 
leaflet will be given to the patient. The written informed consent must be dated and signed by the 
patient and the Investigator prior to any study assessments. Only patients who meet the inclusion 
criteria as noted in Section 7.2 may be screened. Women of childbearing potential will be 
requested to use a medically approved contraceptive method during the entire study. 
This visit will include: 
• Assessment of inclusion and exclusion criteria. 
• Demographic (age, gender, race, ethnicity). 
• Patient’s medical and surgical history and concomitant diseases, as well as alcohol and 
smoking habits. 
• Concomitant and previous medication (within the previous 12 weeks). 
• Βody weight and height measurements. 
• Clinical examination including vital signs: supine systolic and diastolic blood pressure, 
heart rate. 
• Instruction on diet (NCEP-ATPIII TLC diet or equivalent). 
• Collection of adverse events from this point onward. 
• IVRS/IWRS contact for notification of screening and entry in the run-in period: 
- Patients meeting the inclusion/exclusion criteria for eligibility at screening will enter 
the run-in period of the study. IVRS/IWRS is to be contacted for notification of 
screening. Patient number will be allocated by the site using the laboratory 
requisition form. This patient number is composed of a 9-digit number containing the 
3-digit country code, the 3-digit center code and the 3-digit patient chronological 
number (the 3-digit patient chronological number is 001 for the first patient screened 
in a center, 002 for the second patient screened in the same center...). 
• Fasting blood sample for: 
- Lipid parameters:determination TC, LDL-C, HDL-C, TG, non-HDL-C. 
- HbA1c, fasting plasma glucose. 
- Standard laboratory blood test (hematology, serum chemistry). 
- Liver tests (ALT, AST, ALP, γGT and total bilirubin), CPK. 
- Sensitive TSH. 
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- Hepatitis B surface antigen and Hepatitis C antibody tests. 
- Serum pregnancy test (females of childbearing potential only). 
Note: if the patient is not in fasting conditions, the blood sample will not be collected and a new 
appointment will be given the day after to the patient with instruction to be fasted (at least 
10-12 hours fast). 
• 12-lead ECG. 
• Dispensation of atorvastatin 10 mg to allow the patient to continue atorvastatin at the same 
dose until the next visit.  
• The patient will be given: 
- An appointment for the next visit within 1 week ± 1 day (7 days ± 1 day) (Week 0). 
The patient should be seen in the morning and in fasting condition. 
12.1.2 Double-blind treatment period: from Week 0 (V2, D1) to Week 8 (V6) 
12.1.2.1 Baseline (randomization) visit (V2, Week 0, D1) 
Week 0 (V2) should be scheduled 7 days (± 1 day) after Week -1 (V1). 
Patients should be seen in the morning after an overnight fast (no less than 10-12 hours). Only 
after the baseline assessments are completed and eligibility confirmed, the IVRS/IWRS 
should be contacted for randomization. The study treatment injection will take place at the 
investigational site.  
This visit will include: 
• Check of the exclusion criteria and record them in the e-CRF (as appropriate). 
• Βody weight. 
• Clinical examination including vital signs: supine systolic and diastolic blood pressure, 
heart rate. 
• Check of the diet (NCEP-ATPIII TLC diet or equivalent). 
• Recording of the use or change of any concomitant medications. 
• Check of the compliance for atorvastatin 10 mg. 
• Recording of adverse events. 
If the patient is confirmed eligible, the Investigator will start the next study procedures: 
• IVRS/IWRS contact for randomization and allocation of a 7-digit treatment kit number for 
both IPs (SAR236553 and atorvastatin) according to the randomization lists. Investigators 
should never allocate a treatment kit number to a patient without contacting 
IVRS/IWRS.  
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• Fasting blood sample before injection of the study treatment for: 
- Complete panel for lipid parameters determination: TC, LDL-C, HDL-C, TG, non-
HDL-C, ApoB, ApoA-1, ratio ApoB/ApoA-1, Lp(a). 
- Fasting plasma glucose. 
- Standard laboratory blood test (hematology, serum chemistry). 
- Liver tests (ALT, AST, ALP, γGT and total bilirubin), CPK. 
- hs-CRP, library serum. 
- PK assessment of SAR236553. 
- Anti-SAR236553 antibody assessment. 
- DNA sample (only in specifically consented patients).  
• Urine pregnancy test (females of childbearing potential only). 
• Injection of the study treatment (SAR236553 or placebo) and recording of compliance. 
• The patient will be given: 
- One box of five wallets of atorvastatin treatment. 
• The patient will be instructed to take the atorvastatin treatment (2 capsules each day in the 
evening with the dinner) until the next visit. 
An appointment for the next visit within 2 weeks ± 3 days (14 days ± 3 day) (Week 2) will be 
given. The patient should be seen in the morning and in fasting condition. 
12.1.2.2 Visit 3 (V3, Week 2) 
Week 2 (V3) should be scheduled 2 weeks ± 3 days (14 days ± 3 days) after Week 0 (V2). 
Patients should be seen in the morning after an overnight fast (no less than 10-12 hours). The 
study treatment injection will take place at the investigational site. 
This visit will include: 
• Body weight 
• Vital signs: SBP and DBP, heart rate. 
• Recording of the use or change of any concomitant medications. 
• Check of the diet (NCEP-ATPIII TLC diet or equivalent). 
• Recording of adverse events. 
• Fasting blood sample before injection of the study treatment for: 
- Lipid parameters determination: TC, LDL-C, HDL-C, TG, non-HDL-C. 
- PK assessment of SAR236553. 
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• IVRS/IWRS contact for allocation of a treatment kit for SAR236553 IP according to the 
randomization list. 
• Injection of the study treatment (SAR236553 or placebo) and recording of compliance. 
• The patient will be instructed to continue the atorvastatin treatment (2 capsules each day in 
the evening with the dinner) until the next visit. 
An appointment for the next visit within 2 weeks ± 3 days (14 days ± 3 days) (Week 4) will be 
given. The patient should be seen in the morning and in fasting condition. 
12.1.2.3 Visit 4 (V4, Week 4) 
Week 4 (V4) should be scheduled 2 weeks ± 3 days (14 days ± 3 days) after Week 2 (V3). 
Patients should be seen in the morning after an overnight fast (no less than 10-12 hours). The 
study treatment injection will take place at the investigational site. 
This visit will include: 
• Body weight. 
• Vital signs: SBP and DBP, heart rate. 
• Recording of the use or change of any concomitant medications. 
• Check of the diet (NCEP-ATPIII TLC diet or equivalent). 
• Check of the compliance for atorvastatin treatment. 
• Recording of adverse events. 
• Fasting blood sample before injection of the study treatment for: 
- Complete panel for lipid parameters determination: TC, LDL-C, HDL-C, TG, non-
HDL-C, ApoB, ApoA-1, ratio ApoB/ApoA-1, Lp(a). 
- Standard laboratory blood test (hematology, serum chemistry). 
- Liver tests (ALT, AST, ALP, γGT and total bilirubin), CPK. 
- hs-CRP, library serum. 
- PK assessment of SAR236553.  
- Anti-SAR236553 antibody assessment. 
• Urine pregnancy test (females of childbearing potential only). 
• 12-lead ECG. 
• IVRS/IWRS contact for allocation of a treatment kit for both IPs (SAR236553 and 
atorvastatin) according to the randomization lists. 
• Injection of the study treatment (SAR236553 or placebo) and recording of compliance. 
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• The patient will be given: 
- One box of five wallets of atorvastatin treatment. 
• The patient will be instructed to take the atorvastatin treatment (2 capsules each day in the 
evening with the dinner) until the next visit.  
An appointment for the next visit within 2 weeks ± 3 days (14 days ± 3 days) (Week 6) will be 
given. The patient should be seen in the morning and in fasting condition. 
12.1.2.4 Visit 5 (V5, Week 6) 
Week 6 (V5) should be scheduled 2 weeks ± 3 days (14 days ± 3 day) after Week 4 (V4). Patients 
should be seen in the morning after an overnight fast (no less than 10-12 hours). The study 
treatment injection will take place at the investigational site. 
This visit will include: 
• Body weight 
• Vital signs: SBP and DBP, heart rate. 
• Recording of the use or change of any concomitant medications. 
• Check of the diet (NCEP-ATPIII TLC diet or equivalent). 
• Recording of adverse events. 
• Fasting blood sample before injection of the study treatment for: 
- Lipid parameters determination: TC, LDL-C, HDL-C, TG, non-HDL-C. 
- PK assessment of SAR236553. 
• IVRS/IWRS contact for allocation of a treatment kit for SAR236553 IP according to the 
randomization list. 
• Injection of the study treatment (SAR236553 or placebo) and recording of compliance. 
• The patient will be instructed to continue the atorvastatin treatment (2 capsules each day in 
the evening with the dinner) until the next visit. 
An appointment for the next visit within 2 weeks ± 3 days (14 days ± 3 days) (Week 8) will be 
given. The patient should be seen in the morning and in fasting condition. 
12.1.2.5 Visit 6 (V6, Week 8) 
Week 8 (V6) should be scheduled 2 weeks ± 3 days (14 days ± 3 day) after Week 6 (V5). Patients 
should be seen in the morning after an overnight fast (no less than 10-12 hours). 
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This visit will include: 
• Body weight. 
• Clinical examination including vital signs: supine systolic and diastolic blood pressure, 
heart rate. 
• Recording of the use or change of any concomitant medications. 
• Check of the diet (NCEP-ATPIII TLC diet or equivalent). 
• Check of the compliance for atorvastatin treatment. 
• Recording of adverse events. 
• Fasting blood sample for: 
- Complete panel for lipid parameters determination: TC, LDL-C, HDL-C, TG, non-
HDL-C, ApoB, ApoA-1, ratio ApoB/ApoA-1, Lp(a). 
- HbA1c, fasting plasma glucose. 
- Standard laboratory blood test (hematology, serum chemistry). 
- Liver tests (ALT, AST, ALP, γGT and total bilirubin), CPK. 
- hs-CRP, library serum. 
- PK assessment of SAR236553.  
- Anti-SAR236553 antibody assessment. 
• Urine pregnancy test (females of childbearing potential only). 
• 12-lead ECG. 
• IVRS/IWRS contact for notification of the end of study treatment (including SAR236553 
IP and atorvastatin IP). 
An appointment for the next visit within 4 weeks ± 7 days (28 days ± 7 days) (Week 12) will be 
given. The patient should be seen in the morning and in fasting condition. 
12.1.3 Follow-up period: from Week 8 (V6) to Week 16 (V8) 
12.1.3.1 Visit 7 (V7, Week 12) 
Week 12 (V7) should be scheduled 4 weeks ± 7 days (28 days ± 7 days) after Week 8 (V6). 
Patients should be seen in the morning after an overnight fast (no less than 10-12 hours). 
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This visit will include: 
• Body weight. 
• Recording of the use or change of any concomitant medications. 
• Check of the diet (NCEP-ATPIII TLC diet or equivalent). 
• Recording of adverse events. 
• Fasting blood sample for: 
- Lipid parameters determination: TC, LDL-C, HDL-C, TG, non-HDL-C. 
- PK assessment of SAR236553. 
- Anti-SAR236553 antibody assessment. 
- Only in case of persistent clinically relevant abnormal values at Week 8 (V5) for the 
corresponding parameter: 
- Standard laboratory blood test (hematology, serum chemistry). 
- Liver tests (ALT, AST, ALP, γGT and total bilirubin), CPK. 
• Urine pregnancy test (females of childbearing potential only). 
An appointment for the next visit within 4 weeks ± 7 days (28 days ± 7 days) (Week 16) will be 
given. The patient should be seen in the morning and in fasting condition. 
12.1.3.2 Visit 8 (V8, Week 16) 
Week 16 (V8) should be scheduled 4 weeks ± 7 days (28 days ± 7 days) after Week 12 (V7). 
Patients should be seen in the morning after an overnight fast (no less than 10-12 hours). 
This visit will include: 
• Body weight. 
• Clinical examination including vital signs: supine systolic and diastolic blood pressure, 
heart rate. 
• Recording of the use or change of any concomitant medications. 
• Check of the diet (NCEP-ATPIII TLC diet or equivalent). 
• Recording of adverse events. 
• Fasting blood sample for: 
- Lipid parameters determination: TC, LDL-C, HDL-C, TG, non-HDL-C. 
- PK assessment of SAR236553. 
- Anti-SAR236553 antibody assessment. 
- Only in case of persistent clinically relevant abnormal values at Week 8 (V6) and 
Week 12 (V7) for the corresponding parameter: 
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- Standard laboratory blood test (hematology, serum chemistry). 
- Liver tests (ALT, AST, ALP, γGT and total bilirubin), CPK. 
• Urine pregnancy test (females of childbearing potential only). 
• IVRS/IWRS contact for notification of the end of the study. 
12.2 DEFINITION OF SOURCE DATA 
Evaluations that are reported in the e-CRF must be supported by appropriately signed identified 
source documentation related but not limited to the following: 
• Agreement, date, and signature of informed consent mentioning the study identification. 
• Patient identification, last participation in a clinical trial, medical history, associated 
diseases, and data related to the studied pathology. 
• Contraception method for women of childbearing potential. 
• Previous and concomitant medication (including if applicable the lipid lowering 
treatment). 
• Study identification. 
• Treatment number, dates of administration. 
• Dates of visits and assessments including the examination report. 
• Vital signs, height, body weight. 
• Faxed central lab reports (dated and signed by the Principal Investigator or 
Sub-Investigator). 
• IVRS/IWRS confirmation fax (screening, screen failure, enter run-in, randomization, 
treatment reallocation, discontinuation, end of study, unblinding if applicable). 
• ECG records signed and dated. 
• Adverse events and follow-up: 
- In case of SAE, the site should file in the source document at least copies of the 
hospitalization reports and any relevant examination reports documenting the 
follow-up of the SAE. 
• Date of premature study discontinuation (if any) and reason. 
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Source documentation may be found in the following: 
• Patient’s identity. 
• Medical history. 
• Hospital records. 
• Nursing notes. 
• Physician’s notes. 
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13 STATISTICAL CONSIDERATIONS 
13.1 DETERMINATION OF SAMPLE SIZE 
The study is expected to enrol approximately 90 patients. 
To detect a difference of 20% in LDL-C percent change from baseline to Week 8 between 
SAR236553 + high dose of atorvastatin group and SAR236553 placebo + high dose of 
atorvastatin group, assuming a 5% rate of unevaluable primary endpoint, 30 patients by arm will 
result in 95% power, with a standard deviation of 20%, and using a two-sided t-test at the 0.05 
significance level. 
Calculations were made using nQuery Advisor 6.01. 
13.2 ANALYSIS ENDPOINTS 
13.2.1 Demographic and baseline characteristics  
The baseline value for demographic and baseline characteristics is generally defined as the last 
available value before randomization.   
13.2.1.1 Demographic and baseline characteristics 
Demographic characteristics 
Demographic variables are sex (Male, Female), race (White, Black or African American, Asian, 
American Indian or Alaska Native, Native Hawaiian or other Pacific Island, other) age in years 
(continuous and categorical variable : <45, [45 - 65[, and ≥ 65 years), ethnicity (Hispanic or 
Latino, Non Hispanic or Latino). 
Medical and surgical history 
This information will be coded using the version of MedDRA (Medical Dictionary for Regulatory 
Activities) currently in effect at sanofi-aventis at the time of the database lock. 
Disease characteristics at baseline  
Specific disease history includes type of lipid disorders according to the Fredrickson classification 
(IIa, IIb or IV), time from diagnosis, and presence of previous treatment with a lipid lowering 
agent. 
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Other baseline characteristics 
Other baseline characteristics include BMI in kg/m2 (continuous and categorical variable: <30, 
≥30), alcohol habits (frequency: Never, At least monthly, At least weekly, At least daily, and 
amount: 1 or 2, >2 standard drinks per day), smoking habits (Never smoked, Quit smoking, 
Currently smokes). 
13.2.1.2 Prior or concomitant medications 
All medications taken within 12 weeks (84 days) before randomization and until the end of the 
study, including atorvastatin (other than atorvastatin IP) and other Lipid Lowering Therapies are 
to be reported in the corresponding dedicated e-CRF screens. 
All medications will be coded using the World Health Organization-Drug Dictionary (WHO-DD) 
using version currently in effect at sanofi-aventis at the time of the database lock. 
Prior medications are those the patient used within 12 weeks (84 days) prior first injection of 
SAR236553 or placebo for SAR236553. Prior medications can be discontinued before first 
injection or can be ongoing during treatment phase. 
Concomitant medications are any treatments received by the patient concomitantly to the 
SAR236553 (or placebo for SAR236553), on or after randomization and before last injection + 
10 weeks (70 days). A given medication can be classified both as a prior medication and as a 
concomitant medication.  
Atorvastatin 10 mg is to be taken by all patients at stable dose as prior medication for at least 
7 weeks (49 days). 
13.2.2 Efficacy endpoints 
13.2.2.1 Primary efficacy endpoint(s) 
The primary efficacy variable is the percent change in calculated LDL-C from baseline to Week 8, 
which is defined as: 100x (calculated LDL-C value at Week 8 - calculated LDL-C value at 
baseline) / calculated LDL-C value at baseline. 
The baseline calculated LDL-C value will be the average of the last pre-randomization (Visit 1, 
Week -1) calculated LDL-C value and the randomization (Visit 2, Week 0) calculated LDL-C 
value. In case the randomization calculated LDL-C value would be missing, the baseline value 
will consist of the last pre-randomization (Week -1) calculated LDL-C value. 
If a patient discontinues the treatment prematurely during the 8-week treatment period or does not 
have calculated LDL-C value at Week 8, then the last available calculated LDL-C value measured 
during the on-treatment period and before Week 8 will be used as calculated LDL-C value at 
Week 8 (Last Observation Carried Forward [LOCF] procedure).  
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The on-treatment period for calculated LDL-C will be defined as the time from the first 
SAR236553 or placebo for SAR236553 injection up to 21 days after the last SAR236553 or 
placebo for SAR236553 injection, or up to 84 days after the first injection whichever come first.  
Indeed: 
- SAR236553 serum concentrations greater than 10 µg/mL are expected no more than 
21 days after last injection of SAR236553 150 mg dose. 
- In order to maintain steady state phase of SAR236553 serum concentration, 3 weeks 
between two injections of  SAR236553 150 mg should not be exceeded, and this 
would lead to a last visit 12 weeks (84 days) after first injection.  
All LDL-C measurements (scheduled or unscheduled, fasting or not fasting) may be used to 
provide a value for the primary efficacy variable if appropriate according to above definition. 
Time windows used to allocate a time point to a measurement will be defined in the SAP. 
13.2.2.2 Secondary efficacy endpoint(s) 
The secondary efficacy variables are: 
• The absolute change from baseline (mg/dL and mmol/L) in calculated LDL-C to Week 8 
defined as: (calculated LDL-C value at Week 8 - calculated LDL-C value at baseline), 
using same definitions and rules as those defined in Section 13.2.2.1 . 
• The proportion of patients achieving an LDL-C level lower than 100 mg/dL 
(2.59 mmol/L) at Week 8 defined as: (number of patients whose calculated LDL-C value 
at Week 8 is strictly lower than 100 mg/dL / number of patients in the mITT 
population)*100, using same definitions and rules as those defined in Section 13.2.2.1 . 
• The proportion of patients achieving an LDL-C level lower than 70 mg/dL (1.81 mmol/L) 
at Week 8 will be assessed similarly. 
• Percent and absolute (mg/dL and mmol/L) change in total cholesterol from baseline to 
Week 8: same definitions and rules as for percent and absolute change in calculated 
LDL-C from baseline to Week 8. 
• Percent and absolute (mg/dL and mmol/L) change in HDL-C from baseline to Week 8: 
same definitions and rules as for percent and absolute change in calculated LDL-C from 
baseline to Week 8. 
• Percent and absolute (mg/dL and mmol/L) change in TG from baseline to Week 8: same 
definitions and rules as for percent and absolute change in calculated LDL-C from 
baseline to Week 8, excluding measurements on not fasting patients.  
• Percent and absolute (mg/dL and mmol/L) change in non HDL-C from baseline to 
Week 8: same definitions and rules as for percent and absolute change in calculated 
LDL-C from baseline to Week 8. 
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• Percent change in Apo-B from baseline to Week 8: same definition and rules as for the 
percent change in calculated LDL-C from baseline to Week 8, except for baseline value 
that will be the randomization (Visit 2, Week 0) Apo-B value, or, if missing, the last 
unscheduled value assessed within 10 days before randomization. 
• Percent change in Apo-A1 from baseline to Week 8: same definition as for the percent 
change in Apo-B from baseline to Week 8. 
• Absolute change in the ratio Apo-B/Apo-A1 from baseline to Week 8: same definition as 
for the percent change in Apo-B from baseline to Week 8. 
• Percent change in Lp(a) from baseline to Week 8: same definition as for the percent 
change in Apo-B from baseline to Week 8. 
13.2.2.3 Exploratory variables 
Exploratory variables are: 
• Absolute change in HbA1c (%) from baseline to Week 8: same definition and rules as for 
the absolute change in calculated LDL-C from baseline to Week 8, except for baseline 
value that will be the last available value assessed within 10 days before randomization. 
• Absolute change from baseline in fasting plasma glucose (mg/dL and mmol/L) to Week 8: 
same definition and rules as for the absolute change in calculated LDL-C from baseline to 
Week 8, except for baseline value that will be the randomization (Visit 2, Week 0) fasting 
plasma glucose value, without replacement rule if missing. 
• Percent change from baseline in hs-CRP to Week 8: same definition and rules as for the 
percent change in calculated LDL-C from baseline to Week 8, except for baseline value 
that will be the randomization (Visit 2, Week 0) hs-CRP value, or, if missing, the last 
unscheduled value assessed within 10 days before randomization. In a second approach, 
hs-CRP values greater or equal to 10 mg/L will not be included in time point analyses. 
• Percent and absolute (kg) change from baseline in body weight to Week 8: same 
definitions and rules as for percent and absolute change in calculated LDL-C from 
baseline to Week 8, except for baseline value that will be the randomization (Visit 2, 
Week 0) body weight, or, if missing, the last value assessed within 10 days before 
randomization. 
13.2.3 Safety endpoints 
The safety analysis will be based on the reported adverse events (AEs) and other safety 
information, such as clinical laboratory data, vital signs, and ECG. 
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Observation period  
The observation period will be divided into 5 EPOCH: 
• The SCREENING epoch is defined as the time from the signed informed consent date up 
to randomization. 
• The TREATMENT epoch is defined as the time from first injection of SAR236553 or 
placebo for SAR236553 to last injection + 14 days. 
• The RESIDUAL TREATMENT epoch is defined as the time from last injection + 14 days 
to last injection + 70 days (10 weeks). 
The TEAE period will include both TREATMENT and RESIDUAL TREATMENT epochs. 
• The POST-TREATMENT period is defined as the period of time starting the day after the 
end of the TEAE period up to the end of the study (defined as last protocol planned visit or 
the resolution/stabilization of all SAE and AEs with pre-specified monitoring). 
• The on-study observation period is defined as the time from first injection of SAR236553 
or placebo for SAR236553 until the end of the study (defined as last protocol planned visit 
or the resolution/stabilization of all SAE and AEs with pre-specified monitoring). 
13.2.3.1 Adverse events 
AE observation period:  
The AE observations are per the observation periods defined above. 
Adverse event observation period: 
• Pre-treatment AEs are AEs that developed or worsened or became serious from the signed 
informed consent date up to first injection of  SAR236553 or placebo for SAR236553; 
• Treatment-emergent AEs (TEAEs) are AEs that developed or worsened or became serious 
during the TEAE period; 
• Post-treatment AEs are AEs that developed or worsened or became serious during the 
post-treatment period. 
All AEs (including SAEs and AEs with pre-specified monitoring) will be coded to a “Lower 
Level Term (LLT)”, “Preferred Term (PT)”, “High Level term (HLT)”, “High Group Level Term 
(HLGT)” and associated primary “System Organ Class (SOC)” using the version of MedDRA 
(Medical Dictionary for Regulatory Activities) currently in effect at sanofi-aventis at the time of 
the database lock. 
Record the occurrence of AEs (including SAEs and AEs with pre-specified monitoring) from the 
time of signed informed consent until the end of the study. 
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13.2.3.2 Deaths 
Death observation period:  
The deaths observation period are per the observation periods defined above: 
• Death on-study: deaths occurring during the on-study observation period 
• Death on-treatment: deaths occurring during the TEAE period 
• Death post-study: deaths occurring after the end of study 
13.2.3.3 Laboratory safety variables 
The clinical laboratory data consist of blood analysis (hematology, clinical chemistry and 
urinalysis). Clinical laboratory values, provided in conventional units, will be also converted into 
standard international units. Standard international units will be used in all listings and tables. 
13.2.3.4 Vital signs 
Vital Signs include: Heart Rate (HR), Systolic and Diastolic Blood Pressure (SBP and DBP) in 
supine position.  
13.2.3.5 ECG variables 
The ECG will be determined using a centralized automatic and manual reading of all ECGs. 
ECG parameters include: Heart rate, QRS duration, PR interval, QT interval as well as corrected 
QTc (according to both Bazett and Fridericia formula).  
13.2.3.6 Anti-SAR236553 antibodies 
Anti-SAR236553 antibodies (status and titers) will be assessed at Week 0 (baseline), Week 4, 
Week 8, then during the follow-up period at Week 12, and Week 16. 
13.2.4 Pharmacokinetic variables 
Serum SAR236553 concentrations will be assessed at Week 0 (Day 1), and then at each visit up to 
the last visit of the follow-up period (Weeks 2, 4, 6, 8, 12, and 16). 
13.2.5 Pharmacodynamic/genomics variables 
The statistical analysis of the pharmacogenomic substudy will be fully developed in a specific 
SAP. It will include the type and list of markers, as well as the statistical methods and analyses to 
perform. This analysis will be exploratory in nature, with the aim to search for potential 
association between genetic/genomic markers and the response to the treatment.  
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The primary analysis of the candidate genes (PCSK9, ApoB, LDL-R)  will consist in assessing the 
association between each polymorphism (SNP) taken individually first and the primary endpoint. 
Then, in the presence of more than one significant or suggestive association, these SNPs may be 
explored in a multi-marker model.  
The percent change from baseline in LDL-C at week 8 will be analyzed via a statistical model 
similar to the model used in the primary analysis of the study and including additional terms for 
SNP and treatment*SNP interaction. Genotypes will be coded appropriately based on the a priori 
assumed mode of inheritance (dominant, recessive, additive), which will be specified in the 
pharmacogenetic SAP.  
Significance of the genetic association will be assessed with a likelihood ratio test (LRT). In all 
null models, the genetic effect is assumed to be zero (i.e., without treatment*SNP).  Significance 
of the maximum likelihood estimate will be assessed by comparing the alternative model (i.e., 
with treatment*SNP) to its corresponding null model using an LRT, which is chi-square 
distributed with degrees of freedom equal to the number of differing parameters. 
If it is determined that the above approach including the interaction term is not sufficient due to 
technical difficulties or sample size complications, then an alternative strategy will be employed 
to test for SNP main effects within individual treatment arms. A comparison will then be made to 
placebo to assess whether the genetic association is specific to the SAR236553, or seen in all 
groups. The significance in this single SNP association analysis will be determined using the false 
discovery rate (FDR) procedure. 
13.2.6 Health economic variables 
Not applicable. 
13.2.7 Further therapy after stop of IP administration during the study 
Not applicable. 
13.3 DISPOSITION OF PATIENTS 
Screened patients are defined as any patient who met the inclusion criteria and signed the 
informed consent.  
Randomized patients consist of all patients, with signed inform consent, with a treatment kit 
number allocated and recorded in the IVRS/IWRS database, regardless of whether the treatment 
kit was used or not. Patients treated without being randomized will not be considered as 
randomized and will not be included in any efficacy population.   
For any patient randomized more than once, only the data associated with the first randomization 
will be used in any analysis population. The safety experience associated with any later 
randomization will be assessed separately. 
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The safety experience of patients treated and not randomized will be reported separately, and 
these patients will not be in the safety population. 
13.4 ANALYSIS POPULATIONS 
13.4.1 Efficacy populations 
The primary efficacy analysis population will be the modified intent-to-treat (mITT) population. 
13.4.1.1 Modified intent-to-treat population 
Modified ITT (mITT) population: ITT population (i.e., randomized population) with an evaluable 
primary endpoint. The primary endpoint will be considered as evaluable when both of the 
following conditions are met: 
• The Week -1 or Week 0 calculated LDL-C value is available. 
• At least one on-treatment LDL-C value is available. The on-treatment period for the 
primary efficacy variable will be defined as the time from the first SAR236553 or placebo 
for SAR236553 injection up to 21 days after the last injection, or up to 84 days after the 
first SAR236553 or placebo for SAR236553 injection, whichever come first. 
Patients in the mITT population will be analyzed according to the treatment group allocated by 
randomization. 
13.4.2 Safety population 
Safety population is defined as:  
Randomized population who did actually receive at least one dose or partial dose of SAR236553 
or placebo for SAR236553 analyzed according to the treatment actually received.  
In addition:  
• Non-randomized but treated patients will not be part of the safety population, but their 
safety data will be presented separately.  
• Randomized patients for whom it is unclear whether they received SAR236553 (or 
placebo for SAR236553) will be included in the safety population as randomized. 
• For patients receiving SAR236553 IP (active/placebo) differing from the allocated ones, 
the treatment group allocation for as-treated analysis will be defined and documented on a 
case by case basis and in a blinded manner during Data Review: all possible scenarios for 
the identified case will be listed and a treatment group for as-treated analysis will be 
allocated for each scenario using the following principles: to allocate the treatment group 
the closest to the actual treatment received by the patient.   
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13.4.3 Other analysis population 
Analysis populations for anti-SAR236553 antibodies and PK will be defined in the SAP. 
13.5 STATISTICAL METHODS 
13.5.1 Demographic and baseline characteristics 
Continuous data will be summarized using number of available data, mean, SD, median, 
minimum, and maximum for each treatment group. Categorical and ordinal data will be 
summarized using number and percentage of patients in each treatment group. 
Parameters will be summarized on the all randomized population, analyzed in the treatment group 
to which they were randomized.  
Parameters described in Section 13.2.1.1 will be summarized by treatment group and overall using 
descriptive statistics. Medical and surgical history will be presented by decreasing frequency of 
Primary System Organ Class based on the overall incidence across treatment group. 
P-values on demographic and baseline characteristic data will not be calculated. 
No specific description of the safety parameters will be provided at baseline. If relevant, the 
baseline values will be described along with each safety analysis. 
No specific description of the efficacy parameters will be provided at baseline. If relevant, the 
baseline values will be described along with each efficacy analysis. 
13.5.2 Prior or concomitant medications 
The prior and concomitant medications will be presented on the randomized population.  
Medications will be summarized by treatment group according to the WHO-DD dictionary, 
considering the first digit of the ATC class (anatomic category) and the first three digits of the 
ATC class (therapeutic category). All ATC codes corresponding to a medication will be 
summarized, patients will be counted once in each ATC categories (anatomic or therapeutic) 
linked to the medication, therefore patients may be counted several time for the same medication.  
The tables for prior medications will be sorted by decreasing frequency of anatomic category 
followed by all other therapeutic classes based on the overall incidence across treatment groups. 
In case of equal frequency regarding anatomic categories (respectively therapeutic categories), 
alphabetical order will be used. 
The tables for concomitant medications will be sorted by decreasing frequency of anatomic 
category followed by all other therapeutic classes based on the incidence of the SAR236553 
150mg every two weeks + atorvastatin 80 mg group. In case of equal frequency regarding 
anatomic categories (respectively therapeutic categories), alphabetical order will be used. 
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In addition, the following specific medications will be summarized:  
• Background atorvastatin use (as reported in the dedicated e-CRF screen): prior use 
between 84 days and 46 days prior to first SAR236553 or placebo for SAR236553 
injection and within 45 days prior to first SAR236553 or placebo for SAR236553 injection 
will be summarized separately; concomitant use after last SAR236553 or placebo for 
SAR236553 injection will be summarized. Atorvastatin use will be summarized by 
treatment group using average total daily dose (mg/day). 
• Prior, and concomitant other lipid lowering therapies (as reported in the dedicated e-CRF 
screen): prior lipid lowering therapies used between 84 days and 46 days prior to first 
SAR236553 or placebo for SAR236553 injection and within 45 days prior to first 
SAR236553 or placebo for SAR236553 injection will be summarized separately; 
concomitant lipid lowering therapies used up to 21 days after last SAR236553 or placebo 
for SAR236553 injection, and those used more than 21 days after last injection will be 
summarized separately. These medications will be summarized by International 
Nonproprietary Name (INN) and presented by treatment group using counts and 
percentages. 
13.5.3 Extent of study treatment exposure and compliance 
The extent of study treatment exposure and compliance will be assessed and summarized by 
actual SAR236553 treatment received within the safety population. 
13.5.3.1 Extent of investigational product exposure 
The extent of exposure will be assessed by: 
• the actual number of weeks on SAR236553 treatment, defined as: (last injection date – 
first injection date + 14 days)/7 
• the total number of  SAR236553 or placebo for SAR236553 injections by patients. 
SAR236553 or placebo for SAR236553 injection ahead/delay:  
An injection k will be considered as delayed if the time interval between the date of injection k 
and the date of injection (k-1) is > 14 + 3 days (i.e. > 3 days compared to the theoretical day). 
An injection k will be considered as advanced if the time interval between the date of injection 
k and the date of injection (k-1) is < 14 - 3 days (i.e. < 3 days compared to the theoretical day). 
The first injection will not be counted for injection delay/ahead.  
Injection delay will be classified as following: between 4 and 7 days of delay, or more than 
7 days of delay. Injection ahead will be classified as following: between 4 and 7 days ahead, 
or more than 7 days ahead. 
Total number of injections delayed, advanced and number of patients with at least one 
injection delayed, advanced will be summarized by treatment group.  
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13.5.3.2 Compliance to atorvastatin IP 
A given atorvastatin IP administration will be considered as non compliant if the patient did not 
take the planned dose of atorvastatin IP as required by the protocol.  No imputation will be made 
for patients with missing or incomplete data. Atorvastatin IP compliance, above-planned and 
under-planned dosing percentages will be summarized descriptively (N, Mean, SD, Median, Min, 
and Max). The percentage of patients with compliance is < 80% will be summarized. In addition, 
number and percentage of patients with at least one above-planned dosing administration will be 
given, as well as the number and percentage of patients with 0, (0, 20%], and >20% 
under-planned dosing administrations. 
13.5.4 Analyses of efficacy endpoints 
13.5.4.1 Analysis of primary efficacy endpoint(s) 
The percent change from baseline in calculated LDL-C at Week 8-LOCF as defined in  
Section 13.2.2.1 will be analyzed in the mITT population using an analysis of covariance 
(ANCOVA) model with treatment group as fixed effect and the baseline LDL-C as covariate. The 
treatment group factor will have three levels: SAR236553 placebo + atorvastatin 80 mg, 
SAR236553 + atorvastatin 10 mg, SAR236553 + atorvastatin 80 mg.  
Throughout the ANCOVA model, the SAR236553 + atorvastatin 80 mg group will be compared 
to SAR236553 placebo + atorvastatin 80 mg group using appropriate contrast and the 95% 
confidence interval (CI) of the difference will be provided. No formal comparisons with the 
SAR236553 + atorvastatin 10 mg group will be performed: only 95% CIs for difference versus 
other arms will be provided. 
Model assumption checks 
Homogeneity of slopes: 
A treatment group-by-baseline LDL-C interaction term will be added in the primary ANCOVA 
model and the significance of its effect based on SAS Type III sum-of-squares will be tested at the 
10% significance level. If the interaction is significant, a separate-slopes model with terms for 
treatment group and treatment group- by-baseline LDL-C interaction will be fitted to the data, and 
the graph presenting the separate slopes for each treatment group by baseline LDL-C values will 
be provided. 
Gaussian distribution: 
The normality of the residuals of the ANCOVA model will be assessed graphically using 
histogram, and plots of the percentiles (resp. quantiles) of fitted Gaussian distribution versus 
ordered residual values. Skewness and Kurtosis measures, as well as Shapiro-Wilk statistic will be 
also examined. If substantial deviations from the assumptions are found, the normalized (using 
Tukey’s) rank transformation approach to the same ANCOVA model (without Tukey’s rank 
transformation for the baseline covariate) will be performed as a sensitivity test. 
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Homogeneity of variance: 
The homogeneity of variances will be checked by displaying the standard deviations of the 
residuals within each level of the treatment group.  
13.5.4.2 Analyses of secondary efficacy endpoints 
Continuous secondary Week 8-LOCF variables defined in Section 13.2.2.2 will be analyzed in the 
mITT population using the same ANCOVA model as for the primary endpoint with treatment 
group as fixed effect, and corresponding baseline value as covariate. 
Absolute (mg/dL and mmol/L) and percent change from baseline in calculated LDL-C, TC, HDL-
C, TG, and non HDL-C at Week 2, Week 4, Week 6, and Week 8 will be summarized in the 
mITT population using number of available data, mean, SD, median, minimum, and maximum for 
each treatment group. All on-treatment measurements (up to 21 days after the last SAR236553 or 
placebo for SAR236553 injection, or up to 84 days after the first injection whichever come first), 
scheduled or unscheduled, will be assigned to time windows defined in the SAP in order to 
provide an assessment for these time points. For TG, measurements on not fasting patients will be 
excluded. The time profile of each parameter will be also plotted by treatment group with the 
corresponding standard errors. The plots will include LOCF values, and available Week 12 and 
Week 16 post-treatment values. Same kind of plots will be provided for other lipids parameters: 
Apo-B, Apo-A1, ratio Apo-B/Apo-A1, Lp(a). 
Binary secondary variables defined in Section 13.2.2.2 will be analyzed in the mITT population 
using a logistic regression model with factor for treatment and baseline LDL-C value as covariate. 
Exploratory variables defined in Section 13.2.2.2 will be summarized by time points in the mITT 
population using number of available data, mean, SD, median, minimum, and maximum for each 
treatment group (for hs-CRP, Q1 and Q2 will be also provided). The time profile for body weight 
will be also plotted by treatment group with the corresponding standard errors. The plot will also 
include LOCF value, and available Week 12 and Week 16 post-treatment values. 
13.5.4.3 Multiplicity Considerations 
Not applicable. 
13.5.5 Analyses of safety data 
The summary of safety results will be presented by treatment group.  
All safety analyses will be performed on the Safety population as defined in Section 13.4.2, unless 
otherwise specified, using the following common rules: 
• Safety data in patients who do not belong to the safety population (e.g., exposed but not 
randomized) will be listed separately 
• The baseline value is defined as the last available value before randomization. 
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The following definitions will be applied to safety laboratory parameters, vital signs and ECG. 
• The Potentially Clinically Significant Abnormality (PCSA) values are defined as abnormal 
values considered medically important by the sponsor according to predefined 
criteria/thresholds based on literature review and defined by the sponsor for clinical 
laboratory tests, vital signs and ECG.  
• PCSA criteria will determine which patients had at least one PCSA during the on-
treatment period, taking into account all evaluations performed during the on-treatment 
period, including non-scheduled or repeated evaluations.  The number of all such patients 
will be the numerator for the on-treatment PCSA percentage.   
Adverse event incidence tables will present by system-organ-class (SOC) (sorted by 
internationally agreed order), High level group term (HLGT), High level term (HLT) and 
preferred term (PT) sorted in alphabetical order for each treatment group, the number (n) and 
percentage (%) of patients experiencing an AE.  Multiple occurrences of the same event in the 
same patient will be counted only once in the tables within a treatment phase. The denominator 
for computation of percentages is the safety population within each treatment group. 
 
Death: The following deaths summaries will be generated: 
• Number (%) of patients who died by study period (TEAE, on-study, post-study) 
summarized on the safety population by treatment received 
• Death in non-randomized patients or randomized and not treated patients   
TEAE leading to death (death as an outcome on the AE e-CRF screen as reported by the 
Investigator) by primary SOC , HLGT, HLT and PT showing number (%) of patients sorted by 
internationally agreed order of SOC and alphabetic order of HLGT, HLT, and PT. 
13.5.6 Analyses of pharmacokinetic and pharmacodynamic variables 
The antibody status (positive/negative) and antibody titers will be summarized by treatment group 
and visit using descriptive statistics. If appropriate, correlations between antibody titers and PD or 
PK endpoints will be provided by graphical methods. 
Serum SAR236553 concentrations will be summarized by treatment group and visit using 
descriptive statistics.  Serum concentration time profiles will be provided by treatment group. 
Additional plots will be prepared, as deemed necessary. 
Further details will be provided in SAP. 
13.5.7 Analyses of quality of life/health economics variables 
Not applicable. 
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13.6 DATA HANDLING CONVENTIONS 
This section describes general rules for data handling conventions, especially for patients with 
missing data. 
Missing dates will be handled using conservative approaches, and no imputation will be applied at 
the data level: 
• If the date of the last dose of investigational drug is missing, the exposition duration 
should be kept as missing. 
• If a medication date or time is missing or partially missing, it will be considered as a prior, 
and concomitant medication, when no reasonable conclusion can be reached in this 
situation. 
• If onset dates and times are missing or partially missing, the AE will be classified as 
treatment-emergent. If the date and time of the first investigational drug is missing, all 
AEs that occurred after or on the day of randomization will be considered as treatment 
emergent AEs. 
• Handling of PCSAs: If a subject has a missing baseline he will be grouped in the category 
“normal /missing at baseline”. For PCSA with two conditions, one based on a change from 
baseline value or a normal range and the other one on a threshold value, the first condition 
being missing, the PCSA will be based only on the second condition. For PCSA defined 
on a threshold and / or a normal range, this PCSA will be derived using this threshold only 
if the normal range is missing.  For example, for eosinophils the PCSA is > 0.5 GIGA/L or 
> ULN if ULN ≥ 0.5 GIGA /L . When ULN is missing the value 0.5 should be used. 
13.7 INTERIM ANALYSIS 
No interim analysis planned for this study. 
13.8 DATABASE LOCK 
The database is planned to be locked 28 days after Last Patient Last Visit. 
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14 ETHICAL AND REGULATORY STANDARDS 
14.1 ETHICAL PRINCIPLES 
This Clinical Trial will be conducted in accordance with the principles laid down by the 18th 
World Medical Assembly (Helsinki, 1964) and all applicable amendments laid down by the 
World Medical Assemblies, and the ICH guidelines for Good Clinical Practice (GCP). 
In compliance with sanofi-aventis public disclosure commitments, this clinical trial will be 
recorded in the public registry website clinicaltrials.gov before the enrollment of the first patient. 
The registry will contain basic information about the trial sufficient to inform interested patients 
(and their healthcare practitioners) how to enroll in the trial. 
14.2 LAWS AND REGULATIONS 
This Clinical Trial will be conducted in compliance with all international guidelines, and national 
laws and regulations of the country(ies) in which the Clinical Trial is performed, as well as any 
applicable guidelines. Please see Section 15.1. 
14.3 INFORMED CONSENT 
The Investigator (according to applicable regulatory requirements), or a person designated by the 
Investigator, and under the Investigator's responsibility, should fully inform the Patient of all 
pertinent aspects of the Clinical Trial including the written information giving approval/favorable 
opinion by the Ethics Committee (IRB/IEC). All participants should be informed to the fullest 
extent possible about the study, in language and terms they are able to understand. 
Prior to a patient’s participation in the Clinical Trial, the written Informed Consent Form should 
be signed, name filled in and personally dated by the patient or by the patient’s legally acceptable 
representative, and by the person who conducted the informed consent discussion. A copy of the 
signed and dated written Informed Consent Form will be provided to the patient.  
The Informed Consent Form used by the Investigator for obtaining the patient's informed consent 
must be reviewed and approved by the Sponsor prior to submission to the appropriate Ethics 
Committee (IRB/IEC) for approval/favorable opinion. 
14.4 INSTITUTIONAL REVIEW BOARD/INDEPENDENT ETHICS COMMITTEE (IRB/IEC) 
As required by local regulation, the Investigator or the Sponsor must submit this Clinical Trial 
Protocol to the appropriate Ethics Committee (IRB/IEC), and is required to forward to the 
respective other party  a copy of the written and dated approval/favorable opinion signed by the 
Chairman with Ethics Committee (IRB/IEC) composition. 
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The Clinical Trial (study number, Clinical Trial Protocol title and version number), the documents 
reviewed (Clinical Trial Protocol, Informed Consent Form, Investigator’s Brochure, Investigator’s 
curriculum vitae [CV], etc.) and the date of the review should be clearly stated on the written 
(IRB/IEC) approval/favorable opinion. 
IP/NIP will not be released at the study site and the Investigator will not start the study before the 
written and dated approval/favorable opinion is received by the Investigator and the Sponsor. 
During the Clinical Trial, any amendment or modification to the Clinical Trial Protocol should be 
submitted to the Ethics Committee (IRB/IEC) before implementation, unless the change is 
necessary to eliminate an immediate hazard to the patients, in which case the IRB/IEC should be 
informed as soon as possible. It should also be informed of any event likely to affect the safety of 
patients or the continued conduct of the Clinical Trial, in particular any change in safety. All 
updates to the Investigator’s Brochure will be sent to the Ethics Committee (IRB/IEC). 
A progress report is sent to the Ethics Committee (IRB/IEC) at least annually and a summary of 
the Clinical Trial’s outcome at the end of the Clinical Trial. 
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15 STUDY MONITORING 
15.1 RESPONSIBILITIES OF THE INVESTIGATOR(S) 
The Investigator(s) and delegated Investigator staff undertake(s) to perform the Clinical Trial in 
accordance with this Clinical Trial Protocol, ICH guidelines for Good Clinical Practice and the 
applicable regulatory requirements. 
The Investigator is required to ensure compliance with all procedures required by the Clinical 
Trial Protocol and with all study procedures provided by the Sponsor (including security rules). 
The Investigator agrees to provide reliable data and all information requested by the Clinical Trial 
Protocol (with the help of the e-CRF, Discrepancy Resolution Form [DRF] or other appropriate 
instrument) in an accurate and legible manner according to the instructions provided and to ensure 
direct access to source documents by Sponsor representatives. 
If any circuit includes transfer of data particular attention should be paid to the confidentiality of 
the patient's data to be transferred. 
The Investigator may appoint such other individuals as he/she may deem appropriate as Sub-
Investigators to assist in the conduct of the Clinical Trial in accordance with the Clinical Trial 
Protocol. All Sub-Investigators shall be appointed and listed in a timely manner. The 
Sub-Investigators will be supervised by and work under the responsibility of the Investigator. The 
Investigator will provide them with a copy of the Clinical Trial Protocol and all necessary 
information. 
15.2 RESPONSIBILITIES OF THE SPONSOR 
The Sponsor of this Clinical Trial is responsible to Health Authorities for taking all reasonable 
steps to ensure the proper conduct of the Clinical Trial Protocol as regards ethics, Clinical Trial 
Protocol compliance, and integrity and validity of the data recorded on the e-CRFs. Thus, the 
main duty of the Monitoring Team is to help the Investigator and the Sponsor maintain a high 
level of ethical, scientific, technical and regulatory quality in all aspects of the Clinical Trial. 
At regular intervals during the Clinical Trial, the site will be contacted, through monitoring visits, 
letters or telephone calls, by a representative of the Monitoring Team to review study progress, 
Investigator and patient compliance with Clinical Trial Protocol requirements and any emergent 
problems. These monitoring visits, will include but not be limited to review of the following 
aspects : patient informed consent, patient recruitment and follow-up, SAE documentation and 
reporting, AEs with pre-specified monitoring documentation and reporting, AE documentation, IP 
allocation, patient compliance with the IP regimen, IP accountability, concomitant therapy use 
and quality of data. 
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15.3 SOURCE DOCUMENT REQUIREMENTS 
According to the ICH guidelines for Good Clinical Practice, the Monitoring Team must check the 
e-CRF entries against the source documents, except for the pre-identified source data directly 
recorded in the e-CRF. The Informed Consent Form will include a statement by which the patient 
allows the Sponsor’s duly authorized personnel, the Ethics Committee (IRB/IEC), and the 
regulatory authorities to have direct access to original medical records  which support the data on 
the e-CRFs (e.g., patient's medical file, appointment books, original laboratory records, etc.). 
These personnel, bound by professional secrecy, must maintain the confidentiality of all personal 
identity or personal medical information (according to confidentiality and personal data protection 
rules). 
15.4 USE AND COMPLETION OF CASE REPORT FORMS (CRFS) AND ADDITIONAL 
REQUEST 
It is the responsibility of the Investigator to maintain adequate and accurate e-CRFs (according to 
the technology used) designed by the Sponsor to record (according to Sponsor instructions) all 
observations and other data pertinent to the clinical investigation in a timely manner. All e-CRFs 
should be completed in their entirety in a neat, legible manner to ensure accurate interpretation of 
data. 
Should a correction be made, the corrected information will be entered in the e-CRF overwriting 
the initial information. An audit trail allows identifying the modification.  
Data are available within the system to the sponsor as soon as they are entered in the e-CRF. 
The computerized handling of the data by the Sponsor when available in the e-CRF may generate 
additional requests (DRF) to which the Investigator is obliged to respond by confirming or 
modifying the data questioned. The requests with their responses will be managed through the 
e-CRF. 
15.5 USE OF COMPUTERIZED SYSTEMS 
Computerized systems used during the different steps of the study are: 
• For data management activities, an e-CRF will be built using Oracle Clinical. 
• For pharmacokinetic activities, WinNonlin. 
• For statistical activities, nQuery Advisor 6.01, SAS. 
• For pharmacovigilance activities, Clintrace and AWARE.  
• For monitoring activities, IMPACT. 
• For medical writing activities, DOMASYS FDA 21 CFR Part 11 compliant system will be 
used. 
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16 ADMINISTRATIVE RULES 
16.1 CURRICULUM VITAE 
A  current copy of the curriculum vitae describing the experience, qualification and training of 
each Investigator and Sub-Investigator will be signed, dated and provided to the Sponsor prior to 
the beginning of the Clinical Trial. 
16.2 RECORD RETENTION IN STUDY SITES (S) 
The Investigator must maintain confidential all study documentation, and take measures to 
prevent accidental or premature destruction of these documents. 
The Investigator should retain the study documents at least fifteen (15) years after the completion 
or discontinuation of the Clinical Trial. 
However, applicable regulatory requirements should be taken into account in the event that a 
longer period is required. 
The Investigator must notify the Sponsor prior to destroying any study essential documents 
following the Clinical Trial completion or discontinuation. 
If the Investigator's personal situation is such that archiving can no longer be ensured by him/her, 
the Investigator shall inform the Sponsor and the relevant records shall be transferred to a 
mutually agreed upon designee. 
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17 CONFIDENTIALITY 
All information disclosed or provided by the Sponsor (or any company/institution acting on their 
behalf), or produced during the Clinical Trial, including, but not limited to, the Clinical Trial 
Protocol, the CRFs, the Investigator's Brochure and the results obtained during the course of the 
Clinical Trial, is confidential, prior to the publication of results. The Investigator and any person 
under his/her authority agree to undertake to keep confidential and not to disclose the information 
to any third party without the prior written approval of the Sponsor. 
However, the submission of this Clinical Trial Protocol and other necessary documentation to the 
Ethics Committee (IRB/IEC) is expressly permitted, the IRB/IEC members having the same 
obligation of confidentiality. 
The Sub-Investigators shall be bound by the same obligation as the Investigator. The Investigator 
shall inform the Sub-Investigators of the confidential nature of the Clinical Trial. 
The Investigator and the Sub-Investigators shall use the information solely for the purposes of the 
Clinical Trial, to the exclusion of any use for their own or for a third party's account. 
Furthermore, the Investigator and the Sponsor agree to adhere to the principles of personal data 
confidentiality in relation to the patients, Investigator and its collaborators involved in the study. 
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18 PROPERTY RIGHTS 
All information, documents and IP provided by the Sponsor or its designee are and remain the 
sole property of the Sponsor. 
The Investigator shall not mention any information or the Product in any application for a patent 
or for any other intellectual property rights. 
All the results, data, documents and inventions, which arise directly or indirectly from the Clinical 
Trial in any form, shall be the immediate and exclusive property of the Sponsor. 
The Sponsor may use or exploit all the results at its own discretion, without any limitation to its 
property right (territory, field, continuance). The Sponsor shall be under no obligation to patent, 
develop, market or otherwise use the results of the Clinical Trial. 
As the case may be, the Investigator and/or the Sub-Investigators shall provide all assistance 
required by the Sponsor, at the Sponsor's expense, for obtaining and defending any patent, 
including signature of legal documents. 
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19 DATA PROTECTION 
• The patient's personal data, which are included in the Sponsor database shall be treated in 
compliance with all applicable laws and regulations; 
• When archiving or processing personal data pertaining to the Investigator and/or to the 
patients, the Sponsor shall take all appropriate measures to safeguard and prevent access to 
this data by any unauthorized third party. 
• The Sponsor also collects specific data regarding Investigator as well as personal data 
from any person involved in the study which may be included in the Sponsor’s databases, 
shall be treated by both the Sponsor and the Investigator in compliance with all applicable 
laws and regulations. 
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20 INSURANCE COMPENSATION 
The Sponsor certifies that it has taken out a liability insurance policy covering all clinical trials 
under its sponsorship.  This insurance policy is in accordance with local laws and requirements. 
The insurance of the Sponsor does not relieve the Investigator and the collaborators from 
maintaining their own liability insurance policy. An insurance certificate will be provided to the 
Ethics committees/IRB or Health Authorities in countries requiring this document. 
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21 SPONSOR AUDITS AND INSPECTIONS BY REGULATORY 
AGENCIES 
For the purpose of ensuring compliance with the Clinical Trial Protocol, Good Clinical Practice 
and applicable regulatory requirements, the Investigator should permit auditing by or on the 
behalf of the Sponsor and inspection by regulatory authorities. 
The Investigator agrees to allow the auditors/inspectors to have direct access to his/her study 
records for review, being understood that these personnel is bound by professional secrecy, and as 
such will not disclose any personal identity or personal medical information. 
The Investigator will make every effort to help with the performance of the audits and inspections, 
giving access to all necessary facilities, data, and documents. 
As soon as the Investigator is notified of a planned inspection by the authorities, he will inform 
the Sponsor and authorize the Sponsor to participate in this inspection. 
The confidentiality of the data verified and the protection of the patients should be respected 
during these inspections. 
Any result and information arising from the inspections by the regulatory authorities will be 
immediately communicated by the Investigator to the Sponsor. 
The Investigator shall take appropriate measures required by the Sponsor to take corrective 
actions for all problems found during the audit or inspections. 
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22 PREMATURE DISCONTINUATION OF THE STUDY OR 
PREMATURE CLOSE-OUT OF A SITE 
22.1 DECIDED BY THE SPONSOR IN THE FOLLOWING CASES: 
• If the information on the product leads to doubt as to the benefit/risk ratio; 
• If the Investigator has received from the Sponsor all IP, means and information necessary 
to perform the Clinical Trial and has not included any patient after a reasonable period of 
time mutually agreed upon; 
• In the event of breach by the Investigator of a fundamental obligation under this 
agreement, including but not limited to breach of the Clinical Trial Protocol, breach of the 
applicable laws and regulations or breach of the ICH guidelines for Good Clinical 
Practice; 
• If the total number of patients are included earlier than expected; 
In any case the Sponsor will notify the Investigator of its decision by written notice. 
22.2 DECIDED BY THE INVESTIGATOR 
The Investigator must notify (30 days' prior notice) the Sponsor of his/her decision and give the 
reason in writing. 
In all cases (decided by the Sponsor or by the Investigator), the appropriate Ethics Committee(s) 
(IRB/IEC) and Health Authorities should be informed according to applicable regulatory 
requirements. 
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23 CLINICAL TRIAL RESULTS 
The Sponsor will be responsible for preparing a Clinical Study Report and to provide a summary 
of study results to the Investigator.  
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24 PUBLICATIONS AND COMMUNICATIONS 
The Investigator undertakes not to make any publication or release pertaining to the Study and/or 
results of the Study prior to the Sponsor’s written consent, being understood that the Sponsor will 
not unreasonably withhold its approval. 
As the Study is being conducted at multiple sites, the Sponsor agrees that, consistent with 
scientific standards, first presentation or publication of the results of the Study shall be made only 
as part of a publication of the results obtained by all sites performing the Protocol.  However, if no 
multicenter publication has occurred within twelve (12) months of the completion of this Study at 
all sites, the Investigator shall have the right to publish or present independently the results of this 
Study to the review procedure set forth herein.   The Investigator shall provide the Sponsor with a 
copy of any such presentation or publication derived from the Study for review and comment at 
least thirty (30) days in advance of any presentation or submission for publication.  In addition, if 
requested by the Sponsor, any presentation or submission for publication shall be delayed for a 
limited time, not to exceed ninety (90) days, to allow for filing of a patent application or such 
other measures as the Sponsor deems appropriate to establish and preserve its proprietary rights.  
The Investigator shall not use the name(s) of the Sponsor and/or its employees in advertising or 
promotional material or publication without the prior written consent of the Sponsor. The Sponsor 
shall not use the name(s) of the Investigator and/or the collaborators in advertising or promotional 
material or publication without having received his/her and/or their prior written consent(s). 
The sponsor has the right at any time to publish the results of the study. 
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25 CLINICAL TRIAL PROTOCOL AMENDMENTS 
All appendices attached hereto and referred to herein are made part of this Clinical Trial Protocol. 
The Investigator should not implement any deviation from, or changes of the Clinical Trial 
Protocol without agreement by the Sponsor and prior review and documented approval/favorable 
opinion from the IRB/IEC of an amendment, except where necessary to eliminate an immediate 
hazard(s) to Clinical Trial Patients, or when the change(s) involves only logistical or 
administrative aspects of the trial. Any change agreed upon will be recorded in writing, the 
written amendment will be signed by the Investigator and by the Sponsor and the signed 
amendment will be filed with this Clinical Trial Protocol. 
Any amendment to the Clinical Trial Protocol requires written approval/favorable opinion by the 
Ethics Committee (IRB/IEC) prior to its implementation, unless there are overriding safety 
reasons. 
In some instances, an amendment may require a change to the Informed Consent Form. The 
Investigator must receive an IRB/IEC approval/favorable opinion concerning the revised 
Informed Consent Form prior to implementation of the change and patient signature should be 
re-collected if necessary. 
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27 APPENDICES 
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Appendix A General Guidance for the follow-up of laboratory 
abnormalities by sanofi-aventis  
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NOTE: IN ADDITION, AS SOON AS A SERIOUSNESS CRITERION IS MET, THE EVENT SHOULD BE 
NOTIFIED WITHIN 1 WORKING DAY TO THE MONITORING TEAM. 
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Appendix B DNA storage samples (Note: this appendix is for use 
in Phase II-III studies) 
1. PROCEDURE FOR COLLECTION, HANDLING, AND SHIPMENT OF 
OPTIONAL DNA STORAGE SPECIMENS  
• Collection schedule: per protocol. 
• Labeling of samples 
- Each sample tube should have attached to it the label provided by Covance. 
DNA  Subject ID:XXX-001-YYY 
Study Number / Compound (pre-printed) 
Bar Code (preprinted) 
Accession Number (pre-printed) 
- In the event of damage or loss of the provided labels, a new label should be 
immediately requested from Covance. 
• Procedure 
- Using a waterproof pen, write Subject ID Number on label in space provided. 
- Collect 6 mL of blood, using the 6 mL Vacutainer (Becton Dickinson; K2 EDTA with 
HEMOGARD Closure) provided, and gently invert tube at least 8 times permitting the 
specimen to mix with the anticoagulant. 
- Under no circumstances should the tube be centrifuged. 
- Ensure the sample tube is clearly and appropriately labeled as described above and in 
detail in the Covance Laboratory Manual. 
- Immediately freeze and maintain the blood in an upright position at -20°C or colder for 
storage. Samples must be stored on dry ice if a freezer is not immediately available. 
- Complete the Laboratory Requisition Form (provided by Covance) for each sample. 
• Storage 
- Samples must be kept at -20 ºC or colder, organized in a rack in numeric order 
according to the Subject ID, until ready for packaging and shipping. 
• Packaging and shipment 
- Samples and accompanying documents should be packaged according to the detailed 
instructions in the Covance Laboratory Manual provided at the initiation of the study. 
- Samples must be packaged according to IATA Dangerous Goods Regulations, Packing 
Instructions 650, using the packing materials provided by contracted company. 
- In the event that the packaging materials or instructions are lost, please contact the 
study sponsor. 
- Ship samples on dry ice to Covance as described in the Global Study Schedule, using 
the shipping materials provided. 
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• Note: Additional detailed information can be found in the Covance Laboratory Manual, 
provided at the beginning of the study. This includes additional details regarding: 
- Sample collection kits 
- Sample collection procedures 
- Documentation procedures 
- Packing and shipping instructions 
- Sample kit resupply 
- How to get help 
2. SHIPMENT CONTACT NAMES AND ADDRESSES 
 
For Optional DNA Banking Samples: 
Use for the Americas: USA and Canada, as well as Latin America and the Islands (Dominican 
Republic, etc): 
Covance CLS Indianapolis 
8211 SciCor Drive 
Indianapolis, IN 
46214-2985 USA 
Tel. +1 (317) 271-1200 
(local calls) 
Tel: +1 800-462-8885 
Fax: (317) 273-4030 
 
Use for Europe, the Middle East, and Africa: 
Covance CLS Genève 
Rue Moïse-Marcinhes 7 
1217 Meyrin/Genève-CH 
Tel: +41 22-989-7000 
Fax: +41 22-989-1999 
 
Use for Asia-Pacific, including Thailand, Malaysia, and Australia: 
Covance CLS Singapore 
1 International Business Park 
#05-12A/B The Synergy 
Singapore 609917 
Tel: 65-6560-8793 
Fax: 65-6565-5901 
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Use for China only: 
Covance CLS Shanghai 
1st Floor, No. 6 Building 
151 Li Bing Rd 
Zhangjiang Hi-Tech Park 
Shanghai 201203 
China 
Tel: +86 21 51371111 
Fax:+86 21 51371301 
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LIST OF ABBREVIATIONS AND DEFINITION OF TERMS 
Below is a list of abbreviations used in the current template that need to be adapted to the study: 
AE(s) adverse event(s) 
ALP alkaline phosphatase 
ALT alanine aminotransferase 
ANCOVA analysis of covariance 
AST aspartate aminotransferase 
ATC anatomic therapeutic class 
BMI body mass index 
CI Confidence Interval 
CLcr creatinine clearance 
CPK creatine phosphokinase 
CRP C-reactive protein 
CSR clinical study report 
ECG Electrocardiogram 
e-CRF Electronic case report form 
GGT gamma glutamyl transferase 
HDL-C high density lipoprotein cholesterol 
HLGT high level group term 
HLT high level term 
HsCRP High sensitivity C-reactive protein 
ICH international conference on harmonization of technical requirements for 
registration of pharmaceuticals for human use 
IP investigational product 
ITT intent to treat 
IVRS/IWRS interactive voice/web response systems 
LDL-C low density lipoprotein cholesterol 
LLN lower normal limit 
LOCF Last Observation Carried forward 
LP(a) Lipoprotein (a) 
MedDRA medical dictionary for regulatory activities 
mITT modified intent to treat 
Non HDL-C non high density lipoprotein cholesterol 
PCSA potentially clinically significant abnormalities 
PK pharmacokinetic 
PT preferred term 
SAP statistical analysis plan 
SMQ standardized MedDRA query 
SOC System organ class 
TC Total cholesterol 
TEAE treatment emergent adverse event 
TG triglycerides 
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ULN upper normal limit 
WHO-DD World Health Organization – Drug Dictionary 
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1 OVERVIEW AND INVESTIGATIONAL PLAN   
1.1 STUDY DESIGN AND RANDOMIZATION 
This is a multicenter, randomized, double-blind, 3-parallel-group, placebo-controlled, 8-week 
study conducted in the United States to assess the efficacy and safety of SAR236553 in patients 
with an elevated LDL-C (≥ 100 mg/dL or 2.59 mmol/L) treated with a stable dose of atorvastatin 
10 mg.  
During the screening period, patients have to be stabilized to atorvastatin 10 mg for at least 
6 weeks, if they were not already. Then, after 1 additional screening week, patients are centrally 
randomized via IVRS/IWRS in a 1:1:1 ratio to one of the 3 treatment groups described in 
Section 1.4 and treated in a double-blind manner for approximately 8 weeks. The double-blind 
treatment period is then followed by an 8-week follow-up period. 
Approximately 90 patients (30 patients per treatment group) have to be recruited and randomized 
from approximately 20 sites. 
1.2 OBJECTIVES 
1.2.1 Primary objectives 
To evaluate the effect of SAR236553 on low-density lipoprotein cholesterol (LDL-C) levels 
compared with placebo when co-administered with 80 mg of atorvastatin after 8 weeks of 
treatment in patients with LDL-C ≥ 100mg/dL (≥ 2.59 mmol/L) on atorvastatin 10 mg. 
1.2.2 Secondary objectives 
The secondary objectives are: 
• To evaluate the effects of SAR236553 on other lipid levels in comparison with placebo, 
when co-administered with 80 mg of atorvastatin after 8 weeks of treatment.  
• To evaluate the efficacy of SAR236553 when co-administered with a high dose of 
atorvastatin (80 mg) versus atorvastatin 10 mg. 
• To evaluate the safety and tolerability of SAR236553 when co-administered with 
2 different doses of atorvastatin. 
• To evaluate the development of anti-SAR236553 antibodies. 
• To evaluate the pharmacokinetics of SAR236553. 
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1.3 DETERMINATION OF SAMPLE SIZE 
The study is expected to enroll approximately 90 patients. 
To detect a difference of 20% in LDL-C percent change from baseline to Week 8 between 
SAR236553 150 mg + atorvastatin 80 mg group and Placebo for SAR236553 + atorvastatin 
80 mg group, assuming a 5% rate of unevaluable primary endpoint, 30 patients by arm will result 
in 95% power, with a standard deviation of 20%, and using a two-sided t-test at the 0.05 
significance level. 
Calculations were made using nQuery Advisor 6.01. 
1.4 STUDY PLAN 
This study comprises three EPOCHs. 
• The SCREENING epoch is defined as the time from informed consent date up to 
first IP injection. 
There are 2 options depending on the status of the patient at screening: 
- Patients receiving atorvastatin 10 mg at stable dose for at least 6 weeks prior to 
screening. 
In this case, the screening period is of 1 week.  
- Patients receiving a lipid lowering treatment other than atorvastatin or not at stable 
dose of atorvastatin 10 mg for at least 6 weeks prior to screening or drug naive 
patients. 
In this case, there is a run-in period of 6 weeks on atorvastatin 10 mg in addition to 
the 1 week of screening. 
• The DOUBLE-BLIND TREATMENT epoch is defined as the time from first IP injection 
to last IP injection +14 days.  
During this period, the patients receive one of the 3 following treatment groups according to 
randomization schedule: 
- Placebo + atorvastatin 80 mg: placebo for SAR236553 + high dose of atorvastatin 
- SAR236553 150 mg + atorvastatin 80 mg: SAR236553 150 mg + high dose of 
atorvastatin 
- SAR236553 150 mg + atorvastatin 10 mg: SAR236553 150 mg + maintenance of 
atorvastatin dose previously received. 
SAR236553 is administered every 2 weeks on site trough subcutaneous injection and 
atorvastatin is administered orally once daily in the evening at home.  
• The FOLLOW-UP epoch is defined as the time from the day after last IP injection + 
14 days up to the end of the study. 
A study design summary for each screening option is presented in the following figures 
(Figure 1 and Figure 2): 
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Figure 1 – Study design: patients receiving a lipid lowering treatment other than atorvastatin or not at stable dose of atorvastatin 10 mg for at least 
6 weeks prior to screening, or drug naive patients 
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Figure 2 – Study design: patients receiving atorvastatin 10 mg at stable dose for at least 6 weeks prior to screening 
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1.5 MODIFICATIONS TO THE STATISTICAL SECTION OF THE PROTOCOL  
The statistical section of the protocol was never changed in any amendment. 
However, some minor modifications of the statistical section of the protocol have been done and 
are documented in the following table: 
 
Item Change description 
Atorvastatatin exposure 
(see Section 2.4.2 ) 
In order to improve the interpretation of atorvastatin exposure, average daily dose has been replaced 
by compliance. 
Safety baseline definition 
(see Section 2.4.5 ) 
The baseline value is defined as the last available value before first IP injection (instead of 
randomization in the protocol). Actually, for any safety analyses, the first IP injection is used as a 
reference date. 
Efficacy baseline definition
(see  Section 2.1.3.1 ) 
The baseline calculated LDL-C value will be the average of the LDL-C levels measured from Visit 1 
(Week -1) and up to before first IP injection. In the protocol, the baseline definition was “the average 
of the last pre-randomization (Visit 1, week-1) calculated LDL-C value and the randomization (visit 2, 
week 0)”. The revised definition of the SAP ensures consistency with the definition of the efficacy 
period starting the day of the first IP injection.  As a consequence, this has an impact on the m-ITT 
population. 
Efficacy period 
(see Section 2.1.3.1 ) 
The protocol initially defined the efficacy period as “time from the first SAR236553 or placebo for 
SAR236553 injection up to 21 days after the last SAR236553 or placebo for SAR236553 injection, or 
up to 84 days after the first injection whichever comes first”. As the definition of time windows for 
analyses has been specified in the SAP (e.g. week 8=Day 50 to 84), the wording of the definition of 
the efficacy period has been simplified. “The efficacy period will be defined as the time from the first 
IP injection up to 21 days after the last IP injection. Time windows are defined in Section 2.5.4 “.  
m-ITT population 
(see Section 2.3.1.1 ) 
Wording of m-ITT population has been revised based on clarifications listed above for baseline 
definition and efficacy period. 
Per protocol population 
(see Section 2.3.1.2 ) 
A population per protocol has been defined to perform sensitivity analysis of the primary endpoint. 
 
1.6 STATISTICAL MODIFICATIONS MADE IN THE SAP 
Not applicable. 
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2 STATISTICAL AND ANALYTICAL PROCEDURES 
In a concern of simplification, the following terms will be used in this SAP:  
• IP injection: injection of SAR236553 or injection of its placebo,  
• SAR236553 IP: SAR236553 or its placebo, 
• Placebo: placebo for SAR236553, 
• atorvastatin IP: atorvastatin administered during the double-blind period (as reported in 
the dedicated e-CRF screens), 
• atorvastatin non IP: atorvastatin administered outside the double-blind period (as reported 
in the dedicated e-CRF screens). 
2.1 ANALYSIS ENDPOINTS 
2.1.1 Demographic and baseline characteristics 
The baseline value for demographic and baseline characteristics is generally defined as the last 
available value before randomization. 
The baseline values for safety parameters are presented along with the on-treatment summary 
statistics and are defined in Section 2.4.5. 
The baseline values for efficacy parameters are presented alone on randomized population and 
along with the on-treatment summary statistics on efficacy populations. They are described in 
Section 2.1.3. 
Demographic characteristics 
Demographic variables are sex (Male, Female), race (White, Black or African American, Asian, 
American Indian or Alaska Native, Native Hawaiian or other Pacific Island, other), age in years 
(quantitative and categorical variable : <45, [45 - 65[and ≥ 65 years), ethnicity (Hispanic or 
Latino, Not Hispanic or Latino). 
Medical or surgical history 
This information will be coded using the version of MedDRA (Medical Dictionary for Regulatory 
Activities) currently in effect at sanofi-aventis at the time of database lock. 
Medical history of specific interest includes hypertension, type 2 diabetes, coronary artery 
disease, peripheral vascular disease and cerebrovascular disease. The MedDRA codes or SMQ 
that will be used in determining these medical histories are described in Appendix C.  
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Disease characteristics at baseline 
Specific disease history includes type of lipid disorders according to the Fredrickson classification 
(IIa, IIb or IV), time from diagnosis (years), and presence of previous treatment with a lipid 
lowering agent. 
Efficacy lipid parameters 
Efficacy lipid parameters (defined in Section 2.1.3) at baseline will be summarized by treatment 
group. 
Other baseline characteristics 
Other baseline characteristics include BMI in kg/m2 (continuous and categorical variable: <30, 
≥30) and HbA1c (continuous and categorical variable: <5.7%, [5.7% - 6.5%[, ≥6.5%). 
Any technical details related to computation, dates, imputation for missing dates are described in 
Section 2.5.  
2.1.2 Prior or concomitant medications  
All medications taken within 12 weeks (84 days) before randomization and until the end of the 
study, including atorvastatin non IP and other Lipid Lowering Therapies are to be reported in the 
corresponding e-CRF screens. 
All medications will be coded using the World Health Organization-Drug Dictionary (WHO-DD) 
using version currently in effect at sanofi-aventis at the time of database lock. 
• Prior medications are those the patient used within 12 weeks (84 days) prior to first IP 
injection. Prior medications can be discontinued before first dosing or can be ongoing 
during treatment phase.   
• Concomitant medications are any treatments received by the patient concomitantly to the 
SAR236553 IP, from first IP injection to last IP injection + 10 weeks (70 days). A given 
medication can be classified both as a prior medication and as a concomitant medication.  
Atorvastatin 10 mg is to be taken by all patients at stable dose as prior medication for 
approximately 7 weeks (49 days). 
Any technical details related to computation, dates, imputation for missing dates are described in 
Section 2.5. 
Property of the sanofi-aventis group - strictly confidential Page 14 
Statistical Analysis Plan  10-Oct-2011 
SAR236553-DFI11566 Version number: 1 (electronic 1.0) 
2.1.3 Efficacy endpoints 
Efficacy parameters include lipid parameters [i.e. Total cholesterol (TC), LDL-C, HDL-C, 
Triglycerides (TG), non-HDL-C, Apolipoprotein B (ApoB), Apolipoprotein A-1 (ApoA-1), ratio 
ApoB/ApoA-1, Lp(a)].  
All these parameters are measured / calculated by a Central Laboratory, for scheduled or 
unscheduled time points.   
LDL-C levels are calculated using the Friedewald formula at all visits. Non-HDL-C levels are 
calculated in subtracting HDL-C from the TC. 
2.1.3.1 Primary efficacy endpoint(s) 
The primary efficacy variable is the percent change in calculated LDL-C from baseline to Week 8, 
which is defined as: 100x (calculated LDL-C value at Week 8 - calculated LDL-C value at 
baseline) / calculated LDL-C value at baseline. 
The baseline calculated LDL-C value will be the average of the LDL-C levels measured from the 
Visit 1 (Week -1) and up to before first IP injection.  
The calculated LDL-C at Week 8 will be the LDL-C level measured from blood samples collected 
during the efficacy period and within the Week 8 time window.  The efficacy period will be 
defined as the time from the first IP injection up to 21 days after the last IP injection. Time 
windows definitions are given in Section 2.5.4. 
In case of unavailable calculated LDL-C value at Week 8 as defined above, then the last 
calculated LDL-C value measured during the efficacy period and before the Week 8 time window 
will be used to impute the missing Week 8 calculated LDL-C value (Last Observation Carried 
Forward [LOCF] procedure). 
All central laboratory LDL-C measurements (scheduled or unscheduled, fasting or not fasting) 
may be used to provide a value for the primary efficacy variable if appropriate according to the 
above definition. 
2.1.3.2 Secondary efficacy endpoint(s) 
The secondary efficacy variables are: 
• The absolute change from baseline in calculated LDL-C to Week 8 (in mmol/L and 
mg/dL), defined as: (calculated LDL-C value at Week 8 - calculated LDL-C value at 
baseline), using definitions and imputation rule defined in Section 2.1.3.1.  
• The proportion of patients achieving an LDL-C level lower than 100 mg/dL (2.59 
mmol/L) at Week 8, defined as: (number of patients whose calculated LDL-C value at 
Week 8 is strictly lower than 100 mg/dL / number of patients in the mITT 
population)*100, using definitions and imputation rule defined in Section 2.1.3.1. mITT 
population is defined in Section 2.3.1.1. 
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• The proportion of patients achieving an LDL-C level lower than 70 mg/dL (1.81 mmol/L) 
at Week 8 will be assessed similarly. 
• Percent and absolute (mmol/L and mg/dL) change in TC from baseline to Week 8: same 
definitions and rules as for LDL-C.  
• Percent and absolute (mmol/L and mg/dL) change in HDL-C from baseline to Week 8: 
same definitions and rules as for LDL-C.  
• Percent and absolute (mmol/L and mg/dL) change in fasting TG from baseline to Week 8: 
same definitions and rules as for LDL-C, excluding measurements in not fasting patients 
or measurements with missing fasting status.  
• Percent and absolute (mmol/L and mg/dL) change in non HDL-C from baseline to 
Week 8: same definitions and rules as for LDL-C.  
• Percent change in Apo-B from baseline to Week 8: same definitions and rules as for 
LDL-C, except for baseline value that will be the Apo-B value measured at randomization 
visit (Visit 2) and before first IP injection, or, if missing, the last unscheduled value 
obtained from Visit 1 (Week -1) up to before first IP injection. 
• Percent change in Apo-A1 from baseline to Week 8: same definitions and rules as for 
Apo-B. 
• Absolute change in the ratio ApoB/ApoA-1 from baseline to Week 8: same definitions and 
rules as for Apo-B. 
• Percent change in Lp(a) from baseline to Week 8: same definitions and rules as for Apo-B.  
Data handling conventions are described in Section 2.5.2. 
2.1.4 Safety endpoints 
The safety analysis will be based on the reported adverse events (AEs) and other safety 
information, such as clinical laboratory data, vital signs and ECG. 
Safety observation period 
• The PRE-TREATMENT period is defined as the time from the signed informed consent 
date up to the first IP injection. 
• The TEAE period is defined as the time from first IP injection to last IP injection + 
70 days (10 weeks). 
• The POST-TREATMENT period is defined as the period of time starting the day after the 
end of the TEAE period up to the end of the study (defined as last protocol planned visit or 
the resolution/stabilization of all SAE and AEs with pre-specified monitoring). 
• The ON-STUDY OBSERVATION period is defined as the time from first IP injection 
until the end of the study (defined as last protocol planned visit or the 
resolution/stabilization of all SAE and AEs with pre-specified monitoring).  
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2.1.4.1 Adverse events variables 
Adverse event observation period:  
• Pre-treatment AEs are AEs that developed or worsened or became serious during the 
pre-treatment period. 
• Treatment-emergent AEs (TEAEs) are AEs that developed or worsened or became serious 
during the TEAE period; 
• Post-treatment AEs are AEs that developed or worsened or became serious during the 
post-treatment period. 
All AEs (including SAEs and AEs of interest) will be coded to a “Lower Level Term (LLT)”, 
“Preferred Term (PT)”, “High Level term (HLT)”, “High Group Level Term (HLGT)” and 
associated primary “System Organ Class (SOC)” using the version of MedDRA (Medical 
Dictionary for Regulatory Activities) currently in effect at sanofi-aventis at the time of database 
lock. 
AEs of interest include the following terms: 
• Allergic events (using HLGT “Allergic conditions”) 
• Injection site reaction (using HLT “Injection site reactions”)  
2.1.4.2 Deaths 
The deaths observation period are per the observation periods defined above:  
• Death on-study: deaths occurring during the on-study observation period 
• Death on-treatment: deaths occurring during the TEAE period  
• Death post-study: deaths occurring after the end of study  
2.1.4.3 Laboratory safety variables 
Clinical laboratory data consists of blood analysis, including hematology and clinical chemistry. 
Clinical laboratory values after conversion will be analyzed into standard international units and 
international units will be used in all listings and tables. 
Blood samples for clinical laboratories are taken at Week -7 for patients with run-in period, 
Visit 1 (Week -1), Visit 2 (Week 0), Visit 4 (Week 4), Visit 6 (Week 8) or at the early termination 
visit, and during the follow-up period [Visit 7 (Week 12), Visit 8 (Week 16)] in case of persistent 
clinically relevant abnormal values at Visit 6/early termination visit unless otherwise specified.  
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The laboratory parameters (excluding those considered as efficacy or other assessment 
parameters) will be classified as follows: 
• Hematology  
- Red blood cells, platelets and coagulation: hemoglobin, hematocrit, erythrocytes and 
platelets 
- White blood cells: leukocytes with differential blood count (neutrophils, lymphocytes, 
monocytes, basophils, eosinophils).  
• Clinical chemistry  
- Metabolism: total protein, albumin, creatine kinase (ie creatinine phosphokinase or 
CPK) (not measured at Week -7),  
- Electrolytes: sodium, potassium, chloride, calcium, phosphate (=phosphorus), 
bicarbonate, 
- Renal function: creatinine, creatinine clearance, blood urea nitrogen, urate(=uric acid) 
- Liver function (not measured at Week -7): alanine amino transferase (ALT), aspartate 
amino transferase (AST), alkaline phosphatase (ALP), gamma glutamyl transferase 
(GGT) , total bilirubin and in case of total bilirubin values above the normal range, 
must include direct and indirect bilirubin, 
- Troponin I 
Technical formulas are described in Section 2.5.1 and data handling conventions in Section 2.5.3.  
Moreover, LDL-C values <25 mg/dL [0.65 mmol/L] will be considered as safety parameter. 
2.1.4.4 Vital signs variables 
Vital Signs include: Heart Rate (HR), Systolic and Diastolic Blood Pressure (SBP and DBP) in 
supine position.  
2.1.4.5 ECG variables 
The ECG are measured automatically by the device as an automatic ECG and reviewed manually 
for the interpretation.  
ECG parameters include Heart Rate, PR interval, QRS duration, QT interval as well as corrected 
QTc (as calculated by the central laboratory according to both Bazett and Fridericia formulas 
given in Section 2.5.1).  
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2.1.5 Other assessment endpoints 
Other assessment endpoints defined below are exploratory variables.  
They include metabolic (glycated hemoglobin A1c (HbA1c), fasting plasma glucose (FPG)), 
inflammatory (high-sensitivity C-reactive protein (hs-CRP)) and vital sign (weight) parameters: 
• Absolute change in HbA1c (%) from baseline to Week 8: same definitions and rules as for 
LDL-C, except for baseline value that will be the last value before first IP injection. 
• Absolute change from baseline in FPG (mmol/L) to Week 8: same definitions and rules as 
for LDL-C, except for baseline value that will be the FPG value measured at 
randomization visit (Visit 2) and before first IP injection, without replacement rule if 
missing. Absolute change from baseline in mg/dL will be provided upon request. 
• Percent and absolute changes from baseline in hs-CRP to Week 8: same definitions and 
rules as for Apo-B. In a second approach, hs-CRP values greater or equal to 10 mg/L will 
be excluded from analyses.  
• PCSA criteria for hs-CRP will be also defined (see Appendix A).  
• Percent and absolute (kg) change from baseline in body weight to Week 8: same 
definitions and rules as for Apo-B. 
Data handling conventions are described in Section 2.5.3. 
2.1.6 Anti-SAR236553 antibody variables 
Anti-SAR236553 antibodies are assessed at Visit 2 (Week 0), Visit 4 (Week 4), Visit 6 (Week 8) 
and then during the follow-up period at Visit 7 (Week 12), and Visit 8 (Week 16).  
Anti-SAR236553 antibodies variables include status (positive or negative) and titer. 
2.1.7 Pharmacokinetic variables 
Serum SAR236553 concentrations are assessed at Visit 2 (Week 0), and then at each visit up to 
the last visit of the follow-up period (Visits 3 to 8).  
Pharmacokinetic variable is the total SAR236553 concentration at each time point. 
Data handling conventions are described in Section 2.5.3.  
2.1.8 Target PCSK9 variables 
PCSK9 concentrations will be determined using PK samples at Visit 2 (Week 0), and then at each 
visit up to the last visit of the follow-up period (Visits 3 to 8).  
Target variable is the PCSK9 concentration at each time point. 
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2.1.9 Pharmacogenomics endpoints  
Pharmacogenetics endpoints and analysis will be detailed in a separate SAP. 
2.1.10 Quality-of-life endpoints 
Not applicable. 
2.1.11 Health economic endpoints 
Not applicable. 
2.2 DISPOSITION OF PATIENTS 
This section describes patient disposition for both patient study status and the patient analysis 
populations. 
Screened patients are defined as any patient who originally met the inclusion criteria and signed 
the informed consent.   
Randomized patients consist of all screened patients, with a treatment kit number allocated and 
recorded in the IVRS/IWRS database, regardless of whether the treatment kit was used or not.  
For patient study status, the total number of patients for each one of the following categories will 
be presented in the clinical study report (CSR) using a summary table: 
• Screened patients, 
• Screen failure patients and reasons for screen failure (exclusion criteria), 
• Non-randomized but treated patients if any, 
• Randomized patients, 
• Randomized but not treated patients and reasons for not treated, 
• Randomized and treated patients,  
• Patients who did not complete the study treatment period as per protocol,  
• Patients who discontinued study treatment by main reason for permanent treatment 
discontinuation, 
• Status at last study contact. 
For all categories of patients (except for the screened and non randomized categories) percentages 
will be calculated using the number of randomized patients as the denominator. 
Reasons for treatment discontinuation will be supplied in tables giving numbers and percentages 
by treatment group. 
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All important deviations potentially impacting efficacy analyses, randomization and drug 
dispensing irregularities and other important deviations will be summarized in tables giving 
numbers and percentages of deviations by treatment group. 
Additionally, the analysis populations for safety, efficacy, anti-SAR236553 antibody and PK will 
be summarized in a table by patient counts on the randomized population.  
• Efficacy population: Modified intent-to-treat (mITT) population; Per-protocol (PP) 
population, 
• Safety population, 
• Anti-SAR236553 antibody population, 
• PK population. 
2.2.1 Randomization and drug dispensing irregularities 
Randomization and drug dispensing irregularities occur whenever: 
1. A randomization is not in accordance with the protocol-defined randomization method, 
such as: a) the process of treatment arm allocation is not according to the subject 
randomization list and chronological order, b) a patient is randomized twice, OR 
2. A patient is dispensed an IP kit or a dose not allocated by the protocol-defined 
randomization, such as, a) a patient at any time in the study is dispensed a different 
treatment kit than as randomized (which may or may not contain the correct as randomized 
IP), b) a non-randomized patient is treated with IP reserved for randomized patients. 
Randomization and drug dispensing irregularities will be monitored throughout the study and 
reviewed on an ongoing basis.  
All randomization and drug dispensing irregularities will be documented in the clinical study 
report.  If the number of irregularities is large enough to make a tabular summary useful, the 
irregularities will be categorized and summarized among randomized patients (number and 
percentages). Non-randomized, treated patients will be described separately. 
 
Randomization and drug dispensing irregularities to be prospectively identified include but are 
not limited to:  
 
Randomization and Drug Allocation Irregularities 
   Kit dispensation without IVRS/IWRS transaction 
   Erroneous kit dispensation 
   Kit not available 
   Randomization by error 
   Subject randomized twice 
   Subject switched to another site 
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2.3 ANALYSIS POPULATIONS 
Patients treated without being randomized will not be considered as randomized and will not be 
included in any population. The safety experience of these patients will be reported separately.  
Randomized population: includes all randomized patients as defined in Section 2.2. 
For any patient randomized more than once, only the data associated with the first randomization 
will be used in any analysis population. The safety experience associated with any later 
randomization will be assessed separately. 
2.3.1 Efficacy populations 
The primary efficacy analysis population will be the modified intent-to-treat (mITT) population. 
2.3.1.1 Modified intent-to-treat population  
mITT population: randomized population with an evaluable primary endpoint. 
The primary endpoint is evaluable when both of the following conditions are met: 
• Availability of at least one calculated LDL-C value from the Visit 1 (Week -1) and up to 
before first IP injection. 
• Availability of at least one calculated LDL-C value during the efficacy period and, within 
or before the Week 8 time window. The efficacy period is defined in Section 2.1.3.1 and 
the Week 8 time window is defined in Section 2.5.4  
Patients in the mITT population will be analyzed in the treatment group to which they are 
randomized. 
2.3.1.2 Per-protocol population 
Per-protocol (PP) population is a subset of the mITT population, excluding patients: 
• With only one calculated LDL-C measurement available from the Visit 1 (Week -1) and 
up to before first IP injection. 
• With Visit 1 (Week -1) LDL-C performed more than 14 days before randomization. 
• Without calculated LDL-C measurement within the Week 8 time window and during the 
efficacy period. 
• Use of atorvastatin 10 mg not at stable dose or use of a statin other than atorvastatin 10 mg 
or use of other lipid lowering drugs during the pre-treatment period which is defined by 
exclusion criteria E05. 
• With a poor compliance to atorvastatin non IP during the pre-treatment period. 
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• Receiving prohibited concomitant therapy potentially impacting lipids levels during the 
efficacy period (before the primary endpoint assessment (percent change from baseline in 
calculated LDL-C at week-8 LOCF)). 
• With a poor compliance to SAR236553 IP administrations. 
• With non compliance to atorvastatin IP during the 3 days preceding the week-8 LOCF 
LDL-C assessment. 
2.3.2 Safety population 
Safety population: randomized population who did actually receive at least one dose or partial 
dose of SAR236553 IP analyzed according to the treatment actually received. 
In addition:  
• Randomized patients for whom it is unclear whether they took the IP will be included in 
the safety population as randomized. 
• For patients receiving SAR236553 IP (active/placebo) that differ from the allocated ones, 
the treatment group allocation for as-treated analysis will be defined and documented on a 
case by case basis and in a blinded manner during Data Review prior to database lock: all 
possible scenarios for the identified case will be listed and a treatment group for as-treated 
analysis will be allocated for each scenario using the following principles: to allocate the 
treatment group the closest to the actual treatment received by the patient and to analyze 
the patient in the treatment group in which he/she was treated longer. 
• For patient receiving atorvastatin IP (atorvastatin 10 mg / atorvastatin 80 mg) that differ 
from the allocated ones, same principles as those given for SAR236553 IP will be 
followed to determine the treatment group for as-treated analysis. Nevertheless, for 
patients actually treated with Placebo as SAR236553 IP, no treatment group other than the 
existing ones will be created and in case of switch of atorvastatin IP, patients will be 
reported in Placebo + atorvastatin 80 mg group. The patients in this last case will be 
identified and described.  
2.3.3 Anti-SAR236553 antibody population  
The anti-SAR236553 antibody analysis will be performed on all treated patients (safety 
population) with a blood sample on Week 0 (baseline) and at least one evaluable blood samples 
for antibodies on treatment or in follow-up period. 
Patients will be analyzed in the treatment group corresponding to the treatment they actually 
received. 
2.3.4 PK population  
The PK analysis will be performed on all treated patients (safety population) with a blood sample 
on Week 0 (baseline) and at least one evaluable blood samples for PK on treatment or in 
follow-up. 
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Patients will be analyzed in the treatment group corresponding to the treatment they actually 
received. 
2.4 STATISTICAL METHODS 
2.4.1 Demographics and baseline characteristics 
Continuous data will be summarized using number of available data, mean, SD, median, 
minimum and maximum for each treatment group. Categorical and ordinal data will be 
summarized using number and percentage of patients in each treatment group.  
Parameters will be summarized on the randomized population analyzed in the treatment group to 
which they were randomized.  
Parameters described in Section 2.1.1 will be summarized by treatment group and overall using 
descriptive statistics.  
All reported medical and surgical history will be sorted according to SOC internationally agreed 
order and decreasing frequency of HLT based on the incidence in the overall treatment group  
P-values on demographic and baseline characteristic data will not be calculated.  
No specific description of the safety parameters will be provided at baseline. If relevant, the 
baseline values will be described along with each safety analysis. 
Specific description of the efficacy parameters will be provided at baseline (mmol/L and mg/dL), 
as well as number and percentage of patients with screening/run-in HbA1C <5.7%, ≥5.7% and 
<6.5%, ≥6.5%. 
2.4.2 Prior or concomitant medications  
The prior and concomitant medications will be presented on the randomized population.  
Medications will be summarized by treatment group according to the WHO-DD dictionary, 
considering the first digit of the ATC class (anatomic category) and the first three digits of the 
ATC class (therapeutic category). All ATC codes corresponding to a medication will be 
summarized, patients will be counted once in each ATC categories (anatomic or therapeutic) 
linked to the medication, therefore patients may be counted several time for the same medication.  
The table for prior medications will be sorted by decreasing frequency of anatomic category 
followed by all other therapeutic classes based on the overall incidence across treatment groups. 
In case of equal frequency regarding anatomic categories (respectively therapeutic categories), 
alphabetical order will be used. 
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The tables for concomitant medications will be sorted by decreasing frequency of anatomic 
category followed by all other therapeutic classes based on the incidence of the SAR236553 
150 mg + atorvastatin 80 mg. In case of equal frequency regarding anatomic categories 
(respectively therapeutic categories), alphabetical order will be used.  
In addition, atorvastatin non IP and other lipid lowering therapies will be summarized as follows.  
Atorvastatin non IP 
Atorvastatin non IP intake (as reported in the dedicated e-CRF screens) will be described within 
the 45 days preceding the first IP injection. 
Atorvastatin non IP use will be summarized descriptively by treatment group in term of treatment 
compliance, above-planned and under-planned dosing percentages as quantitative variables 
(Number, Mean, SD, Median, Min, and Max). The percentage of patients whose compliance is 
<80% and ≥ 80% will be also summarized. 
Compliance 
A given administration will be considered as non compliant if the patient did not take the planned 
dose of treatment as required by the protocol.  No imputation will be made for patients with 
missing or incomplete data.  
Percentage of compliance for a patient will be defined as the number of administrations the 
patient was compliant divided by the total number of administrations the patient was planned to 
take within the 45 days preceding the first IP injection.  
Above-planned dosing percentage for a patient will be defined as the number of administrations 
the patient took a higher dose than planned divided by the total number of administrations the 
patient was planned to take within the 45 days preceding the first IP injection. 
Under-planned dosing percentage for a patient will be defined as the number of administrations 
the patient took a lower dose than planned divided by the total number of administrations the 
patient was planned to take within the 45 days preceding the first IP injection. 
Moreover, atorvastatin non IP will be summarized by treatment group using counts and 
percentages during the FOLLOW-UP epoch (as defined in Section 1.4). 
Other lipid lowering therapies 
Other lipid lowering therapies intake (as reported in the dedicated e-CRF screens) will be 
described on the 3 following periods separately:  
• Within the 45 days preceding the first IP injection, 
• During the DOUBLE-BLIND TREATMENT epoch (as defined in Section 1.4), 
• During the FOLLOW-UP epoch (as defined in Section 1.4). 
Other lipid lowering therapies will be summarized by International Nonproprietary Name (INN) 
and presented by treatment group using counts and percentages. 
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2.4.3 Extent of investigational product exposure and compliance  
The extent of IP exposure and compliance will be assessed and summarized by actual treatment 
within the safety population (see Section 2.3.2). 
2.4.3.1 Extent of investigational product exposure 
SAR236553 IP 
The extent of exposure will be assessed by: 
• Duration of IP exposure (weeks), defined as: (last IP injection date – first IP injection date 
+ 14 days)/7, regardless of unplanned intermittent discontinuations. Non-integer values 
will be rounded to one decimal place. 
• The total number of IP administrations by patient. 
• Duration of observation period (weeks), defined as: (last contact date – first IP injection 
date+1)/7. Non-integer values will be rounded to one decimal place. 
Duration of IP exposure will be summarized descriptively as a quantitative variable (Number, 
Mean, SD, Median, Min, and Max). In addition, duration of treatment exposure will also be 
summarized by counts and percentages for each of the following cumulative categories: ≥2 weeks, 
≥4 weeks, ≥6 weeks, ≥7 weeks, more than 8 weeks.  
The total number of IP administrations by patient will be summarized similarly using the 
following cumulative categories: ≥1 administration, ≥2 administrations, ≥3 administrations, 
≥4 administrations.  
The duration of observation period will be summarized similarly using the following cumulative 
categories: ≥2 weeks, ≥4 weeks, ≥6 weeks, ≥8 weeks, ≥12 weeks, ≥16 weeks. 
Additionally, dosing modifications will be assessed by injection ahead/delay.  
An injection k will be considered as delayed if the time interval between the date of injection k 
and the date of injection (k-1) is >14 + 3 days (ie, >3 days compared to the theoretical number of 
days between two injections). An injection k will be considered as advanced if the time interval 
between the date of injection k and the date of injection (k-1) is <14 - 3 days (ie, <3 days 
compared to the theoretical number of days). The first injection will not be counted for injection 
delay/ahead.  
Injection delay will be classified as following: between 4 and 7 days of delay, or more than 7 days 
of delay. Injection ahead will be classified as following: between 4 and 7 days ahead, or more 
than 7 days ahead. 
Total number of injections delayed, advanced and number of patients with at least one injection 
delayed, advanced will be summarized by treatment group. 
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Atorvastatin IP 
The extent of IP exposure will be assessed by the duration of IP exposure. 
Duration of IP exposure (weeks) is defined as: (last dose of atorvastatin IP date – first dose of 
atorvastatin IP date + 1 day) / 7, regardless of unplanned intermittent discontinuations. 
Non-integer values will be rounded to one decimal place.  
Duration of IP exposure will be summarized descriptively as a quantitative variable (Number, 
Mean, SD, Median, Min, and Max). In addition, duration of treatment exposure will also be 
summarized by counts and percentages for each of the following cumulative categories: ≥2 weeks, 
≥4 weeks, ≥6 weeks, ≥7 weeks, more than 8 weeks.  
2.4.3.2 Compliance  
SAR236553 IP 
Standard compliance is not applicable as treatment is delivered by cycle.  
The injection frequency will be presented instead. 
The injection frequency will be defined for each patient as the average number of days between 
2 patient’s injections, that is: (last IP injection date – first IP injection date)/(number of patient’s 
IP injection -1). 
The injection frequency will be summarized descriptively as a quantitative variable (Number, 
Mean, SD, Median, Min, and Max).  
Atorvastatin IP 
Compliance 
A given administration will be considered as non compliant if the patient did not take the planned 
dose of treatment as required by the protocol.  No imputation will be made for patients with 
missing or incomplete data.  
Percentage of compliance for a patient will be defined as the number of administrations the 
patient was compliant divided by the total number of administrations the patient was planned to 
take from the first to the last atorvastatin IP administration.  
Above-planned dosing percentage for a patient will be defined as the number of administrations 
the patient took a higher dose than planned divided by the total number of administrations the 
patient was planned to take from the first to the last atorvastatin IP administration.  
Under-planned dosing percentage for a patient will be defined as the number of administrations 
the patient took a lower dose than planned divided by the total number of administrations the 
patient was planned to take from the first to the last atorvastatin IP administration. 
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Treatment compliance, above-planned and under-planned dosing percentages will be summarized 
descriptively as quantitative variables (Number, Mean, SD, Median, Min, and Max). The 
percentage of patients whose compliance is <80% and ≥ 80% will be also summarized.  
Overdose  
Cases of overdose for SAR236553 IP and atorvastatin IP (defined as at least twice the dose during 
the planned intervals) will constitute AEs and be listed as such. More generally, dosing 
irregularities will be listed in Section 2.2.1. 
2.4.4 Analyses of efficacy endpoints 
2.4.4.1 Analysis of primary efficacy endpoint(s) 
The percent change from baseline in calculated LDL-C at Week 8-LOCF as defined in 
Section 2.1.3.1 will be analyzed in the mITT population using an analysis of covariance 
(ANCOVA) model with treatment group as fixed effect and the baseline LDL-C as covariate. The 
treatment group factor will have three levels: placebo + atorvastatin 80 mg, SAR236553 150 mg + 
atorvastatin 10 mg and SAR236553 150 mg + atorvastatin 80 mg.   
Throughout the ANCOVA model, the SAR236553 150 mg + atorvastatin 80 mg group will be 
compared to the placebo + atorvastatin 80 mg group using appropriate contrast and the 
95% confidence interval (CI) of the difference will be provided.  
No formal comparisons with the SAR236553 150 mg + atorvastatin 10 mg group will be 
performed: only 95% CIs for difference versus the other arms will be provided. 
Model assumption checks 
Homogeneity of slopes: 
Given the low sample sizes in each treatment group, the homogeneity of slopes assumption will 
be explored by means of the following outputs: 
• The treatment group-by-baseline LDL-C interaction term will be added in the primary 
ANCOVA model and its significance level will be examined. 
• A separate-slopes model with terms for treatment group and treatment group-by-baseline 
LDL-C interaction will be fitted to the data, and the graph presenting the observed and 
predicted values by baseline LDL-C values will be provided. Predicted values within a 
same treatment group will be joined to form the 3 regression lines of the separate slopes 
model. 
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Gaussian distribution: 
The normality of the residuals of the ANCOVA model will be assessed graphically using 
histogram, and plots of the percentiles (resp. quantiles) of fitted Gaussian distribution versus 
ordered residual values. Skewness and Kurtosis measures, as well as Shapiro-Wilk statistic will 
be also examined. If substantial deviations from the assumptions are found, the rank analysis of 
covariance as proposed in (1) will be used to compare the SAR236553 150 mg + atorvastatin 
80 mg group to placebo + atorvastatin 80 mg group. The test statistic associated to this 
comparison will be used to build 95% confidence interval and estimate of the location shift. 
Homogeneity of variance: 
The homogeneity of variances will be checked by displaying the variance of the residuals within 
each level of the treatment group. A scatter plot of predicted versus residual values will be also 
provided. 
Sensitivity analyses: 
Sensitivity to per protocol: 
The primary ANCOVA model will be re-run in the per protocol population. 
Sensitivity to baseline definition: 
In order to assess the sensitivity of the primary analysis to baseline definition, the primary 
ANCOVA model will be re-run in the mITT population using as baseline value the last available 
LDL-C value measured from Visit 1 (Week -1) and before first injection. 
Subgroup analyses: 
Treatment group-by-BMI interaction: 
The treatment group-by-BMI interaction will be explored using an ANCOVA model including 
terms for treatment group, BMI (<30 kg/m2, ≥30 kg/m2), treatment group-by-BMI interaction, and 
baseline LDL-C. Least Square Means Difference of SAR236553 150 mg + atorvastatin 80 mg 
versus placebo + atorvastatin 80 mg will be provided, as well as the corresponding standard error 
and 95% confidence interval, within each BMI category. 
2.4.4.2 Analyses of secondary efficacy endpoints 
Continuous secondary efficacy variables defined in Section 2.1.3.2 will be analyzed in the mITT 
population using the same ANCOVA model as for the primary endpoint with treatment group as 
fixed effect, and corresponding baseline value as covariate.  
For TG and Lp(a) known to have non Gaussian distribution, the rank-based ANCOVA described 
in Section 2.4.4.1 will be used. This analysis will be also used for other secondary efficacy 
variables if substantial deviation from the assumption of Gaussian distribution is found. 
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Binary secondary efficacy variables defined in Section 2.1.3.2 will be analyzed in the mITT 
population using an exact conditional logistic regression model with treatment group and baseline 
LDL-C level as effects. In case of computing issues, the baseline LDL-C level will be entered in 
the model as a categorical variable using quartiles. For SAR236553 150 mg + atorvastatin 80 mg 
group, exact odds ratio versus placebo + atorvastatin 80 mg, 95% confidence interval, and p-value 
will be provided. 
For continuous and binary secondary endpoints, p-values will be provided for descriptive 
purposes only. 
Central laboratory values (mmol/L and mg/dL), absolute and percent change from baseline in 
calculated LDL-C, TC, HDL-C, TG, and non HDL-C at Week 2, Week 4, Week 6, Week 8, 
Week 8-LOCF, Week 12 and Week 16 time points will be summarized in the mITT population 
using number of available data, mean, SD, median, minimum, and maximum for each treatment 
group. All measurements performed during the efficacy period, scheduled or unscheduled, fasting 
or non fasting, will be assigned to time windows defined in Table 1 (Section 2.5.4) in order to 
provide an assessment for Week 2 to Week 8 time points. All measurements performed during the 
follow-up period, scheduled or unscheduled, fasting or non fasting, will be assigned to time 
windows defined in Table 2 (Section 2.5.4) in order to provide an assessment for Week 12 to 
Week 16 time points. The follow-up period starts on the day after the efficacy period and ends on 
the day of the patient’s last contact date within the study. The time profile in percent change from 
baseline of each parameter will be also plotted by treatment group with the corresponding 
standard errors. The plots will include LOCF values, and available Week 12 and Week 16 post-
treatment values. For TG and Lp(a), summary statistics will include Q1 and Q3, and medians 
(instead of means) by time point will be plotted. For TG, measurements on not fasting patients 
will be excluded. 
Similar summaries will be performed for Apo-B, Apo-A1, and Lp(a) percent change from 
baseline at Week 4 and Week 8 time points. Summaries of ratio Apo-B/Apo-A1 will be performed 
on absolute change from baseline. 
In addition, for calculated LDL-C, number and percentage of patients achieving 50% or more of 
reduction from baseline in calculated LDL-C will be also provided at each time point.  
2.4.4.3 Multiplicity issues 
Primary efficacy analysis 
Not applicable 
Secondary efficacy analyses 
No adjustment for multiple secondary endpoints will be made. Results of secondary analysis 
should be considered as supportive only. 
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2.4.5 Analyses of safety data 
The summary of safety results will be presented by treatment group.  
General common rules 
All safety analyses will be performed on the Safety population as defined in Section 2.3.2, unless 
otherwise specified, using the following common rules: 
• The baseline value is defined as the last available value before first IP injection.  
• The Potentially Clinically Significant Abnormality (PCSA) values are defined as abnormal 
values considered medically important by the sponsor according to predefined 
criteria/thresholds based on literature review and defined by the sponsor for clinical 
laboratory tests, vital signs and ECG (PCSA version dated September 2009,  
see Appendix A).  
• PCSA criteria will determine which patients had at least one PCSA during the TEAE 
period, taking into account all evaluations performed during the TEAE period, including 
non-scheduled or repeated evaluations.  The number of all such patients will be the 
numerator for the on-treatment PCSA percentage.   
• The treatment emergent PCSA denominator by group for a given parameter will be based 
on the number of patients assessed for that given parameter in the TEAE period by 
treatment group on the safety population. 
• For quantitative safety parameters based on central laboratory/reading measurements, 
descriptive statistics will be used to summarize results and change from baseline values by 
visit and treatment group. These summaries will include only measurements performed 
during the efficacy period defined in Section 2.1.3.1 as well as last efficacy period value 
and worst efficacy period value. The last efficacy period value is defined as the last value 
collected during the efficacy period. The worst efficacy period value is defined as the 
nadir and /or the peak value (according to the direction (minimum or maximum) of the 
abnormality as defined in the PCSA list) observed during the efficacy period. Time 
windows for time points are defined in Section 2.5.4. 
• The analysis of the safety variables will be essentially descriptive and no systematic 
testing is planned.  
 
All safety presentations will be generated using standard tables when available and will follow 
safety guideline recommendations. 
2.4.5.1 Analyses of adverse events 
Generalities:  
The primary focus of adverse event reporting will be on TEAEs. Pre- and post-treatment AEs will 
be described separately.  
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If an AE date/time of onset (occurrence, worsening, or becoming serious) is incomplete, an 
imputation algorithm will be used to classify the AE as pre-treatment, TEAE, or post-treatment. 
The algorithm for imputing date / time of onset will be conservative and will classify an AE as a 
treatment emergent unless there is definitive information to determine it is pre- or post-treatment. 
Details on classification of AEs with missing or partial onset dates are provided in Section 2.5.3. 
Adverse event incidence tables will present by system-organ-class (SOC), High group level term 
(HLGT), High level term (HLT) and preferred term (PT) sorted in alphabetical order for each 
treatment group, the number (n) and percentage (%) of patients experiencing an AE.  Multiple 
occurrences of the same event in the same patient will be counted only once in the tables within a 
treatment phase. The denominator for computation of percentages is the safety population within 
each treatment group. 
Sorting within tables should ensure same presentation for the set of all AE within the observation 
period (pre-treatment, TEAE and post-treatment).  For that purpose, the table of all TEAEs 
presented by system organ class (SOC) and preferred term (PT) sorted by internationally agreed 
order of SOC and decreasing frequency of PT within SOC will define the presentation order for 
all other tables unless otherwise specified. Sorting will be based on results for the SAR236553 
150 mg + atorvastatin 80 mg group.  
Analysis of all TEAE(s):  
The following TEAE summaries will be generated for the safety population. 
• Overview of TEAEs, summarizing number (%) of patients with any 
- TEAE, 
- serious TEAE, 
- TEAE leading to death, 
- TEAE leading to permanent treatment discontinuation. 
• All TEAEs by primary SOC, HLGT, HLT, and PT, showing number (%) of patients with 
at least one TEAE sorted by SOC internationally agreed order. The other level (HLGT, 
HLT, PT) will be presented in an alphabetic order. 
• All TEAEs by primary SOC and PT, showing number (%) of patients with at least one 
TEAE, sorted by SOC internationally agreed order and decreasing incidence of PTs within 
SOC. This sorting order will be applied to all other tables, unless otherwise specified.  
• All TEAEs by primary SOC and PT, that occurred in more than 10% of patients in any 
treatment group. 
• All TEAEs regardless of relationship and related to SAR236553 IP by primary SOC, 
HLGT, HLT and PT, showing number (%) of patients with at least one TEAE, sorted by 
SOC internationally agreed order. The other level (HLGT, HLT, PT) will be presented in 
an alphabetic order. 
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• All TEAEs regardless of relationship and related to atorvastatin IP by primary SOC, 
HLGT, HLT and PT, showing number (%) of patients with at least one TEAE, sorted by 
SOC internationally agreed order. The other level (HLGT, HLT, PT) will be presented in 
an alphabetic order.  
• All TEAEs by maximal severity, presented by primary SOC and PT, showing number (%) 
of patients with at least one TEAE by severity (i.e., mild, moderate, or severe), sorted by 
sorting order defined above.  
Analysis of all treatment emergent SAE(s):  
• All treatment emergent SAEs by primary SOC, HLGT, HLT and PT, showing number (%) 
of patients with at least one serious TEAE, sorted by SOC internationally agreed order. 
The other level (HLGT, HLT, PT) will be presented in an alphabetic order. 
• All treatment emergent SAEs regardless of relationship and related to SAR236553 IP by 
primary SOC, HLGT, HLT and PT, showing number (%) of patients with at least one 
treatment emergent SAE, sorted by SOC internationally agreed order. The other level 
(HLGT, HLT, PT) will be presented in an alphabetic order.  
• All treatment emergent SAEs regardless of relationship and related to atorvastatin IP by 
primary SOC, HLGT, HLT and PT, showing number (%) of patients with at least one 
treatment emergent SAE, sorted by SOC internationally agreed order. The other level 
(HLGT, HLT, PT) will be presented in an alphabetic order.  
Analysis of all TEAE(s) leading to treatment discontinuation:  
• All TEAEs leading to treatment discontinuation, by primary SOC, HLGT, HLT and PT, 
showing number (%) of patients sorted by SOC internationally agreed order. The other 
level (HLGT, HLT, PT) will be presented in an alphabetic order. 
Analysis of SMQ “Hepatic disorders”:  
• All TEAEs, by standardized MedDRA query (SMQ) and PT, showing number (%) of 
patients, with at least one PT sorted by decreasing incidence of PTs within SMQ. 
Analysis of Pre-treatment & Post-treatment AEs:  
• All pre-treatment AEs by primary SOC and PT, showing number (%) of patients with at 
least one pre-treatment AEs sorted by SOC internationally agreed order and decreasing 
incidence of PTs within SOC. 
If any, 
• All pre-treatment AEs leading to study discontinuation by primary SOC and PT, showing 
number (%) of patients, sorted by SOC internationally agreed order and decreasing 
incidence of PTs within SOC,  
• All post-treatment AEs by primary SOC and PT, showing number (%) of patients with at 
least one post-treatment AEs, sorted by SOC internationally agreed order and decreasing 
incidence of PTs within SOC, 
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• All post-treatment serious AEs by primary SOC and PT, showing number (%) of patients 
with at least one post-treatment serious AEs, sorted by SOC internationally agreed order 
and decreasing incidence of PTs within SOC. 
For the pre-treatment & post-treatment AEs categories described above, a summary table or a 
listing will be presented depending on the number of patients. 
2.4.5.2 Analyses of deaths 
The following deaths summaries will be generated on the safety population. 
• Number (%) of patients who died by study period (on-study, on-treatment, post-study). 
• Death in non-randomized patients or randomized but not treated patients (summary table 
or listing depending on the number of patients). 
• TEAE leading to death (death as an outcome on the AE CRF page as reported by the 
Investigator) by primary SOC , HLGT, HLT and PT showing number (%) of patients 
sorted by internationally agreed order of SOC and alphabetic order of HLGT, HLT, and 
PT (summary table or listing depending on the number of patients). 
2.4.5.3 Analyses of laboratory variables  
The summary statistics (including number, mean, median, standard deviation, minimum and 
maximum) of all laboratory variables (central laboratory values and changes from baseline) will 
be calculated for each following study assessment (baseline, each efficacy period time point, last 
efficacy period value and worst efficacy period value) by treatment group. This section will be 
organized by biological function as specified in Section 2.1.4.3. 
The incidence of PCSAs (defined in Appendix A) for parameters described in Section 2.1.4.3 at 
any time during the TEAE period will be summarized by biological function and treatment group 
whatever the baseline level and according to the following baseline status categories:   
• Normal/Missing, 
• Abnormal according to PCSA criterion or criteria. 
For calcium, phosphate and troponin I, for which no PCSA criterion is defined, similar table using 
the normal range will be provided.  
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Drug-Induced Liver Injury 
The liver function tests, namely AST, ALT, ALP and total bilirubin are used to assess possible 
drug induced liver toxicity. 
A graph of distribution of peak values of ALT versus peak values of total bilirubin will be 
presented. Note that the ALT and total bilirubin values are presented on a logarithmic scale. The 
graph will be divided into 4 quadrants with a vertical line corresponding to 3xULN for ALT and a 
horizontal line corresponding to 2xULN for total bilirubin. 
Listing of possible Hy’s Law cases identified by treatment group (e.g., subjects with any elevated 
ALT>3xULN, and associated with an increase in bilirubin ≥2xULN) with: ALT, AST, ALP, total 
bilirubin and the following complementary parameters (if available): direct and indirect bilirubin 
will be provided.  
The incidence of liver related AEs will be summarized by treatment group. The selection of 
preferred terms will be based on standardized MedDRA query (SMQ) Hepatic disorders.  
 
LDL-C values <25 mg/dL 
The number and percentage of patients with calculated LDL-C < 25 mg/dL (respectively, 
calculated LDL-C < 15 mg/dL) during efficacy period will be provided by treatment group at 
Week 2, Week 4, Week 6 and Week 8 timepoints. 
Individual LDL-C time profile for patients with LDL-C <25 mg/dL [0.65 mmol/L] will be 
provided. The plot will include available Week 12 and Week 16 follow-up values. 
All laboratory data presentations will be generated using Guideline for the Analysis and 
Reporting of Safety Data from Clinical Trials. 
2.4.5.4 Analyses of vital sign variables 
The summary statistics (including number, mean, median, standard deviation, minimum and 
maximum) of all vital signs variables (values and changes from baseline) will be calculated for 
each following study assessment (baseline, each efficacy period time point, last efficacy period 
value and worst efficacy period value) by treatment group.  For SBP and DBP, mean changes 
from baseline with the corresponding standard error will be plotted over time (at same time 
points) in each treatment group.  
The incidence of PCSAs at any time during the TEAE period will be summarized by treatment 
group whatever the baseline level.  
2.4.5.5 Analyses of ECG variables 
The summary statistics (including number, mean, median, standard deviation, minimum and 
maximum) of all ECG variables (values and changes from baseline) will be calculated for each 
following study assessment (baseline, each efficacy period time point, last efficacy period value 
and worst efficacy period value) by treatment group.   
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The incidence of PCSAs at any time during the TEAE period will be summarized by treatment 
group whatever the baseline level and according to the following baseline status categories:  
• Normal/Missing 
• Abnormal according to PCSA criterion or criteria 
2.4.5.6 Analyses of other assessment endpoints 
Exploratory variables defined in Section 2.1.5 will be summarized (values and changes and/or 
percent changes from baseline) in the m-ITT population including only patients who had that 
variable assessed post-baseline by time point using number of available data, mean, SD, median, 
minimum, and maximum for each treatment group. The time profile (including LOCF value) of 
each parameter will be also plotted by treatment group with the corresponding standard errors. 
For hs-CRP, Q1 and Q3 will be also provided in table, and in a second approach, values greater or 
equal to 10 mg/L will be excluded from analyses. Additionally, the incidence of PCSA at any time 
during the TEAE period will be summarized by treatment group using descriptive statistics. 
For body weight, the plot will also include available Week 12 and Week 16 follow-up values. 
2.4.6 Analyses of anti-SAR236553 antibody variables 
Anti-SAR236553 antibodies analyses will be conducted on the anti-SAR236553 antibodies 
population as defined in Section 2.3.3).  
Same time windows as for efficacy, safety and PK parameters (Section 2.5.4) will be used to 
allocate a time point to anti-SAR236553 antibodies measurements. These common time windows 
are defined to provide more homogeneous data for time point-specific analyses. 
The antibody status (positive/negative) and antibody titers will be summarized by treatment group 
and time point visit using descriptive statistics: 
• at baseline (Week 0 assessment is defined as any sample taken prior first IP injection), 
• Week 4 and Week 8 time points, if measured during the efficacy period, 
• Week 12 and Week 16 time points, if measured during the follow-up period. 
Antibody status will be summarized by visit and by treatment group using number and percentage 
of patients with positive status. For patients with positive antibody status, antibody titers will be 
summarized using descriptive statistics for each treatment group and time point. 
A listing of anti-SAR236553 antibodies status and titer will be provided by treatment group. 
Adverse events of interest (e.g. allergic events) will be also described for patients with positive 
anti SAR236553 antibodies (summary table or listing depending on the number of patients with 
positive antibody status). 
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2.4.7 Analyses of pharmacokinetic and pharmacodynamic variables 
Pharmacokinetic analyses will be conducted on the PK population as defined in Section 2.3.4.  
Same time windows as for efficacy, safety and anti-SAR236553 antibodies parameters 
(Section 2.5.4) will be used to allocate a time point to PK assessments. 
The SAR236553 total concentration will be summarized by treatment group and time point visit 
using descriptive statistics: 
• at baseline (Week 0 assessment is defined as any sample taken prior first IP injection),  
• Week 2, Week 4, Week 6 and Week 8 time points if measured during the efficacy period, 
• Week 12 and Week 16 time points, if measured during the follow-up period. 
Total concentration time profiles (Mean +/- SE or Median, as appropriate) will be provided by 
treatment group using graphs.  
For analyses of individual PK variables, the relative time from previous injection will be used 
(previous injections are defined as injections done at least one day prior PK sampling). 
Graphs per treatment group showing individual concentration (y-axis) and relative time from 
previous injection (x-axis) will be also provided to assess the total concentration relative time 
profile after previous IP injection. In order to assess the PK/immunogenicity relationship, this 
graph will be also split by visit using different symbols for antibodies positive and negative status. 
The following pharmacokinetics/pharmacodynamics (PK/PD) analyses will be provided at 
Week 8-LOCF, which is the main analysis time point: for each active treatment group, a scatter 
plot of the individual primary efficacy endpoint (percent change from baseline in calculated 
LDL-C) versus individual SAR236553 concentration at the same visit will be provided. This 
graph will be also displayed using different symbols for antibodies positive and negative status to 
assess the relationship between anti SAR236553 antibodies, concentration and efficacy.  
To assess the PD/immunogenicity relationship, the primary endpoint could be summarized by 
antibody status (negative, positive) at Week 8-LOCF per active treatment group (if relevant 
depending on the number of patients per status subgroup). A plot of the individual primary 
efficacy endpoint (percent change from baseline in calculated LDL-C at week 8-LOCF) versus 
active treatment groups will be provided, using different symbols for antibodies positive and 
negative status to assess the relationship between anti SAR236553 antibodies, active treatment 
groups and efficacy. 
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2.4.8 Analyses of target PCSK9 variables 
Target (PCSK9) analyses will be conducted on the PK population as defined in Section 2.3.4.  
Same time windows as for efficacy, safety and anti-SAR236553 antibodies parameters 
(Section 2.5.4) will be used to allocate a time point to PCSK9 assessment. The PCSK9 
concentration will be summarized by treatment group and time point visit using descriptive 
statistics: 
• at baseline (Week 0 assessment is defined as any sample taken before or at the day of the 
first IP injection), 
• Week 2, Week 4, Week 6 and Week 8 time points, if measured during the efficacy period, 
• Week 12 and Week 16 time points, if measured during the follow-up period. 
PCSK9 concentration time profiles (Mean +/- standard error or Median, as appropriate) will be 
provided by treatment group using graphs. Additional graphical presentations of PD or PK 
endpoints versus PCSK9 concentrations may be provided if deemed helpful for the interpretation 
of the data. 
2.5 DATA HANDLING CONVENTIONS 
2.5.1 General conventions 
The following formulas will be used for computations of parameters. 
Demographic and baseline characteristics formulas: 
Time from diagnosis (years) = (Date of informed consent – Date of diagnosis*) / 365.25.  
(*): as only the month and the year of diagnosis are reported in the CRF, the day of start will be put equal 
to 1 for computation purpose. In case the month of diagnosis would be missing, it will be put equal to 
JANUARY if the year of diagnosis equals the year of informed consent; it will be put equal to JUNE 
if the year of diagnosis does not equal the year of informed consent. 
Renal function formulas:  
Creatinine clearance value will be derived using the equation of Cockroft and Gault: 
For Male:  
CLcr (mL/min) = [ ( 140 - age (years) ) x weight (kg) ] / [ 0.814 x serum creatinine (μmol/L) ] 
For Female:  result above multiplied by 0.85 for females. 
Weight and serum creatinine value should be recorded at the same visit.  
For patients performing a run-in period, as weight is not collected at Week-1, Creatinine clearance 
will not be calculated. 
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QTc formulas: 
QTcB (ms) =QT/RR1/2 
QTcF (ms) =QT/RR1/3, 
where QT is the uncorrected QT interval measured in ms, and RR is automatically measured. 
2.5.2 Data handling conventions for secondary efficacy variables 
Rules defined for the primary efficacy variable will apply. 
Moreover, 
• In case of a value below the detection limit for TC, HDL-C, TG, Lp(a) , a value halfway 
between zero and the detection limit will be used for calculation.  
• In case of HDL-C value beyond the upper limit of linearity, a value equals to the upper 
limit of linearity plus one will be used for calculation. This will apply to all HDL-C values 
collected during the study (including pre-treatment values). 
2.5.3 Missing data 
For categorical variables, patients with missing data are not included in calculations of 
percentages unless otherwise specified. When relevant, the number of patients with missing data 
is presented. 
Handling of computation of treatment duration if atorvastatin IP end of treatment date is 
missing  
For the calculation of the treatment duration, the date of the last dose of IP is equal to the date of 
last administration reported on the “End of treatment” CRF page. If this date is missing, the 
exposure duration should be kept as missing.  
The last dose intake should be clearly identified in the CRF and should not be approximated by 
the last returned package date. 
Handling of medication missing/partial dates 
No imputation of medication start/end dates or times will be performed. If a medication date or 
time is missing or partially missing, so it can not be determined whether it was taken prior or 
concomitantly, it will be considered as a prior, concomitant, and a post-treatment medication. 
Property of the sanofi-aventis group - strictly confidential Page 39 
Statistical Analysis Plan  10-Oct-2011 
SAR236553-DFI11566 Version number: 1 (electronic 1.0) 
Handling of AEs with missing or partial date/time of onset 
Missing or partial missing AE onset dates and times will be imputed so that if the partial AE onset 
date/time information does not indicate that the AE started prior to treatment or after the TEAE 
period, the AE will be classified as treatment-emergent. No imputation of AE end dates/times will 
be performed.  These data imputations are for categorization purpose only and will not be used in 
listings. No imputation is planned for date/time of AE resolution. 
Handling of AE when date and time of first investigational drug date is missing 
When the date and time of the first investigational drug is missing all adverse events that occurred 
after or on the day of randomization should be considered as treatment emergent adverse events. 
The exposure duration should be kept as missing. 
Handling of missing relationship to investigational product of AEs 
If the assessment of the relationship to investigational product is missing, then the relationship to 
investigational product has to be assumed and the AE considered as such in the frequency tables 
of possibly related AEs, but no imputation should be done at the data level. 
Handling of missing severity of AEs 
If the severity is missing for one of the treatment emergent occurrences of an AE, the maximal 
severity on the remaining occurrences will be considered. If the severity is missing for all the 
occurrences a “missing” category will be added in summary table. 
Handling of PCSA  
If a subject has a missing baseline he will be grouped in the category ”normal /missing at 
baseline”. 
For PCSA with two conditions, one based on a change from baseline value or a normal range and 
the other one on a threshold value, the first condition being missing, the PCSA will be based only 
on the second condition. 
For PCSA defined on a threshold and/or a normal range, this PCSA will be derived using this 
threshold if the normal range are missing.  E.g. for eosinophils the PCSA is > 0.5 GIGA/L or 
>ULN if ULN ≥0.5 GIGA/L . When ULN is missing the value 0.5 should be used. 
Measurements flagged as invalid by the laboratory will not be summarized nor be taken into 
account in the computation of PCSA values.   
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Handling of laboratory safety variables below the lower limit of quantification or above the 
upper limit of quantification  
For laboratory safety data below the lower limit of quantification (LLOQ), half of the lower limit 
value (ie, LLOQ/2) will be used for statistical summaries. For data above the upper limit of 
quantification (ULOQ), the upper limit value (ie, ULOQ) will be used for statistical summaries. 
Handling of other assessment endpoints below the lower limit of quantification 
In case of hs-CRP value below the detection limit, a value halfway between zero and the detection 
limit will be used for calculation. 
Handling of PK data below the lower limit of quantification 
For PK data below the lower limit of quantification (LLOQ), half of the lower limit value 
(ie, LLOQ/2) will be used for statistical summaries. 
2.5.4 Windows for time points 
Data analyzed by time point (including efficacy, laboratory safety data, vital signs, ECG, 
anti-SAR236553 antibodies and PK) will be summarized using the time windows given in the 
tables below.  
These time windows will be applicable for all analyses using any of the defined populations, and 
they are defined to provide more homogeneous data for time point-specific analyses. 
Table 1 – Time windows definitions for efficacy period 
Time point Targeted study day Time window (study days) 
Week 2 15 1* to 21 
Week 4 29 22 to 35 
Week 6 43 36 to 49 
Week 8 57 50 to 84 
Study days are calculated from the day of first injection, the day of first injection being Day 1. 
(*): after first injection. 
Table 2 – Time windows definitions for follow-up period 
Time point Targeted follow-up day Time window (follow-up days) 
Week 16 42 22 to 56 
Week 20 70 > 56 
Follow-up days are calculated from the day after the day of last injection, the day after the day of last injection being Day 1. 
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If multiple valid values of a variable exist within a time window, the nearest from the targeted 
study day will be selected for the statistical analysis by time point. If the difference is a tie, the 
value after the targeted study day will be used. If multiple valid values of a variable exist within a 
same day, then the first value of the day will be selected.  
2.5.5 Unscheduled visits 
Unscheduled visit measurements of laboratory data, vital signs, ECG may be used to provide a 
measurement for a time window, a baseline, a last efficacy value or a worst efficacy value, if 
appropriate according to their definition. The measurements may also be used to determine 
abnormal/PCSA laboratory, vital sign or ECG values. 
2.5.6 Pooling of centers for statistical analyses 
Not applicable. 
The randomization scheme was not stratified by center because the primary efficacy variable is 
centrally assessed and expected to not be influenced by the center when other factors such as 
background statin therapy are already controlled. Therefore, the center will not be added as factor 
in the primary analysis model. 
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3 INTERIM ANALYSIS 
No interim analysis planned for this study. 
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4 DATABASE LOCK 
The database is planned to be locked at approximately 4 weeks after last patient last visit. 
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5 SOFTWARE DOCUMENTATION 
All summaries and statistical analyses will be generated using SAS version 9.2 or higher. 
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Appendix A Potentially clinically significant abnormalities 
(PCSA) criteria  
 
(From QSD-002295 – Version 3.0 –14-SEP-2009 based on content from PCSA List issued on 27-JAN-2009) 
Parameter PCSA Comments 
Clinical Chemistry 
ALT By distribution analysis : 
>3 ULN 
>5 ULN 
>10 ULN 
>20 ULN 
Enzymes activities must be expressed in ULN, 
not in IU/L.  
Concept paper on DILI – FDA draft Guidance 
Oct 2007. 
Internal DILI WG Oct 2008. 
Categories are cumulative. 
First row is mandatory. Rows following one 
mentioning zero can be deleted. 
AST By distribution analysis : 
>3 ULN 
>5 ULN 
>10 ULN 
>20 ULN 
Enzymes activities must be expressed in ULN, 
not in IU/L.  
Concept paper on DILI – FDA draft Guidance 
Oct 2007. 
Internal DILI WG Oct 2008. 
Categories are cumulative. 
First row is mandatory. Rows following one 
mentioning zero can be deleted. 
Alkaline Phosphatase >1.5 ULN Enzymes activities must be expressed in ULN, 
not in IU/L. 
Concept paper on DILI – FDA draft Guidance 
Oct 2007. 
Internal DILI WG Oct 2008. 
Total Bilirubin >1.5 ULN 
>2 ULN 
Must be expressed in ULN, not in µmol/L or 
mg/L. Categories are cumulative. 
Concept paper on DILI – FDA draft Guidance 
Oct 2007. 
Internal DILI WG Oct 2008. 
Conjugated Bilirubin >35% Total Bilirubin and TBILI>1.5 ULN Conjugated bilirubin dosed on a case-by-case 
basis. 
ALT and Total Bilirubin ALT>3 ULN and TBILI>2 ULN Concept paper on DILI – FDA draft Guidance 
Oct 2007. 
Internal DILI WG Oct 2008. 
To be counted within a same treatment phase, 
whatever the interval between measurement. 
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(From QSD-002295 – Version 3.0 –14-SEP-2009 based on content from PCSA List issued on 27-JAN-2009) 
Parameter PCSA Comments 
CPK >3 ULN 
>10 ULN 
FDA Feb 2005. 
Am J Cardiol April 2006. 
Categories are cumulative. 
First row is mandatory. Rows following one 
mentioning zero can be deleted. 
Creatinine ≥150 μmol/L (Adults) 
≥30% change from baseline 
≥100% change from baseline 
Benichou C., 1994. 
 
Creatinine Clearance 
(Cokcroft’s formula) 
<30 ml/min (severe renal impairment) 
≥30 - <50 ml/min (moderate renal impairment) 
≥50 - ≤80 ml/min (mild renal impairment) 
Use is optional. 
FDA criteria May 1998. 
Uric Acid 
Hyperuricemia  
Hypouricemia  
 
>408 μmol/L 
<120 μmol/L  
Harrison- Principles of internal Medicine 17th Ed., 
2008. 
Blood Urea Nitrogen ≥17 mmol/L  
Chloride <80 mmol/L 
>115 mmol/L 
 
Sodium ≤129 mmol/L 
≥160 mmol/L 
 
Potassium <3 mmol/L 
≥5.5 mmol/L 
FDA Feb 2005. 
Total Cholesterol ≥7.74 mmol/L  Threshold for therapeutic intervention. 
Triglycerides ≥4.6 mmol/L Threshold for therapeutic intervention. 
Lipasemia ≥3 ULN  
Amylasemia ≥3 ULN  
Glucose 
Hypoglycaemia 
Hyperglycaemia 
 
≤3.9 mmol/L and <LLN 
≥11.1 mmol/L (unfasted); ≥7 mmol/L (fasted) 
 
ADA May 2005. 
ADA Jan 2008. 
HbA1c >8%  
Albumin ≤25 g/L  
CRP >2 ULN or >10 mg/L (if ULN not provided)  FDA Sept 2005. 
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(From QSD-002295 – Version 3.0 –14-SEP-2009 based on content from PCSA List issued on 27-JAN-2009) 
Parameter PCSA Comments 
Hematology 
WBC <3.0 Giga/L (Non-Black); <2.0 Giga/L (Black) 
≥16.0 Giga/L 
Increase in WBC: not relevant. 
To be interpreted only if no differential count 
available. 
Lymphocytes >4.0 Giga/L  
Neutrophils <1.5 Giga/L (Non-Black);<1.0 Giga/L (Black) International Consensus meeting on drug-
induced blood cytopenias, 1991. 
FDA criteria. 
Monocytes >0.7 Giga/L  
Basophils >0.1 Giga/L  
Eosinophils >0.5 Giga/L or >ULN (if ULN≥0.5 Giga/L) Harrison- Principles of internal Medicine 17th Ed., 
2008. 
Hemoglobin ≤115 g/L (Male); ≤95 g/L (Female) 
≥185 g/L (Male); ≥165 g/L (Female) 
 
Decrease from Baseline ≥20 g/L 
Criteria based upon decrease from baseline are 
more relevant than based on absolute value. 
Other categories for decrease from baseline can 
be used (≥30 g/L, ≥40 g/L, ≥50 g/L). 
Hematocrit ≤0.37 v/v (Male) ; ≤0.32 v/v (Female) 
≥0.55 v/v (Male) ; ≥0.5 v/v (Female) 
 
RBC ≥6 Tera/L Unless specifically required for particular drug 
development, the analysis is redundant with that 
of Hb. 
Otherwise, consider FDA criteria. 
Platelets <100 Giga/L 
≥700 Giga/L 
International Consensus meeting on drug-
induced blood cytopenias, 1991. 
Urinalysis 
pH ≤4.6 
≥8 
 
Vital signs 
HR ≤50 bpm and decrease from baseline ≥20 bpm 
≥120 bpm and increase from baseline≥20 bpm 
To be applied for all positions (including missing) 
except STANDING. 
SBP ≤95 mmHg and decrease from baseline ≥20mmHg 
≥160 mmHg and increase from baseline ≥20 mmHg 
To be applied for all positions (including missing) 
except STANDING. 
DBP ≤45 mmHg and decrease from baseline ≥10 mmHg 
≥110 mmHg and increase from baseline ≥10 mmHg 
To be applied for all positions (including missing) 
except STANDING. 
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(From QSD-002295 – Version 3.0 –14-SEP-2009 based on content from PCSA List issued on 27-JAN-2009) 
Parameter PCSA Comments 
Orthostatic Hypotension 
Orthostatic SDB 
Orthostatic DBP 
 
≤-20 mmHg 
≤-10 mmHg 
 
Weight ≥5% increase from baseline  
≥5% decrease from baseline 
FDA Feb 2007. 
ECG Ref.: CPMP 1997 guideline. 
HR ≤50 bpm and decrease from baseline ≥20 bpm 
≥120 bpm and increase from baseline ≥20 bpm 
 
PR ≥220 ms and increase from baseline ≥20 ms  
QRS ≥120 ms  
QTc 
Borderline 
Prolonged* 
Additional 
 
Absolute values (ms)  
Borderline: 431-450 ms (Male); 451-470 ms (Female) 
Prolonged: >450 ms (Male); >470 ms (Female) 
≥500 ms 
 
Increase from baseline 
Borderline: Increase from baseline 30-60 ms 
Prolonged:  Increase from baseline >60 ms 
To be applied to any kind of QT correction 
formula.  
 
 
 
* QTc prolonged and ΔQTc>60 ms are the PCSA 
to be identified in individual subjects/patients 
listings. 
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Appendix B Summary of statistical analyses 
 
EFFICACY ANALYSIS: 
 Analysis  Supportive Subgroup Other 
Endpoint Population Primary Analysis Analysis* Analysis* Analyses* 
Primary Endpoint 
The percent change from baseline in calculated 
LDL-C at Week 8-LOCF 
mITT ANCOVA with treatment group as fixed 
factor and baseline LDL-C value as a 
covariate. 
Comparison: SAR236553 + atorvastatin 
80 mg group versus placebo for 
SAR236553 + atorvastatin 80 mg group  
No formal comparisons with the 
SAR236553 + atorvastatin 10 mg group 
Yes 
Rank-based 
ANCOVA with 
treatment group as 
fixed factor, and 
baseline LDL-C value 
as a covariate, if 
normality assumption 
violated 
Yes  
Subgroups: BMI. 
Model Assumption checks: 
- Homogeneity of slopes 
- Homogeneity of variances 
Sensitivity analyses: 
- Sensitivity to per protocol 
- Sensitivity to baseline definition 
 
Secondary Endpoints 
The absolute change from baseline in 
calculated LDL-C and in ratio of Apo B to Apo 
A-1 at Week 8 – LOCF;  
Percent and absolute change in non-HDL-C, 
and HDL-C from baseline to Week 8-LOCF; 
Percent change in Apo B, Apo A-1 from 
baseline to Week 8-LOCF 
mITT ANCOVA with treatment group as fixed 
factor and baseline value as a covariate. 
No adjustment for multiplicity. 
No No No 
Percent and absolute change in Triglycerides 
from baseline to Week 8-LOCF; 
Percent change in Lp(a) from baseline to Week 
8-LOCF; 
mITT Rank-based ANCOVA with treatment group 
as fixed factor, and baseline value as a 
covariate 
No No No 
Proportion of patients achieving an LDL-C level 
lower than 100 mg/dL (resp. 70 mg/dL)at Week 
8-LOCF 
mITT An exact conditional logistic regression 
model with treatment group as effect and 
category of baseline level as covariate 
No No No 
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SAFETY ANALYSES: 
 Analysis  Supportive Subgroup Other 
Endpoint Population Primary Analysis Analysis* Analysis* Analyses* 
Adverse Events Safety Follow safety guidelines No No No 
Laboratory data Safety Follow safety guidelines No No No 
Vital signs Safety Follow safety guidelines No No No 
ECG parameter Safety Follow safety guidelines No No No 
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Appendix C List of codes and SMQ for medical history analyses  
 
Medical history of specific 
interest 
MedDRA Codes or SMQ 
Hypertension Hypertension SMQ (20000147) 
Type 2 diabetes Diabetes mellitus, Type 2 Diabetes mellitus, Insulin-requiring type 2 
diabetes mellitus 
Coronary Artery disease Other ischaemic heart disease SMQ (20000168) 
Peripheral Vascular disease PTs selected using a company MedDRA Query defined in  
Table 3  
Cerebrovascular disease Cerebrovascular disorders SMQ (20000060) 
MedDRA version 14.0 
 
Table 3 – Peripheral Vascular disease Preferred terms selection 
PT code Preferred Term T PT code Preferred Term 
10057517 Angiogram peripheral abnormal 10062610 Ischaemic limb pain 
10062760 Ankle brachial index decreased 10059084 Ischaemic ulcer 
10062542 Arterial insufficiency 10024124 Leg amputation 
10062599 Arterial occlusive disease 10028862 Necrosis ischaemic 
10003175 Arterial spasm 10028872 Necrosis of artery 
10060965 Arterial stenosis 10062993 Pedal pulse decreased 
10049867 Arterial stenosis limb 10062585 Peripheral arterial occlusive disease 
10061659 Arteriogram abnormal 10069379 Peripheral arterial reocclusion 
10003210 Arteriosclerosis 10057521 Peripheral artery aneurysm 
10003212 Arteriosclerosis Moenckeberg-type 10057520 Peripheral artery dissection 
10065418 Arteriosclerosis obliterans 10034568 Peripheral coldness 
10003222 Arteriosclerotic gangrene 10034568 Peripheral coldness 
10003880 Axillary vein thrombosis 10061340 Peripheral embolism 
10059126 Blue toe syndrome 10034576 Peripheral ischaemia 
10007649 Cardiovascular disorder 10053351 Peripheral revascularisation 
10069696 Coeliac artery occlusion 10034636 Peripheral vascular disorder 
10068057 Dependent rubor 10037469 Pulse absent 
10060734 Diabetic foot 10040943 Skin ulcer 
10060803 Diabetic foot infection 10063900 Steal syndrome 
10012665 Diabetic gangrene 10069695 Subclavian artery occlusion 
10063547 Diabetic macroangiopathy 10050180 Subclavian artery stenosis 
10056340 Diabetic ulcer 10068016 Temperature difference of extremities 
10061815 Diabetic vascular disorder 10043913 Toe amputation 
10049927 Dry gangrene 10054880 Vascular insufficiency 
10059385 Extremity necrosis 10053648 Vascular occlusion 
10016426 Femoral arterial stenosis 10057469 Vascular stenosis 
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PT code Preferred Term T PT code Preferred Term 
10016427 Femoral artery aneurysm 10047503 Visceral arterial ischaemia 
10052326 Femoral artery dissection 10042569 superior vena cava syndrome 
10068365 Femoral artery embolism 10070911 inferior vena cava syndrome 
10052019 Femoral artery occlusion 10071026 arterectomy 
10017711 Gangrene 10063164 vestibular ischaemia 
10021338 Iliac artery embolism 10070995 vascular compression 
10064601 Iliac artery occlusion 10071138 malnutrition-inflammation-
atherosclerosis syndrome 
10053216 Iliac artery stenosis 10064849 extrinsic iliac vein compression 
10021340 Iliac artery thrombosis   
10058992 Iliac vein occlusion   
10022562 Intermittent claudication   
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